Immuno-Oncology (I-O) research is the investigation of innovative approaches that aim to harness the body’s natural immune response to fight cancer.

Bristol-Myers Squibb has been committed to advancing this fundamentally different approach to cancer research and continues to build upon our past discoveries to advance our current research.
7 DAILY SCIENTIFIC PROGRAM
- Saturday, October 14, 2017 74
- Sunday, October 15, 2017 77
- Monday, October 16, 2017 82
- Tuesday, October 17, 2017 96
- Wednesday, October 18, 2017 111

8 POSTER SESSIONS
- Poster Session 1
  - Monday, October 16
    - At a Glance 124
    - In Detail 125
- Poster Session 2
  - Tuesday, October 17
    - At a Glance 139
    - In Detail 140
- Poster Session 3
  - Wednesday, October 18
    - At a Glance 154
    - In Detail 155

9 AUTHOR INDEX
- Author Index 170

10 MAPS AND FLOOR PLANS
- PACIFICO Yokohama
  - Maps and Floor Plans 206
Dear Colleagues,

On behalf of the International Association for the Study of Lung Cancer (IASLC) and the Regional Organizing Committee, it is a great pleasure to welcome you to the IASLC 18th World Conference on Lung Cancer in Yokohama, Japan.

With WCLC now being an annual Conference and with delegates from more than 100 countries attending, WCLC has become the premier international meeting to discuss the latest findings in the field of lung cancer and thoracic malignancies. In more than 150 sessions the scientific program will cover a variety of groundbreaking topics that illustrate the latest scientific and clinical developments but also provide the ideal forum to discuss and really understand how they can affect your practice day to day.

The program includes stimulating presentations from more than 350 world renowned keynote speakers as well as more than 2,000 oral, mini oral and poster abstract presentations. Please note that each day a different set of posters will be displayed in the Exhibit Hall, so make sure to visit the Exhibit Hall each day. Posters will be on display for the entire day with presenters being asked to stand by their poster during the morning and afternoon networking breaks.

We encourage you to participate actively in the discussions and hope the meeting helps in the exchange of information and development of new collaborations. Take advantage of the various networking opportunities the Conference provides. Seating areas will be placed throughout the Exhibition Hall and refreshments will be provided throughout each day in the Exhibit Hall, allowing you to network with friends, colleagues, exhibitors and sponsors.

We also would like to extend our gratitude and thanks to all sponsors and exhibitors for their continued support to WCLC and IASLC. Without them this Conference wouldn’t be possible.

We hope that, despite an intense Conference program, you also will be able to get some glimpses of Yokohama, Japan.

Yokohama has developed as an outer part of Tokyo for the last 150 years, therefore creating unique cultures making Yokohama a unique city among Japan’s biggest cities. Because of this, Yokohama has also played host to many international organizations and conferences. Yokohama is a city rich in history, architecture and culture!

Thank you for joining us in Yokohama for WCLC 2017. We can’t wait to see you.

Yours sincerely,

Dr. Hisao Asamura, MD and Dr. Keunchil Park, MD, PhD
IASLC WCLC 2017 Co-Presidents
As the representative for the people of Yokohama, I am pleased to welcome International Association for the Study of Lung Cancer (IASLC) President David Carbone and other distinguished guests from various countries. I would also like to extend my heartfelt gratitude to Prof. Hisao Asamura and Prof. Keunchil Park (who will serve as IASLC WCLC 2017 Conference Co-Presidents), and to all others whose dedicated efforts brought so many participants to WCLC 2017.

With more than 3.7 million citizens, Yokohama is Japan's largest single municipality, and we strive every day to provide healthier lives and improved healthcare for those living in our city. Particularly in the area of treatments for cancer, which is said to affect one in every two Japanese citizens, we are pursuing comprehensive measures based on the Yokohama City Ordinance for Measures to Eliminate Cancer. In addition to promoting cancer prevention and early detection and making appropriate treatments available, we work to support cancer patients, their families, and cancer-related research in the field of medicine as well as a wide array of other areas such as welfare and employment.

In Yokohama's bayside region, which has been designated as "Life Innovation Keihin Coastal Area Comprehensive Special Zones for International Competitiveness Development" by the Japanese government, we actively promote and support efforts in areas including development of medical diagnostic technologies and development of pharmaceutical drugs in response to increasingly personalized treatment approaches. Additionally, in the field of drug development, we are involved in the creation of new cancer drugs.

During the WCLC 2017 period, we will be lighting up various locations around Yokohama in lavender, the color used to promote cancer awareness. We plan to utilize the opportunity presented by this Conference to encourage all citizens of Yokohama to take greater notice of and interest in cancer-related issues.

I hope that all who attend WCLC 2017 will enjoy their stay in our city. With gorgeous waterfront scenery, a good selection of places to eat and shop, and other such attractions, visitors can truly enjoy themselves after Conference sessions.

In closing, I would like to express my sincere hope that WCLC 2017 will provide opportunities for its many participants to engage in fruitful discussions and lively exchanges.
IASLC AND THE 18TH WORLD CONFERENCE ON LUNG CANCER
GRATEFULLY ACKNOWLEDGE THE GENEROUS SUPPORT OF ITS OFFICIAL SPONSORS:

DIAMOND SPONSORS

PLATINUM SPONSORS

SILVER SPONSORS

BRONZE SPONSORS

SUPPORTERS

CONTRIBUTORS
ONSITE REGISTRATION
PACIFICO CONFERENCE CENTER, LEVEL 2F
Saturday, October 14 14:00 – 18:00
Sunday, October 15 07:00 – 20:00
Monday, October 16 06:30 – 16:00
Tuesday, October 17 06:30 – 16:00
Wednesday, October 18 06:30 – 16:00

SPEAKER PREVIEW CENTER
PACIFICO CONFERENCE CENTER, LEVEL 3F
Saturday, October 14 14:00 – 18:00
Sunday, October 15 07:00 – 20:00
Monday, October 16 06:30 – 17:30
Tuesday, October 17 06:30 – 17:30
Wednesday, October 18 06:30 – 16:30

EXHIBIT HALL
PACIFICO EXHIBITION HALL, HALL B + C
Monday, October 16 09:30 – 16:00
Tuesday, October 17 09:30 – 16:00
Wednesday, October 18 09:30 – 16:00

MEDIA ROOM
PACIFICO CONFERENCE CENTER, ROOM 421, LEVEL 4F
Sunday, October 15 15:00 – 19:00
Monday, October 16 08:00 – 19:00
Tuesday, October 17 08:00 – 19:00
Wednesday, October 18 08:00 – 18:00

COAT AND BAGGAGE CHECK
PACIFICO CONFERENCE CENTER, LEVEL 1F
Saturday, October 14 07:30 – 19:30
Sunday, October 15 07:00 – 21:00
Monday, October 16 06:30 – 19:30
Tuesday, October 17 06:30 – 19:30
Wednesday, October 18 06:30 – 18:00

POSTER PICK UP
PACIFICO EXHIBITION HALL, EXHIBIT HALL (HALL B + C)
Monday, October 16 08:00 – 16:00
Tuesday, October 17 08:00 – 16:00
Wednesday, October 18 08:00 – 10:30

IASLC BUSINESS MEETING
PACIFICO ANNEX HALL, F201 + F202, LEVEL 2F
Monday, October 16 14:30 – 15:30

All day refreshments and light snacks will be served in the Exhibit Hall throughout opening hours.
Thank you for being a member!

As an IASLC member, you receive:

- Collaboration with a multidisciplinary global team of thoracic oncology experts and leaders
- Member access to the Journal of Thoracic Oncology, the premier journal in lung cancer, as well as the latest classification and staging publications
- Multidisciplinary education including the latest in ground-breaking research and treatment of thoracic malignancies

See us in the Exhibit Hall at Booth 2404 or at the IASLC Membership Booth at Registration | Apply at iaslc.org
### IASLC AND COMMITTEES

<table>
<thead>
<tr>
<th>Committee</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>International Association for the Study of Lung Cancer (IASLC)</td>
<td>10</td>
</tr>
<tr>
<td>IASLC Board of Directors</td>
<td>11</td>
</tr>
<tr>
<td>IASLC Foundation</td>
<td>11</td>
</tr>
<tr>
<td>WCLC 2017 Committees</td>
<td>13</td>
</tr>
<tr>
<td>Regional Organizing Committee</td>
<td>13</td>
</tr>
<tr>
<td>International Program Committee</td>
<td>13</td>
</tr>
<tr>
<td>International Abstract Review Committee</td>
<td>16</td>
</tr>
</tbody>
</table>
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association’s membership includes nearly 7,000 lung cancer specialists in over 100 countries. IASLC members work to enhance the understanding of lung cancer among scientists, members of the medical community and the public. IASLC publishes the Journal of Thoracic Oncology, a valuable resource for medical specialists and scientists who focus on the detection, prevention, diagnosis and treatment of lung cancer.

**THE IASLC MISSION IS:**

To embrace the study of the etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and other thoracic malignancies

To provide education and information about lung cancer and other thoracic malignancies to IASLC members, to the medical community at large, and to the public

To use all available means to eliminate lung cancer and other thoracic malignancies as a health threat for the individual patient and throughout the world
Support the IASLC Foundation by attending the Joint IASLC Foundation – JLCS Concert

Monday, October 16, 2017, 19:30 – 20:30
(See next page for details.)
VIOLINIST
Ms. Akiko Suwanai

THE TOKYO CITY PHILHARMONIC ORCHESTRA
KEN TAKASEKI, CONDUCTOR

JOINT IASLC FOUNDATION
JLCS CONCERT

VIOLIN CONCERTO IN D MAJOR, OP. 35 (TCHAIKOVSKY)

MONDAY, OCTOBER 16, 2017
19:30–20:30
Minatomirai Hall, Yokohama

Across from PACIFICO Yokohama

Join us for a benefit concert in support of the IASLC Foundation.

This performance is given in honor of those who have been afflicted by lung cancer and those who have dedicated their lives to research, diagnoses, and treatment of the disease.

Ticket Price: 50 USD

Tickets can be purchased at Registration. Limited seats available.
WCLC 2017 COMMITTEES

REGIONAL ORGANIZING COMMITTEE

PRESIDENTS
Hisao Asamura, Japan & Keunchil Park, Korea

MEMBERS
Myung-Ju Ahn, Korea  Yuko Nakayama, Japan
Akihiko Gemma, Japan  Young Taek Oh, Korea
Norihiko Ikeda, Japan  Yuichiro Ohe, Japan
Young Tae Kim, Korea  Jeong-Seon Ryu, Korea
Katsumi Kubota, Japan  Ikuo Sekine, Japan
Tetsuya Mitsudomi, Japan  Shun-ichi Watanabe, Japan
Kazuhiko Nakagawa, Japan  Yasushi Yatabe, Japan

INTERNATIONAL PROGRAM COMMITTEE

EPIDEMIOLOGY/PRIMARY PREVENTION/TOBACCO CONTROL AND CESSATION
CHAIR
Tomotaka Sobue, Japan
CO-CHAIR
Nise Yamaguchi, Brazil
Carolyn Dresler, USA
Haruyuki Kawai, Japan
Gabor Kovacs, Hungary
Manfred Neuberger, Austria
Martina Potschke-Langer, Germany

RADIOLOGY/STAGING/SCREENING
CHAIR
Shuji Sakai, Japan
CO-CHAIR
Ramon Rami-Porta, Spain
Sergi Call, Spain
John Field, UK
Edward F. Patz, USA
Helmut Prosch, Austria
Motoyasu Sagawa, Japan
Kenji Suzuki, Japan
Ignacio Wistuba, USA
Javier Zulueta, Spain

BIOLOGY/PATHOLOGY
CHAIR
Takashi Kohno, Japan
CO-CHAIRS
Yasushi Yatabe, Japan
Pan-Chyr Yang, Taiwan
Jin-Haeng Chung, Taiwan
Montse Sanchez-Cespedes, Spain
Sanja Dacic, USA
Martin Filipits, USA
Ramakrishna Govindan, USA
Fred R. Hirsch, USA
Ryohei Katayama, Japan
Keith Kerr, UK
Luis Montuenga, Spain
Andrew Nicholson, UK
Iver Petersen, Germany
Helmut Popper, Austria
Benjamin Solomon, Australia
Roman Thomas, Germany
William Travis, USA

EARLY STAGE NSCLC
CHAIR
Young Tae Kim, Korea
CO-CHAIR
Ichiro Yoshino, Japan
Thomas D’Amico, USA
Elie Fadel, France
Glennwood Goss, Canada
Jang-Ming Lee, Taiwan
Eric Lim, UK
Heather Wakelee, USA
Kazuhiro Yasufuku, Canada
### Locally Advanced NSCLC

**Chair:**
Young-Taek Oh, Korea

**Co-Chairs:**
- Yi-Long Wu, China
- Philip Bonomi, USA
- Wilfried Eberhardt, Germany
- Hans Hoffmann, Germany
- Françoise Mornex, France
- Yuichiro Ohe, Japan
- Everett Vokes, USA
- Milada Zemanova, Czech Republic

### Advanced NSCLC

**Chair:**
Michael Boyer, Australia

**Co-Chairs:**
- Li Zhang, China
- Ikuo Sekine, Japan
- Lucio Crinò, Italy
- Peter Ellis, Canada
- David R. Gandara, USA
- Glenwood Goss, Canada
- Christian Manegold, Germany
- Mary O’Brien, UK
- Nir Peled, Israel
- Robert Pirker, Austria
- Elisabeth Quoix, France
- Martin Schuler, Germany
- Daniel Shao Weng Tan, Singapore
- Konstantinos N. Syrigos, Greece
- James Chih-Hsin Yang, Taiwan

### SCLC/Neuroendocrine Tumors

**Chair:**
Sumitra Thongprasert, Thailand

**Co-Chair:**
Akihiko Gemma, Japan

- James C. Yao, USA
- Hiroaki Akamatsu, Japan
- Hideo Kunitoh, Japan
- Nirush Lërçprasertsook, Thailand
- Pieter E. Postmus, UK
- Jens Benn Sørensen, Denmark
- Sabine Zöchbauer-Müller, Austria

### Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies

**Chairs:**
- Meinoshin Okumura, Japan
- Mir Ali Reza Hoda, Austria

**Co-Chairs:**
- Jhingook Kim, Korea
- Frank Detterbeck, USA
- Wentao Fang, China
- Joseph S. Friedberg, USA
- Nicolas Girard, France
- Keiko Shibuya, Japan
- Nico van Zandwijk, Australia
- David Waller, UK

### Locally Advanced NSCLC

**Chair:**
Young-Taek Oh, Korea

**Co-Chairs:**
- Yi-Long Wu, China
- Philip Bonomi, USA
- Wilfried Eberhardt, Germany
- Hans Hoffmann, Germany
- Françoise Mornex, France
- Yuichiro Ohe, Japan
- Everett Vokes, USA
- Milada Zemanova, Czech Republic

### Advanced NSCLC

**Chair:**
Michael Boyer, Australia

**Co-Chairs:**
- Li Zhang, China
- Ikuo Sekine, Japan
- Lucio Crinò, Italy
- Peter Ellis, Canada
- David R. Gandara, USA
- Glenwood Goss, Canada
- Christian Manegold, Germany
- Mary O’Brien, UK
- Nir Peled, Israel
- Robert Pirker, Austria
- Elisabeth Quoix, France
- Martin Schuler, Germany
- Daniel Shao Weng Tan, Singapore
- Konstantinos N. Syrigos, Greece
- James Chih-Hsin Yang, Taiwan

### SCLC/Neuroendocrine Tumors

**Chair:**
Sumitra Thongprasert, Thailand

**Co-Chair:**
Akihiko Gemma, Japan

- James C. Yao, USA
- Hiroaki Akamatsu, Japan
- Hideo Kunitoh, Japan
- Nirush Lërçprasertsook, Thailand
- Pieter E. Postmus, UK
- Jens Benn Sørensen, Denmark
- Sabine Zöchbauer-Müller, Austria

### Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies

**Chairs:**
- Meinoshin Okumura, Japan
- Mir Ali Reza Hoda, Austria

**Co-Chairs:**
- Jhingook Kim, Korea
- Frank Detterbeck, USA
- Wentao Fang, China
- Joseph S. Friedberg, USA
- Nicolas Girard, France
- Keiko Shibuya, Japan
- Nico van Zandwijk, Australia
- David Waller, UK

### Mesothelioma

**Chair:**
Kwun Fong, Australia

**Co-Chair:**
Seiki Hasegawa, Japan

- Paul Baas, Netherlands
- Dean Fennell, UK
- Hedy Lee Kindler, USA
- Pyng Lee, Singapore
- Takashi Nakano, Japan
- Anna Nowak, Australia
- Harvey Pass, USA
- Yoshitaka Sekido, Japan
- Jan van Meerbeeck, Belgium
- Walter Weder, Switzerland

### Surgery

**Chair:**
Norihiko Ikeda, Japan

**Co-Chair:**
Wentao Fang, China

Alessandro Brunelli, UK
Dominique Grunenwald, France
Walter Klepetko, Austria
Eric Vallieres, USA
Giulia Veronesi, Italy
Shun-ichi Watanabe, Japan

### Radiotherapy

**Chair:**
Kazushige Hayakawa, Japan

**Co-Chair:**
Hak Choy, USA

Yong Chan Ahn, Korea
Jeffery Bradley, USA
Karim Dieckmann, Austria
Corinne Favrel-Finn, UK
Jacek Jassem, Poland
Billy Loo, USA
Yasushi Nagata, Japan
Yuko Nakayama, Japan
Jinming Yu, China

### Chemotherapy/Targeted Therapy

**Chair:**
Yuichiro Ohe, Japan

**Co-Chair:**
Myung-Jun Ahn, Korea

Benjamin Besse, France
Federico Cappuzzo, Italy
Byoung Chul Cho, Korea
Oliver Gautschi, Switzerland
Roy Herbst, USA
Pasi A. Jänne, USA
Julian Molina, USA
Sai-Hong Ou, USA
Robert Pirker, Austria
Martin Sebastian, Germany
Lecia Sequist, USA
Rolf Stahel, Switzerland
Caicun Zhou, China
IMMUNOLOGY AND IMMUNOTHERAPY
CHAIR
Tony Mok, Hong Kong
CO-CHAIR
Kazuhiko Nakagawa, Japan
Charles Butts, Canada
Rafiti Hassan, USA
Clarissa Mathias, Brazil
Martin Reck, Germany
Naiyer Rizvi, USA
Christian Rolfo, Belgium
David Spigel, USA

REGIONAL ASPECTS/HEALTH POLICY/PUBLIC HEALTH
CHAIRS
Anna Nowak, Australia
Purvish Parikh, India
CO-CHAIRS
Christoph Zielinski, Austria
Digambar Behera, India
Paul A. Bunn Jr., USA
Nagahiro Sajo, Japan

PATIENTS SUPPORT AND ADVOCACY GROUP
CHAIR
Yoichi Nakanishi, Japan
CO-CHAIR
Christina Ng, Malaysia
Bonnie Addario, USA
Ingeborg Beunders, Austria
Kazu Hasegawa, Japan
Rudolf Huber, Germany
Laksmi Sita Andarini, Indonesia
Emily Stone, Australia
Stefania Vallone, Italy

PULMONARY/ENDOSCOPY
CHAIR
Jeong-Seon Ryu, Korea
CO-CHAIR
Kazuhiko Yasufuku, Canada

YOUNG INVESTIGATORS
CHAIR
Miyako Satouchi, Japan
CO-CHAIR
Thanynan Reungwetwattana, Thailand
Yasushi Goto, Japan
Maximilian Hochmair, Austria
Sukhmani Padda, USA
Naiyarat Prasongsuk, Thailand
Wang Shuhang, China
Amanda Tufman, Germany
Stefan Zimmermann, Switzerland

EDUCATION/PUBLICATION/CAREER DEVELOPMENT
CHAIR
Sanghoon Jheon, Korea
CO-CHAIR
Massayuki Noguchi, Japan
Alex Adjei, USA
Peter Berzinec, Slovakia
Edin Hamzah, Malaysia
Pierre Massion, USA
Barbara Melosky, Canada
Mari Mino-Kenudson, USA
Enrico Ruﬁni, Italy
Navneet Singh, India
Erik Thunnissen, Netherlands
Yi-Long Wu, China

PALLIATIVE CARE/ETHICS/NURSES
CHAIR
Kaoru Kubota, Japan
CO-CHAIRS
Chong-Kin Liam, Malaysia
In Gak Kwon, Korea
Jean Klastersky, Belgium
Jeffrey Crawford, USA
Richard Lim, Malaysia
Phichai Chansriwong, Thailand
Richard Gralla, USA

CO-CHAIRS
Christoph Zielinski, Austria
Digambar Behera, India
Paul A. Bunn Jr., USA
Nagahiro Sajo, Japan

CO-CHAIRS
Kazuhiro Yasufuku, Canada

CO-CHAIRS
Rudolf Huber, Germany

CO-CHAIRS
Laksmi Sita Andarini, Indonesia

CO-CHAIRS
Emily Stone, Australia

CO-CHAIRS
Stefania Vallone, Italy

CLINICAL DESIGN AND STATISTICS
CHAIR
Daniel Shao Weng Tan, Singapore
CO-CHAIR
Mary Redman, USA
Stefan Michiels, France
Lothar Pilz, Germany

CO-CHAIRS
Peter Berzinec, Slovakia
Edin Hamzah, Malaysia
Pierre Massion, USA
Barbara Melosky, Canada
Mari Mino-Kenudson, USA
Enrico Ruﬁni, Italy
Navneet Singh, India
Erik Thunnissen, Netherlands
Yi-Long Wu, China
The objectives of this Symposium are to:
- Discuss key unmet needs in the management of patients with SCLC
- Discuss emerging therapeutics for the management of SCLC
- Evaluate emerging biomarker testing in SCLC

<table>
<thead>
<tr>
<th>TIME</th>
<th>TOPIC</th>
<th>PRESENTER</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:45 – 12:50</td>
<td>Welcome &amp; Introductions</td>
<td>Dr. Koichi Goto (Chair)</td>
</tr>
<tr>
<td>12:50 – 13:15</td>
<td>Opportunities &amp; Challenges in SCLC Patients Care</td>
<td>Dr. Benjamin Besse</td>
</tr>
<tr>
<td>13:15 – 13:45</td>
<td>Novel Therapeutics in SCLC &amp; the Changing Treatment Landscape</td>
<td>Dr. Maya Gottfried</td>
</tr>
<tr>
<td>13:45 – 14:10</td>
<td>Incorporating Biomarker Testing &amp; Targeted Therapies into the SCLC Treatment Paradigm</td>
<td>Dr. Wilfried Eberhardt</td>
</tr>
<tr>
<td>14:10 – 14:15</td>
<td>Closing Remarks</td>
<td>Dr. Koichi Goto (Chair)</td>
</tr>
<tr>
<td>14:15</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>
8th Latin American Conference on Lung Cancer

Córdoba, Argentina
August 15-18, 2018

For more information, please visit www.iaslc.org.
SECTION 3

GENERAL CONFERENCE INFORMATION

Registration ........................................... 20
Press and Media .................................... 23
Information for Invited Faculty and Abstract Presenters 26
CME Accreditation Information .................. 28
Onsite Services and General Information ........ 31
REGISTRATION

REGISTRATION LOCATION AND HOURS

PACIFCO CONFERENCE CENTER,
LEVEL 2F

HOURS OF OPERATION

<table>
<thead>
<tr>
<th>Day</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, October 14</td>
<td>14:00 – 18:00</td>
</tr>
<tr>
<td>Sunday, October 15</td>
<td>07:00 – 20:00</td>
</tr>
<tr>
<td>Monday, October 16</td>
<td>06:30 – 16:00</td>
</tr>
<tr>
<td>Tuesday, October 17</td>
<td>06:30 – 16:00</td>
</tr>
<tr>
<td>Wednesday, October 18</td>
<td>06:30 – 16:00</td>
</tr>
</tbody>
</table>

REGISTRATION MATERIALS

REGISTRATION MATERIALS INCLUDE:

- **Name Badge** including barcode which will provide access for any signed up scientific sessions and Opening Ceremony and Welcome Reception
- **Tickets** for IASLC Foundation Concert and Conference Dinner (if applicable)
- **Ribbons** (if applicable)
- **Program at a Glance**
  (not included in Accompanying Person Registration)
- **Abstract USB Stick**
  (not included in Accompanying Person Registration)

DELEGATE BAGS INCLUDE:

- **Printed Onsite Program**
  (only if printed version selected at time of registration)
- **Printed Abstract Book**
  (only if printed version selected at time of registration)
- **Abstract USB Stick**
- **Invitation Flyers** for Industry Supported Symposia
- **Additional Promotional Flyers** from Sponsors and Exhibitors
- **2016 Scientific Advance Article**
- **IASLC EGFR Atlas**
- **IASLC Information/Folder**
- **IASLC Lung Cancer News**

NAME BADGES

Delegates and guests are requested to wear their name badge at all times in order to participate in the Scientific Sessions, Networking Events and Exhibition.

DELEGATE HELP DESK

PACIFCO CONFERENCE CENTER,
LEVEL 2F

SUPPORTED BY

TOURS AND ACCOMMODATION DESK

PACIFCO CONFERENCE CENTER,
LEVEL 2F

SUPPORTED BY
ADVANCING CANCER CARE THROUGH INNOVATION

For more than 5 decades, Lilly Oncology has been dedicated to delivering innovative treatment approaches with the goal of improving the outcomes of people living with cancer. We are driven to accelerate the pace and progress of cancer care by developing a broad portfolio of therapies, including those tailored to unique patients and those that modulate the immune system.

For more information on all our clinical trials, visit Lilly.com.
The IASLC Foundation supports the education of fellows and young investigators who will be the next generation of lung cancer physicians and scientists.

Help others succeed

For more information visit: www.iaslc.org/foundation
PRESS AND MEDIA

PRESS AND MEDIA REGISTRATION AND ACCESS
Press and Media passes are issued to journalists, including photographers and freelance journalists, after providing proof of accreditation. Pre-registered Press and Media representatives are required to check in at the regular Registration Counters. Non-registered Press and Media representatives should proceed to the New Registration counter.

INTERVIEW POLICY
All interviews outside of press conferences must be arranged in advance with interviewees and must take place in IASLC approved and designated rooms. No last-minute or hallway interviews are permitted anywhere inside the conference facility. The IASLC provides designated complimentary interview rooms (Room 416 and 417) for up to two hours. Sign up is required (online via wc1c2017.iaslc.org/press-media/press-media/ or onsite in the Media Room, Room 421). For questions, please see the IASLC staff in the Media Room.

USE OF THE IASLC WCLC SCIENTIFIC PROGRAM CONTENT
Please be aware that the information and materials displayed and/or presented at all sessions of this meeting are the property of the IASLC World Conference on Lung Cancer. Members of the media are permitted to photograph or record and transmit/share any presentation’s slides without approval from the presenter and/or the IASLC unless explicitly forbidden. All information distributed must adhere to the IASLC’s embargo policy. Commercial firms cannot copy, photocopy, transform to electronic format, reproduce or distribute information or materials displayed at this meeting without the written permission of the International Association for the Study of Lung Cancer. Use of the WCLC/IASLC name and/or logo in any fashion by any commercial entity for any purpose is expressly prohibited without the express written permission of the International Association for the Study of Lung Cancer. Interviews conducted through photography, videotaping and audio recording are allowed for news coverage only in the following areas/events:
- Press Conferences
- Interview rooms
- Other designated locations
- Recording in common areas requires permission and/or an IASLC staff escort

COPYRIGHT
Reproduction of materials such as abstract data, posters, presentation slides, etc., requires first obtaining permission from the listed author(s) and/or presenter(s). Photography of sessions, trade show booths, event setup, etc. is prohibited by IASLC/WCLC. The WCLC has a designated staff photographer and can provide WCLC 2017 event photography for journalists who wish to run photos of the event in their given media. Please contact Becky Bunn, IASLC Public Relations Manager at Becky.Bunn@iaslc.org for any press and media related questions.

SOCIAL MEDIA POLICY
Organizations may use social media to disseminate news and information regarding abstracts being presented at the WCLC. All information distributed through social media channels must adhere to the IASLC’s embargo policy. Organizations promoting their research through Twitter are welcome to include the IASLC’s World Conference hashtag, #WCLC2017. Members of the media are permitted to photograph or record and transmit/share on any social media platform any presentation’s slides without approval from the presenter and/or the IASLC unless explicitly forbidden. Representatives from academic institutions are permitted to share slides, but not for the media to re-transmit. Only non-flash photography is allowed of slide presentations.

For complete guidelines and media policies please refer to the Conference website at wc1c2017.iaslc.org/press-media/press-media/
JOIN TODAY!
As an IASLC member, you will receive:

- Collaboration with a multidisciplinary global team of thoracic oncology experts and leaders
- Member access to the *Journal of Thoracic Oncology*, the premier journal in lung cancer, as well as the latest classification and staging publications
- Multidisciplinary education including the latest in ground-breaking research and treatment of thoracic malignancies

See us in the Exhibit Hall at Booth 2404 or at the IASLC Membership Booth at Registration | Apply at iaslc.org

FELLOWS, RESIDENTS AND TRAINEES MAY APPLY FOR A FREE, NON-VOTING FELLOW MEMBERSHIP!
November is Lung Cancer Awareness Month (LCAM), an annual, month-long initiative designed to raise awareness of lung cancer, cultivate hope amongst those affected by this disease and inspire action to help reduce the impact of lung cancer and increase the number of survivors throughout the world.

Now in its second year, the LCAM initiative is a unique effort that brings together more than 20 global non-profits that focus on thoracic cancers. The initiative unites the individual efforts of these groups around a set of common goals: to combat the stigma that surrounds lung cancer, showcase the diverse lives touched by this disease, and increase awareness for the recent scientific advances now making a real difference in the lives of lung cancer patients.

To help us fight the stigma and spread hope, we need patients, caregivers, physicians, and advocates alike to join in and take action. Share your story at lcam.org/share-your-story/, or visit our partner page to consider making a donation to one of our partner organizations working hard to fight lung cancer at lcam.org/partners/. For more information, please email Kristin.schultz@iaslc.org or visit lcam.org.
INFORMATION FOR INVITED FACULTY AND ABSTRACT PRESENTERS

DISCLOSURE INFORMATION

All invited speakers as well as oral and mini oral abstract presenters must include a slide with their financial disclosure information. Without a disclosure slide you will not be allowed to present!

PRESENTATION SLIDE TEMPLATE

All invited speakers as well as oral and mini oral abstract presenters are asked to use the IASLC/WCLC presentation slide template for their presentation.

REGISTRATION

INVITED FACULTY

'Invited Faculty' Registration Counter
(Session Chairs, Invited Speakers, Abstract Discussants)

ABSTRACT PRESENTERS

'Registered Delegate' Counter

NO FILE SUBMISSIONS WILL BE ACCEPTED IN THE SESSION ROOMS.

Computers are available to preview and upload presentations. Presenters should make sure all fonts appear as expected and all sound/video clips are working properly. The final version must be submitted to the Speaker Preview Center, no presentation submissions will be accepted in the Session Rooms.

SPEAKER PREVIEW CENTER

PACIFICO CONFERENCE CENTER, LEVEL 3F

Saturday, October 14  14:00 – 18:00
Sunday, October 15  07:00 – 20:00
Monday, October 16  06:30 – 17:30
Tuesday, October 17  06:30 – 17:30
Wednesday, October 18  06:30 – 16:30
**ORAL ABSTRACT PRESENTERS**

- You will have a total of **10 minutes**; **8 minutes of presentation**, followed by **2 minutes** time for questions from the audience. **Time limits will be strictly enforced.**
- You are asked to prepare a PPT Presentation with **maximum 10 slides** (not including title and disclosure slide).
- Please be in room for your session 10 minutes before the start time of the session. The Session Chairs will start and end strictly on time.
- **All presenters MUST include statement disclosing any conflict of interest related to your abstract as the first slide of your presentation.**

**MINI ORAL PRESENTERS**

- You will have a total of **5 minutes** (no Q&A). **Time limits will be strictly enforced.**
- Please be in room for your session 10 minutes before the start time of the session. The Session Chairs will start and end strictly on time.
- You are asked to prepare a PPT Presentation with **maximum 6 slides** (not including title and disclosure slide).
- **All presenters MUST include statement disclosing any conflict of interest related to your abstract as the first slide of your presentation.**

**POSTER PRESENTERS**

- **ALL POSTER PRESENTATIONS/BOARDS ARE LOCATED IN THE EXHIBIT HALL (HALL B + C)**

Each Poster Board is identified by a sign with the assigned Poster Number. The Poster Number corresponds with the pre-assigned Poster Number provided in your confirmation letter and printed in the Abstract Book and this Onsite Program.

**SUPPORTED BY**

P1: Poster Session 1  
Monday, October 16

P2: Poster Session 2  
Tuesday, October 17

P3: Poster Session 3  
Wednesday, October 18

**POSTER DISPLAY TIME**

<table>
<thead>
<tr>
<th></th>
<th>Monday – Wednesday</th>
<th>09:30 – 16:00</th>
</tr>
</thead>
</table>

**PRESENTERS IN ATTENDANCE**

<table>
<thead>
<tr>
<th></th>
<th>Monday – Wednesday</th>
<th>10:00 – 10:45</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>14:30 – 15:30</td>
</tr>
</tbody>
</table>

**POSTER PRINTING SERVICE**

If you have ordered to have your poster printed by the Conference at an additional charge, you may pick up your poster onsite.

**POSTER PICK UP**

- **PACIFICO EXHIBITION HALL, EXHIBIT HALL (HALL B + C)**

<table>
<thead>
<tr>
<th>Date &amp; Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday, October 16</td>
</tr>
<tr>
<td>Tuesday, October 17</td>
</tr>
<tr>
<td>Wednesday, October 18</td>
</tr>
</tbody>
</table>
CME ACCREDITATION INFORMATION

FINANCIAL/COMMERCIAL RELATIONSHIPS & COI DISCLOSURES

All official Conference sessions will be accredited except for the Poster Sessions, Hands-On Training Sessions, and Industry Supported Symposia.

All individuals able to influence or control content of any CME certified activity that will be presented were required to complete an electronic Financial Relationships/Conflicts of Interest Disclosure Form prior to the Conference. In addition, abstract submitters provided disclosure information for all co-authors at the time of abstract submission.

Individuals who refused to disclose relevant financial relationships were eliminated from presenting at the Conference.

Definition of Conflicts of Interest: www.acmec.org/requirements/accreditation-requirements-cme-providers/policies-and-definitions-definition-commercial-interest

All commercial relationships and conflicts of interest were identified and thoroughly vetted by the IASLC Ethics Committee, CME Subcommittee, Education Committee and/or an independent reviewer. COI was evaluated by the Board of Directors of the IASLC for fair balance, scientific and editorial objectivity of studies utilized in this activity, and patient care recommendations. IASLC CME is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial entity.

All non-FDA approved uses of products must be clearly identified. Disclosures may be made in form of a slide, printed material, or oral statement. Each presenter should reveal his/her disclosure information during his/her presentation with the visual aid of a slide.

HOW TO RECEIVE CME CREDIT

A Conference electronic evaluation form will be emailed to learners after the Conference. Participants that wish to receive CME credits will have to complete the online evaluation form in order to receive their CME certificate. CME credits will only be provided for the sessions that learners are scanned in for. The CME certificate will be ready for you to print or save upon completion. This information is used not only to evaluate the present activity, but also to plan for future programs.

Your opinion is very valuable! Thank you for your participation.

Your opinion is very valuable! Thank you for your participation.

CREDIT STATEMENT

IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACME) to provide continuing medical education for physicians.

IASLC designates this live activity for a maximum of 21 AMA PRA Category 1 Credits™. Physicians will receive credits based on the sessions they attended and were scanned for. Ensure that you get your badge scanned when going into a session!

GOAL & PURPOSE

The WCLC is an educational and scientific event which, due to its multidisciplinary nature, will cover all aspects of the management of lung cancers, mesothelioma, thymic and other thoracic malignancies.

Participants will learn about tobacco control and smoking cessation programs and how to implement them in their daily practice. Participants will update their knowledge on early detection and screening.

The Conference will provide lectures on accurate diagnosis, including molecular diagnosis, state-of-the-art treatment of thoracic malignancies, and recent diagnostic and therapeutic advances. Participants will learn about palliative care and its implementation in daily practice.

Participants will be informed about the possibilities for continuous medical education. They will learn about clinical trial designs and how to become successful investigators of co-operative research groups. The Conference will also allow participants to be better informed about patient support and advocacy groups.

Overall, the participants of the WCLC will benefit in regard to learning the best clinical practice in the area of lung cancer and other thoracic malignancies.

TARGET AUDIENCE

This CME live Conference is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists, advanced practice nurses, and physician assistants.

LEARNING OBJECTIVES

At the end of the Conference the attendee will be able to:

- Identify effective global lung cancer prevention strategies.
- Improve their ability to participate in tobacco control and smoking cessation programs.
- Recognize the current approaches and strategies for early detection and screening of lung cancer.
- Demonstrate the best methods to implement multi-disciplinary tumor boards into community practices.
- Examine evidence-based therapeutic regimens for early stage and locally advanced NSCLC.
- Distinguish evidence-based therapeutic regimens for metastatic NSCLC based on biomarker status and patient/tumor characteristics.
- Define best practices regarding the application of targeted therapies for metastatic NSCLC in frontline and then subsequent settings following acquired resistance to the targeted therapy.
- Describe current and emerging immunotherapy strategies in the context of clinical trials findings and patient selection in metastatic NSCLC.
- Integrate clinical data on maintenance therapy in NSCLC to determine which patients would benefit most from a maintenance regimen.
- Review the clinical significance of optimal biopsy, specimen flow and molecular testing for personalized medicine in non-academic settings.
- Illustrate the molecular pathways that hold promise for therapeutic intervention.
- Outline current therapeutic approaches for limited and extensive small cell lung cancer (SCLC).
- Describe current therapeutic approaches for patients with mesothelioma and thymoma.
- Predict optimal and best practice approaches for supportive and palliative care of patients with thoracic cancers.
- Evaluate the support and survivorship resources available for lung cancer patients and their families.
- Illustrate important aspects of clinical trial design and master protocols.
- Explain to more junior investigators and students on research and technology advances, and encourage them to initiate investigations in lung cancer research.

OFFICIAL LANGUAGE

The official language of the IASLC 18th World Conference on Lung Cancer is English.

DISCLAIMER

The information presented at the IASLC 18th World Conference on Lung Cancer is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Visit the IASLC’s Social Media Corner on Level 3F of the Conference Center & Join the Conversation!

- View live feeds from Twitter, Facebook and Instagram
- Take your photo in front of our special Mt. Fuji backdrop
- Pin your country on our world map
- Learn how to post on social media
- Get your free gift

#WCLC2017
RESEARCH GRANT

The International Association for the Study of Lung Cancer (IASLC) and Free ME From Lung Cancer (FMFLC) are proud to announce a Joint Fellowship Award for the Early Detection of Lung Cancer.

US$200,000 (US $100,000 per year for two years)

APPLICATION DEADLINE
OCTOBER 31, 2017

For guidelines and application, please visit www.IASLC.org. Questions? E-mail: Pia.Hirsch@iaslc.org.
Download the free IASLC WCLC 2017 mobile app for a convenient way to stay up-to-date via your phone or tablet. View the full scientific schedule, abstracts, exhibit information including floor plan and exhibitor company descriptions, and general Conference and venue information on our easy to use app!

The app is compatible with all iOS devices (iPhone, iTouch and iPad) and all Android mobile devices. Timely updates on program or room changes will be distributed through the mobile app via notification alerts.

All audio and webcast recordings including presentations, abstracts and electronic versions of most posters will be available in the Virtual Meeting within 24 hours. Check your name badge for login details.

For the first time, the IASLC will have a Social Media Corner to assist and encourage attendees to use and follow social media throughout the Conference.

Plan to stop by the IASLC Social Media Corner on Level 3F of the PACIFICO Conference Center (at the top of the escalators) as often as you like during the Conference — there will always be something going on. Not social media savvy? No problem. We’re here to help!

Here’s what’s happening:
- View live feeds from Twitter, Instagram and Facebook
- Take your photo in front of our special Mt. Fuji backdrop
- Pin your country on our world map
- Learn how to post on social media
- Get your free gift

IASLC SOCIAL MEDIA ACCOUNTS TO FOLLOW:
- @iaslc
- facebook.com/iaslc
- laslc.lung

CONFERENCE HASHTAG: 
#WCLC2017
ABSTRACTS

Abstracts selected for IASLC WCLC are presented in Oral, Mini Oral and Poster Sessions. The top 3 abstracts are presented in the Presidential Symposium on Tuesday, October 17, 08:15–09:45.

All accepted and confirmed abstracts are published in a supplement of the Journal of Thoracic Oncology, which will be posted online on the JTO website in December 2017.

All accepted and confirmed abstracts except for those included in Press Releases and/or Press Conferences are also available on the Abstract USB Stick which is handed out along with your delegate bag. If you requested a printed version of the Abstract Book, please pick it up along with your delegate bag.

ABSTRACTS ONLINE

Attendees are invited to view the abstracts in the virtual meeting available on the Conference website. The virtual meeting allows searching for abstracts, topics, presenters, sessions and keywords, selecting abstracts of interest and building your own personal conference calendar. It is free for all WCLC delegates.

GET THE WCLC 2017 VIRTUAL MEETING AT

library.iaslc.org

All accepted abstracts are also included in the WCLC 2017 Mobile App.

ACCREDITATION

See CME Accreditation and CME Certificate

ATTIRE

Business casual is appropriate for all sessions and networking events. Room temperature can vary in session rooms. We encourage attendees to dress in layers for their personal comfort.

ATM

7-ELEVEN STORE, LEVEL 2F PACIFICO EXHIBITION HALL

An ATM is located in the 7-Eleven store on Level 2F in the PACIFICO Exhibition Hall.

BAGGAGE CHECK

PACIFICO CONFERENCE CENTER, LEVEL 1F

See Coat and Baggage Check

BREAKFAST

The Conference does NOT provide breakfast unless otherwise indicated in the program.

BUSINESS CENTER

Delegates may use the two Business Centers, located at PACIFICO.

Opening Hours 09:00 – 18:00

Exhibition Hall

LEVEL 2F (OUTSIDE HALL B, ROOM B14)

Conference Center

LEVEL 1F (SELF SERVICE CENTER)

CELL PHONES

As a courtesy to fellow attendees, please turn off cell phones during scientific sessions.
CERTIFICATE OF ATTENDANCE

International attendees can request a ‘Certificate of Attendance’ by completing the Conference evaluation form available on the Conference website at the conclusion of the Conference. After completing the evaluation form you will be able to download your Certificate of Attendance.

CHARGING STATIONS

Charging Stations are located in the Exhibit Hall (Hall B + C) allowing delegates to power up their cell phones, laptops and other electronic devices for free.

CME ACCREDITATION AND CME CERTIFICATE

This activity is planned for 21 AMA PRA Category 1 Credit(s)™. Please see page 28 in this book for further information.

International attendees can request a ‘CME Certificate’ by completing the Conference evaluation form available on the Conference website at the conclusion of the Conference. After completing the evaluation form you will be able to download your CME Certificate.

Delegates will only receive credits for the sessions they actually attended and were scanned for. Ensure that you get your badge scanned when going into a session!

COAT AND BAGGAGE CHECK

A coat and baggage check will be available at PACIFICO Conference Center.

CONVENIENCE STORES

7-Eleven Store

Daily YAMAZAKAI

English speaking staff are available at both stores.

DELEGATE LOUNGES

Delegate Lounges are available and located in the Exhibit Hall (Hall B + C). These lounges are specifically designed to provide a comfortable seating area for delegates to rest, conduct brief meetings or network with colleagues.
FOREIGN CURRENCY EXCHANGE

7-ELEVEN, DAILY YAMAZAKI | EXHIBITION HALL LEVEL 2F
INTERCONTINENTAL HOTEL | 2ND FLOOR

You can withdraw Japanese Yen with international credit cards at the ATM in the 7-Eleven and the Daily YAMAZAKI store. There is also a foreign currency exchange machine on the 2nd floor of the Intercontinental Hotel.

IASLC

Business Meeting

ANNEX HALL F201 + F202

Monday, October 16 14:30 – 15:30

All IASLC Members are invited to attend the IASLC Business Meeting. Light refreshments will be provided. IASLC WCLC Travel and Advocacy Award Winners will be presented with their awards.

IASLC Booth

Please visit the IASLC Booth (#2404) in the Exhibit Hall (Hall B + C) for updates on membership, society-sponsored meetings and events, the IASLC Foundation, JTO and general information.

For membership inquiries you can also visit the IASLC membership counter in the registration area on Level 2F of the Conference Center.

IASLC Social Media Corner

Please visit the IASLC Social Media Corner on Level 3F of the Conference Center and share your WCLC experience with us.

INTERNET CAFÉ

SUPPORTED BY

EXHIBIT HALL (HALL B + C)

Keep in touch with home and office! The Internet Café is located in the Exhibit Hall (Hall B + C) adjacent to the Exhibit Showcase Theater. Computers with internet and printers are available to delegates on a complimentary basis. The Internet Café is open during Exhibit Hall Hours. Internet sessions are limited to 15 minute per delegate.

LOCKERS

Coin operated lockers (small, medium, large) are available and located in seven places at PACIFICO Yokohama.

CONFERENCE CENTER, LEVEL 1F ENTRANCE
SMALL | JPY300/DAY

CONFERENCE CENTER, LEVEL 2F ENTRANCE
SMALL, MEDIUM, LARGE | JPY300-600/DAY

EXHIBITION HALL, LEVEL 1F, IN FRONT OF EXHIBIT HALL (HALL B)
MEDIUM, LARGE, VERY LARGE | JPY400-600/DAY

EXHIBITION HALL, LEVEL 1F, IN FRONT OF EXHIBIT HALL (BETWEEN HALL B AND C)
SMALL, MEDIUM, LARGE | JPY300-500/DAY

EXHIBITION HALL, LEVEL 1F, IN FRONT OF PLENARY HALL (HALL D)
SMALL, LARGE | JPY300-500/DAY

EXHIBITION HALL, LEVEL 2F, IN FRONT OF GATE 1
SMALL, LARGE | JPY300-500/DAY

ANNEX HALL, LEVEL 2F
SMALL, LARGE | JPY300-500/DAY

LOST AND FOUND

PACIFICO CONFERENCE CENTER, LEVEL 2F

Lost and found items should be returned/claimed at the Delegate Help Desk.

MEDIA ROOM

PACIFICO CONFERENCE CENTER LEVEL 4F, ROOM 421

Wireless internet and a copier are available. Please see page 23 in this book for further information.
NEWSPAPER

A daily Conference Newspaper will be available from Sunday to Wednesday at no charge to Conference delegates. The Newspaper will be distributed at various points at PACIFICO. A PDF version of each edition will also be available on the Conference website and the Mobile App.

PARKING

MINATO MIRAI PARKING LOT (PACIFICO EXHIBITION HALL)

The cost of Minato Mirai Parking Lot (PACIFICO Exhibition Hall) is as follows:

WEEKDAY PARKING | JPY1,350, FROM 07:00–24:00
WEEKEND PARKING | JPY1,850, FROM 07:00–24:00

POSTERS ONLINE

All abstracts accepted for poster presentation will be presented as traditional printed posters to be displayed on poster boards in the Exhibit Hall (Hall B + C). In addition to the printed poster, each presenter is required to submit an electronic version of their poster to be made available in the Virtual Meeting (library.iaslc.org), which is free of charge to all delegates.

PRESS

Please see page 23 in this book for further information.

RESTAURANTS

There are plenty of restaurants choices in Yokohama and Tokyo. The staff at the Delegate Help Desk will be happy to assist with recommendations and bookings.

The mall across from PACIFICO and the Intercontinental Hotel provides a great variety of restaurants and food courts.

SHIPPING

PACIFICO LOGISTICS CENTER, LOCATED ON LEVEL 2F IN THE PACIFICO EXHIBITION HALL

The PACIFICO Logistics Center can assist with shipping needs and baggage deposit services.

SMOKING

Smoking is prohibited in all areas of the PACIFICO Yokohama.

SPEAKER PREVIEW CENTER

All Presenters are required to submit and/or preview their slides at least 24 hours prior to their scheduled presentation to ensure compatibility with the Conference AV Equipment.

PACIFICO CONFERENCE CENTER, LEVEL 3F

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, October 14</td>
<td>14:00 – 18:00</td>
</tr>
<tr>
<td>Sunday, October 15</td>
<td>07:00 – 20:00</td>
</tr>
<tr>
<td>Monday, October 16</td>
<td>06:30 – 17:30</td>
</tr>
<tr>
<td>Tuesday, October 17</td>
<td>06:30 – 17:30</td>
</tr>
<tr>
<td>Wednesday, October 18</td>
<td>06:30 – 16:30</td>
</tr>
</tbody>
</table>

PUBLIC TRANSPORTATION

We strongly recommend that you take public transportation whenever possible. Yokohama/Tokyo has one of the most modern and efficient public transportation networks. For assistance, please visit the Delegate Help Desk in the PACIFICO Conference Center, Level 2F.
VIRTUAL MEETING

All oral sessions are recorded (slides and audio) and will be made available as a Virtual Meeting through the IASLC Virtual Library within 24 hours.

The WCLC 2017 Virtual Meeting is included in your registration and can be accessed through library.iaslc.org.

Your personal Virtual Meeting Access Code is the same as your Delegate ID Number and can be found on your badge or through your WCLC 2017 confirmation email. After you enter your Access Code and confirm your account details, you’ll be able to view any presentations that have been marked as “Now Available”.

To start viewing, please visit: library.iaslc.org.

WIRELESS INTERNET

SUPPORTED BY Lily Oncology

WCLC is providing free Wi-Fi throughout the PACIFICO Yokohama. To ensure a positive Wi-Fi experience for all users please do not use your own wireless Hotspot device. These additional Wi-Fi devices create significant RF interference which can interfere with all Wi-Fi networks. Please turn these devices off and connect to the Wi-Fi network WCLC and open your web browser to connect to the Internet.

To connect to the Wi-Fi, connect to the network FREE-PACIFICO Wi-Fi and open the browser for internet access.

WATER STATIONS

SUPPORTED BY Lily Oncology

Water stations will be placed throughout PACIFICO Yokohama.

DISCLAIMER

The organizers have made every attempt to ensure that all information in this publication is correct. The organizers take no responsibility for changes to the program or any loss that may occur as a result of changes to the program. Some of the information provided in this publication has been provided by external sources. Although every effort has been made to ensure the accuracy, currency and reliability of the content, the organizers accept no responsibility in that regard.
EXHIBIT INFORMATION

PACIFICO EXHIBITION HALL, HALL B + C

All day refreshments and light snacks will be served in the Exhibit Hall throughout opening hours.

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday, October 16</td>
<td>09:30 – 16:00</td>
</tr>
<tr>
<td>Tuesday, October 17</td>
<td>09:30 – 16:00</td>
</tr>
<tr>
<td>Wednesday, October 18</td>
<td>09:30 – 16:00</td>
</tr>
</tbody>
</table>

EXHIBIT FEATURES

- Exhibit Information Booth with
  - Information Desk
  - Show Service Provider Desk
  - Poster Pick Up Counter
- Publication table for promotional materials or related events and organizations
- Internet Stations (attached to Showcase Theater)
- Charging Stations
- Food & Beverage Stations
- Barista Coffee Stations
- Delegate Lounges
- Patient Advocacy Lounge
- Exhibit Showcase Theater
- Not for Profit Pavilion
- Publisher’s Corner

EXHIBIT SHOWCASE SESSIONS

Monday, October 16 13:00 - 14:00

EXH 01: THERMO FISHER: NEXT GENERATION SEQUENCING – CHANGING PARADIGM IN NSCLC PATIENT MANAGEMENT

As number of targeted therapies in NSCLC is rapidly increasing, simultaneous testing for multiple biomarkers is becoming progressively important to ensure a timely diagnosis and start of treatment. Next Generation Sequencing (NGS) technology has been significantly advancing cancer research for some time and now is finally ready for a daily routine patient testing

Objective of this session is to

- Explain basic science and principle of NGS and its application in NSCLC patient testing
- Introduce the first NGS in vitro diagnostic (IVD) test for NSCLC, simultaneously delivering multiple biomarker results for multiple targeted therapies – Oncomine Dx Target Test
- Give forum for multiple stakeholders – clinicians, laboratories and patients - discussion

Tuesday, October 17 10:00 - 10:30

EXH 02: ASTRAZENECA: THE ROLE OF PD-L1 IN TREATMENT DECISION MAKING FOR NSCLC PATIENTS

Agenda

1. Current Therapy Landscape in NSCLC
2. Identifying The Right Patient For IO: The Choice of Test | The Importance of the Algorithm
3. Optimising the Sample Testing Journey
4. What’s Next for Precision Medicine in NSCLC

POSTER SESSIONS

All poster presentations have been assigned a consecutive publication number for locating the abstract/poster in this brochure, the Abstract Book and the Poster Boards in the Exhibit Hall (Hall B + C).

POSTER PICK UP COUNTER

Poster Presenters who had their poster printed by the Conference, can pick up their poster at the Poster Pick Up Counter at the Exhibit Information Booth in the Exhibit Hall during the following times:

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday, October 16</td>
<td>08:00 – 16:00</td>
</tr>
<tr>
<td>Tuesday, October 17</td>
<td>08:00 – 16:00</td>
</tr>
<tr>
<td>Wednesday, October 18</td>
<td>08:00 – 10:30</td>
</tr>
</tbody>
</table>

POSTERS ONLINE

All abstracts accepted for poster presentation will be presented as traditional printed posters to be displayed on poster boards in the Exhibit Hall (Hall B + C). In addition to the printed poster, each presenter is required to submit an electronic version of their poster to be made available in the Virtual Meeting (library.iaslc.org), which is free of charge to all delegates.
### BY EXHIBITOR

<table>
<thead>
<tr>
<th>COMPANY NAME</th>
<th>BOOTH #</th>
</tr>
</thead>
<tbody>
<tr>
<td>AbbVie</td>
<td>1304</td>
</tr>
<tr>
<td>AME Publishing Company</td>
<td>1212</td>
</tr>
<tr>
<td>Amoy Diagnostics Co., Ltd.</td>
<td>2010</td>
</tr>
<tr>
<td>AstraZeneca</td>
<td>105</td>
</tr>
<tr>
<td>Boehringer Ingelheim International GmbH</td>
<td>1300</td>
</tr>
<tr>
<td>Bristol-Myers Squibb (BMS)</td>
<td>804</td>
</tr>
<tr>
<td>Bruker</td>
<td>1713</td>
</tr>
<tr>
<td>Celgene Corporation</td>
<td>808</td>
</tr>
<tr>
<td>EIT Health LUCINDA: AI &amp; Lung Cancer</td>
<td>1114</td>
</tr>
<tr>
<td>F. Hoffmann - La Roche</td>
<td>2400</td>
</tr>
<tr>
<td>Global Lung Cancer Coalition (GLCC)</td>
<td>1112</td>
</tr>
<tr>
<td>Guardant Health, Inc.</td>
<td>2008</td>
</tr>
<tr>
<td>IASLC</td>
<td>2404</td>
</tr>
<tr>
<td>International Thoracic Oncology Nursing Forum (ITONF)</td>
<td>615</td>
</tr>
<tr>
<td>Korean Association for Lung Cancer (KALC)</td>
<td>1113</td>
</tr>
<tr>
<td>Lilly Oncology</td>
<td>100</td>
</tr>
<tr>
<td>Median Technologies</td>
<td>2009</td>
</tr>
<tr>
<td>MSD</td>
<td>1704</td>
</tr>
<tr>
<td>Novartis</td>
<td>800</td>
</tr>
<tr>
<td>PANAGENE Inc.</td>
<td>1812</td>
</tr>
<tr>
<td>Peregrine Pharmaceuticals</td>
<td>1712</td>
</tr>
<tr>
<td>Pfizer Oncology</td>
<td>1308</td>
</tr>
<tr>
<td>Polish Lung Cancer Group - Polska Grupa Raka Pluca</td>
<td>616</td>
</tr>
<tr>
<td>Sanomics Limited</td>
<td>1813</td>
</tr>
<tr>
<td>Scanlan International, Inc.</td>
<td>2308</td>
</tr>
<tr>
<td>Takeda Oncology</td>
<td>1900</td>
</tr>
<tr>
<td>Thermo Fisher Scientific</td>
<td>2411</td>
</tr>
</tbody>
</table>

### BY BOOTH NUMBER

<table>
<thead>
<tr>
<th>BOOTH #</th>
<th>COMPANY NAME</th>
</tr>
</thead>
<tbody>
<tr>
<td>100</td>
<td>Lilly Oncology</td>
</tr>
<tr>
<td>105</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>615</td>
<td>International Thoracic Oncology Nursing Forum (ITONF)</td>
</tr>
<tr>
<td>616</td>
<td>Polish Lung Cancer Group - Polska Grupa Raka Pluca</td>
</tr>
<tr>
<td>800</td>
<td>Novartis</td>
</tr>
<tr>
<td>804</td>
<td>Bristol-Myers Squibb (BMS)</td>
</tr>
<tr>
<td>808</td>
<td>Celgene Corporation</td>
</tr>
<tr>
<td>1112</td>
<td>Global Lung Cancer Coalition (GLCC)</td>
</tr>
<tr>
<td>1113</td>
<td>Korean Association for Lung Cancer (KALC)</td>
</tr>
<tr>
<td>1114</td>
<td>EIT Health LUCINDA: AI &amp; Lung Cancer</td>
</tr>
<tr>
<td>1212</td>
<td>AME Publishing Company</td>
</tr>
<tr>
<td>1300</td>
<td>Boehringer Ingelheim International GmbH</td>
</tr>
<tr>
<td>1304</td>
<td>Abbvie</td>
</tr>
<tr>
<td>1308</td>
<td>Pfizer Oncology</td>
</tr>
<tr>
<td>1704</td>
<td>MSD</td>
</tr>
<tr>
<td>1712</td>
<td>Peregrine Pharmaceuticals</td>
</tr>
<tr>
<td>1713</td>
<td>Bruker</td>
</tr>
<tr>
<td>1812</td>
<td>PANAGENE Inc.</td>
</tr>
<tr>
<td>1813</td>
<td>Sanomics Limited</td>
</tr>
<tr>
<td>1900</td>
<td>Takeda Oncology</td>
</tr>
<tr>
<td>2008</td>
<td>Guardant Health, Inc.</td>
</tr>
<tr>
<td>2009</td>
<td>Median Technologies</td>
</tr>
<tr>
<td>2010</td>
<td>Amoy Diagnostics Co., Ltd.</td>
</tr>
<tr>
<td>2308</td>
<td>Scanlan International, Inc.</td>
</tr>
<tr>
<td>2400</td>
<td>F. Hoffmann - La Roche</td>
</tr>
<tr>
<td>2404</td>
<td>IASLC</td>
</tr>
<tr>
<td>2411</td>
<td>Thermo Fisher Scientific</td>
</tr>
</tbody>
</table>
AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook or LinkedIn.

AME publishes over 40 peer-reviewed journals, including Journal of Thoracic Disease (JTD), Translational Cancer Research (TCR), Translational Lung Cancer Research (TLCR), Annals of Translational Medicine (ATM), as well as a series of books including Lung Cancer, Lung Cancer Precision Medicine, Art of Operative Techniques, Video-Assisted Thoracic Surgery, The Robotic Thoracic Surgery. During this period, AME has established editorial offices in Hong Kong, Guangzhou, Changsha, Nanjing, Shanghai, Beijing, Chengdu, Taipei, and Sydney. AME represents “Academic Made Easy, Excellent and Enthusiastic”. “Patients come first” is the core value of AME.

Amoy Diagnostics Co., Ltd. is an R&D based provider of state-of-the-art diagnostic products and services in area of human oncology personalized healthcare. We have a rich portfolio of tests that focuses on detecting mutations and measuring gene expression in various samples including FFPE cancer tissue, body fluids & whole blood.

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Through scientific innovation and collaboration, Boehringer Ingelheim is committed to discovering and developing novel anti-cancer agents that address unmet needs across a broad range of solid and hematological malignancies. Approved agents are for specific NSCLC sub-types and the oncology portfolio is supported by a strong early pipeline. As part of our unique research approach, we seek out strong partnerships and remain dedicated to delivering treatments that improve cancer patients’ lives.

Bristol-Myers Squibb is a global BioPharma company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Around the world, our medicines help millions of people in their fight against such diseases as cancer, cardiovascular disease, hepatitis B and hepatitis C, HIV/AIDS and rheumatoid arthritis. The Bristol-Myers Squibb Foundation’s philanthropic programs seek to promote health equity and improve the health outcomes among populations disproportionately affected by serious diseases and conditions, giving new hope to some of the world’s most vulnerable people.

Offering the largest range of Preclinical Imaging systems, Bruker is committed to supporting the scientific community with high-end instruments dedicated to disease research, translational science and Molecular Imaging. Our non-invasive in-vivo imaging modalities are designed to deliver greater scientific insight based on animal-centric solutions.

Bruker offers advanced preclinical imaging solutions for a broad spectrum of application areas, such as oncology, neurology, cardiology, inflammation, infectious diseases, functional and anatomical neuroimaging, orthopedics, cardiac imaging and stroke models. Our range of imaging modalities includes PET/SPECT/CT Imaging, MRI, PET/MRI Imaging and microCT imaging.
Celgene Corporation is a global biopharmaceutical company that is helping healthcare providers turn incurable cancers into chronic, manageable diseases, as well as manage serious inflammatory conditions through innovative therapies. This dedication to medical progress goes hand-in-hand with our industry-leading patient support and access programs.

LUCINDA project (Oxford, Groningen, Heidelberg & Optellum) is developing the world’s first image-based risk stratification software for incidental and screen detected nodules for CT.

Visit our exhibit to:
- Learn about image-based nodule risk stratification
- Understand the real benefit of Deep Learning
- See the prototype & get involved in product development and trials.

For more information, visit: www.optellum.com/eit-health-lucinda.

The Global Lung Cancer Coalition promotes global understanding of the burden of lung cancer and the right of patients to effective early detection, better treatment and supportive care. Serving as the international voice of lung cancer patients, the Global Lung Cancer Coalition is committed to improving disease outcomes for all.

Guardant Health is focused on conquering cancer by using its breakthrough blood-based assays, vast data sets, and advanced analytics. Using both molecular and digital tools, Guardant Health is addressing challenges across the cancer care continuum. The company has raised more than $500 million from leading investors. Its first product, the Guardant360 assay, came to market in 2014, and is now the most widely ordered comprehensive liquid biopsy commercially available.

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association’s membership includes nearly 7,000 lung cancer specialists in over 100 countries. IASLC members work to enhance the understanding of lung cancer among scientists, members of the medical community and the public. IASLC publishes the Journal of Thoracic Oncology, a valuable resource for medical specialists and scientists who focus on the detection, prevention, diagnosis and treatment of lung cancer.

International Thoracic Oncology Nursing Forum is a global group of nurses with a mission to promote and support excellence in Thoracic Oncology Nursing. ITONF leads the International Thoracic Oncology Nursing community in evidence-based thoracic cancer care in an effort to improve outcomes for thoracic oncology patients and reduce the burden of thoracic cancers globally.

The Korean Association for Lung Cancer (KALC) is the only academic association in Korea dedicated to the study of lung cancer. KALC promotes multi-disciplinary approach and collaboration among physicians and scientists, and advocates for the rights of lung cancer patients.

For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. To learn more about Lilly’s commitment to people with cancer, please visit www.LillyOncology.com.
Since 2002, Median has been doing one thing and one thing only — expanding the boundaries of the identification, interpretation, analysis and reporting of imaging data in the medical world. Median is at the heart of innovative imaging solutions with our oncology-focused Lesion Management Solution (LMS) software and iBiopsy® for imaging phenotyping. These software, together with our global team of imaging experts, are advancing development of treatments and the monitoring and diagnosing of patients with cancer — it’s a smart blend of technology, science and service. We empower healthcare, pharma, biotech and medical device companies with the most meaningful information about their patients and treatments so we can all help people with their health challenges. This is how we are helping to create a healthier world.

For 125 years, MSD has been a global health care leader working to help the world be well. MSD is a tradename of Merck & Co., Inc., Kenilworth, N.J., USA. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. For more information, visit www.msd.com.

Novartis Oncology is a global leader in transforming outcomes for people with cancer. Our research is driven by a distinctive scientific and clinical strategy focused on precision oncology—understanding how cancer develops on a genomic level and developing drugs that hone in on those targets. For more information, visit www.novartisoncology.com.

PANAGENE is the exclusive PNA and PNA based molecular diagnostic reagent provider. Real-time PCR based PANAGENE kits facilitate more reliable MDx tests in short time in your site directly. PANAGENE’s EGFR, KRAS, EML4-ALK, ROS1 kits provide the diagnostic solution for the patients in lung cancer in high sensitivity and specificity.

Peregrine Pharmaceuticals is committed to improving the lives of patients by manufacturing high quality products for biotechnology and pharmaceutical companies, as well as advancing and licensing investigational immunotherapy and related products. The company is evaluating its lead clinical immunomodulatory candidate, bavituximab, in multiple combination therapy oncology trials.

Pfizer Oncology is committed to pursuing innovative treatments that are helping to redefine life with cancer. As an oncology leader with one of the most robust oncology pipelines in the industry, we are focused on translating scientific pipelines into clinical application. Additionally, we are dedicated to working collaboratively with the community to make a positive impact on people’s lives. www.pfizer.com

Polish Lung Cancer Group – PolGRP multidisciplinary association established in 2002. Its primary role is didactic and educational equally spreading lung cancer knowledge in Poland. Every year in November organizes annual conference with IASLC accreditation also awarded to “Best of WCLC” meeting. Its Lung Cancer Registry contains above 30,000 records.

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare — a strategy that aims to fit the right treatment to each patient in the best way possible.
Sanomics is a pioneering genomics technology company based in Hong Kong. Using a new generation of proprietary technologies, Sanomics offers blood-based liquid biopsy for cancer patients. Genomics biomarker is essential to personalized management of cancer. Presence or absence of the abnormal mutations will help physicians to determine the treatment strategy.

Highest quality surgical products designed and manufactured by the Scanlan family since 1921. Titanium and stainless steel instrument designs including Scanlan® LEGACY needle holders and forceps, and Super Cut™ Scissors. Full line Scanlan® VATS instruments including D'Amico Clamps, Suctions, Biopsy Forceps, Gonzalez-Rivas Dissector, Rocco Nodule Clamps and Khan Decortication Grasper.

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.

Thermo Fisher Scientific Inc. is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. For more information, please visit www.thermofisher.com.

Innovative Oncology

Down through the millennia, marine organisms have evolved a range of substances with biological activity that they use for survival, defense, attack and communication. These substances hold great promise for the development of new drugs.

Our commitment to patients and to research has made PharmaMar a world leader and the first Spanish Company to have compounds in all the different phases of development up to market.

4 compounds in different stages of clinical development

30 clinical trials ongoing

72,3 million euros invested in R&D in 2016

8 affiliates in Europe and USA

80 countries with a commercial presence

www.pharmamar.com
IASLC AND CONFERENCE AWARDS

IASLC Distinguished Award Winners 46
IASLC Fellowship Award Winners 49
IASLC Academy Award Winners 49
IASLC International Mentorship Award Winners 50
WCLC 2017 Young Investigator Award Winners 51
WCLC 2017 Developing Nation Award Winners 52
IASLC/WCLC 2017 Patient Advocacy Award Winners 53
2017 Nurse and Allied Health Professional Award Winners 53
WCLC 2017 Lectureship Award Winners 54
IASLC DISTINGUISHED AWARDS

IASLC PAUL A. BUNN, JR. SCIENTIFIC AWARD

(FORMERLY IASLC SCIENTIFIC AWARD)

THE IASLC PAUL A. BUNN, JR. SCIENTIFIC AWARD IS GIVEN TO AN IASLC SCIENTIST FOR LIFETIME SCIENTIFIC CONTRIBUTIONS IN THORACIC MALIGNANCY RESEARCH AND WHO HAS ALSO CONTRIBUTED TO THE ORGANIZATION’S DEVELOPMENT.

Prof. Tony S. K. Mok was trained at the University of Alberta, Canada and he subsequently completed a fellowship in medical oncology at the Princess Margaret Hospital in Canada. After working as a community oncologist in Toronto, Canada for seven years, he returned to Hong Kong in 1996 to pursue an academic career.

He is Li Shu Fan Medical Foundation Named Professor of Clinical Oncology and Chairman of Clinical Oncology at The Chinese University of Hong Kong, Hong Kong. His main research interest focuses on biomarker and molecular targeted therapy in lung cancer. He co-founded the Lung Cancer Research Group, and has led a number of important multinational clinical trials, which include the IPASS (IRESSA Pan-Asia Study), a landmark study that established the role of first-line gefitinib in patients with EGFR mutation.

Prof. Mok has contributed to over 200 articles in international peer-reviewed journals, including the New England Journal of Medicine, Science, Lancet and Journal of Clinical Oncology, and contributed to multiple editorials and textbooks. He is active and experienced in serving the academic societies. He is now Fellow of American Society of Clinical Oncology and Chairman of Clinical Oncology at The Chinese University of Hong Kong, Hong Kong. His main research interest focuses on biomarker and molecular targeted therapy in lung cancer. He co-founded the Lung Cancer Research Group, and has led a number of important multinational clinical trials, which include the IPASS (IRESSA Pan-Asia Study), a landmark study that established the role of first-line gefitinib in patients with EGFR mutation.

Prof. Mok has contributed to over 200 articles in international peer-reviewed journals, including the New England Journal of Medicine, Science, Lancet and Journal of Clinical Oncology, and contributed to multiple editorials and textbooks. He is active and experienced in serving the academic societies. He is now Fellow of American Society of Clinical Oncology and Chairman of Clinical Oncology at The Chinese University of Hong Kong, Hong Kong. His main research interest focuses on biomarker and molecular targeted therapy in lung cancer. He co-founded the Lung Cancer Research Group, and has led a number of important multinational clinical trials, which include the IPASS (IRESSA Pan-Asia Study), a landmark study that established the role of first-line gefitinib in patients with EGFR mutation.

Prof. Mok has contributed to over 200 articles in international peer-reviewed journals, including the New England Journal of Medicine, Science, Lancet and Journal of Clinical Oncology, and contributed to multiple editorials and textbooks. He is active and experienced in serving the academic societies. He is now Fellow of American Society of Clinical Oncology and Chairman of Clinical Oncology at The Chinese University of Hong Kong, Hong Kong. His main research interest focuses on biomarker and molecular targeted therapy in lung cancer. He co-founded the Lung Cancer Research Group, and has led a number of important multinational clinical trials, which include the IPASS (IRESSA Pan-Asia Study), a landmark study that established the role of first-line gefitinib in patients with EGFR mutation.

Prof. Mok has contributed to over 200 articles in international peer-reviewed journals, including the New England Journal of Medicine, Science, Lancet and Journal of Clinical Oncology, and contributed to multiple editorials and textbooks. He is active and experienced in serving the academic societies. He is now Fellow of American Society of Clinical Oncology and Chairman of Clinical Oncology at The Chinese University of Hong Kong, Hong Kong. His main research interest focuses on biomarker and molecular targeted therapy in lung cancer. He co-founded the Lung Cancer Research Group, and has led a number of important multinational clinical trials, which include the IPASS (IRESSA Pan-Asia Study), a landmark study that established the role of first-line gefitinib in patients with EGFR mutation.

Prof. Mok has contributed to over 200 articles in international peer-reviewed journals, including the New England Journal of Medicine, Science, Lancet and Journal of Clinical Oncology, and contributed to multiple editorials and textbooks. He is active and experienced in serving the academic societies. He is now Fellow of American Society of Clinical Oncology and Chairman of Clinical Oncology at The Chinese University of Hong Kong, Hong Kong. His main research interest focuses on biomarker and molecular targeted therapy in lung cancer. He co-founded the Lung Cancer Research Group, and has led a number of important multinational clinical trials, which include the IPASS (IRESSA Pan-Asia Study), a landmark study that established the role of first-line gefitinib in patients with EGFR mutation.

Prof. Mok has contributed to over 200 articles in international peer-reviewed journals, including the New England Journal of Medicine, Science, Lancet and Journal of Clinical Oncology, and contributed to multiple editorials and textbooks. He is active and experienced in serving the academic societies. He is now Fellow of American Society of Clinical Oncology and Chairman of Clinical Oncology at The Chinese University of Hong Kong, Hong Kong. His main research interest focuses on biomarker and molecular targeted therapy in lung cancer. He co-founded the Lung Cancer Research Group, and has led a number of important multinational clinical trials, which include the IPASS (IRESSA Pan-Asia Study), a landmark study that established the role of first-line gefitinib in patients with EGFR mutation.

Prof. Mok has contributed to over 200 articles in international peer-reviewed journals, including the New England Journal of Medicine, Science, Lancet and Journal of Clinical Oncology, and contributed to multiple editorials and textbooks. He is active and experienced in serving the academic societies. He is now Fellow of American Society of Clinical Oncology and Chairman of Clinical Oncology at The Chinese University of Hong Kong, Hong Kong. His main research interest focuses on biomarker and molecular targeted therapy in lung cancer. He co-founded the Lung Cancer Research Group, and has led a number of important multinational clinical trials, which include the IPASS (IRESSA Pan-Asia Study), a landmark study that established the role of first-line gefitinib in patients with EGFR mutation.

Prof. Mok has contributed to over 200 articles in international peer-reviewed journals, including the New England Journal of Medicine, Science, Lancet and Journal of Clinical Oncology, and contributed to multiple editorials and textbooks. He is active and experienced in serving the academic societies. He is now Fellow of American Society of Clinical Oncology and Chairman of Clinical Oncology at The Chinese University of Hong Kong, Hong Kong. His main research interest focuses on biomarker and molecular targeted therapy in lung cancer. He co-founded the Lung Cancer Research Group, and has led a number of important multinational clinical trials, which include the IPASS (IRESSA Pan-Asia Study), a landmark study that established the role of first-line gefitinib in patients with EGFR mutation.

Prof. Mok has contributed to over 200 articles in international peer-reviewed journals, including the New England Journal of Medicine, Science, Lancet and Journal of Clinical Oncology, and contributed to multiple editorials and textbooks. He is active and experienced in serving the academic societies. He is now Fellow of American Society of Clinical Oncology and Chairman of Clinical Oncology at The Chinese University of Hong Kong, Hong Kong. His main research interest focuses on biomarker and molecular targeted therapy in lung cancer. He co-founded the Lung Cancer Research Group, and has led a number of important multinational clinical trials, which include the IPASS (IRESSA Pan-Asia Study), a landmark study that established the role of first-line gefitinib in patients with EGFR mutation.

Prof. Mok has contributed to over 200 articles in international peer-reviewed journals, including the New England Journal of Medicine, Science, Lancet and Journal of Clinical Oncology, and contributed to multiple editorials and textbooks. He is active and experienced in serving the academic societies. He is now Fellow of American Society of Clinical Oncology and Chairman of Clinical Oncology at The Chinese University of Hong Kong, Hong Kong. His main research interest focuses on biomarker and molecular targeted therapy in lung cancer. He co-founded the Lung Cancer Research Group, and has led a number of important multinational clinical trials, which include the IPASS (IRESSA Pan-Asia Study), a landmark study that established the role of first-line gefitinib in patients with EGFR mutation.

Prof. Mok has contributed to over 200 articles in international peer-reviewed journals, including the New England Journal of Medicine, Science, Lancet and Journal of Clinical Oncology, and contributed to multiple editorials and textbooks. He is active and experienced in serving the academic societies. He is now Fellow of American Society of Clinical Oncology and Chairman of Clinical Oncology at The Chinese University of Hong Kong, Hong Kong. His main research interest focuses on biomarker and molecular targeted therapy in lung cancer. He co-founded the Lung Cancer Research Group, and has led a number of important multinational clinical trials, which include the IPASS (IRESSA Pan-Asia Study), a landmark study that established the role of first-line gefitinib in patients with EGFR mutation.

Prof. Mok has contributed to over 200 articles in international peer-reviewed journals, including the New England Journal of Medicine, Science, Lancet and Journal of Clinical Oncology, and contributed to multiple editorials and textbooks. He is active and experienced in serving the academic societies. He is now Fellow of American Society of Clinical Oncology and Chairman of Clinical Oncology at The Chinese University of Hong Kong, Hong Kong. His main research interest focuses on biomarker and molecular targeted therapy in lung cancer. He co-founded the Lung Cancer Research Group, and has led a number of important multinational clinical trials, which include the IPASS (IRESSA Pan-Asia Study), a landmark study that established the role of first-line gefitinib in patients with EGFR mutation.

Prof. Mok has contributed to over 200 articles in international peer-reviewed journals, including the New England Journal of Medicine, Science, Lancet and Journal of Clinical Oncology, and contributed to multiple editorials and textbooks. He is active and experienced in serving the academic societies. He is now Fellow of American Society of Clinical Oncology and Chairman of Clinical Oncology at The Chinese University of Hong Kong, Hong Kong. His main research interest focuses on biomarker and molecular targeted therapy in lung cancer. He co-founded the Lung Cancer Research Group, and has led a number of important multinational clinical trials, which include the IPASS (IRESSA Pan-Asia Study), a landmark study that established the role of first-line gefitinib in patients with EGFR mutation.

Prof. Mok has contributed to over 200 articles in international peer-reviewed journals, including the New England Journal of Medicine, Science, Lancet and Journal of Clinical Oncology, and contributed to multiple editorials and textbooks. He is active and experienced in serving the academic societies. He is now Fellow of American Society of Clinical Oncology and Chairman of Clinical Oncology at The Chinese University of Hong Kong, Hong Kong. His main research interest focuses on biomarker and molecular targeted therapy in lung cancer. He co-founded the Lung Cancer Research Group, and has led a number of important multinational clinical trials, which include the IPASS (IRESSA Pan-Asia Study), a landmark study that established the role of first-line gefitinib in patients with EGFR mutation.
**IAWLC AND CONFERENCE AWARDS**

**Yasushi Yatabe**

**MARY J. MATTHEWS\PATHOLOGY/TRANSLATIONAL RESEARCH AWARD**

THE MARY J. MATTHEWS PATHOLOGY/TRANSLATIONAL RESEARCH AWARD IS GIVEN TO AN IASLC SCIENTIST FOR LIFETIME SCIENTIFIC ACHIEVEMENTS IN PATHOLOGY-TRANSLATIONAL RESEARCH OF THORACIC MALIGNANCIES.

Yasushi Yatabe, MD, PhD, is Chief of the Department of Pathology and Molecular Diagnostics at the Aichi Cancer Center Hospital, Chikusa-ku Nagoya, Japan. He is a surgical and molecular pathologist, and is recognized as one of the leading experts in lung cancer research. In addition, Dr. Yatabe is active in a number of professional societies, holding positions in a chair, Pathology Committee of the International Association for the Study of Lung Cancer (2015-2017), a chapter editor of the WHO classification of tumors of lung, pleura, thymus and heart (2015) and a co-chair of the revised CAP/IASLC/AMP Molecular Testing Guidelines. He is also an editor for several oncology and pathology journals, including an associate editor of the Journal of Thoracic Oncology.

Dr. Yatabe received his medical degree from Tsukuba University, School of Medicine in 1991, and subsequently completed his PhD in 1995 at Nagoya University in Japan. He then began work as a Senior Pathologist at the Aichi Cancer Center Hospital until 1998. After spending 2 years of post-doctoral fellowship at the Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA, Dr. Yatabe returned to the Aichi Cancer Center Hospital in 2000.

Dedicated to research, Dr. Yatabe has published more than 400 articles in peer-reviewed journals, and presented his work at many national and international conferences. His research is focused on the molecular pathogenesis of the clonal evolution of cancer and lung cancer, with contributions to the expansion and integration of molecular oncology and pathology, as seen in the representative work (reference #8, and #10). Due to his diligence, Dr. Yatabe has earned a number of awards throughout his career, including the Japanese Society of Pathology “Pathology Research Award” in 2001 and the Japanese Lung Cancer Society “Shinonoi-Kawai Award” in 2009.

**Carolyn Dresler**

**JOSEPH W. CULLEN\PREVENTION/EARLY DETECTION AWARD**

THE JOSEPH W. CULLEN PREVENTION/EARLY DETECTION AWARD IS GIVEN TO AN IASLC SCIENTIST FOR LIFETIME SCIENTIFIC ACHIEVEMENTS IN PREVENTION RESEARCH OF THORACIC MALIGNANCIES.

Carolyn Dresler, MD, MPA, by day, is the Associate Director for Medical and Health Sciences for the Office of Science at the Center for Tobacco Products within the FDA. Prior to this she was the Director for the Arkansas Department of Health Tobacco Prevention and Cessation Program. Before Arkansas, she was the Head of the Group for Tobacco and Cancer at the International Agency for Research on Cancer in Lyon, France.

In 2002-2003 she completed a Master in Public Administration at the Kennedy School of Government at Harvard University. She is a USA Board Certified Thoracic Surgeon (University of Toronto) with Surgical Oncology training (Memorial Sloan Kettering), with a specific interest in the diagnosis, treatment and most of all, prevention of lung cancer. She is a former Board member for the International Association for the Study of Lung Cancer.

Her academic practices of thoracic surgery were at Washington University in St. Louis, Missouri and then at Fox Chase Cancer Center in Philadelphia, Pennsylvania.

Her passion is utilizing the human rights framework to improve tobacco control and is the founding President of the Human Rights and Tobacco Control Network. Her goal is to have fewer people dying from tobacco, specifically from tobacco-caused lung cancer.
# IASLC AND CONFERENCE AWARDS

## PREVIOUS IASLC DISTINGUISHED AWARD WINNERS

<table>
<thead>
<tr>
<th>YEAR</th>
<th>IASLC MERIT AWARD</th>
<th>IASLC MARY J. MATTHEWS PATHOLOGY/TRANSLATIONAL RESEARCH AWARD</th>
<th>IASLC JOSEPH W. CULLEN PREVENTION/EARLY DETECTION AWARD</th>
<th>IASLC PAUL A. BUNN, JR. SCIENTIFIC AWARD (FORMERLY IASLC SCIENTIFIC AWARD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1991</td>
<td>Clifton Mountain</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1994</td>
<td>Y. Shimosato</td>
<td>Geno Saccamanno</td>
<td>Jesse Steinfeld</td>
<td>Robert Ginsberg</td>
</tr>
<tr>
<td></td>
<td>N. Bleehen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1997</td>
<td>Heine H. Hansen</td>
<td>William Travis</td>
<td>Clifford Douglas</td>
<td>John D. Minna</td>
</tr>
<tr>
<td>2000</td>
<td>Desmond Carney</td>
<td>Yokio Shimosato</td>
<td>Daniel C. Ihde</td>
<td></td>
</tr>
<tr>
<td>2003</td>
<td>Paul A. Bunn, Jr.</td>
<td>Adi Gazdar</td>
<td>Paul van Houtte</td>
<td></td>
</tr>
<tr>
<td>2005</td>
<td>Harubumi Kato</td>
<td>Elisabeth Brambilla</td>
<td>Nigel Gray</td>
<td>Thierry LeChevalier</td>
</tr>
<tr>
<td>2007</td>
<td>Peter Goldstraw</td>
<td>Fred R. Hirsch</td>
<td>James Mulshine</td>
<td>Frances Shepherd</td>
</tr>
<tr>
<td>2009</td>
<td>Giorgio Scagliotti</td>
<td>Masayuki Noguchi</td>
<td>Stephen Lam</td>
<td>Bruce Johnson Tom Lynch</td>
</tr>
<tr>
<td>2011</td>
<td>David Ball</td>
<td>Philip Hasleton</td>
<td>John Field</td>
<td>Nagahiro Saijo</td>
</tr>
<tr>
<td>2013</td>
<td>James Jett</td>
<td>Tetsuya Mitsudomi</td>
<td>Pieter Postmus</td>
<td>David Gandara</td>
</tr>
<tr>
<td>2015</td>
<td>Harvey Pass</td>
<td>Ming Tsao</td>
<td>Jacek Jassem</td>
<td>Yi-Long Wu</td>
</tr>
<tr>
<td>2016</td>
<td>Sumitra Thongprasert Keunchil Park</td>
<td>Keith Kerr</td>
<td>Ugo Pastorino</td>
<td>Roy Herbst</td>
</tr>
</tbody>
</table>

IASLC AND CONFERENCE AWARDS

PREVIOUS IASLC DISTINGUISHED AWARD WINNERS

<table>
<thead>
<tr>
<th>YEAR</th>
<th>IASLC MERIT AWARD</th>
<th>IASLC MARY J. MATTHEWS PATHOLOGY/TRANSLATIONAL RESEARCH AWARD</th>
<th>IASLC JOSEPH W. CULLEN PREVENTION/EARLY DETECTION AWARD</th>
<th>IASLC PAUL A. BUNN, JR. SCIENTIFIC AWARD (FORMERLY IASLC SCIENTIFIC AWARD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1991</td>
<td>Clifton Mountain</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1994</td>
<td>Y. Shimosato</td>
<td>Geno Saccamanno</td>
<td>Jesse Steinfeld</td>
<td>Robert Ginsberg</td>
</tr>
<tr>
<td></td>
<td>N. Bleehen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1997</td>
<td>Heine H. Hansen</td>
<td>William Travis</td>
<td>Clifford Douglas</td>
<td>John D. Minna</td>
</tr>
<tr>
<td>2000</td>
<td>Desmond Carney</td>
<td>Yokio Shimosato</td>
<td>Daniel C. Ihde</td>
<td></td>
</tr>
<tr>
<td>2003</td>
<td>Paul A. Bunn, Jr.</td>
<td>Adi Gazdar</td>
<td>Paul van Houtte</td>
<td></td>
</tr>
<tr>
<td>2005</td>
<td>Harubumi Kato</td>
<td>Elisabeth Brambilla</td>
<td>Nigel Gray</td>
<td>Thierry LeChevalier</td>
</tr>
<tr>
<td>2007</td>
<td>Peter Goldstraw</td>
<td>Fred R. Hirsch</td>
<td>James Mulshine</td>
<td>Frances Shepherd</td>
</tr>
<tr>
<td>2009</td>
<td>Giorgio Scagliotti</td>
<td>Masayuki Noguchi</td>
<td>Stephen Lam</td>
<td>Bruce Johnson Tom Lynch</td>
</tr>
<tr>
<td>2011</td>
<td>David Ball</td>
<td>Philip Hasleton</td>
<td>John Field</td>
<td>Nagahiro Saijo</td>
</tr>
<tr>
<td>2013</td>
<td>James Jett</td>
<td>Tetsuya Mitsudomi</td>
<td>Pieter Postmus</td>
<td>David Gandara</td>
</tr>
<tr>
<td>2015</td>
<td>Harvey Pass</td>
<td>Ming Tsao</td>
<td>Jacek Jassem</td>
<td>Yi-Long Wu</td>
</tr>
<tr>
<td>2016</td>
<td>Sumitra Thongprasert Keunchil Park</td>
<td>Keith Kerr</td>
<td>Ugo Pastorino</td>
<td>Roy Herbst</td>
</tr>
</tbody>
</table>
IASLC FELLOWSHIP AWARD WINNERS | 2016 – 2017

ESRA AKBAY
UT Southwestern Medical Center, Dallas, Texas, USA

VALSAMO ANAGNOSTOU
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, USA

LUIZ HENRIQUE ARAUJO
Brazilian National Cancer Institute, INCA, Brazil

PUEY LING CHIA
Olivia Newton-John Cancer Research Institute, Austin Health, Victoria, Australia

SIDDHARTHA DEVARAKONDA
Washington University School of Medicine, St. Louis, Michigan, USA

JULIE GEORGE
Department of Translational Genomics, University of Cologne, Cologne, Germany

ROBIN MJELLE
Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology NTNU, Norway

NICOLAS REYNOIRD
Institute Albert Bonnoin, Centre Recherche INSERM U1209 - CNRS - UGA, Grenoble, France

APICHAT TANTRAWORASIN
Department of Thoracic Surgery, Icahn School of Medicine at Mount Sinai, New York, USA

IASLC ACADEMY AWARD WINNERS

SUREIN ARULANANDA
Olivia Newton-John Cancer Research Institute, Australia

AHMED BADAWY
Alexandria University, Egypt

MARTA HONORIO
Hospital Prof. Doutor Fernando Fonseca (HFF), Portugal

JENNIFER LEWIS
Vanderbilt University Medical Center, USA

JESSICA LIN
Dana-Farber Cancer Institute/ Massachusetts General Hospital, USA

TAN LING
National Cancer Centre Singapore, Singapore

BENJAMIN LOK
Princess Margaret Cancer Centre, Canada

ALEXANDER LOUIE
London Regional Cancer Program, Canada

DEEBYA MISHRA
B P Koirala Institute of Health Sciences, Nepal

FABIO MORAES
Princess Margaret Cancer Centre, Canada

PABLO MUNOZ
Princess Margaret Cancer Centre, Canada

FRANCESCO PASSIGLIA
Palermo University Hospital, Italy

ERIN SCHENK
Mayo Clinic, USA

The IASLC Academy Award Winners will be recognized and presented with their award during the IASLC Business Meeting, Monday, October 16, 14:30 – 15:30, F201 + F202 (Annex Hall).
The IASLC International Mentorship Award Winners will receive their award during the IASLC Business Meeting on Monday, October 16, 14:30 – 15:30, F201 + F202 (Annex Hall).

NOOR ALSAADOUN
University of Calgary, Canada
P1.06–005: Sex-Based Disparities in NSCLC: An Evidence-Based Study

ASEEM RAI BHATNAGAR
Linear Accelerator Center, SMS Hospital, Jaipur, India
P2.10–007: Quality of Life across Various Treatment Lines in Metastatic Lung Cancer Patients

WANDEE CHANPRASERTPINYO
Ramathibodi Hospital, Mahidol University, Thailand
OA 11.04: Effect of Early Palliative Care on Aggressiveness of Cancer Care near End of Life in Lung Cancer Patients

VALERIA DENNINGHOFF
CEMIC, Argentina
P2.02–071: Prospective Molecular Study of 22 Genes by NGS in Patients with Non-Small Cell Lung Cancer (NSCLC) in Argentina: A Single Institution Experience

JIN KANG
Division of Pulmonary Oncology, Cancer Center, Guangdong Lung Cancer Institute (GLCI), Guangdong General Hospital (GGH), China
P1.01–009: Clinically Primary and Secondary Resistance to ALK Inhibitors in ALK-Positive Advanced Non-Small-Cell Lung Cancer

MADIHA KANWAL
Kunming Institute of Zoology, University of Chinese Academy of Sciences, Kunming, China
P1.02–040: Genetic Risk Evaluation in Families with Lung Cancer History in High Lung Cancer Mortality Region of Xuanwei, China

MILICA KONTIC
Clinic for Pulmonology, Clinical Center of Serbia, Serbia
P3.05–005: Hypermethylation of the RASSF1A and SOX1 Genes in Tumor DNA Predicts Unfavorable Overall Survival in Surgically Resected NSCLC Patients

MIAN XIE
The First Affiliated Hospital of Guangzhou Medical University, China
MA 16.11: Alterations of Notch Pathway among Patients with Adenoid Cystic Carcinoma of the Trachea and Its Impact on Survival

WENHUA LIANG
The First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou, China
P3.02–008: Non-Invasive Diagnosis of Solitary Pulmonary Nodules Using High-Throughput Targeted DNA Methylation Sequencing of Circulating Tumor DNA

FARIZ NURWIDYA
Department of Pulmonology and Respiratory Medicine, Universitas Indonesia, Indonesia
P1.02–065: Histone Deacetylase Inhibition Alters Stem Cell Phenotype in Gefitinib-Resistant Lung Cancer Cells with EGFR Mutation

ABHISHEK SHANKAR
All India Institute of Medical Sciences, Delhi, India
P3.06–007: Level of Awareness of Various Aspects of Lung Cancer Among College Students in India: Impact of Cancer Awareness Programme

VORALAK VICHAPAT
Mahidol University, Thailand
P2.01–009: The Efficacy of Bevacizumab Adding in Standard First Line Chemotherapy and Maintenance Treatment in Advanced NSCLC: A Network Meta-Analysis
The WCLC 2017 Young Investigator Award Winners will receive their award during the IASLC Business Meeting on Monday, October 16, 14:30 – 15:30, F201 + F202 (Annex Hall).

**SUPPORTED BY**

AstraZeneca

---

**HAVAL BALATA**
University Hospital of South Manchester, UK

OA 15.04: Community-Based Lung Cancer Screening, Targeting High-Risk Ever Smokers in Deprived Areas of Manchester: an NHS Implementation Project

---

**JOSHUA BAUMI**
Perelman School of Medicine at the University of Pennsylvania, USA

OA 17.08: Phase II Study of Pembrolizumab for Oligometastatic Non-Small Cell Lung Cancer (NSCLC) Following Completion of Locally Ablative Therapy (LAT)

---

**KEZHONG CHEN**
Peking University People’s Hospital, China

OA 07.01: A Prospective Study of Perioperative Rapid Clearance of Circulating Tumor DNA in RO Resected Non-Small Cell Lung Cancer Patients

---

**HANBO CHEN**
London Health Sciences Centre, Canada

OA 16.01: Stereotactic Ablative Radiotherapy Versus Surgery in Early Lung Cancer: A Meta-analysis of Propensity Score-Adjusted Studies

---

**BHASIRATHBHAI DHOLARIA**
Mayo Clinic, USA

OA 06.07: Survival Trends Among Non-Small Cell Lung Cancer (NSCLC) Patients Over a Decade: Impact of Initial Therapy at Academic Centers

---

**KATEY ENFIELD**
British Columbia Cancer Research Centre, Canada

OA 07.07: Inhibition of the Novel Oncogene ELF3 Abolishes Lung Adenocarcinoma Growth

---

**ROBERTO FERRARA**
Medical Oncology Gustave Roussy, France

MA 10.11: Hyperprogressive Disease (HPD) Is Frequent in Non-Small Cell Lung Cancer (NSCLC) Patients (Pts) Treated with Anti PDI/PO-L1 Agents (IO)

---

**MEREDITH GIULIANI**
University of Toronto and Princess Margaret Cancer Centre, Canada

MA 13.09: Toxicity and Second Primary Lung Cancers in Late Survivors Following Lung SBRT

---

**FRANCESCO GUERRERA**
University of Torino, Italy

OA 16.02: Risk of Recurrence in Stage I Adenocarcinoma of the Lung: A Multi-Institutional Study on Interaction with Type of Surgery and Type of Nodal Staging

---

**GILLIANNE LAI**
National Cancer Centre Singapore, Singapore

OA 09.07: Clonality of c-MET Copy Number Gain as a Determinant of Primary TKI Resistance in EGFR-Mutant NSCLC

---

**MARCE NICOŚ**
Medical University of Lublin, Poland

OA 08.03: Effect of TOP2A and ERCC1 Genes Polymorphism on the Efficacy and Toxicity of Cisplatin and Etoposide Therapy in SCLC Patients

---

**JI SOO PARK**
Yonsei Cancer Centre, Korea

MA 12.01: A Phase Ib Study of the Combination of Afatinib and Ruxolitinib in EGFR Mutant NSCLC Progressed on EGFR-TKI: An Updated Analysis

---

**ALEXANDRE REUBEN**
The University of Texas MD Anderson Cancer Center, USA

OA 13.05: Immune, Molecular and T Cell Repertoire Landscape of 235 Resected Non-Small Cell Lung Cancers and Paired Normal Lung Tissues

---

**SARA RICCIARDI**
Division of Thoracic Surgery, University Hospital of Pisa, Italy

MA 17.01: Skip N2, an Independent Prognostic Factor of Survival: Analysis of a Favourable N2 Subgroup

---

**KATHARINE SEE**
Royal Melbourne Hospital, Australia

MA 14.09: Impact of Lung Cancer Perceived Risk, Screening Eligibility and Worry on LDCT Screening Preference – Challenges for Engaging Patients at High Risk
IASLC AND CONFERENCE AWARDS

MICHAEL SHARPNACK
The Ohio State University Comprehensive Cancer Center, USA
OA 18.02: The Landscape of Alteration of DNA Integrity-Related Genes and Their Association with Tumor Mutation Burden Non-Small Cell Lung Cancer

YAAKOV TOLWIN
Tel Aviv University, Israel
MA 18.11: High Incidence of Lung Cancer in Early Stage TCC Patients

JOAN ELIAS WALTER
University of Groningen, University Medical Center Groningen, The Netherlands
OA 15.06: Management of Nonresolving New Solid Nodules after Initial Detection in Incidence Rounds of CT Lung Cancer Screening

MARISSA WILLIAMS
Asbestos Diseases Research Institute, Australia
MA 19.06: Multiple Mechanisms Contribute to Downregulation of Tumour Suppressor microRNAs in Malignant Pleural Mesothelioma

YAAKOV TOLWIN
Tel Aviv University, Israel
MA 18.11: High Incidence of Lung Cancer in Early Stage TCC Patients

JOAN ELIAS WALTER
University of Groningen, University Medical Center Groningen, The Netherlands
OA 15.06: Management of Nonresolving New Solid Nodules after Initial Detection in Incidence Rounds of CT Lung Cancer Screening

MARISSA WILLIAMS
Asbestos Diseases Research Institute, Australia
MA 19.06: Multiple Mechanisms Contribute to Downregulation of Tumour Suppressor microRNAs in Malignant Pleural Mesothelioma

WCLC 2017 DEVELOPING NATION AWARD WINNERS

The WCLC 2017 Developing Nation Award Winners will receive their award during the IASLC Business Meeting on Monday, October 16, 14:30 – 15:30, F201 + F202 (Annex Hall).

SUPPORTED BY

AstraZeneca

GULRUHK BOTIRALIEVA
National Cancer Research Center, Uzbekistan
P2.02–049: Immunohistochemical Approach in Predicting Primary Lung Cancer Outcome: A Single Center Study

GAMZE ÇETINKAYA
Uludag University, Turkey
P2.14–016: Pulmonary Resection After Curative Intent Chemoradiation of NSCLC

TATIANA IONOVA
Multinational Center for Quality of Life Research, Russia
P1.01–056: Quality of Life and Clinical Outcomes of Nivolumab as 2+ Line Treatment in Advanced Refractory NSCLC Pts: Interim Analysis

AKHIL KAPOOR
Tata Memorial Hospital, India
P1.01–021: FISH and IHC Discordance in ALK Rearranged Non Small Cell Lung Cancer

SZE SHYANG KHO
Sarawak General Hospital, Myanmar
P2.12–002: Radial Probe Endobronchial Ultrasound (R-EBUS) Guided Transbronchial Cryobiopsy In The Diagnosis of Peripheral Lung Mass

HENGRUI LIANG
The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, China State Key Laboratory of Respiratory Disease, China
MA 12.11: The Alteration of T790M Prevalence Between 19 Deletions and L858R in NSCLC After EGFR-TKIs Therapy, a Meta-Analysis
QIANWEN LIU  
Sun Yat-sen University Cancer Center, China  
QA 03.07: Developing Prognostic Nomogram and Evaluating Its Role in Personalized Adjuvant Chemotherapy for Patients with ESCC

HÜSEYIN MELEK  
Uludag University, Turkey  
MA 17.08: The Validity of TNM Classification After Induction Treatment in Patients with NSCLC: Pulmonary Resection with or Without Induction Treatment

MANGESH PATIL  
Tata Memorial Hospital, India  
P2.14–005: Determination of Optimal Cut off SUV Threshold for Auto-Contouring of GTV Using PETCT for Early Stage NSCLC

AMRITA SINGH  
Thapar University, India  
P2.06–004: Role of Polymorphic Variants of BER and DSBR Pathway Genes in Modulating Lung Cancer Susceptibility and Prognosis of North Indian Population

APICHAT TANTRAWORASIN  
Chiang Mai University, Thailand  
OA 04.08: Is Lobe-Specific Lymph Node Dissection in Clinical N0-1 Non-Small Cell Lung Cancer Adequate for Pathological Nodal Staging

ANA PAULA TEIXEIRA  
National Cancer Institute - Ministry of Health, Brazil  
P3.06–006: The Government Willingness to Legislate Tobacco Control and Changes on Individual Behavior in Brazil

LIN TONG  
Shanghai Respiratory Research Institute, China  
MA 20.13: etDNA: Tumor-Derived DNA from Pleural Effusion Supernatant as a Promising Source for NGS-Based Mutation Profiling in Lung Cancer

NATTHAYA TRIPHURIDET  
Chulabhorn Hospital, Thailand  
P2.06–006: Screening Values for CEA and Cyfra 21-1 for Lung Cancer in Combination with Low Dose CT (LDCT) in High-Risk Populations

DONGSHENG YUE  
Tianjin Medical University Cancer Institute and Hospital, China  
OA 16.04: Efficacy and Safety of Erlotinib vs Vinorelbine/Cisplatin as Adjuvant Therapy for Stage IIIA EGFR Mutant NSCLC Patients

FEI ZHOU  
Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China  
P3.15–015: LCNEC Tumor Location, Divided into Central and Peripheral Type, Has Distinct Clinicopathologic Feature, Genomic Characteristics and Survival

ZHI XUAN LIN  
Chi Mei Medical Center, Taiwan  
P1.10–006: Adverse Events After First-Line Target Therapy for Non-Small Cell Lung Cancer Patients in a Case Management Model

IASLC PATIENT ADVOCACY AWARD WINNERS

The IASLC Patient Advocacy Award Winners will receive their award during the IASLC Business Meeting on Monday, October 16, 14:30 – 15:30, F201 + F202 (Annex Hall).

ANNE MARIE CERATO  
Canada

ANNIE CACCIATO  
USA

ADITYA MANNA  
India

ANDREA PRIAS  
Peru

CSABA LÁSZLÓ DÉGI  
Romania

WCLC 2017 NURSE AND ALLIED HEALTH PROFESSIONAL AWARD WINNERS

The IASLC Nurse and Allied Health Professional Award Winners will receive their award during the IASLC Business Meeting on Monday, October 16, 14:30 – 15:30, F201 + F202 (Annex Hall).

LAERKE WINTHER  
University of Copenhagen, Denmark  
P2.10–003: The Deterioration and Prognostic Value of Functional Capacity in Patients with Lung Cancer: A Systematic Review

ZHI XUAN LIN  
Chi Mei Medical Center, Taiwan  
P1.10–006: Adverse Events After First-Line Target Therapy for Non-Small Cell Lung Cancer Patients in a Case Management Model
WCLC 2017 LECTURESHIP AWARDS

WCLC 2017 Lectureship Award Winners will receive their award before their presentation in the Abstract Session.

NEW

JAMES COX LECTURESHIP AWARD IN RADIATION ONCOLOGY

IASLC is introducing the James Cox Lectureship Award for Radiation Oncology. In the future the award will be presented to the best abstract in Radiation Oncology.

James Cox will give his award presentation during the Presidential Symposium, Tuesday, October 17, 08:15 – 09:45.

DANIEL C. IDHE LECTURESHIP AWARD - COMBINED MODALITY

DIRK DE RUYSCHER
Maastricht University Medical Center, Netherlands

MA 17.10: Toxicity Results from the Randomized Phase III NVALT-11 Study of Prophylactic Cranial Irradiation vs. Observation in Stage III NSCLC

ROBERT J. GINSBERG LECTURESHIP AWARD - SURGERY

FRANCESCO GUERRERA
University of Torino, Italy

OA 16.02: Risk of Recurrence in Stage I Adenocarcinoma of the Lung: A Multi-Institutional Study on Interaction with Type of Surgery and Type of Nodal Staging

CLIFTON MOUNTAIN LECTURESHIP AWARD - SURGERY/STAGING

HERBERT DECALUWE
University Hospitals KU Leuven, Belgium

OA 16.06: Mediastinal Staging by Video-mediastinoscopy in Clinical N1 Non-Small Cell Lung Cancer: a Prospective Multi-centre Study

TSUGUO NARUKE LECTURESHIP AWARD - STAGING

MATTHEW SMELTZER
University of Memphis School of Public Health, USA

OA 15.08: Thoroughness of Staging and the Outcomes of Surgical Resection Outcomes in Potentially Curable Non-Small Cell Lung Cancer (NSCLC)

HEINE HANSEN LECTURESHIP AWARD - SMALL CELL LUNG CANCER

TAOFEEK OWONIKOKO
Emory University, USA

OA 08.06: Exploratory Analysis for Predictors of Benefit of PARP Inhibitor Therapy in Extensive Stage Small Cell Lung Cancer: ECOG-ACRIN 2511 Study

ADI GAZDAR LECTURESHIP AWARD - TRANSLATIONAL RESEARCH

KATEY ENFIELD
BC Cancer Research Centre, Canada

OA 07.07: Inhibition of the Novel Oncogene ELF3 Abolishes Lung Adenocarcinoma Growth

NURSE & ALLIED HEALTH LECTURESHIP AWARD

MORTEN QUIST
Rigshospitalet, University of Copenhagen, Denmark

OA 11.02: Exercise Improves Functional Capacity in Patients with Advance Stage Lung Cancer

NEW

JAMES COX LECTURESHIP AWARD IN RADIATION ONCOLOGY

IASLC is introducing the James Cox Lectureship Award for Radiation Oncology. In the future the award will be presented to the best abstract in Radiation Oncology.

James Cox will give his award presentation during the Presidential Symposium, Tuesday, October 17, 08:15 – 09:45.

DANIEL C. IDHE LECTURESHIP AWARD - COMBINED MODALITY

DIRK DE RUYSCHER
Maastricht University Medical Center, Netherlands

MA 17.10: Toxicity Results from the Randomized Phase III NVALT-11 Study of Prophylactic Cranial Irradiation vs. Observation in Stage III NSCLC

ROBERT J. GINSBERG LECTURESHIP AWARD - SURGERY

FRANCESCO GUERRERA
University of Torino, Italy

OA 16.02: Risk of Recurrence in Stage I Adenocarcinoma of the Lung: A Multi-Institutional Study on Interaction with Type of Surgery and Type of Nodal Staging

CLIFTON MOUNTAIN LECTURESHIP AWARD - SURGERY/STAGING

HERBERT DECALUWE
University Hospitals KU Leuven, Belgium

OA 16.06: Mediastinal Staging by Video-mediastinoscopy in Clinical N1 Non-Small Cell Lung Cancer: a Prospective Multi-centre Study

TSUGUO NARUKE LECTURESHIP AWARD - STAGING

MATTHEW SMELTZER
University of Memphis School of Public Health, USA

OA 15.08: Thoroughness of Staging and the Outcomes of Surgical Resection Outcomes in Potentially Curable Non-Small Cell Lung Cancer (NSCLC)

HEINE HANSEN LECTURESHIP AWARD - SMALL CELL LUNG CANCER

TAOFEEK OWONIKOKO
Emory University, USA

OA 08.06: Exploratory Analysis for Predictors of Benefit of PARP Inhibitor Therapy in Extensive Stage Small Cell Lung Cancer: ECOG-ACRIN 2511 Study

ADI GAZDAR LECTURESHIP AWARD - TRANSLATIONAL RESEARCH

KATEY ENFIELD
BC Cancer Research Centre, Canada

OA 07.07: Inhibition of the Novel Oncogene ELF3 Abolishes Lung Adenocarcinoma Growth

NURSE & ALLIED HEALTH LECTURESHIP AWARD

MORTEN QUIST
Rigshospitalet, University of Copenhagen, Denmark

OA 11.02: Exercise Improves Functional Capacity in Patients with Advance Stage Lung Cancer
### Saturday, October 14, 2017

- **Symposium on the Advances in Lung Cancer CT Screening**
  - [Ticketed Event]
  - 09:00–18:00

### Sunday, October 15, 2017

- **Unopposed Industry Symposium - Takeda Oncology**
  - 11:30–13:00

### Monday, October 16, 2017

- **Plenary Session PL 01: Prevention, Screening, and Management of Screen-Detected Lung Cancer**
  - 08:15–09:45

- **Press Conference**
  - 10:30–11:30

- **Educational Sessions**
  - Includes Mini Symposia, Educational Session, Pro-Con Sessions, Grand Rounds Sessions
  - 11:30–13:00

### Additional Information

- **Registration**
  - 06:30–16:00
  - 09:30–16:00 Exhibit Hall open | Posters on Display

- **Speaker Preview Center**
  - 07:00–20:00

- **Press Conference**
  - 10:00–10:45

- **Educational Sessions**
  - Includes Mini Symposia, Educational Session, Pro-Con Sessions, Grand Rounds Sessions
  - 11:00–12:30

- **Poster Session P1 with Presenters Present**
  - 10:00–10:45
  - 14:30–15:30

- **IASLC Business Meeting**
  - 14:30–15:30
### TUESDAY
**OCTOBER 17, 2017**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>06:30–16:00</td>
<td>Registration open</td>
</tr>
<tr>
<td>06:30–17:30</td>
<td>Speaker Preview Center open</td>
</tr>
<tr>
<td>09:30–16:00</td>
<td>Exhibit Hall open</td>
</tr>
<tr>
<td>07:00–08:00</td>
<td>Meet the Expert Sessions</td>
</tr>
<tr>
<td>07:00–08:00</td>
<td>Opposed Industry Symposia</td>
</tr>
<tr>
<td>08:00–08:30</td>
<td>Highlights of the Previous Day Sessions</td>
</tr>
<tr>
<td>08:30–09:00</td>
<td>Presidential Symposium Including James Cox Lectureship and Top 3 Abstract Presentations</td>
</tr>
<tr>
<td>09:00–10:00</td>
<td>Oral and Mini Oral Abstract Sessions</td>
</tr>
<tr>
<td>10:00–10:45</td>
<td>Poster Session P2 with Presenters Present</td>
</tr>
<tr>
<td>11:00–12:30</td>
<td>Educational Sessions *Includes Mini Symposia, Educational Session, Pro-Con Sessions, Grand Rounds Sessions</td>
</tr>
<tr>
<td>12:45–14:15</td>
<td>Unopposed Industry Supported Symposium Medscape - Supported by an Independent Educational Grant from AstraZeneca Pharmaceuticals LP</td>
</tr>
<tr>
<td>14:30–15:30</td>
<td>Poster Session P2 with Presenters Present</td>
</tr>
<tr>
<td>15:45–17:30</td>
<td>Oral and Mini Oral Abstract Sessions</td>
</tr>
<tr>
<td>17:45–19:15</td>
<td>Unopposed Industry Supported Symposium - MSD</td>
</tr>
</tbody>
</table>

### WEDNESDAY
**OCTOBER 18, 2017**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>06:30–16:00</td>
<td>Registration open</td>
</tr>
<tr>
<td>06:30–16:30</td>
<td>Speaker Preview Center open</td>
</tr>
<tr>
<td>09:30–16:00</td>
<td>Exhibit Hall open</td>
</tr>
<tr>
<td>07:00–08:00</td>
<td>Meet the Expert Sessions</td>
</tr>
<tr>
<td>07:00–08:00</td>
<td>Opposed Industry Symposia</td>
</tr>
<tr>
<td>08:00–08:30</td>
<td>Highlights of the Previous Day Sessions</td>
</tr>
<tr>
<td>08:30–09:00</td>
<td>Plenary Session PL 03: Immunology in Lung Cancer Update 2017</td>
</tr>
<tr>
<td>09:00–10:00</td>
<td>Oral and Mini Oral Abstract Sessions</td>
</tr>
<tr>
<td>10:00–10:45</td>
<td>Poster Session P3 with Presenters Present</td>
</tr>
<tr>
<td>11:00–12:30</td>
<td>Educational Sessions *Includes Mini Symposia, Educational Session, Grand Rounds Sessions</td>
</tr>
<tr>
<td>12:45–14:15</td>
<td>Unopposed Industry Supported Symposium AbbVie</td>
</tr>
<tr>
<td>14:30–15:30</td>
<td>Oral and Mini Oral Abstract Sessions</td>
</tr>
<tr>
<td>15:45–17:30</td>
<td>Educational Sessions *Includes Mini Symposia, Educational Session, Pro-Con Sessions, Grand Rounds Sessions</td>
</tr>
<tr>
<td>16:30–17:45</td>
<td>Closing Plenary Session</td>
</tr>
</tbody>
</table>
## SESSIONS AT A GLANCE | BY DAY

### SATURDAY | OCTOBER 14, 2017

<table>
<thead>
<tr>
<th>TOPIC</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
<th>TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>RADIOLOGY/STAGING/SCREENING</td>
<td>WS 01</td>
<td>IASLC Supporting the Implementation of Quality Assured Global CT Screening Workshop (By Invitation Only)</td>
<td>F203 (Annex Hall)</td>
<td>08:30 – 21:00</td>
</tr>
<tr>
<td>RADIOLOGY/STAGING/SCREENING</td>
<td>WS 02</td>
<td>IASLC Symposium on the Advances in Lung Cancer CT Screening (Ticketed Session)</td>
<td>F201 + F202 (Annex Hall)</td>
<td>09:00 – 18:15</td>
</tr>
</tbody>
</table>

### SUNDAY | OCTOBER 15, 2017

<table>
<thead>
<tr>
<th>TOPIC</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
<th>TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADVANCED NSCLC</td>
<td>JCSE 01</td>
<td>Joint IASLC/CSCO/CAALC Session: Immunotherapy for Management of Lung Cancer: Ongoing Research from East and West</td>
<td>F203 (Annex Hall)</td>
<td>07:30 – 11:30</td>
</tr>
<tr>
<td>SCIENTIFIC SYMPOSIUM</td>
<td>YI 01</td>
<td>Young Investigator and First Time Attendee Session</td>
<td>F201 + F202 (Annex Hall)</td>
<td>08:00 – 11:30</td>
</tr>
<tr>
<td>ISS</td>
<td>SS 01</td>
<td>Supporting the Clinical Management of Lung Cancer Patients through Innovation in Diagnostics – Roche</td>
<td>Room 315</td>
<td>08:15 – 12:00</td>
</tr>
<tr>
<td>MESENTHOMA/NURSES/PALLIATIVE CARE/Ethics</td>
<td>WS 03</td>
<td>ITONF Lung Cancer and Mesothelioma Workshop (Ticketed Session)</td>
<td>Room 313</td>
<td>12:15 – 17:55</td>
</tr>
<tr>
<td>PULMONOLOGY/ENDOSCOPY</td>
<td>WS 04</td>
<td>Minimally Invasive Diagnosis and Staging of Lung Cancer – Interventional Pulmonology Hands-On Workshop (Ticketed Session)</td>
<td>Room 416 + 417</td>
<td>13:00 – 17:00</td>
</tr>
<tr>
<td>ISS</td>
<td>ISS 02</td>
<td>Treatment Selection Strategies in Advanced NSCLC – Implications and Global Perspectives – Lilly Oncology</td>
<td>Room 303 + 304</td>
<td>15:00 – 16:30</td>
</tr>
<tr>
<td>ISS</td>
<td>ISS 03</td>
<td>Management of Advanced NSCLC; Where Do Immune Checkpoint Inhibitors Fit In? – Medscape – Supported by an Independent Educational Grant from AstraZeneca Pharmaceuticals LP</td>
<td>Room 301 + 302</td>
<td>16:45 – 18:15</td>
</tr>
</tbody>
</table>

---

**Opening Ceremony**

**ARRIVE EARLY – ADDITIONAL SECURITY IN PLACE! DOORS WILL BE CLOSED AT 18:25**

Badge required for all attendees including those only attending as a paid guest of a delegate.

**Welcome Reception**

National Convention Hall | 18:30 – 20:00

---

### MONDAY | OCTOBER 16, 2017

<table>
<thead>
<tr>
<th>TOPIC</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
<th>TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISS</td>
<td>ISS 04</td>
<td>Integrating Liquid Biopsy into Clinical Care: Common Questions and Challenges – Guardant Health</td>
<td>F201 + F202 (Annex Hall)</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>ISS</td>
<td>ISS 05</td>
<td>What’s New in SCLC? Assessing Emerging Therapeutic Options – Medscape – Supported by an Independent Educational Grant from AbbVie</td>
<td>F203 + F204 (Annex Hall)</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>RADIOLOGY/STAGING/SCREENING</td>
<td>MTE 01</td>
<td>Management of Small Nodules Detected by CT Screening (Sign Up Required)</td>
<td>Room 301 + 302</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>BIOLOGY/PATHOLOGY</td>
<td>MTE 02</td>
<td>Appropriate and Optimized Handling of Specimens (Sign Up Required)</td>
<td>Room 316</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>SURGERY</td>
<td>MTE 03</td>
<td>Surgery for T4 Lung Cancer (Sign Up Required)</td>
<td>Room 303 + 304</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>RADIOTHERAPY</td>
<td>MTE 04</td>
<td>Radiotherapy for SCLC (Sign Up Required)</td>
<td>Room 31 + 312</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>BIOLOGY/PATHOLOGY</td>
<td>MTE 05</td>
<td>Neuroendocrine Tumors: Pathology and Genetic Update (Sign Up Required)</td>
<td>Room 313 + 314</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>BY DAY</td>
<td>SESSIONS AT A GLANCE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>BIOLOGY/PATHOLOGY</strong></td>
<td>MTE 06 Lung Cancer Pathology Update <em>(Sign Up Required)</em> Room 315 07:00 – 08:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CHEMOTHERAPY/TARGETED THERAPY</strong></td>
<td>MTE 07 Molecular Biology: Minimum Requirement for Clinicians <em>(Sign Up Required)</em> Room 501 07:00 – 08:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PULMONOLOGY/ENDOSCOPY</strong></td>
<td>MTE 08 Technical Details of EBUS and EUS <em>(Sign Up Required)</em> Room 502 07:00 – 08:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>NURSING/PALLIATIVE CARE/ETHICS</strong></td>
<td>MTE 09 Management of Difficult Symptoms <em>(Sign Up Required)</em> Room 503 07:00 – 08:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CHEMOTHERAPY/TARGETED THERAPY</strong></td>
<td>MTE 10 Bridging the Gap between Genomics and Clinics <em>(Sign Up Required)</em> Room 511 + 512 07:00 – 08:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>RADIOLOGY/STAGING/SCREENING</strong></td>
<td>PL 01 Prevention, Screening, and Management of Screen-Detected Lung Cancer Plenary Hall (Hall D) 08:15 – 09:45</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Press Conference** Room 418 10:00 – 10:45

**Poster Viewing with Presenters Present - Poster Session P1** Exhibit Hall (Hall B + C) 10:00 – 10:45

| **CLINICAL DESIGN, STATISTICS AND CLINICAL TRIALS** | MS 01 Clinical Development of Novel Agents Main Hall 11:00 – 12:30 |
| **REGIONAL ASPECTS/HEALTH POLICY/PUBLIC HEALTH** | MS 02 Ethnic Differences: Biology or Myth Room 501 11:00 – 12:30 |
| **EARLY STAGE NSCLC** | MS 03 Best Practice for Small-Sized Early Stage Lung Cancer: Standard Surgery, Limited Resection, SBRT F203 + F204 (Annex Hall) 11:00 – 12:30 |
| **PATIENT ADVOCACY** | MS 04 Joint IASLC/GLCC Session Current Issues in Lung Cancer Advocacy Room 316 11:00 – 12:30 |
| **RADIOLOGY/STAGING/SCREENING** | ES 01 New TNM and WHO Classification Room 301 + 302 11:00 – 12:30 |
| **RADIOLOGY/STAGING/SCREENING** | ES 02 Diagnostic and Interventional Radiology in Lung Cancer: Update 2017 Room 315 11:00 – 12:30 |
| **CHEMOTHERAPY/TARGETED THERAPY** | GR 01 What to Do at the Time of Progression on Targeted Therapy Room 303 + 304 11:00 – 12:30 |
| **RADIOTHERAPY** | OA 01 The New Aspect of Radiation Therapy F201 + F202 (Annex Hall) 11:00 – 12:30 |
| **MESOTHELIOMA** | OA 02 Mesothelioma: Challenges For New Treatment F205 + F206 (Annex Hall) 11:00 – 12:30 |
| **THYMIC MALIGNANCES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES** | OA 03 Mediastinal and Esophageal Tumor: Insight and New Treatment Room 311 + 312 11:00 – 12:30 |
| **SCLC/NEUROENDOCRINE TUMORS** | MA 01 SCLC: Research Perspectives Room 503 11:00 – 12:30 |
| **CLINICAL DESIGN, STATISTICS AND CLINICAL TRIALS** | MA 02 Emerging Targets Room 511 + 512 11:00 – 12:30 |
| **ADVANCED NSCLC** | MA 03 Chemotherapy Room 502 11:00 – 12:30 |
| **PATIENT ADVOCACY** | MA 04 Advocacy: Listen to the Patients Room 313 + 314 11:00 – 12:30 |
| **ISS** | ISS 06 Maximizing Clinical Benefit from TKIs in the Treatment of Advanced NSCLC – Boehringer Ingelheim Pharma GmbH & Co. KG Main Hall 12:45 – 14:15 |
| **EXH 01 Thermo Fisher: Next Generation Sequencing – Changing Paradigm in NSCLC Patient Management** | Exhibit Showcase Theater (Hall B + C) 13:00 – 14:00 |
| **IASLC Business Meeting** | F201 + F202 (Annex Hall) 14:30 – 15:30 |

**Poster Viewing with Presenters Present - Poster Session P1** Exhibit Hall (Hall B + C) 14:30 – 15:30

| **IMMUNOLOGY AND IMMUNOTHERAPY** | MS 05 Clinical Issues of Immune Checkpoint Inhibitors Main Hall 15:45 – 17:30 |
| **THYMIC MALIGNANCES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES** | MS 06 Combined Modality Treatment for Thymic and Pleural Malignancy F201 + F202 (Annex Hall) 15:45 – 17:30 |
| **SCLC/NEUROENDOCRINE TUMORS** | MS 07 Neuroendocrine Tumors other than SCLC: Pathology to Patient Management F203 + F204 (Annex Hall) 15:45 – 17:30 |
| **MESOTHELIOMA** | MS 08 Novel Treatment for Mesothelioma Room 316 15:45 – 17:30 |
| **EPIDEMIOLOGY/PRIMARY PREVENTION/TOBACCO CONTROL AND CESSATION** | MS 09 Global Perspectives in Eliminating the Major Cause of Lung Cancer Room 315 15:45 – 17:30 |
| **NURSING/PALLIATIVE CARE/ETHICS** | MS 10 Evidence Based Care: Interpreting the Research and Enhancing Practice F205 + F206 (Annex Hall) 15:45 – 17:30 |
| **NURSING/PALLIATIVE CARE/ETHICS** | ES 03 Current Topics for Nurses & Allied Health Room 313 + 314 15:45 – 17:30 |
## SESSIONS AT A GLANCE | BY DAY

### EARLY STAGE NSCLC
- **PC 01**  1-1. Surgery vs Non-Surgical Local Treatment for Small-Sized NSCLC
- **1-2. What is the role of Local Therapy in Non-CNS Oligometastatic NSCLC?**
  - Room 502
  - 15:45 – 17:30

### ADVANCED NSCLC
- **OA 06**  1-2. Surgery vs Non-Surgical Local Treatment for Small-Sized NSCLC
  - Room 301 + 302
  - 15:45 – 17:30

### SURGERY
- **OA 04**  Surgery from Minimal to Radical
  - Room 311 + 312
  - 15:45 – 17:30

### ADVANCED NSCLC CHEMOTHERAPY/ TARGETED THERAPY
- **OA 05**  Next Generation TKI
  - Room 301 + 302
  - 15:45 – 17:30

### EPIDEMIOLOGY/ PRIMARY PREVENTION/ TOBACCO CONTROL AND CESSATION
- **OA 06**  Global Tobacco Control and Epidemiology I
  - Room 511 + 512
  - 15:45 – 17:30

### BIOLOGY/PATHOLOGY
- **OA 07**  Biomarker for Lung Cancer
  - Room 503
  - 15:45 – 17:30

### IMMUNOLOGY AND IMMUNOTHERAPY
- **MA 05**  Immuno-Oncology: Novel Biomarker Candidates
  - Room 303 + 304
  - 15:45 – 17:30

### BIOLOGY/PATHOLOGY
- **MA 06**  Lung Cancer Biology I
  - Room 501
  - 15:45 – 17:30

### PULMONOLOGY/ENDOSCOPY
- **WS 05**  superDimension™ Electromagnetic Navigation Bronchoscopy - Bridging the Diagnostic and Therapeutic Domains in Lung Cancer – Medtronic
  - Minatomirai Hall
  - 19:15 – 20:30

### TUESDAY | OCTOBER 17, 2017

<table>
<thead>
<tr>
<th>TOPIC</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
<th>TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISS</td>
<td>ISS 08</td>
<td>Optimising the Continuum of Care for Patients with Oncogenic-Driven NSCLC</td>
<td>F201 + F202 (Annex Hall)</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>ISS</td>
<td>ISS 09</td>
<td>The Evolution of Targetable Oncogenic Drivers in NSCLC: Novel Treatment Paradigms – Novartis</td>
<td>F203 + F204 (Annex Hall)</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>ADVANCED NSCLC CLINICAL DESIGN, STATISTICS AND CLINICAL TRIALS IMMUNOLOGY AND IMMUNOTHERAPY PATIENT ADVOCACY SURGERY BIOLOGY/PATHOLOGY EPIDEMIOLOGY PRIMARY PREVENTION/TOBACCO CONTROL AND CESSATION</td>
<td>SH 01</td>
<td>WCLC 2017 Highlights of the Previous Day</td>
<td>Room 502</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>CHEMOTHERAPY/ TARGETED THERAPY SCLC/NEUROENDOCRINE TUMORS RADIOTHERAPY BIOLOGY/PATHOLOGY MESOTHELIOMA THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES</td>
<td>SH 02</td>
<td>WCLC 2017 Highlights of the Previous Day</td>
<td>Room 503</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>EDUCATION/PUBLICATION/CAREER DEVELOPMENT</td>
<td>MTE 11</td>
<td>How to Write a Scientific Paper (Sign Up Required)</td>
<td>Room 511 + 512</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>NURSING/PALLIATIVE CARE/ETHICS</td>
<td>MTE 12</td>
<td>Oncology Nursing (Sign Up Required)</td>
<td>Room 316</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>MESOTHELIOMA</td>
<td>MTE 13</td>
<td>Malignant Pleural Mesothelioma: State of the Art (Sign Up Required)</td>
<td>Room 501</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>RADIOLOGY/STAGING/SCREENING</td>
<td>MTE 14</td>
<td>Imaging of Lung Cancer (Sign Up Required)</td>
<td>F205 + F206 (Annex Hall)</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>IMMUNOLOGY AND IMMUNOTHERAPY</td>
<td>MTE 15</td>
<td>Biomarkers for Immune Checkpoint Inhibitors (Sign Up Required)</td>
<td>Room 301 + 302</td>
<td>07:00 – 08:00</td>
</tr>
</tbody>
</table>

---

**ES**  EDUCATIONAL SESSION  **JCSE**  JOINT IASLC/CSCO/CAALC SESSION  **PC**  PRO-CON SESSION

**EXH**  EXHIBIT SHOWCASE SESSION  **MA**  MINI ORAL ABSTRACT SESSION  **PL**  PLENARY SESSION

**GR**  GRAND ROUNDS SESSION  **MS**  MINI SYMPOSIUM  **SH**  HIGHLIGHT OF THE PREVIOUS DAY SESSION

**ISS**  INDUSTRY SUPPORTED SYMPOSIUM  **MTE**  MEET THE EXPERT SESSION (SIGN UP REQUIRED)  **SS**  SCIENTIFIC SYMPOSIUM

**OA**  ORAL ABSTRACT SESSION  **WS**  WORKSHOP

---

IASLC 18th World Conference on Lung Cancer / Onsite Program  WWW.IASLC.ORG
**BY DAY | SESSIONS AT A GLANCE**

**SURGERY**
- MTE 16 Technical Issues after Neoadjuvant Chemoradiation – Surgeon’s Perspective (Sign Up Required)
  - Room 311 + 312
  - 07:00 – 08:00

**SCLC/NEUROENDOCRINE TUMORS**
- MTE 17 Neuroendocrine Tumor (Sign Up Required)
  - Room 418
  - 07:00 – 08:00

**ADVANCED NSCLC**
- MTE 18 Treatment for Squamous Cell Carcinoma (Sign Up Required)
  - Room 313 + 314
  - 07:00 – 08:00

**PULMONOLOGY/ENDOSCOPY**
- MTE 19 Laser Therapy for Early Stage and Airway Obstruction (Sign Up Required)
  - Room 317
  - 07:00 – 08:00

**BIOLOGY/PATHOLOGY**
- MTE 20 Liquid Biopsy (Sign Up Required)
  - Room 303 + 304
  - 07:00 – 08:00

**CHEMOTHERAPY/TARGETED THERAPY**
- MTE 21 Search for Novel Driver Mutations (Sign Up Required)
  - Room 315
  - 07:00 – 08:00

**EARLY STAGE NSCLC IMMUNOLOGY AND IMMUNOTHERAPY SURGERY**
- PL 02 Presidential Symposium including Top 3 Abstracts and James Cox Lectureship Award Presentation
  - Plenary Hall (Hall D)
  - 08:15 – 09:45

**Surgery**
- EXH 02 AstraZeneca: The Role of PD-L1 in Treatment Decision Making for NSCLC Patients
  - Exhibit Showcase Theater (Hall B + C)
  - 10:00 – 10:30

- Poster Viewing with Presenters Present - Poster Session P2
  - Exhibit Hall (Hall B + C)
  - 10:00 – 10:45

**Locally Advanced NSCLC**
- MS 11 Combined Modality Treatment for Superior Sulcus Tumors
  - Room 503
  - 11:00 – 12:30

**Regional Aspects/Health Policy/Public Health**
- MS 12 Sustainable Care System in Each Region
  - Room 501
  - 11:00 – 12:30

**ADVANCED NSCLC**
- MS 13 How to Deal with CNS Metastases
  - Room 502
  - 11:00 – 12:30

**NURSING/PALLIATIVE CARE/ETHICS**
- MS 14 QOL Evaluation in Practice from the Viewpoint of Physicians and Nurses
  - Room 315
  - 11:00 – 12:30

**BIOLOGY/PATHOLOGY**
- ES 04 Biology of Lung Cancer
  - F201 + F202 (Annex Hall)
  - 11:00 – 12:30

**IMMUNOLOGY AND IMMUNOTHERAPY**
- GR 02 Management of Immunotherapy-Related Adverse Events
  - Main Hall
  - 11:00 – 12:30

**SCLC/NEUROENDOCRINE TUMORS**
- PC 02 Is Radiotherapy Necessary for Extensive SCLC? (Thoracic Radiation/PCI)
  - F203 + F204 (Annex Hall)
  - 11:00 – 12:30

**ADVANCED NSCLC CHEMOTHERAPY/TARGETED THERAPY**
- OA 09 EGFR TKI Resistance
  - Room 301 + 302
  - 11:00 – 12:30

**NURSING/PALLIATIVE CARE/ETHICS**
- MA 08 Supportive Care and Communication
  - Room 511 + 512
  - 11:00 – 12:30

**LOCALY ADVANCED NSCLC RADIOTherAPY**
- MA 09 The Current Status of Radiation Oncology
  - Room 316
  - 11:00 – 12:30

**ADVANCED NSCLC IMMUNOLOGY AND IMMUNOTHERAPY**
- MA 10 Immunotherapy I
  - Room 303 + 304
  - 11:00 – 12:30

**ADVANCED NSCLC CHEMOTHERAPY/TARGETED THERAPY**
- MA 11 Emerging Diagnostic/Biomarkers in NSCLC
  - Room 313 + 314
  - 11:00 – 12:30

**ADVANCED NSCLC CHEMOTHERAPY/TARGETED THERAPY**
- MA 12 Circumventing EGFR Resistance
  - F205 + F206 (Annex Hall)
  - 11:00 – 12:30

**ISS**
- ISS 10 Evolving Decisions and Best Practices: Management of EGFR-Mutated NSCLC – Medscape – Supported by an Independent Educational Grant from AstraZeneca Pharmaceuticals LP
  - Main Hall
  - 12:45 – 14:15

**JTO**
- JTO Meet the JTO Editor
  - Room 511 + 512
  - 14:30 – 15:30

- Poster Viewing with Presenters Present - Poster Session P2
  - Exhibit Hall (Hall B + C)
  - 14:30 – 15:30

**BIOLOGY/PATHOLOGY**
- MS 15 Molecular Testing
  - Room 301 + 302
  - 15:45 – 17:30

**RADIOTHERAPY CHEMOTHERAPY/TARGETED THERAPY**
- MS 16 Future Direction of Chemoradiotherapy for Inoperable Non-Small Cell Lung Cancer
  - Room 302
  - 15:45 – 17:30

**CLINICAL DESIGN, STATISTICS AND CLINICAL TRIALS**
- MS 17 Lessons Learned from Negative Trials
  - Room 303 + 304
  - 15:45 – 17:30

**IMMUNOLOGY AND IMMUNOTHERAPY**
- MS 18 Biomarker for Anti-PD-L1 Therapy
  - Main Hall
  - 15:45 – 17:30

**PATIENT ADVOCACY**
- MS 19 Elevating the Lung Cancer Voice: Raising Awareness and Creating Community
  - Room 315
  - 15:45 – 17:30
# Sessions at a Glance | By Day

## Wednesday | October 18, 2017

<table>
<thead>
<tr>
<th>Topic</th>
<th>Session Title</th>
<th>Room</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advanced NSCLC</td>
<td>WCLC 2017 Highlights of the Previous Day</td>
<td>F201 + F202 (Annex Hall)</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>Immunology and Immunotherapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Early Stage NSCLC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Radiology/Staging/Screening</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biology/Pathology</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Locally Advanced NSCLC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epidemiology/Primary Prevention/Tobacco Control and Cessation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ISS</td>
<td>Pembrolizumab: The New Standard of Care in Advanced Lung Cancer – MSD</td>
<td>Main Hall</td>
<td>17:45 – 19:15</td>
</tr>
<tr>
<td>Conference Dinner (Ticketed Event)</td>
<td>Plenary Hall (Hall D)</td>
<td>19:30 – 22:30</td>
<td></td>
</tr>
</tbody>
</table>

## Wednesday | October 18, 2017

<table>
<thead>
<tr>
<th>Topic</th>
<th>Session Title</th>
<th>Room</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nursing/Palliative Care/Ethics</td>
<td>Management of Elderly Patients with Lung Cancer (Sign Up Required)</td>
<td>Room 303 + 304</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies</td>
<td>Mediastinal Tumors including Thymic Tumors, Lymphoma, Germ Cell Tumors: Biopsy, Diagnosis and Treatment (Sign Up Required)</td>
<td>Room 311 + 312</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>Biology/Pathology</td>
<td>Basic Cytology for Clinicians (Sign Up Required)</td>
<td>Room 313 + 314</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>Epidemiology/Primary Prevention/Tobacco Control and Cessation</td>
<td>Tobacco Control – Practical Issues (Sign Up Required)</td>
<td>Room 316</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>Clinical Design, Statistics and Clinical Trials</td>
<td>Clinical Trial Design for Novel Treatment (Sign Up Required)</td>
<td>Room 315</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>Radiology/Staging/Screening</td>
<td>CT Screening for Lung Cancer (Sign Up Required)</td>
<td>Room 501</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>Immunology and Immunotherapy</td>
<td>Immunotherapy for Earlier Stage NSCLC (Sign Up Required)</td>
<td>Room 301 + 302</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>BY DAY</td>
<td>SESSIONS AT A GLANCE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>----------------------</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| **RADIOTherapy** | MTE 29 Stereotactic Body Radiation Therapy for Early Stage Lung Cancer *(Sign Up Required)*  
Room 502 07:00 – 08:00 |
| **SURGERY** | MTE 30 Surgery after Concurrent Chemoradiotherapy *(Sign Up Required)*  
Room 503 07:00 – 08:00 |
| **CHEMOTHERAPY/TARGETED THERAPY** | MTE 31 Perspectives of Anti-Angiogenesis *(Sign Up Required)*  
Room 418 07:00 – 08:00 |
| **IMMUNOLOGY AND IMMUNOTHERAPY** | PL 03 Immunology in Lung Cancer Update 2017  
Plenary Hall (Hall D) 08:15 – 09:45 |
| | Poster Viewing with Presenters Present - Poster Session P3  
Exhibit Hall (Hall B + C) 10:00 – 10:45 |
| **NURSING/PALLIATIVE CARE/ETHICS** | MS 20 Value-based Management for Special Populations  
Room 501 11:00 – 12:30 |
| **Epidemiology/Primary Prevention/Tobacco control and Cessation** | MS 21 Being Mortal: Learning from ZEN  
Room 316 11:00 – 12:30 |
| **PULMONOLOGY/ENDOSCOPY** | ES 07 Recent Advances in Diagnostics and Interventional Bronchoscopy  
Room 503 11:00 – 12:30 |
| **CHEMOTHERAPY/TARGETED THERAPY** | ES 08 Molecular Diagnostics and Targeted Therapy  
Main Hall 11:00 – 12:30 |
| **EARLY STAGE NSCLC** | GR 03 Treatment Options for Early Stage Lung Cancer Patients with Limited Pulmonary Reserve  
F205 + F206 (Annex Hall) 11:00 – 12:30 |
| **CHEMOTHERAPY/TARGETED THERAPY** | PC 03 3-1 What is the Optimal Sequence of ALK-TKI for ALK-Positive Lung Cancer? (Alectinib First or Crizotinib First)  
3-2 Which Do you Prefer: Liquid Biopsy or Tissues Biopsy for Molecular Diagnosis?  
Room 303 + 304 11:00 – 12:30 |
| **ADVANCED NSCLC** | OA 10 Liquid Biopsy for Genomic Alterations  
F201 + F202 (Annex Hall) 11:00 – 12:30 |
| **NURSING/PALLIATIVE CARE/ETHICS** | OA 11 Reducing Burden: Patient-Centered Care  
Room 313 + 314 11:00 – 12:30 |
| **ADVANCED NSCLC** | OA 12 Emerging Genomic Targets  
F203 + F204 (Annex Hall) 11:00 – 12:30 |
| **IMMUNOLOGY AND IMMUNOTHERAPY** | OA 13 Immuno-Biology  
Room 301 + 302 11:00 – 12:30 |
| **CLINICAL DESIGN, STATISTICS AND CLINICAL TRIALS** | OA 14 New Paradigms in Clinical Trials  
Room 311 + 312 11:00 – 12:30 |
| **MESOTHELIOMA** | MA 19 Mesothelioma: Bench to Bedside  
Room 315 11:00 – 12:30 |
| **ISS** | ISS 12 SCLC Biomarker Testing Symposium – AbbVie  
Main Hall 12:45 – 14:15 |
| | Poster Viewing with Presenters Present - Poster Session P3  
Exhibit Hall (Hall B + C) 14:30 – 15:30 |
| **LOCALLY ADVANCED NSCLC** | MS 23 Management of N2 NSCLC: What "Operable" Means?  
P203 + P204 (Annex Hall) 14:30 – 16:15 |
| **RADIOLOGY(STAGING/SCREENING)** | MS 24 Management of GGO-Containing Nodule  
Room 503 14:30 – 16:15 |
| **CHEMOTHERAPY/TARGETED THERAPY** | MS 25 Novel Molecular Targets (KRAS/MET/Novel Fusions): Druggable or Not?  
Main Hall 14:30 – 16:15 |
| **BIOLOGY/PATHOLOGY** | MS 26 Re-Modeling Microenvironment Mimicking Human Cancer  
Room 502 14:30 – 16:15 |
| **PATIENT ADVOCACY** | MS 27 Engaging Patients in Research: Best Practices  
Room 311 + 312 14:30 – 16:15 |
| **SCLC/NEUROENDOCRINE TUMORS** | ES 09 Recent Progress in the Management of Small Cell Lung Cancer  
Room 501 14:30 – 16:15 |
| **RADIOTherapy** | ES 10 Radiation Treatment Update  
F201 + F202 (Annex Hall) 14:30 – 16:15 |
| **RADIOLOGY(STAGING/SCREENING)** | OA 15 Diagnostic Radiology, Staging and Screening for Lung Cancer II  
Room 303 + 304 14:30 – 16:15 |
| **EARLY STAGE NSCLC** | OA 16 Treatment Strategies and Follow Up  
Room 315 14:30 – 16:15 |
| **ADVANCED NSCLC** | OA 17 Immunotherapy II  
Room 301 + 302 14:30 – 16:15 |
| **BIOLOGY/PATHOLOGY** | OA 18 Lung Cancer Pathology and Genetics  
Room 316 14:30 – 16:15 |
| **PULMONOLOGY/ENDOSCOPY** | MA 20 Recent Advances in Pulmonology/Endoscopy  
P205 + P206 (Annex Hall) 14:30 – 16:15 |
| PL 04 Closing Plenary: Where We Are Now, and Where We Will Be in 10 Years  
Main Hall 16:30 – 17:45 |
### ADVANCED NSCLC

<table>
<thead>
<tr>
<th>TOPIC</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>DATE</th>
<th>ROOM</th>
<th>TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADVANCED NSCLC</td>
<td>JCSE 01</td>
<td>Joint IASLC/CSCO/CAALC Session: Immunotherapy for Management of Lung Cancer: Ongoing Research from East and West</td>
<td>Sunday, October 15</td>
<td>F203 (Annex Hall)</td>
<td>07:30 – 11:30</td>
</tr>
<tr>
<td>ADVANCED NSCLC</td>
<td>MA 03</td>
<td>Chemotherapy</td>
<td>Monday, October 16</td>
<td>Room 502</td>
<td>11:00 – 12:30</td>
</tr>
<tr>
<td>ADVANCED NSCLC</td>
<td>OA 05</td>
<td>Next Generation TKI</td>
<td>Monday, October 16</td>
<td>Room 301 + 302</td>
<td>15:45 – 17:30</td>
</tr>
<tr>
<td>ADVANCED NSCLC</td>
<td>PC 01</td>
<td>1-1. Surgery vs Non-Surgical Local Treatment for Small-Sized NSCLC 1-2. What is the role of Local Therapy in Non-CNS Oligometastatic NSCLC?</td>
<td>Monday, October 16</td>
<td>Room 502</td>
<td>15:45 – 17:30</td>
</tr>
<tr>
<td>ADVANCED NSCLC</td>
<td>MTE 18</td>
<td>Treatment for Squamous Cell Carcinoma (Sign Up Required)</td>
<td>Tuesday, October 17</td>
<td>Room 313 + 314</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>ADVANCED NSCLC</td>
<td>SH 01</td>
<td>WCLC 2017 Highlights of the Previous Day</td>
<td>Tuesday, October 17</td>
<td>Room 502</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>ADVANCED NSCLC</td>
<td>MS 13</td>
<td>How to Deal with CNS Metastases</td>
<td>Tuesday, October 17</td>
<td>Room 502</td>
<td>11:00 – 12:30</td>
</tr>
<tr>
<td>ADVANCED NSCLC</td>
<td>OA 09</td>
<td>EGFR TKI Resistance</td>
<td>Tuesday, October 17</td>
<td>Room 301 + 302</td>
<td>11:00 – 12:30</td>
</tr>
<tr>
<td>ADVANCED NSCLC</td>
<td>MA 10</td>
<td>Immunotherapy I</td>
<td>Tuesday, October 17</td>
<td>Room 303 + 304</td>
<td>11:00 – 12:30</td>
</tr>
<tr>
<td>ADVANCED NSCLC</td>
<td>MA 11</td>
<td>Emerging Diagnostic/Biomarkers in NSCLC</td>
<td>Tuesday, October 17</td>
<td>Room 313 + 314</td>
<td>11:00 – 12:30</td>
</tr>
<tr>
<td>ADVANCED NSCLC</td>
<td>MA 12</td>
<td>Circumventing EGFR Resistance</td>
<td>Tuesday, October 17</td>
<td>F205 + F206 (Annex Hall)</td>
<td>11:00 – 12:30</td>
</tr>
<tr>
<td>ADVANCED NSCLC</td>
<td>MA 07</td>
<td>ALK, ROS and HER2</td>
<td>Tuesday, October 17</td>
<td>Room 316</td>
<td>15:45 – 17:30</td>
</tr>
<tr>
<td>ADVANCED NSCLC</td>
<td>SH 03</td>
<td>WCLC 2017 Highlights of the Previous Day</td>
<td>Wednesday, October 18</td>
<td>F201 + F202 (Annex Hall)</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>ADVANCED NSCLC</td>
<td>OA 10</td>
<td>Liquid Biopsy for Genomic Alterations</td>
<td>Wednesday, October 18</td>
<td>F201 + F202 (Annex Hall)</td>
<td>11:00 – 12:30</td>
</tr>
<tr>
<td>ADVANCED NSCLC</td>
<td>OA 12</td>
<td>Emerging Genomic Targets</td>
<td>Wednesday, October 18</td>
<td>F203 + F204 (Annex Hall)</td>
<td>11:00 – 12:30</td>
</tr>
<tr>
<td>ADVANCED NSCLC</td>
<td>OA 17</td>
<td>Immunotherapy II</td>
<td>Wednesday, October 18</td>
<td>Room 301 + 302</td>
<td>14:30 – 16:15</td>
</tr>
</tbody>
</table>

### BIOLOGY / PATHOLOGY

<table>
<thead>
<tr>
<th>TOPIC</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>DATE</th>
<th>ROOM</th>
<th>TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>BIOLOGY/PATHOLOGY</td>
<td>MTE 02</td>
<td>Appropriate and Optimized Handling of Specimens (Sign Up Required)</td>
<td>Monday, October 16</td>
<td>Room 316</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>BIOLOGY/PATHOLOGY</td>
<td>MTE 05</td>
<td>Neuroendocrine Tumors: Pathology and Genetic Update (Sign Up Required)</td>
<td>Monday, October 16</td>
<td>Room 313 + 314</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>BIOLOGY/PATHOLOGY</td>
<td>MTE 06</td>
<td>Lung Cancer Pathology Update (Sign Up Required)</td>
<td>Monday, October 16</td>
<td>Room 315</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>BIOLOGY/PATHOLOGY</td>
<td>OA 07</td>
<td>Biomarker for Lung Cancer</td>
<td>Monday, October 16</td>
<td>Room 503</td>
<td>15:45 – 17:30</td>
</tr>
<tr>
<td>BIOLOGY/PATHOLOGY</td>
<td>MA 06</td>
<td>Lung Cancer Biology I</td>
<td>Monday, October 16</td>
<td>Room 501</td>
<td>15:45 – 17:30</td>
</tr>
<tr>
<td>BIOLOGY/PATHOLOGY</td>
<td>SH 01</td>
<td>WCLC 2017 Highlights of the Previous Day</td>
<td>Tuesday, October 17</td>
<td>Room 502</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>BIOLOGY/PATHOLOGY</td>
<td>SH 02</td>
<td>WCLC 2017 Highlights of the Previous Day</td>
<td>Tuesday, October 17</td>
<td>Room 503</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>BIOLOGY/PATHOLOGY</td>
<td>MTE 20</td>
<td>Liquid Biopsy (Sign Up Required)</td>
<td>Tuesday, October 17</td>
<td>Room 303 + 304</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>BIOLOGY/PATHOLOGY</td>
<td>ES 04</td>
<td>Biology of Lung Cancer</td>
<td>Tuesday, October 17</td>
<td>F201 + F202 (Annex Hall)</td>
<td>11:00 – 12:30</td>
</tr>
<tr>
<td>Topic</td>
<td>Session Title</td>
<td>Date</td>
<td>Room</td>
<td>Time</td>
<td></td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>---------------------------</td>
<td>-----------------------</td>
<td>------------</td>
<td></td>
</tr>
<tr>
<td>Biology/Pathology</td>
<td>MS 15 Molecular Testing</td>
<td>Tuesday, October 17</td>
<td>Room 301 + 302</td>
<td>15:45 - 17:30</td>
<td></td>
</tr>
<tr>
<td>Biology/Pathology</td>
<td>MA 15 Lung Cancer Biology II</td>
<td>Tuesday, October 17</td>
<td>Room 501</td>
<td>15:45 - 17:30</td>
<td></td>
</tr>
<tr>
<td>Biology/Pathology</td>
<td>MTE 24 Basic Cytology for Clinicians (Sign Up Required)</td>
<td>Wednesday, October 18</td>
<td>Room 313 + 314</td>
<td>07:00 - 08:00</td>
<td></td>
</tr>
<tr>
<td>Biology/Pathology</td>
<td>SH 03 WCLC 2017 Highlights of the Previous Day</td>
<td>Wednesday, October 18</td>
<td>F201 + F202 (Annex Hall)</td>
<td>07:00 - 08:00</td>
<td></td>
</tr>
<tr>
<td>Biology/Pathology</td>
<td>SH 04 WCLC 2017 Highlights of the Previous Day</td>
<td>Wednesday, October 18</td>
<td>F203 + F204 (Annex Hall)</td>
<td>07:00 - 08:00</td>
<td></td>
</tr>
<tr>
<td>Biology/Pathology</td>
<td>OA 18 Lung Cancer Pathology and Genetics</td>
<td>Wednesday, October 18</td>
<td>Room 316</td>
<td>14:30 - 16:15</td>
<td></td>
</tr>
<tr>
<td>Biology/Pathology</td>
<td>MS 26 Re-Modeling Microenvironment Mimicking Human Cancer</td>
<td>Wednesday, October 18</td>
<td>Room 502</td>
<td>14:30 - 16:15</td>
<td></td>
</tr>
</tbody>
</table>

**CHEMOTHERAPY / TARGETED THERAPY**

<table>
<thead>
<tr>
<th>Topic</th>
<th>Session Title</th>
<th>Date</th>
<th>Room</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemotherapy/Targeted Therapy</td>
<td>JCSE 01 Joint IASLC/CSCO/CAALC Session: Immunotherapy for Management of Lung Cancer: Ongoing Research from East and West</td>
<td>Sunday, October 15</td>
<td>F203 (Annex Hall)</td>
<td>07:30 – 11:30</td>
</tr>
<tr>
<td>Chemotherapy/Targeted Therapy</td>
<td>MTE 07 Molecular Biology: Minimum Requirement for Clinicians (Sign Up Required)</td>
<td>Monday, October 16</td>
<td>Room 501</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>Chemotherapy/Targeted Therapy</td>
<td>MTE 10 Bridging the Gap between Genomics and Clinics (Sign Up Required)</td>
<td>Monday, October 16</td>
<td>Room 511 + 512</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>Chemotherapy/Targeted Therapy</td>
<td>GR 01 What to Do at the Time of Progression on Targeted Therapy</td>
<td>Monday, October 16</td>
<td>Room 303 + 304</td>
<td>11:00 – 12:30</td>
</tr>
<tr>
<td>Chemotherapy/Targeted Therapy</td>
<td>MA 03 Chemotherapy</td>
<td>Monday, October 16</td>
<td>Room 502</td>
<td>11:00 – 12:30</td>
</tr>
<tr>
<td>Chemotherapy/Targeted Therapy</td>
<td>OA 05 Next Generation TKI</td>
<td>Monday, October 16</td>
<td>Room 301 + 302</td>
<td>15:45 – 17:30</td>
</tr>
<tr>
<td>Chemotherapy/Targeted Therapy</td>
<td>MTE 21 Search for Novel Driver Mutations (Sign Up Required)</td>
<td>Tuesday, October 17</td>
<td>Room 315</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>Chemotherapy/Targeted Therapy</td>
<td>SH 02 WCLC 2017 Highlights of the Previous Day</td>
<td>Tuesday, October 17</td>
<td>Room 503</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>Chemotherapy/Targeted Therapy</td>
<td>OA 09 EGFR TKI Resistance</td>
<td>Tuesday, October 17</td>
<td>Room 301 + 302</td>
<td>11:00 – 12:30</td>
</tr>
<tr>
<td>Chemotherapy/Targeted Therapy</td>
<td>MA 11 Emerging Diagnostic/Biomarkers in NSCLC</td>
<td>Tuesday, October 17</td>
<td>Room 313 + 314</td>
<td>11:00 – 12:30</td>
</tr>
<tr>
<td>Chemotherapy/Targeted Therapy</td>
<td>MA 12 Circumventing EGFR Resistance</td>
<td>Tuesday, October 17</td>
<td>F205 + F206 (Annex Hall)</td>
<td>11:00 – 12:30</td>
</tr>
<tr>
<td>Chemotherapy/Targeted Therapy</td>
<td>MA 07 ALK, ROS and HER2</td>
<td>Tuesday, October 17</td>
<td>Room 316</td>
<td>15:45 – 17:30</td>
</tr>
<tr>
<td>Radiotherapy/Chemotherapy/Targeted Therapy</td>
<td>MS 16 Future Direction of Chemoradiotherapy for Inoperable Non-Small Cell Lung</td>
<td>Tuesday, October 17</td>
<td>Room 502</td>
<td>15:45 – 17:30</td>
</tr>
<tr>
<td>Chemotherapy/Targeted Therapy</td>
<td>SH 04 WCLC 2017 Highlights of the Previous Day</td>
<td>Wednesday, October 18</td>
<td>F203 + F204 (Annex Hall)</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>Chemotherapy/Targeted Therapy</td>
<td>MTE 31 Perspectives of Anti-Angiogenesis (Sign Up Required)</td>
<td>Wednesday, October 18</td>
<td>Room 418</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>Chemotherapy/Targeted Therapy</td>
<td>ES 08 Molecular Diagnostics and Targeted Therapy</td>
<td>Wednesday, October 18</td>
<td>Main Hall</td>
<td>11:00 – 12:30</td>
</tr>
<tr>
<td>Chemotherapy/Targeted Therapy</td>
<td>PC 03 3-1 What is the Optimal Sequence of ALK-TKI for ALK-Positive Lung Cancer? (Alectinib First or Crizotinib First) 3-2 Which Do you Prefer: Liquid Biopsy or Tissues Biopsy for Molecular Diagnosis?</td>
<td>Wednesday, October 18</td>
<td>Room 303 + 304</td>
<td>11:00 – 12:30</td>
</tr>
<tr>
<td>Chemotherapy/Targeted Therapy</td>
<td>OA 12 Emerging Genomic Targets</td>
<td>Wednesday, October 18</td>
<td>F203 + F204 (Annex Hall)</td>
<td>11:00 – 12:30</td>
</tr>
<tr>
<td>Radiology/Staging/Screening/Chemotherapy/Targeted Therapy Surgery</td>
<td>MS 24 Management of GGO-Containing Nodule</td>
<td>Wednesday, October 18</td>
<td>Room 503</td>
<td>14:30 – 16:15</td>
</tr>
<tr>
<td>Chemotherapy/Targeted Therapy</td>
<td>MS 25 Novel Molecular Targets (KRAS/MET/Novel Fusions): Druggable or Not?</td>
<td>Wednesday, October 18</td>
<td>Main Hall</td>
<td>14:30 – 16:15</td>
</tr>
<tr>
<td>TOPIC</td>
<td>#</td>
<td>SESSION TITLE</td>
<td>DATE</td>
<td>ROOM</td>
</tr>
<tr>
<td>-------</td>
<td>---</td>
<td>---------------</td>
<td>------</td>
<td>------</td>
</tr>
<tr>
<td>CLINICAL DESIGN, STATISTICS AND CLINICAL TRIALS</td>
<td>MS 01</td>
<td>Clinical Development of Novel Agents</td>
<td>Monday, October 16</td>
<td>Main Hall</td>
</tr>
<tr>
<td>CLINICAL DESIGN, STATISTICS AND CLINICAL TRIALS</td>
<td>MA 02</td>
<td>Emerging Targets</td>
<td>Monday, October 16</td>
<td>Room 511 + 512</td>
</tr>
<tr>
<td>CLINICAL DESIGN, STATISTICS AND CLINICAL TRIALS</td>
<td>SH 01</td>
<td>WCLC 2017 Highlights of the Previous Day</td>
<td>Tuesday, October 17</td>
<td>Room 502</td>
</tr>
<tr>
<td>CLINICAL DESIGN, STATISTICS AND CLINICAL TRIALS</td>
<td>MS 17</td>
<td>Lessons Learned from Negative Trials</td>
<td>Tuesday, October 17</td>
<td>Room 303 + 304</td>
</tr>
<tr>
<td>CLINICAL DESIGN, STATISTICS AND CLINICAL TRIALS</td>
<td>MTE 26</td>
<td>Clinical Trial Design for Novel Treatment (Sign Up Required)</td>
<td>Wednesday, October 18</td>
<td>Room 315</td>
</tr>
<tr>
<td>CLINICAL DESIGN, STATISTICS AND CLINICAL TRIALS</td>
<td>OA 14</td>
<td>New Paradigms in Clinical Trials</td>
<td>Wednesday, October 18</td>
<td>Room 311 + 312</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TOPIC</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>DATE</th>
<th>ROOM</th>
<th>TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>EARLY STAGE NSCLC</td>
<td>MS 03</td>
<td>Best Practice for Small-Sized Early Stage Lung Cancer: Standard Surgery, Limited Resection, SBRT</td>
<td>Monday, October 16</td>
<td>F203 + F204 (Annex Hall)</td>
<td>11:00 – 12:30</td>
</tr>
<tr>
<td>EARLY STAGE NSCLC</td>
<td>PC 01</td>
<td>1-1. Surgery vs Non-Surgical Local Treatment for Small-Sized NSCLC 1-2. What is the role of Local Therapy in Non-CNS Oligometastatic NSCLC?</td>
<td>Monday, October 16</td>
<td>Room 502</td>
<td>15:45 – 17:30</td>
</tr>
<tr>
<td>EARLY STAGE NSCLC</td>
<td>PL 02</td>
<td>Presidential Symposium (incl. Top 3 Rated Abstracts)</td>
<td>Tuesday, October 17</td>
<td>Plenary Hall (Hall D)</td>
<td>08:15 – 09:45</td>
</tr>
<tr>
<td>EARLY STAGE NSCLC</td>
<td>MA 13</td>
<td>New Insights of Diagnosis and Update of Treatment</td>
<td>Tuesday, October 17</td>
<td>Room 311 + 312</td>
<td>15:45 – 17:30</td>
</tr>
<tr>
<td>EARLY STAGE NSCLC</td>
<td>SH 03</td>
<td>WCLC 2017 Highlights of the Previous Day</td>
<td>Wednesday, October 18</td>
<td>F201 + F202 (Annex Hall)</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>EARLY STAGE NSCLC</td>
<td>GR 03</td>
<td>Treatment Options for Early Stage Lung Cancer Patients with Limited Pulmonary Reserve</td>
<td>Wednesday, October 18</td>
<td>F205 + F206 (Annex Hall)</td>
<td>11:00 – 12:30</td>
</tr>
<tr>
<td>EARLY STAGE NSCLC</td>
<td>OA 16</td>
<td>Treatment Strategies and Follow Up</td>
<td>Wednesday, October 18</td>
<td>Room 315</td>
<td>14:30 – 16:15</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TOPIC</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>DATE</th>
<th>ROOM</th>
<th>TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>EDUCATION / PUBLICATION / CAREER DEVELOPMENT</td>
<td>YI 01</td>
<td>Young Investigator and First Time Attendee Session</td>
<td>Sunday, October 15</td>
<td>F201 + F202 (Annex Hall)</td>
<td>08:00 – 11:30</td>
</tr>
<tr>
<td>EDUCATION / PUBLICATION / CAREER DEVELOPMENT</td>
<td>MTE 11</td>
<td>How to Write a Scientific Paper (Sign Up Required)</td>
<td>Tuesday, October 17</td>
<td>Room 311 + 312</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>EDUCATION / PUBLICATION / CAREER DEVELOPMENT</td>
<td>JTO</td>
<td>Meet the JTO Editor</td>
<td>Tuesday, October 17</td>
<td>Room 311 + 312</td>
<td>14:30 – 15:30</td>
</tr>
</tbody>
</table>
## Epidemiology / Primary Prevention / Tobacco Control and Cessation

<table>
<thead>
<tr>
<th>Topic</th>
<th>#</th>
<th>Session Title</th>
<th>Date</th>
<th>Room</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epidemiology / Primary Prevention / Tobacco Control and Cessation</td>
<td>MS 09</td>
<td>Global Perspectives in Eliminating the Major Cause of Lung Cancer</td>
<td>Monday, October 16</td>
<td>Room 315</td>
<td>15:45 – 17:30</td>
</tr>
<tr>
<td>Epidemiology / Primary Prevention / Tobacco Control and Cessation</td>
<td>OA 06</td>
<td>Global Tobacco Control and Epidemiology I</td>
<td>Monday, October 16</td>
<td>Room 511 + 512</td>
<td>15:45 – 17:30</td>
</tr>
<tr>
<td>Epidemiology / Primary Prevention / Tobacco Control and Cessation</td>
<td>SH 01</td>
<td>WCLC 2017 Highlights of the Previous Day</td>
<td>Tuesday, October 17</td>
<td>Room 502</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>Epidemiology / Primary Prevention / Tobacco Control and Cessation</td>
<td>MA 18</td>
<td>Global Tobacco Control and Epidemiology II</td>
<td>Tuesday, October 17</td>
<td>Room 511 + 512</td>
<td>15:45 – 17:30</td>
</tr>
<tr>
<td>Epidemiology / Primary Prevention / Tobacco Control and Cessation</td>
<td>SH 03</td>
<td>WCLC 2017 Highlights of the Previous Day</td>
<td>Wednesday, October 18</td>
<td>F201 + F202 (Annex Hall)</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>Epidemiology / Primary Prevention / Tobacco Control and Cessation</td>
<td>MTE 25</td>
<td>Tobacco Control – Practical Issues (Sign Up Required)</td>
<td>Wednesday, October 18</td>
<td>Room 316</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>Epidemiology / Primary Prevention / Tobacco Control and Cessation</td>
<td>MS 22</td>
<td>The Cost of Lung Cancer</td>
<td>Wednesday, October 18</td>
<td>Room 502</td>
<td>11:00 – 12:30</td>
</tr>
</tbody>
</table>

## Immunology and Immunotherapy

<table>
<thead>
<tr>
<th>Topic</th>
<th>#</th>
<th>Session Title</th>
<th>Date</th>
<th>Room</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immunology and Immunotherapy</td>
<td>JCSE 01</td>
<td>Joint IASLC/CSCO/CAALC Session: Immunotherapy for Management of Lung Cancer: Ongoing Research from East and West</td>
<td>Sunday, October 15</td>
<td>F203 (Annex Hall)</td>
<td>07:30 – 11:30</td>
</tr>
<tr>
<td>Immunology and Immunotherapy</td>
<td>MS 05</td>
<td>Clinical Issues of Immune Checkpoint Inhibitors</td>
<td>Monday, October 16</td>
<td>Main Hall</td>
<td>15:45 – 17:30</td>
</tr>
<tr>
<td>Immunology and Immunotherapy</td>
<td>MA 05</td>
<td>Immuno-Oncology: Novel Biomarker Candidates</td>
<td>Monday, October 16</td>
<td>Room 303 + 304</td>
<td>15:45 – 17:30</td>
</tr>
<tr>
<td>Immunology and Immunotherapy</td>
<td>SH 01</td>
<td>WCLC 2017 Highlights of the Previous Day</td>
<td>Tuesday, October 17</td>
<td>Room 502</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>Immunology and Immunotherapy</td>
<td>MTE 15</td>
<td>Biomarkers for Immune Checkpoint Inhibitors (Sign Up Required)</td>
<td>Tuesday, October 17</td>
<td>Room 301 + 302</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>Immunology and Immunotherapy</td>
<td>PL 02</td>
<td>Presidential Symposium (incl. Top 3 Rated Abstracts)</td>
<td>Tuesday, October 17</td>
<td>Plenary Hall (Hall D)</td>
<td>08:15 – 09:45</td>
</tr>
<tr>
<td>Immunology and Immunotherapy</td>
<td>GR 02</td>
<td>Management of Immunotherapy-Related Adverse Events</td>
<td>Tuesday, October 17</td>
<td>Main Hall</td>
<td>11:00 – 12:30</td>
</tr>
<tr>
<td>Immunology and Immunotherapy</td>
<td>MA 10</td>
<td>Immunotherapy I</td>
<td>Tuesday, October 17</td>
<td>Room 303 + 304</td>
<td>11:00 – 12:30</td>
</tr>
<tr>
<td>Immunology and Immunotherapy</td>
<td>MS 18</td>
<td>Biomarker for Anti-PD-L1 Therapy</td>
<td>Tuesday, October 17</td>
<td>Main Hall</td>
<td>15:45 – 17:30</td>
</tr>
<tr>
<td>Immunology and Immunotherapy</td>
<td>SH 03</td>
<td>WCLC 2017 Highlights of the Previous Day</td>
<td>Wednesday, October 18</td>
<td>F201 + F202 (Annex Hall)</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>Immunology and Immunotherapy</td>
<td>MTE 28</td>
<td>Immunotherapy for Earlier Stage NSCLC (Sign Up Required)</td>
<td>Wednesday, October 18</td>
<td>Room 301 + 302</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>Immunology and Immunotherapy</td>
<td>PL 03</td>
<td>Immunology in Lung Cancer Update 2017</td>
<td>Wednesday, October 18</td>
<td>Plenary Hall (Hall D)</td>
<td>08:15 – 09:45</td>
</tr>
<tr>
<td>Immunology and Immunotherapy</td>
<td>OA 13</td>
<td>Immuno-Biology</td>
<td>Wednesday, October 18</td>
<td>Room 301 + 302</td>
<td>11:00 – 12:30</td>
</tr>
<tr>
<td>Immunology and Immunotherapy</td>
<td>OA 17</td>
<td>Immunotherapy II</td>
<td>Wednesday, October 18</td>
<td>Room 301 + 302</td>
<td>14:30 – 16:15</td>
</tr>
</tbody>
</table>
## Locally Advanced NSCLC

<table>
<thead>
<tr>
<th>Topic</th>
<th>Session</th>
<th>Date</th>
<th>Room</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Locally Advanced NSCLC</td>
<td>MS 11</td>
<td>Tuesday, October 17</td>
<td>Room 503</td>
<td>11:00 – 12:30</td>
</tr>
<tr>
<td></td>
<td>MA 09</td>
<td>Tuesday, October 17</td>
<td>Room 316</td>
<td>11:00 – 12:30</td>
</tr>
<tr>
<td></td>
<td>MA 17</td>
<td>Tuesday, October 17</td>
<td>F203 + F204</td>
<td>15:45 – 17:30</td>
</tr>
<tr>
<td></td>
<td>SH 04</td>
<td>Wednesday, October 18</td>
<td>F203 + F204</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td></td>
<td>MS 23</td>
<td>Wednesday, October 18</td>
<td>F203 + F204</td>
<td>14:30 – 16:15</td>
</tr>
</tbody>
</table>

## Mesothelioma

<table>
<thead>
<tr>
<th>Topic</th>
<th>Session</th>
<th>Date</th>
<th>Room</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mesothelioma</td>
<td>WS 03</td>
<td>Sunday, October 15</td>
<td>Room 313</td>
<td>12:15 – 17:55</td>
</tr>
<tr>
<td></td>
<td>OA 02</td>
<td>Monday, October 16</td>
<td>F205 + F206</td>
<td>11:00 – 12:30</td>
</tr>
<tr>
<td></td>
<td>MS 08</td>
<td>Monday, October 16</td>
<td>Room 316</td>
<td>15:45 – 17:30</td>
</tr>
<tr>
<td></td>
<td>SH 02</td>
<td>Tuesday, October 17</td>
<td>Room 503</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td></td>
<td>MTE 13</td>
<td>Tuesday, October 17</td>
<td>Room 501</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td></td>
<td>MA 19</td>
<td>Wednesday, October 18</td>
<td>Room 315</td>
<td>11:00 – 12:30</td>
</tr>
</tbody>
</table>

## Nursing / Palliative Care / Ethics

<table>
<thead>
<tr>
<th>Topic</th>
<th>Session</th>
<th>Date</th>
<th>Room</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nursing/Palliative Care/Ethics</td>
<td>WS 03</td>
<td>Sunday, October 15</td>
<td>Room 313</td>
<td>12:15 – 17:55</td>
</tr>
<tr>
<td></td>
<td>MTE 09</td>
<td>Monday, October 16</td>
<td>Room 503</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td></td>
<td>ES 03</td>
<td>Monday, October 16</td>
<td>Room 313 + 314</td>
<td>15:45 – 17:30</td>
</tr>
<tr>
<td></td>
<td>MS 10</td>
<td>Monday, October 16</td>
<td>F205 + F206</td>
<td>15:45 – 17:30</td>
</tr>
<tr>
<td></td>
<td>MTE 12</td>
<td>Tuesday, October 17</td>
<td>Room 316</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td></td>
<td>MS 14</td>
<td>Tuesday, October 17</td>
<td>Room 315</td>
<td>11:00 – 12:30</td>
</tr>
<tr>
<td></td>
<td>MA 08</td>
<td>Tuesday, October 17</td>
<td>Room 511 + 512</td>
<td>11:00 – 12:30</td>
</tr>
<tr>
<td></td>
<td>ES 06</td>
<td>Tuesday, October 17</td>
<td>F201 + F202</td>
<td>15:45 – 17:30</td>
</tr>
<tr>
<td></td>
<td>SH 04</td>
<td>Wednesday, October 18</td>
<td>F203 + F204</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td></td>
<td>MTE 22</td>
<td>Wednesday, October 18</td>
<td>Room 303 + 304</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td></td>
<td>MS 20</td>
<td>Wednesday, October 18</td>
<td>Room 501</td>
<td>11:00 – 12:30</td>
</tr>
</tbody>
</table>
### Onsite Program / IASLC 18th World Conference on Lung Cancer

**By Track**

**Sessions at a Glance**

#### Nursing/Palliative Care/Ethics
- **MS 21** Being Mortal: Learning from ZEN  
  Wednesday, October 18  
  Room 316  
  11:00 – 12:30
- **OA 11** Reducing Burden: Patient-Centered Care  
  Wednesday, October 18  
  Room 313 + 314  
  11:00 – 12:30

#### Patient Advocacy

<table>
<thead>
<tr>
<th>Topic</th>
<th>#</th>
<th>Session Title</th>
<th>Date</th>
<th>Room</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient Advocacy</td>
<td>MA 04</td>
<td>Advocacy: Listen to the Patients</td>
<td>Monday, October 16</td>
<td>Room 313 + 314</td>
<td>11:00 – 12:30</td>
</tr>
<tr>
<td>Patient Advocacy</td>
<td>MS 04</td>
<td>Joint IASLC/GLCC Session Current Issues in Lung Cancer Advocacy</td>
<td>Monday, October 16</td>
<td>Room 316</td>
<td>11:00 – 12:30</td>
</tr>
<tr>
<td>Patient Advocacy</td>
<td>SH 01</td>
<td>WCLC 2017 Highlights of the Previous Day</td>
<td>Tuesday, October 17</td>
<td>Room 502</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>Patient Advocacy</td>
<td>MS 19</td>
<td>Elevating the Lung Cancer Voice: Raising Awareness and Creating Community</td>
<td>Tuesday, October 17</td>
<td>Room 315</td>
<td>15:45 – 17:30</td>
</tr>
<tr>
<td>Patient Advocacy</td>
<td>OA 11</td>
<td>Reducing Burden: Patient-Centered Care</td>
<td>Wednesday, October 18</td>
<td>Room 313 + 314</td>
<td>11:00 – 12:30</td>
</tr>
<tr>
<td>Patient Advocacy</td>
<td>MS 27</td>
<td>Engaging Patients in Research: Best Practices</td>
<td>Wednesday, October 18</td>
<td>Room 311 + 312</td>
<td>14:30 – 16:15</td>
</tr>
</tbody>
</table>

#### Pulmonology/Endoscopy

<table>
<thead>
<tr>
<th>Topic</th>
<th>#</th>
<th>Session Title</th>
<th>Date</th>
<th>Room</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonology/Endoscopy</td>
<td>WS 04</td>
<td>Minimally Invasive Diagnosis and Staging of Lung Cancer – Interventional Pulmonology Hands-On Workshop</td>
<td>Sunday, October 15</td>
<td>Room 416 + 417</td>
<td>13:00 – 17:00</td>
</tr>
<tr>
<td>Pulmonology/Endoscopy</td>
<td>MTE 08</td>
<td>Technical Details of EBUS and EUS (Sign Up Required)</td>
<td>Monday, October 16</td>
<td>Room 502</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>Pulmonology/Endoscopy</td>
<td>WS 05</td>
<td>superDimension™ Electromagnetic Navigation Bronchoscopy - Bridging the Diagnostic and Therapeutic Domains in Lung Cancer - Medtronic</td>
<td>Monday, October 16</td>
<td>Room 315</td>
<td>19:15 – 20:30</td>
</tr>
<tr>
<td>Pulmonology/Endoscopy</td>
<td>MTE 19</td>
<td>Laser Therapy for Early Stage and Airway Obstruction (Sign Up Required)</td>
<td>Tuesday, October 17</td>
<td>Room 317</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>Pulmonology/Endoscopy</td>
<td>ES 07</td>
<td>Recent Advances in Diagnostics and Interventional Bronchoscopy</td>
<td>Wednesday, October 18</td>
<td>Room 503</td>
<td>11:00 – 12:30</td>
</tr>
<tr>
<td>Pulmonology/Endoscopy</td>
<td>MA 20</td>
<td>Recent Advances in Pulmonology/Endoscopy</td>
<td>Wednesday, October 18</td>
<td>F205 + F206 (Annex Hall)</td>
<td>14:30 – 16:15</td>
</tr>
</tbody>
</table>

#### Radiology/Staging/Screening

<table>
<thead>
<tr>
<th>Topic</th>
<th>#</th>
<th>Session Title</th>
<th>Date</th>
<th>Room</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radiology/Staging/Screening</td>
<td>WS 01</td>
<td>IASLC Supporting the Implementation of Quality Assured Global CT Screening Workshop (By Invitation Only)</td>
<td>Saturday, October 14</td>
<td>F203 (Annex Hall)</td>
<td>08:30 – 21:00</td>
</tr>
<tr>
<td>Radiology/Staging/Screening</td>
<td>WS 02</td>
<td>IASLC Symposium on the Advances in Lung Cancer CT Screening (Ticketed Session)</td>
<td>Saturday, October 14</td>
<td>F201 + F202 (Annex Hall)</td>
<td>09:00 – 18:15</td>
</tr>
<tr>
<td>Radiology/Staging/Screening</td>
<td>SS 01</td>
<td>Supporting the Clinical Management of Lung Cancer Patients through Innovation in Diagnostics – Roche</td>
<td>Sunday, October 15</td>
<td>Room 315</td>
<td>08:15 – 12:00</td>
</tr>
<tr>
<td>Radiology/Staging/Screening</td>
<td>MTE 01</td>
<td>Management of Small Nodules Detected by CT Screening (Sign Up Required)</td>
<td>Monday, October 16</td>
<td>Room 301 + 302</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>Radiology/Staging/Screening</td>
<td>PL 01</td>
<td>Prevention, Screening, and Management of Screen-Detected Lung Cancer</td>
<td>Monday, October 16</td>
<td>Penoyer Hall (Hall D)</td>
<td>08:15 – 09:45</td>
</tr>
<tr>
<td>Radiology/Staging/Screening</td>
<td>ES 01</td>
<td>New TNM and WHO Classification</td>
<td>Monday, October 16</td>
<td>Room 301 + 302</td>
<td>11:00 – 12:30</td>
</tr>
<tr>
<td>Radiology/Staging/Screening</td>
<td>ES 02</td>
<td>Diagnostic and Interventional Radiology in Lung Cancer: Update 2017</td>
<td>Monday, October 16</td>
<td>Room 315</td>
<td>11:00 – 12:30</td>
</tr>
<tr>
<td>Radiology/Staging/Screening</td>
<td>MTE 14</td>
<td>Imaging of Lung Cancer (Sign Up Required)</td>
<td>Tuesday, October 17</td>
<td>F205 + F206 (Annex Hall)</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>Radiology/Staging/Screening</td>
<td>MA 14</td>
<td>Diagnostic Radiology, Staging and Screening for Lung Cancer I</td>
<td>Tuesday, October 17</td>
<td>F205 + F206 (Annex Hall)</td>
<td>15:45 – 17:30</td>
</tr>
<tr>
<td>Radiology/Staging/Screening</td>
<td>SH 03</td>
<td>WCLC 2017 Highlights of the Previous Day</td>
<td>Wednesday, October 18</td>
<td>F201 + F202 (Annex Hall)</td>
<td>07:00 – 08:00</td>
</tr>
</tbody>
</table>
### SESSIONS AT A GLANCE

#### BY TRACK

<table>
<thead>
<tr>
<th>Topic</th>
<th>Session Title</th>
<th>Date</th>
<th>Room</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>RADIOLOGY/STAGING/SCREENING</strong></td>
<td>MTE 27 CT Screening for Lung Cancer (Sign Up Required)</td>
<td>Wednesday, October 18</td>
<td>Room 501</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td><strong>RADIOLOGY/STAGING/SCREENING</strong></td>
<td>MS 24 Management of GGO-Containing Nodule</td>
<td>Wednesday, October 18</td>
<td>Room 503</td>
<td>14:30 – 16:15</td>
</tr>
<tr>
<td><strong>RADIOLOGY/STAGING/SCREENING</strong></td>
<td>OA 15 Diagnostic Radiology, Staging and Screening for Lung Cancer II</td>
<td>Wednesday, October 18</td>
<td>Room 303 + 304</td>
<td>14:30 – 16:15</td>
</tr>
</tbody>
</table>

#### RADIOLOGY/STAGING/SCREENING

##### TOPIC # SESSION TITLE DATE ROOM TIME

- **MTE 04 Radiotherapy for SCLC (Sign Up Required)**
  - Monday, October 16
  - Room 311 + 312
  - 07:00 – 08:00

- **OA 01 The New Aspect of Radiation Therapy**
  - Monday, October 16
  - F201 + F202 (Annex Hall)
  - 11:00 – 12:30

- **SH 02 WCLC 2017 Highlights of the Previous Day**
  - Tuesday, October 17
  - Room 503
  - 07:00 – 08:00

- **MA 09 The Current Status of Radiation Oncology**
  - Tuesday, October 17
  - Room 316
  - 11:00 – 12:30

- **MS 16 Future Direction of Chemoradiotherapy for Inoperable Non-Small Cell Lung Cancer**
  - Tuesday, October 17
  - Room 502
  - 15:45 – 17:30

- **SH 04 WCLC 2017 Highlights of the Previous Day**
  - Wednesday, October 18
  - F203 + F204 (Annex Hall)
  - 07:00 – 08:00

- **MTE 29 Stereotactic Body Radiation Therapy for Early Stage Lung Cancer (Sign Up Required)**
  - Wednesday, October 18
  - Room 502
  - 07:00 – 08:00

- **ES 10 Radiation Treatment Update**
  - Wednesday, October 18
  - F201 + F202 (Annex Hall)
  - 14:30 – 16:15

#### REGIONAL ASPECTS / HEALTH POLICY / PUBLIC HEALTH

##### TOPIC # SESSION TITLE DATE ROOM TIME

- **MS 02 Ethnic Differences: Biology or Myth**
  - Monday, October 16
  - Room 501
  - 11:00 – 12:30

- **MS 12 Sustainable Care System in Each Region**
  - Tuesday, October 17
  - Room 501
  - 11:00 – 12:30

#### SCLC / NEUROENDOCRINE TUMORS

##### TOPIC # SESSION TITLE DATE ROOM TIME

- **JCSE 01 Joint IASLC/CSCO/CAALC Session: Immunotherapy for Management of Lung Cancer: Ongoing Research from East and West**
  - Sunday, October 15
  - F203 (Annex Hall)
  - 07:30 – 11:30

- **MA 01 SCLC: Research Perspectives**
  - Monday, October 16
  - Room 503
  - 11:00 – 12:30

- **MS 07 Neuroendocrine Tumors other than SCLC: Pathology to Patient Management**
  - Monday, October 16
  - F203 + F204 (Annex Hall)
  - 15:45 – 17:30

- **SH 02 WCLC 2017 Highlights of the Previous Day**
  - Tuesday, October 17
  - Room 503
  - 07:00 – 08:00

- **MTE 17 Neuroendocrine Tumor (Sign Up Required)**
  - Tuesday, October 17
  - Room 418
  - 07:00 – 08:00

- **PC 02 Is Radiotherapy Necessary for Extensive SCLC? (Thoracic Radiation/PCI)**
  - Tuesday, October 17
  - F203 + F204 (Annex Hall)
  - 11:00 – 12:30

- **OA 08 Neuroendocrine Carcinoma: Translation**
  - Tuesday, October 17
  - Room 311 + 312
  - 11:00 – 12:30
### SCLC/NEUROENDOCRINE TUMORS

**SH 04**  
**WCLC 2017 Highlights of the Previous Day**  
**Wednesday, October 18**  
**F203 + F204 (Annex Hall)**  
**07:00 – 08:00**

**ES 09**  
**Recent Progress in the Management of Small Cell Lung Cancer**  
**Wednesday, October 18**  
**Room 501**  
**14:30 – 16:15**

### BY TRACK

#### SURGERY

<table>
<thead>
<tr>
<th>TOPIC</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>DATE</th>
<th>ROOM</th>
<th>TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>SURGERY</td>
<td>JCSE 01</td>
<td>Joint IASLC/CSCO/CAALC Session: Immunotherapy for Management of Lung Cancer: Ongoing Research from East and West</td>
<td>Sunday, October 15</td>
<td>F203 (Annex Hall)</td>
<td>07:30 – 11:30</td>
</tr>
<tr>
<td>RADIOLGY/STAGING/SCREENING</td>
<td>MTE 01</td>
<td>Management of Small Nodules Detected by CT Screening (<em>Sign Up Required</em>)</td>
<td>Monday, October 16</td>
<td>Room 301 + 302</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>SURGERY</td>
<td>MTE 03</td>
<td>Surgery for T4 Lung Cancer (<em>Sign Up Required</em>)</td>
<td>Monday, October 16</td>
<td>Room 303 + 304</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>SURGERY</td>
<td>OA 04</td>
<td>Surgery from Minimal to Radical</td>
<td>Monday, October 16</td>
<td>Room 311 + 312</td>
<td>15:45 – 17:30</td>
</tr>
<tr>
<td>SURGERY</td>
<td>SH 01</td>
<td>WCLC 2017 Highlights of the Previous Day</td>
<td>Tuesday, October 17</td>
<td>Room 502</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>SURGERY</td>
<td>MTE 16</td>
<td>Technical Issues after Neoadjuvant Chemoradiation – Surgeon’s Perspective (<em>Sign Up Required</em>)</td>
<td>Tuesday, October 17</td>
<td>Room 311 + 312</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>SURGERY</td>
<td>PL 02</td>
<td>Presidential Symposium (incl. Top 3 Rated Abstracts)</td>
<td>Tuesday, October 17</td>
<td>Plenary Hall (Hall D)</td>
<td>08:15 – 09:45</td>
</tr>
<tr>
<td>SURGERY</td>
<td>ES 05</td>
<td>Surgical Skills</td>
<td>Tuesday, October 17</td>
<td>Room 503</td>
<td>15:45 – 17:30</td>
</tr>
<tr>
<td>SURGERY</td>
<td>MTE 30</td>
<td>Surgery after Concurrent Chemoradiotherapy (<em>Sign Up Required</em>)</td>
<td>Wednesday, October 18</td>
<td>Room 503</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>SURGERY</td>
<td>MS 24</td>
<td>Management of GGO-Containing Nodule</td>
<td>Wednesday, October 18</td>
<td>Room 503</td>
<td>14:30 – 16:15</td>
</tr>
</tbody>
</table>

#### THYMIC MALIGNANCIES / ESOPHAGEAL CANCER / OTHER THORACIC MALIGNANCIES

<table>
<thead>
<tr>
<th>TOPIC</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>DATE</th>
<th>ROOM</th>
<th>TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES</td>
<td>OA 03</td>
<td>Mediastinal and Esophageal Tumor: Insight and New Treatment</td>
<td>Monday, October 16</td>
<td>Room 311 + 312</td>
<td>11:00 – 12:30</td>
</tr>
<tr>
<td>THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES</td>
<td>MS 06</td>
<td>Combined Modality Treatment for Thymic and Pleural Malignancy</td>
<td>Monday, October 16</td>
<td>F201 + F202 (Annex Hall)</td>
<td>15:45 – 17:30</td>
</tr>
<tr>
<td>THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES</td>
<td>SH 02</td>
<td>WCLC 2017 Highlights of the Previous Day</td>
<td>Tuesday, October 17</td>
<td>Room 503</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES</td>
<td>MA 16</td>
<td>Mediastinal, Tracheal and Esophageal Tumor: Multimodality Approaches</td>
<td>Tuesday, October 17</td>
<td>Room 313 + 314</td>
<td>15:45 – 17:30</td>
</tr>
<tr>
<td>THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES</td>
<td>SH 04</td>
<td>WCLC 2017 Highlights of the Previous Day</td>
<td>Wednesday, October 18</td>
<td>F203 + F204 (Annex Hall)</td>
<td>07:00 – 08:00</td>
</tr>
<tr>
<td>THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES</td>
<td>MTE 23</td>
<td>Mediastinal Tumors including Thymic Tumors, Lymphoma, Germ Cell Tumors: Biopsy, Diagnosis and Treatment (<em>Sign Up Required</em>)</td>
<td>Wednesday, October 18</td>
<td>Room 311 + 312</td>
<td>07:00 – 08:00</td>
</tr>
</tbody>
</table>

#### INDUSTRY SUPPORTED SYMPOSIA

<table>
<thead>
<tr>
<th>TOPIC</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>DATE</th>
<th>ROOM</th>
<th>TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>INDUSTRY SUPPORTED SYMPOSIUM</td>
<td>ISS 01</td>
<td>Treatment Options for Patients with ALK+ NSCLC: How is the Paradigm Changing? – Takeda Oncology</td>
<td>Sunday, October 15</td>
<td>Room 303 + 304</td>
<td>11:30 – 13:00</td>
</tr>
<tr>
<td>INDUSTRY SUPPORTED SYMPOSIUM</td>
<td>ISS 02</td>
<td>Treatment Selection Strategies in Advanced NSCLC – Implications and Global Perspectives – Lilly Oncology</td>
<td>Sunday, October 15</td>
<td>Room 303 + 304</td>
<td>15:00 – 16:30</td>
</tr>
<tr>
<td>INDUSTRY SUPPORTED SYMPOSIUM</td>
<td>ISS 03</td>
<td>Management of Advanced NSCLC. Where Do Immune Checkpoint Inhibitors Fit In? – Medscape – Supported by Independent Educational Grant from AstraZeneca Pharmaceuticals LP</td>
<td>Sunday, October 15</td>
<td>Room 301 + 302</td>
<td>16:45 – 18:15</td>
</tr>
</tbody>
</table>
### INDUSTRY SUPPORTED SYMPOSIUM

**ISS 04** Integrating Liquid Biopsy into Clinical Care: Common Questions and Challenges – Guardant Health  
**Date:** Monday, October 16  
**Time:** 07:00 – 08:00  
**Location:** F201 + F202 (Annex Hall)

**ISS 05** What’s New in SCLC? Assessing Emerging Therapeutic Options – Medscape  
**Date:** Monday, October 16  
**Time:** 07:00 – 08:00  
**Location:** F203 + F204 (Annex Hall)

**ISS 06** Maximizing Clinical Benefit from TKIs in the Treatment of Advanced NSCLC – Boehringer Ingelheim Pharma GmbH & Co. KG  
**Date:** Monday, October 16  
**Time:** 12:45 – 14:15  
**Location:** Main Hall

**ISS 07** The Evolving I-O Treatment Landscape in Thoracic Cancers: Clinical Updates and Future Directions – Bristol-Myers Squibb  
**Date:** Monday, October 16  
**Time:** 17:45 – 19:15  
**Location:** Main Hall

**ISS 08** Optimising the Continuum of Care for Patients with Oncogenic-Driven NSCLC – Pfizer Oncology  
**Date:** Tuesday, October 17  
**Time:** 07:00 – 08:00  
**Location:** F201 + F202 (Annex Hall)

**ISS 09** The Evolution of Targetable Oncogenic Drivers in NSCLC: Novel Treatment Paradigms – Novartis  
**Date:** Tuesday, October 17  
**Time:** 07:00 – 08:00  
**Location:** F203 + F204 (Annex Hall)

**ISS 10** Evolving Decisions and Best Practices: Management of EGFR-Mutated NSCLC – Medscape  
**Date:** Tuesday, October 17  
**Time:** 12:45 – 14:15  
**Location:** Main Hall

**ISS 11** Pembrolizumab: The New Standard of Care in Advanced Lung Cancer – MSD  
**Date:** Tuesday, October 17  
**Time:** 17:45 – 19:15  
**Location:** Main Hall

**ISS 12** SCLC Biomarker Testing Symposium – AbbVie  
**Date:** Wednesday, October 18  
**Time:** 12:45 – 14:15  
**Location:** Main Hall

### SCIENTIFIC SYMPOSIUM

<table>
<thead>
<tr>
<th>TOPIC</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>DATE</th>
<th>ROOM</th>
<th>TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCIENTIFIC SYMPOSIUM</td>
<td>SS 01</td>
<td>Supporting the Clinical Management of Lung Cancer Patients through Innovation in Diagnostics – Roche</td>
<td>Sunday, October 15</td>
<td>Room 315</td>
<td>08:15 – 12:00</td>
</tr>
</tbody>
</table>
SESSION 2
Radiological Imaging – Quality Assurance and Training

CHAIRS: NING WU, CHINA, DAVID BALDWIN, UK, & MATTHIJS OUDKERK, NETHERLANDS

09:50 WS 01.10: Reviews of International Guidelines for Management of Pulmonary Nodules (i.e. NCCN/LUNG-RADS, BTS, Fleischner IELCAP, etc.)
David F. Yankelevitz, Icahn School of Medicine at Mount Sinai, USA

10:05 WS 01.11: Planning for European Registries for CT Screened Images – What Are Their Objectives?
Matthijs Oudkerk, University of Groningen, Netherlands

10:20 WS 01.12: Planning for USA Registries for CT Screened Images – What Are Their Objectives?
Ricardo S. Avila, Accumetra, LLC, USA

10:35 WS 01.13: Next Generation CT Scanners for Lung Cancer Screening – Way Forward
Sebastian Schmidt, Siemens Healthcare GmbH, Germany

10:50 Discussion

11:00 Tea/Coffee Break

SESSION 3
Added Value to Lung Cancer CT Screening Programs

CHAIRS: NIR PELED, ISRAEL & KWUN FONG, AUSTRALIA

11:30 WS 01.17: The Potential of Radio-omics and Deep Learning
Anthony Reeves, Cornell University, USA

11:45 WS 01.18: Lung Cancer Indicator Detection Trial (LuCID)
Marc Phillipe Van Der Schee, Owlstone Medical Ltd, UK

12:00 Discussion

12:05 Lunch
SESSION 4:
The Concept of Collaboration in CT Screening Programs
CHAIRS: ANGELA MEREDITH CRISWELL, USA
& DAVID YANKELEVITZ, USA

David Gierada, Washington University School of Medicine, USA

13:33 WS 01.23: Radiology Leading But Integrated?
David F. Yankelevitz, Icahn School of Medicine at Mount Sinai, USA

13:41 WS 01.24: Designs of Possible Biomarkers for Future Screening Programs?
John Field, The University of Liverpool, UK

13:49 WS 01.25: Smoking Cessation – How to Integrate?
Jamie Ostroff, SomaLogic, Inc., USA

13:57 WS 01.26: COPD Integration into CT Screening – Patient Benefit?
Javier Zulueta, Clinica Universidad de Navarra, Spain

14:05 WS 01.27: Surgical Integration at the Earliest Stages Planned CT Screening?
Jesper Holst Pedersen, Rigshospitalet, Copenhagen University, Denmark

14:13 Discussion

SESSION 5
The Current Global Implementation of CT Lung Cancer Screening Programs
CHAIRS: ROBERT SMITH, USA
& SHUJI SAKAI, JAPAN

14:30 WS 01.30.01 China - Overview of Lung Cancer Screening in China from 2000
Matthijs Oudkerk, University of Groningen, University Medical Center Groningen, Netherlands

14:40 WS 01.30.02: China - The Beijing University - CT Screening Trial
Ning Wu, Chinese Academy of Medical Sciences & Peking Union Medical College, China

14:50 WS 01.31: Japan
Kazuto Ashizawa, Nagasaki University Graduate School of Biomedical Sciences, Japan

15:00 WS 01.32: Canada & Australia
Kwun M. Fong, The Prince Charles Hospital, Australia

15:20 WS 01.33: EU Commission Recommendations on Screening
Denis Horgan, European Alliance for Personalised Medicine, Belgium

15:30 WS 01.34: CT Screening in USA – Current Issues around Implementation – Lessons to be Learnt
James L. Mulshine, Rush University, USA

15:40 WS 01.35: USA Roundtable Update
Ella Kazerooni, University of Michigan, USA

15:50 WS 01.36: NELSON – Update
Harry J. De Koning, Erasmus MC, Netherlands

16:00 Tea/Coffee Break

SESSION 6

16:20 What Priorities and Recommendations Should the IASLC Executive Focus On: How They Can Support Leadership in this Area of Lung Cancer (Round Table Discussion)
CHAIRS: JAMES L. MULSHINE, USA
& JOHN FIELD, UK

1. How Do We Ensure Smoking Cessation is Integrated into Best Practice Screening?
Angela Meredith Criswell, Lung Cancer Alliance, USA

2. How Do We Optimise an International Approach to Pulmonary Nodules Management?
Matthijs Oudkerk, University of Groningen, University Medical Center Groningen, Netherlands

3. How to Talk About Lung Cancer Screening Which is More Appropriate to the Public?
Sam M. Janes, University College London, UK

4. Can We Implement International Standards for Quantitative CT Imaging within Lung Cancer?
David F. Yankelevitz, Icahn School of Medicine at Mount Sinai, USA

5. How Can IASLC Lead Global Lung Cancer Progress Over the Next 10 Years?
Kwun M. Fong, University of Queensland Thoracic Research Centre at The Prince Charles Hospital, Australia

18:00 Networking Dinner

09:00 – 18:15 WS 02: IASLC Symposium on the Advances in Lung Cancer CT Screening (Ticketed Session)
TRACK: RADIOLOGY/STAGING/SCREENING
ROOM: F201 + F202 (ANNEX HALL)

09:00 WS 02.01: Welcome to the Special Symposium
Giulia Veronesi, Italy & Claudia Henschke, USA

SESSION 1
Status of Lung Cancer Screening in USA and Europe
CHAIRS: ROBERT SMITH, USA
& GIULIA VERONESI, ITALY

09:10 WS 02.03: Lung Cancer Screening – IELCAP Contribution to CT Screening Implementation
Claudia I. Henschke, Icahn School of Medicine at Mount Sinai, USA

10:10 WS 02.04: Lung Cancer Screening Status in Europe
Giulia Veronesi, Humanitas Research Hospital, Italy

10:40 WS 02.05: The European Commission Recommendations on Lung Cancer Screening
Denis Horgan, European Alliance for Personalized Medicine, Belgium

11:00 Group Discussion

11:30 Tea/Coffee Break
SESSION 2

Current Lung Cancer Screening Guidelines (Panel Discussion)

CHAIRS: JAVIER ZULUETA, SPAIN & CLAUDIA HENSCHKE, USA

12:00 WS 02.09: Lung Cancer Guidelines
David Yankelevitz, Icahn School of Medicine at Mount Sinai, USA
Matthew Callister, Leeds Teaching Hospitals, UK
Stephen Lam, British Columbia Cancer Agency, Canada,
Sadayuki Murayama, Graduate School of Medical Science, University of the Ryukyus, Japan
Nasser Altorki, Cornell University, USA
John Field, The University of Liverpool, UK

13:00 Lunch

SESSION 3

Early Detection Biomarkers

CHAIRS: NIR PELED, ISRAEL & LUIS MONTUENGA, SPAIN

14:00 WS 02.12: Lung Cancer Biomarkers – Do We Have Good Candidates for Early Detection?
Pierre P. Massion, Vanderbilt Ingram Cancer Center, USA

14:30 WS 02.13: New Approaches to Interventional Pulmonology for Lung Cancer Screening
Nir Peled, Soroka Medical Center, Israel

15:00 WS 02.14: The Airway Transcriptome
Avrum Spira, Boston University School of Medicine, USA

15:30 WS 02.15: Quality Control for Lung Imaging Biomarkers
Ricardo S. Avila, Accumetra, LLC, USA

16:00 Tea/Coffee Break

SESSION 4

Lung Cancer Screening’s Impact on COPD and Smoking Cessation

CHAIRS: ANDREA BORONDY KITSS, USA & KAZUTO ASHIZAWA, JAPAN

16:15 WS 02.18: Lung Cancer Screening and COPD – A Pneumologist’s Viewpoint
Javier Zulueta, Clinica Universidad de Navarra, Spain

16:45 WS 02.19: Tobacco Cessation in the CT Screening Setting – The Way Forward?
Jamie Ostroff, SomaLogic, Inc., USA

17:15 WS 02.20: Communicating Complex Issues Simply: Pivotal Role of Nursing in Lung Cancer Screening
Joelle Thirsk Fathi, University of Washington, USA

18:00 Final Discussion
07:00 – 21:00  COAT AND BAGGAGE CHECK OPEN
PACIFICO CONFERENCE CENTER,
LEVEL 1F

07:00 – 20:00  REGISTRATION OPEN
PACIFICO CONFERENCE CENTER,
LEVEL 2F

07:00 – 20:00  SPEAKER PREVIEW CENTER OPEN
PACIFICO CONFERENCE CENTER,
LEVEL 3F

07:30 – 11:30  JCSE 01: Joint IASLC/CSCO/CAALC Session: 
Immunotherapy for Management of Lung Cancer: Ongoing Research from East and West

TRACK: IMMUNOLOGY AND IMMUNOTHERAPY
CHEMOTHERAPY/TARGETED THERAPY
ADVANCED NSCLC
SCLC/NEUROENDOCRINE TUMORS
SURGERY

ROOM: F203 (ANNEX HALL)

07:30  JCSE 01.01: Breakfast and Poster Viewing

07:55  JCSE 01.02: Welcome and Introduction
Roy S. Herbst, Yale School of Medicine | Yale Cancer Center | Sloom Cancer Hospital at Yale-New Haven, USA

08:00  JCSE 01.03: The Science of Immunotherapy
Ray S. Herbst, Yale School of Medicine | Yale Cancer Center | Smilow Cancer Hospital at Yale-New Haven, USA

08:20  JCSE 01.05: PD-1+CD8+ T and iNKT Cell Based Immunotherapy on Lung Cancer
Jianqing Xu, Shanghai Public Health Clinical Center, Fudan University, China

08:40  JCSE 01.06: ctDNA Based Tumor Mutation Burden Evaluation for Predicting Immunotherapy Effect
Jie Hu, Zhongshan Hospital Fudan University, China

09:00  JCSE 01.07: Ongoing Trials in China on Checkpoint Inhibitors and Other Immunotherapies
Qing Zhou, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, China

09:20  Coffee Break and Poster Viewing

09:45  JCSE 01.09: Therapeutic Practices in Europe for Immunotherapy, including Biomarkers
Solange Peters, Lausanne University Hospital CHUV, Switzerland

10:05  JCSE 01.10: The Main Treatment Failure Pattern for Completely Resected Stage II–IIIA (N1–N2) EGFR-Mutation Positive Lung Cancer
Songtao Xu, Zhongshan Hospital Fudan University, China

10:20  JCSE 01.11: A Multicenter, Non-Interventional Study on Real World EGFR Testing and in Patients with IIIb/IV NSCLC in Northern China
Ying Cheng, Jilin Provincial Cancer Hospital, China

10:35  JCSE 01.12: A Phase II Study of Fruquintinib in Combination with Gefitinib in Stage IIIb/IV NSCLC Patients Harboring EGFR Activating Mutations
Shun Lu, Shanghai Chest Hospital, Shanghai Jiaotong University School of Medicine, China

10:50  JCSE 01.13: Discussant Oral Abstracts JCSE 01.10, JCSE 01.11 and JCSE 01.12
Joel W. Neal, Stanford Cancer Institute/Stanford University, USA

10:55  Breakfast and Coffee Breaks provided

11:10  JCSE 01.14: Discussant Poster Abstracts JCSE 01.15 – JCSE 01.28
Bob T. Li, Memorial Sloan Kettering Cancer Center, USA
Jonathan W. Riess, University of California Davis Cancer Center, USA

11:30  JCSE 01.15: Next Generation Sequencing of Large-Cell Neuroendocrine Carcinoma Reveals an Association of PIK3CA Mutations with Brain Metastases
Mian Xie, The First Affiliated Hospital of Guangzhou Medical University, China

11:35  JCSE 01.16: Altered Expression of Programmed Death-1 Receptor(PD-1) and Its Ligand PD-L1, PD-L2 after Neo-Adjuvant Chemotherapy in Lung Cancer
Wenyu Sun, The First Hospital of Jinlin University, China

11:50  JCSE 01.17: The Correlation of DLL3 Expression with High-Grade Pulmonary Neuroendocrine Carcinoma Clinicopathologic Features and Prognose
Li-Xu Yan, Guangdong General Hospital, Guangdong Academy of Medical Sciences, China

11:55  JCSE 01.18: Uncommon Mutation Types of EGFR and Response to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell Lung Cancer Patients
Yun Fan, Zhejiang Cancer Hospital, China

12:10  JCSE 01.19: EGFR Mutation Correlates with Uninflamed Phenotype and Weak Immunogenicity, Causing Impaired Response to PD-1 Blockade in NSCLC
Zhong-Yi Dong, Guangdong Lung Cancer Institute, Guangdong General Hospital, China
JCSE 01.20: Primary Tumor Resection versus Maintenance Therapy for Patients with Oligometastatic Non-Small Cell Lung Cancer
Xiaozheng Kang, Peking University Cancer Hospital, China

JCSE 01.21: Combination of Biomarker and Clinicopathologic Characters May Circle out Beneficiaries through Second-Line Immunotherapy: A Meta Analyse
Si-Yang Liu, Guangdong Lung Cancer Institute; Guangdong General Hospita & Guangdong Academy of Medical Sciences, China

JCSE 01.22: Is Preoperative EGF-TKI Comparable with Chemotherapy for Stage II-IIIA Lung Adenocarcinoma?
Rongrong Chen, Geneplus-Beijing, China

JCSE 01.23: The Feasibility of Osimertinib Treatment on Brain Metastases in NSCLC Patients After 1st Generation EGF-TKI Resistance: A Preliminary Study
Chao Lyu, Peking University Cancer Hospital, China

JCSE 01.24: Detection of EGFR, ALK and Other Driver Oncogenes from Plasma ctDNA by Single Molecule Amplification and Re-sequencing Technology (cSMART)
Tony Mok, The Chinese University of Hong Kong, Hong Kong

JCSE 01.25: Detection of EGFR T790M Mutations by Four Testing Platforms in ctDNA from Chinese Patients with Advanced NSCLC
Xu-Chao Zhang, Guangdong Lung Cancer Institute, Gunagdong General Hospital and Guangdong Academy of Medical, China

JCSE 01.26: Circulating Cell-Free DNA of Cerebrospinal Fluid May Function as Liquid biopsy for Leptomeningeal Metastases of ALK Rearrangement NSCLC
Yangsi Li, Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

JCSE 01.27: Patients with ALK IHC-Positive/FISH-Negative NSCLC Benefit from ALK TKI Treatment: Response Data from the Global ALEX Trial
Tony Mok, State Key Laboratory of South China, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong

JCSE 01.28: NGS Sequencing Based Liquid / Tissue Biopsy Identified Coexistence of HER2 Amplification and Mutation in Advanced NSCLC Patients
Ronrong Chen, Geneplus-Beijing, China

11:30 JCSE 01.29: Closing Remarks

08:40 YI 01.04: Clinical Trials 101
Julie R. Brahmer, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, USA

08:55 YI 01.05: Investigator Initiated Trials
Daniel Shao Weng Tan, National Cancer Centre Singapore, Singapore

09:10 Coffee Break

09:40 YI 01.07: How to Get Your Paper Published
Alex Adjei, Roswell Park Cancer Institute, USA

09:55 YI 01.08: Why Should I Publish? An Overview of the Manuscript Cycle: From Submission to Publication
Jim Jett, Mayo Clinic, USA

10:10 YI 01.09: How to Prepare an Abstract for an International Conference and How to Prepare Your Presentation for the Conference (Tips and Tricks)
Michael Boyer, Chris O’Brien Lifehouse, Australia

10:25 YI 01.10: How to Write a Grant Application for Young Investigators
Heather A. Wakelee, Stanford Cancer Institute/Stanford University, USA

10:40 YI 01.11: The Young Investigator Travel Award Experience – A Report from a Previous Award Winner
Takahiro Karasaki, Graduate School of Medicine, The University of Tokyo, Japan

10:45 YI 01.12: Making the Most of the WCLC: A Guide for First Time Attendee – From an Expert Perspective
Suresh Senan, VU University Medical Center, Netherlands

11:00 YI 01.13: Making the Most of the WCLC: A Guide for First Time Attendee – From a Second Time Attendee
Deepali Jain, All India Institute of Medical Sciences, India

11:05 Question and Answer Session

09:15 – 12:00 SS 01: Supporting the Clinical Management of Lung Cancer Patients through Innovation in Diagnostics - Roche (Sign Up Required)

08:15 SS 01.01: Welcome & Opening

08:30 SS 01.02: Unmet Medical Needs and Challenges in Lung Cancer Patient Management - A Pulmonologists Perspective
Ramón Marrades, Hospital Clinic de Barcelona, Spain

08:47 SS 01.03: Protein-based Biomarkers as Tools to Support Clinical Decision Making with Results from the Laboratory
Rafael Molina, University de Barcelona, Spain

09:05 SS 01.04: Panel - Question and Answer Session

09:20 Break

09:35 SS 01.05: Integrated Tissue and Molecular Diagnostics for Optimal Lung Cancer Patient Care
Stephen Finn, St James’s Hospital, Ireland

09:40 YI 01.07: How to Get Your Paper Published
Alex Adjei, Roswell Park Cancer Institute, USA

09:55 YI 01.08: Why Should I Publish? An Overview of the Manuscript Cycle: From Submission to Publication
Jim Jett, Mayo Clinic, USA

10:10 YI 01.09: How to Prepare an Abstract for an International Conference and How to Prepare Your Presentation for the Conference (Tips and Tricks)
Michael Boyer, Chris O’Brien Lifehouse, Australia

10:25 YI 01.10: How to Write a Grant Application for Young Investigators
Heather A. Wakelee, Stanford Cancer Institute/Stanford University, USA

10:40 YI 01.11: The Young Investigator Travel Award Experience – A Report from a Previous Award Winner
Takahiro Karasaki, Graduate School of Medicine, The University of Tokyo, Japan

10:45 YI 01.12: Making the Most of the WCLC: A Guide for First Time Attendee – From an Expert Perspective
Suresh Senan, VU University Medical Center, Netherlands

11:00 YI 01.13: Making the Most of the WCLC: A Guide for First Time Attendee – From a Second Time Attendee
Deepali Jain, All India Institute of Medical Sciences, India

11:05 Question and Answer Session

09:15 – 12:00 SS 01: Supporting the Clinical Management of Lung Cancer Patients through Innovation in Diagnostics - Roche (Sign Up Required)
SESSION 1

Local Therapies for Lung Cancer and Mesothelioma

CHAIR: CAITLIN BRODERICK, AUSTRALIA

13:00 WS 03.03: Welcome Address
Beth Ivimey, Chris O’Brien Lifehouse, Australia

13:05 WS 03.04: The Oncology Nurse Role in the Treatment of Lung Cancer and Mesothelioma: The Recent Practice in Japan
Miki Hosoya, National Cancer Center Japan, Japan

13:30 WS 03.05: Explaining Radiation Treatments in Lung Cancer
Mary Duffy, Peter MacCallum Cancer Centre, Australia

13:50 WS 03.06: Local Treatments for Lung Cancer – Blade vs Beam: A Debate
David L. Ball, Peter MacCallum Cancer Centre, Australia
Melissa Culligan, University of Maryland Medical Center – Thoracic Surgery, USA

SESSION 2

Wellness and Supportive Care for Lung Cancer and Mesothelioma Patients

CHAIR: KATHLEEN ANN GAMBLIN, USA

14:20 WS 03.08: Acute Thoracic Oncology Nursing
Philippa Jones, NIHR Clinical Research Network, UK

14:40 WS 03.09: Living Well with Lung Cancer and Mesothelioma
Pippa Labuc, Guy’s & St Thomas’ NHS Foundation Trust, UK

15:00 Panel Discussion

15:10 Break

SESSION 3

Systemic Treatments for Lung Cancer and Mesothelioma

CHAIR: MASSEY NEMATOLLAHI, CANADA

15:25 WS 03.13: Targeted Therapies: Toxicities Management and Care
Alexandre Chan, National University of Singapore, Singapore

15:50 WS 03.14: Targeted Therapies: Case Studies and Experience from Different Regions & Q&A
Facilitator: Beth Ivimey, Chris O’Brien Lifehouse, Australia
Alexandre Chan, National University of Singapore, Singapore
Caitlin Broderick, W A Cancer and Palliative Care Network, Australia
Beth Eaby-Sandy, University of Pennsylvania Health System, USA
John McPhelim, Hairmyres Hospital, UK

16:15 WS 03.15: Immuno-oncology Overview
Marianne Davies, Yale Cancer Center, USA

16:35 WS 03.16: Japan’s Challenges in Immunotherapy for Lung Cancer as a Pioneer: The Nurses View
Kimura Yasutaka, Meio University, Japan

16:55 WS 03.17: Latest Advances in the Treatment of Malignant Pleural Mesothelioma
Mary Hesdorffer, Mesothelioma Applied Research Foundation, USA
**17:20 WS 03.18: Mesothelioma Online Educational Programs, ITONF Nurse Education Programs & N&AH Immunotherapy Guidelines Launch**
Facilitator: Melissa Culligan, University of Maryland Medical Center – Thoracic Surgery, USA
Kathleen Ann Gamblin, Northside Hospital Cancer Institute, USA
Liz Darlison, University Hospitals of Leicester NHS Trust, UK
Anne Fraser, ADHB, New Zealand

**17:55 WS 03.19: Close**
Melissa Culligan, University of Maryland Medical Center – Thoracic Surgery, USA

---

**13:00 – 17:00 WS 04: Minimally Invasive Diagnosis and Staging of Lung Cancer – Interventional Pulmonology Hands-On Workshop (Ticketed Session)**

**13:00 WS 04.01: Welcome and Introduction**
Kazuhiro Yasufuku, Division of Thoracic Surgery, Toronto General Hospital, University Health Network, Canada

**13:10 WS 04.02: EBUS-TBNA – Role in Invasive Mediastinal Staging**
Kazuhiro Yasufuku, Division of Thoracic Surgery, Toronto General Hospital, University Health Network, Canada

**13:30 WS 04.03: Specimen Acquisition and Processing**
Takahiro Nakajima, Department of Thoracic Surgery, Chiba University School of Medicine, Japan

**13:50 WS 04.04: Radial Probe EBUS – Methods and Results**
Takehiro Izumo, Respiratory Endoscopy Division, National Cancer Center, Japan

**14:10 WS 04.05: Navigational Bronchoscopy**
Laura Donahoe, Division of Thoracic Surgery, Toronto General Hospital, University Health Network, Canada

**14:30 WS 04.06: Hands-On Session (5 work stations):**
1. EBUS-TBNA
2. Radial Probe EBUS
3. Specimen Handling
4. Navigational Bronchoscopy (superDimension)
5. Navigational Bronchoscopy (BF Navi)

---

**13:30 – 14:30 Press Conference**

**15:00 – 16:30 ISS 02: Treatment Selection Strategies in Advanced NSCLC – Implications and Global Perspectives – Lilly Oncology**

**15:00 ISS 02.01: Welcome & Introduction**
Kazuhiko Nakagawa, Kindai University Faculty of Medicine, Japan
Nick Thatcher, The Christie Hospital, UK

**15:05 ISS 02.02: Increasing Complexity of Therapeutic Decision-Making for Advanced NSCLC**
David R. Gandara, UC Davis Comprehensive Cancer Center, USA

**15:25 ISS 02.03: How Long Do I Treat? When to Stop? Implications for Clinical Practice**
Silvia Novello, University of Turin, Italy

**15:40 ISS 02.04: Illustrative and Interactive Case Study Discussions**
Hidehito Horinouchi, National Cancer Center Hospital, Japan,
Myung-Ju Ahn, Samsung Medical Center, Korea,
Oscar Arrieta, Instituto Nacional de Cancerología, Mexico

**16:10 ISS 02.05: Global Perspectives on the Changing Treatment Paradigm in Advanced NSCLC**
James Chih-Hsin Yang, National Taiwan University, Taiwan

**16:20 ISS 02.06: Panel Discussion**
Kazuhiko Nakagawa, Kindai University Faculty of Medicine, Japan,
Nick Thatcher, The Christie Hospital, UK

**16:30 ISS 02.07: Symposium Closes**

---

**16:45 – 18:15 ISS 03: Management of Advanced NSCLC: Where Do Immune Checkpoint Inhibitors Fit In? – Medscape – Supported by Independent Educational Grant from AstraZeneca Pharmaceuticals LP**

**16:45 ISS 03.01: Welcome and Introductions**
Hossein Borghaei, Fox Chase Cancer Center, USA

**16:50 ISS 03.02: Where Do Checkpoint Inhibitors Fit in Second-Line Therapy?**
Fabrice Barlesi, Aix-Marseille University, France

**17:05 ISS 03.03: Where Do Checkpoint Inhibitors Fit in First-Line Therapy?**
Edward B. Garon, UCLA Medical Center, USA

**17:20 ISS 03.04: The Immune Effects of Immune Checkpoint Inhibitors: ir-AEs**
Hossein Borghaei, Fox Chase Cancer Center, USA

**17:35 ISS 03.05: Double, Double, Toil and Trouble With Combination Therapy?**
Edward B. Garon, UCLA Medical Center, USA

---

For information on topics and speakers, please visit the Press & Media page on the Conference website at: wclc2017.iaslc.org/press-media/press-media/
17:50 ISS 03.06: The Future of Checkpoint Inhibitors in Your Practice
Hossein Borghaei, Fox Chase Cancer Center, USA

18:00 ISS 03.07: Concluding Remarks
Hossein Borghaei, Fox Chase Cancer Center, USA,
Fabrice Barlesi, Aix-Marseille University, France,
Edward B. Garon, UCLA Medical Center, USA

18:05 ISS 03.08: Question and Answer Session

18:30 – 20:00 Opening Ceremony
ROOM: NATIONAL CONVENTION HALL

IMPORTANT NOTE
Increased security will be in place and doors will be closed at 18:25. No further entrance after 18:25.
Please ensure to arrive at least 30 minutes early.
Badges are required for ALL attendees including those attending as paid guests of delegates

Taiko Drummer Performances
Welcome Addresses by IASLC and Local Dignitaries
Distinguished Award Winner Presentations

20:00 – 21:00 Welcome Reception
ROOM: NATIONAL CONVENTION HALL
Food & Beverages provided
07:00 – 08:00 ISS 04: Integrating Liquid Biopsy into Clinical Care: Common Questions and Challenges – Guardant Health

TRACK: INDUSTRY SUPPORTED SYMPOSIUM
ROOM: F201 + F202 (ANNEX HALL)
CHAIRS: RAFAEL ROSELL, SPAIN & GEOFFREY R. OXNARD, USA

07:00 ISS 04.01: Welcome and Clinical NSCLC Overview
Rafael Rosell, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Spain

07:15 ISS 04.02: Considerations When Choosing a Liquid
Geoffrey R. Oxnard, Dana-Farber Cancer Institute, USA

07:30 ISS 04.03: Clinical Application of Liquid Biopsy
Luis E. Raez, Memorial Cancer Institute, USA

07:37 ISS 04.04: When Tissue and Plasma Are Discordant: Why This Can Occur and What Next?
Nir Peled, Soroka Medical Center, Israel

07:45 ISS 04.05: What is the Number and Can I Treat When it’s Low?
Nir Peled, Soroka Medical Center, Israel

07:53 ISS 04.06: Question and Answer Session

07:00 – 08:00 ISS 05: What’s New in SCLC? Assessing Emerging Therapeutic Options - Medscape - Supported by an Independent Educational Grant from AbbVie

TRACK: INDUSTRY SUPPORTED SYMPOSIUM
ROOM: F203 + F204 (ANNEX HALL)
CHAIR: CHARLES M. RUDIN, USA

07:00 ISS 05.01: Welcome and Introduction
Charles M. Rudin, Memorial Sloan Kettering Cancer Center, USA

07:05 ISS 05.02: Why Is SCLC Such a Hard Nut to Crack?
Jeffrey Crawford, Duke Cancer Institute, USA

07:15 ISS 05.03: What’s in the Phase 3 Pipeline for SCLC? Immunotherapies
Antonio Rossi, S.G. Moscati Hospital, Italy

07:25 ISS 05.04: What’s in the Phase 3 Pipeline for SCLC? Novel Biological Targets
Enriqueta Felip, Hospital Universitari Vall d’Hebron, Spain

07:35 ISS 05.05: Panel Discussion: What is the Likely Impact on Clinical Practice and the SCLC Landscape?
Charles M. Rudin, Memorial Sloan Kettering Cancer Center, USA,
Jeffrey Crawford, Duke Cancer Institute, USA,
Enriqueta Felip, Hospital Universitari Vall d’Hebron, Spain,
Antonio Rossi, S.G. Moscati Hospital, Italy

07:50 ISS 05.06: Summary and Conclusion
Charles M. Rudin, Memorial Sloan Kettering Cancer Center, USA

07:55 ISS 05.07: Question and Answer Session
07:00 – 08:00 MTE 01: Management of Small Nodules Detected by CT Screening (Sign Up Required)

TRACK: RADIOLOGY/STAGING/SCREENING SURGERY
ROOM: 301 + 302

07:00 MTE 01.01: Management of Small Nodules Detected by CT Screening; A Surgeon’s Perspective
Jun Nakajima, The University of Tokyo Hospital, Japan

07:00 – 08:00 MTE 02: Appropriate and Optimized Handling of Specimens (Sign Up Required)

TRACK: BIOLOGY/PATHOLOGY
ROOM: 316

07:00 MTE 02.01: Appropriate and Optimized Handling of Surgically Resected Specimens
Erik Thunnissen, VU University Medical Center, Netherlands

07:30 MTE 02.02: Appropriate and Optimized Handling of Biopsy or Cytology Specimens
Mari Mino-Kenudson, Massachusetts General Hospital & Harvard Medical School, USA

07:00 – 08:00 MTE 03: Surgery for T4 Lung Cancer (Sign Up Required)

TRACK: SURGERY
ROOM: 303 + 304

07:00 MTE 03.01: Do Extended Resections Improve T4 Lung Cancer Outcomes?
Dominique H. Grunenwald, Pierre & Marie Curie University, France

07:00 – 08:00 MTE 04: Radiotherapy for SCLC (Sign Up Required)

TRACK: RADIOTHERAPY
ROOM: 311 + 312

07:00 MTE 04.01: Role of Radiotherapy in Multimodality Treatment for SCLC
Corinne Faivre-Finn, Univ. of Manchester, UK

07:30 MTE 04.02: General Principles of PCI in the Treatment of SCLC
David L. Ball, Peter MacCallum Cancer Centre, Australia

07:00 – 08:00 MTE 05: Neuroendocrine Tumors: Pathology and Genetic Update (Sign Up Required)

TRACK: BIOLOGY/PATHOLOGY
ROOM: 313 + 314

07:00 MTE 05.01: Neuroendocrine Tumors: Pathology and Genetic Update
Elisabeth Brambilla, Institut Albert Bonniot, Hopital Albert Michallon, France

07:00 – 08:00 MTE 06: Lung Cancer Pathology Update (Sign Up Required)

TRACK: BIOLOGY/PATHOLOGY
ROOM: 315

07:00 MTE 06.01: Lung Cancer Pathology Update
Prudence Russell, St. Vincent’s Hospital / University of Melbourne, Australia
Andre L. Moreira, New York University School of Medicine, USA

07:00 – 08:00 MTE 07: Molecular Biology: Minimum Requirement for Clinicians (Sign Up Required)

TRACK: CHEMOTHERAPY/TARGETED THERAPY
ROOM: 501

07:00 MTE 07.01: Molecular Biology that Clinicians Should Know: From a Clinical Viewpoint
Prasad S. Adusumilli, Memorial Sloan Kettering Cancer Center, USA

07:30 MTE 07.02: Molecular Biology that Clinicians Should Know: From a Basic Viewpoint
Martin Filipits, Medical University of Vienna, Austria

07:00 – 08:00 MTE 08: Technical Details of EBUS and EUS (Sign Up Required)

TRACK: PULMONOLOGY/ENDOSCOPY
ROOM: 502

07:00 MTE 08.01: Technical Aspects of EBUS-TBNA for Clinicians
Takahiro Nakajima, Chiba University Graduate School of Medicine, Japan

07:30 MTE 08.02: Clinical Aspects of EUS(B)-FNA
Bin Hwangbo, National Cancer Center, Korea
MONDAY, OCTOBER 16, 2017

10:00 – 10:45 Networking Opportunity
& Poster Presenters Present for P1 Posters
EXHIBIT HALL (HALL B + C)
Refreshments provided

P1.01 Advanced NSCLC
P1.02 Biology/Pathology
P1.03 Chemotherapy/Targeted Therapy
P1.04 Clinical Design, Statistics and Clinical Trials
P1.05 Early Stage NSCLC
P1.06 Epidemiology/Primary Prevention/Tobacco Control and Cessation
P1.07 Immunology and Immunotherapy
P1.08 Locally Advanced NSCLC
P1.09 Mesothelioma
P1.10 Nursing/Palliative Care/Ethics
P1.11 Patient Advocacy
P1.12 Pulmonology/Endoscopy
P1.13 Radiotherapy
P1.14 Radiotherapy
P1.15 SCLC/Neuroendocrine Tumors
P1.16 Surgery
P1.17 Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies

11:00 – 12:30 MS 01: Clinical Development of Novel Agents

11:00 MS 01.01: Expansion Cohorts in Phase I Trials: Non Controlled Phase II or Translational Science?
Benjamin Besse, Gustave Roussy, France

11:20 MS 01.02: Are We Categorizing Biomarkers Too Quickly?
Jack Lee, MD Anderson Cancer Center, USA

11:40 MS 01.03: Innovative Trial Designs: What is the Minimal Burden of Proof for Drug Approval?
Giuseppe Giaccone, Georgetown University, USA

12:00 MS 01.04: Is “Big Data” the Solution to the Complex Therapeutic Landscape?
Yu Shyr, Vanderbilt University Medical Center, USA

12:20 Question and Answer Session
MONDAY, OCTOBER 16, 2017

11:00 – 12:30  MS 02: Ethnic Differences: Biology or Myth
TRACK: REGIONAL ASPECTS/HEALTH POLICY/PUBLIC HEALTH
ROOM: 501
CHAIRS: RONALD NATALE, USA & JEONG-SEON RYU, KOREA

11:00  MS 02.01: Lung Cancer Genomics
Ramaswamy Govindan, Washington University School of Medicine, USA

11:15  MS 02.02: Molecular Epidemiology
Tomoya Kawaguchi, Graduate school of Medicine, Osaka City University, Japan

11:30  MS 02.03: Chemotherapy: Efficacy and Toxicity Difference According to Ethnicity
Martin Edelman, Fox Chase Cancer Center, USA

11:45  MS 02.04: Targeted Agents and Immunotherapy: Efficacy and Toxicity Difference According to Ethnicity
Luis Paz-Ares, Hospital Universitario 12 de Octubre, Spain

12:00  MS 02.05: Is Ethnicity a Prognostic Factor in Lung Cancer
Viola Zhu, Chao Family Comprehensive Cancer Center, UC Irvine, USA

12:15  Question and Answer Session

11:00 – 12:30  ES 01: New TNM and WHO Classification
TRACK: RADIOLOGY/STAGING/SCREENING
ROOM: 301 + 302
CHAIRS: MASAYUKI NOGUCHI, JAPAN & PETER GOLDSHWART, USA

11:00  ES 01.01: New TNM Classification
Ramón Rami-Porta, Hospital Universitari Mutua Terrassa, and CIBERES Lung Cancer Group, Spain

11:20  ES 01.02: New Histological Classification
William D. Travis, Memorial Sloan Kettering Cancer Center, USA

11:40  ES 01.03: Immunohistochemistry, Chromosomal and DNA Analysis, and Molecular Testing
Yasushi Yatabe, Aichi Cancer Center, Japan

12:00  ES 01.04: Staging and Pathology of Multiple Nodules Presenting in the Lungs
Andrew G. Nicholson, Royal Brompton and Harefield NHS Foundation Trust and National Heart and Lung Institute, UK

12:20  Question and Answer Session

11:00 – 12:30  ES 02: Diagnostic and Interventional Radiology in Lung Cancer: Update 2017
TRACK: RADIOLOGY/STAGING/SCREENING
ROOM: 315
CHAIRS: DAVID F. YANKELEVITZ, USA & SHUJI SAKAI, JAPAN

11:00  ES 02.01: The Dutch-Belgian Lung Cancer Screening Trial (NELSON)
Harry J. De Koning, Erasmus MC, Netherlands
11:00 – 12:30  OA 01: The New Aspect of Radiation Therapy

**TRACK:** Radiation Therapy  
**ROOM:** F201 + F202 (ANNEX HALL)  
**CHAIRS:** MASAIRO HIRADOKA, JAPAN & SUNG HWAN KIM, KOREA

11:00 11:00 OA 01.01: A Randomized Trial of SABR vs Conventional Radiotherapy for Inoperable Stage I Non-Small Cell Lung Cancer: TROG 09.02 (CHISEL)  
David L. Ball, Peter MacCallum Cancer Centre, Australia

11:10 OA 01.02: Stereotactic Radiotherapy as Salvage Treatment After Surgery and Curative Intended Radiotherapy for Patients with NSCLC  
Olfred Hansen, Odense University Hospital, Denmark

11:20 OA 01.03: Patterns of Change in High-Risk Radiological Features in Patients without Local Recurrence after SABR for Early-Stage NSCLC  
Merle Ilona Ronden, VU Medical Center, Netherlands

11:30 OA 01.04: Discussant – OA 01.01, OA 01.02, OA 01.03  
Jin Hee Kim, Keimyung University Dongsan Medical Center, Korea

11:45 OA 01.05: Analysis of Radiotherapy Quality Assurance Data for the Convert Trial – Does Non-Compliance to Protocol Affect Survival?  
Elena Wilson, University College London Hospitals NHS Foundation Trust, London, UK, UK

11:55 OA 01.06: Radiation Therapy is Associated with an Increased Incidence of Cardiac Events in Small Cell Lung Cancer Patients  
Matthew Jeffrey Ferris, Winship Cancer Institute at Emory University, USA

12:05 OA 01.07: Tracking Major Symptom Burden from Chemotherapy Concurrent with 3D vs. IMRT vs. Proton Beam Radiotherapy for NSCLC  
Qiuling Shi, University of Texas MD Anderson Cancer Center, USA

12:15 OA 01.08: Discussant – OA 01.05, OA 01.06, OA 01.07  
Yukinori Matsuo, Kyoto University, Japan

11:00 – 12:30  OA 02: Mesothelioma: Challenges For New Treatment

**TRACK:** Mesothelioma  
**ROOM:** F205 + F206 (ANNEX HALL)  
**CHAIRS:** SEIKI HASEGAWA, JAPAN & ANNA NOWAK, AUSTRALIA

11:00 OA 02.01: Randomized Phase II Study of Anetumab Ravtansine or Vinorelbine in Patients with Metastatic Pleural Mesothelioma  
Hedy Lee Kindler, University of Chicago, USA

11:10 OA 02.02: Ipilimumab and Nivolumab in the Treatment of Recurrent Malignant Pleural Mesothelioma: A Phase II Study  
Paul Baas, Netherlands Cancer Institute, Netherlands

11:20 OA 02.03: Prophylactic Irradiation of Tracts (PIT) in Patients with Pleural Mesothelioma: Results of a Multicentre Phase III Trial  
Neil Bayman, The Christie NHS Foundation Trust, UK

11:30 OA 02.04: Discussant – OA 02.01, OA 02.02, OA 02.03  
Daniel H. Sterman, NYU Langone Medical Center, USA

11:45 OA 02.05: RESPECT-MESO: An International Randomised Controlled Trial to Assess Early Specialist Palliative Care in Malignant Pleural Mesothelioma  
Silvia Novello, University of Turin, Department of Oncology, S. Luigi Hospital, Italy

11:55 OA 02.06: Radioimmunotherapy Combining CTLA-4 Blockade or Low-Dose Cyclophosphamide with Local Radiation in Murine Malignant Mesothelioma  
Mikihiro Kohno, Toronto General Research Institute, Canada

12:05 OA 02.07: Surgical Selection in Pleurectomy Decortication for Mesothelioma – an Overview from Screening and Selection from MARS 2 Pilot  
Eric Lim, Royal Brompton Hospital, UK
11:00 – 12:30 MA 01: SCLC: Research Perspectives

**11:00**
**MA 01.01: Metastatic Behavior of Pulmonary Neuroendocrine Carcinomas Is Associated with Epithelial to Mesenchymal Transition Gene Profile**
Tabatha Gutierrez Prieto, Faculdade de Medicina da USP, Brazil

**11:05**
**MA 01.02: Multigene Mutation Profiling and Clinical Characteristics of Small-Cell Lung Cancer in Never-Smokers Versus Heavy Smokers**
Andrés F. Cardona, Foundation for Clinical and Applied Cancer Research – FICMAC, Colombia

---

**11:10**
**MA 01.03: The Potential of ctDNA Sequencing in Disease Monitoring and Depicting Genomic Evolution of Small-Cell Lung Cancer Under Therapy**
Jianjun Zhang, The University of Texas MD Anderson Cancer Center, USA

**11:15**
**MA 01.04: Discussant – MA 01.01, MA 01.02, MA 01.03**
Charles Andrew Butts, Cross Cancer Institute, Canada

**11:30**
**MA 01.05: Activity and Safety of the Combination of PM0183 and Doxorubicin in Relapsed SCLC: Final Results of a Phase Ib Trial**
Emiliano Calvo, START Madrid – HM CIIOC, Hospital Madrid Norte Sanchinarro, Spain

**11:35**
**MA 01.06: A Phase II Study of Etitinotecan Pegol (NKTR-102) in Patients with Chemotherapy-Resistant Small Cell Lung Cancer**
Hongbin Chen, Roswell Park Cancer Institute, USA

**11:40**
**MA 01.07: Lanreotide Maintenance in SCLC Expressing Somatostatine Receptors: Efficacy Results of Multicenter Randomized G04.2011 Trial**
Sara Pilotto, University of Verona, Azienda Ospedaliera Universitaria Integrata (AOUI), Italy

**11:45**
**MA 01.08: Discussant – MA 01.05, MA 01.06, MA 01.07**
Anne Tsao, University of Texas M.D. Anderson Cancer Center, USA

**12:00**
**MA 01.09: Treatment Patterns in Extensive Disease Small Cell Lung Cancer Across the United States, Europe, and Japan**
Yong Yuan, Bristol-Myers Squibb, USA

**12:05**
**MA 01.10: Outcome Based on Baseline Total Lymphocyte Count & Neutrophil-To-Lymphocyte Ratio in Extensive Stage Small-Cell Lung Cancer**
Ryoko Suzuki, The University of Texas MD Anderson Cancer Center, USA

**12:10**
**MA 01.11: Timing of Thoracic Radiotherapy Is More Important Than Dose Escalation in Patients with Limited-Stage Small Cell Lung Cancer**
Xiao Hu, Zhejiang Cancer Hospital, Zhejiang Key Laboratory of Radiation Oncology, China

**12:15**
**MA 01.12: Discussant – MA 01.09, MA 01.10, MA 01.11**
Anand Swaminath, McMaster University, Canada

---

**11:00 – 12:30 MA 02: Emerging Targets**

**11:00**
**MA 02.01: Evidence of Clinical Activity of Sitravatinib in Combination with Nivolumab in NSCLC Patients Progressing on Prior Checkpoint Inhibitors**
Ticiana A. Leal, University of Wisconsin Carbone Cancer Center, USA

**11:05**
**MA 02.02: Phase 2 Study of Pembrolizumab Plus CC-486 vs Pembrolizumab Plus Placebo in Previously Treated Patients with Advanced NSCLC**
Luis Paz-Ares, Hospital Universitario Doce de Octubre, Spain

**11:10**
**MA 02.03: Selective Histone Deacetylase Inhibitor ACY-241 Plus Nivolumab for Refractory Advanced NSCLC: Results From a Phase 1b Study**
Mark Awad, Dana- Farber Cancer Institute, USA
11:15 MA 02.04: Discussant – MA 02.01, MA 02.02, MA 02.03
Grace K. Dy, Roswell Park Cancer Institute, USA

11:30 MA 02.05: Nivolumab in Advanced Non-Squamous NSCLC Patients with KRAS Mutations: Results from the Italian Expanded Access Program (EAP)
Domenico Galetta, Istituto Tumori “Giovanni Paolo II”, Italy

11:35 MA 02.06: BRAF Mutant NSCLC: Correlation with PD-L1 Expression, TMB, MSI and Response to Anti-BRAF Therapy
Elizabeth Dudnik, Rabin Medical Center, Israel

11:40 MA 02.07: A Phase II Study of Pembrolizumab in EGFR Mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naïve Patients with Advanced NSCLC
Aaron Lisberg, University of California, USA

11:45 MA 02.08: Discussant – MA 02.05, MA 02.06, MA 02.07
Barbara Melosky, British Columbia Cancer Agency, Canada

12:00 MA 02.09: A Ph I/II Study of BGB324, a Selective AXL Inhibitor as Monotherapy and in Combination with Erlotinib in Advanced NSCLC
Don Lynn Gibbons, MD Anderson Cancer Center, USA

12:05 MA 02.10: Phase I Study of ABBV-399 (Telisotuzumab Vedotin) as Monotherapy and in Combination with Erlotinib in NSCLC
Jonathan Wade Goldman, UCLA, USA

12:10 MA 02.11: A Phase I Trial of Erlotinib and Onalespib in EGFR-mutant NSCLC: Focus on EGFR Exon 20 Insertions
Jonathan W. Riess, University of California Davis Cancer Center, USA

12:15 MA 02.12: Discussant – MA 02.09, MA 02.10, MA 02.11
Dean A. Fennell, University of Leicester & Leicester University Hospitals, UK

11:00 – 12:30 MA 03: Chemotherapy
TRACK: ADVANCED NSCLC CHEMOTHERAPY/TARGETED THERAPY
ROOM: 502
CHAIRS: JIN-HYOUNG KANG, KOREA & WU-CHOU SU, TAIWAN

11:00 MA 03.01: Nab-Paclitaxel ± CC-486 as Second-Line Treatment of Advanced NSCLC: Results from the ABOUND.2L+ Study
Ramaswamy Govindan, Washington University School of Medicine, USA

11:05 MA 03.02: Timing of B12/Folate Supplementation in NSCLC Patients on Pemetrexed Based Chemotherapy: Final Results of the PEMVITASTART Randomized Trial
Navneet Singh, Postgraduate Institute of Medical Education and Research (PGIMER), India

11:10 MA 03.03: Nedaplatin plus Docetaxel versus Cisplatin plus Docetaxel as First-Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung
Shun Lu, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

11:15 MA 03.04: Discussant – MA 03.01, MA 03.02, MA 03.03
Adrian G. Sacher, Dana-Farber Cancer Institute, USA

11:30 MA 03.05: Bevacizumab Combined with Chemotherapy for Patients with Advanced NSCLC and Brain Metastasis. A French Cohort Study
Jaafar Bennouna, University Hospital, France

11:35 MA 03.06: Effect of 2L Ramucirumab after Rapid Time to Progression on 1L Therapy: Subgroup Analysis of REVEL in Advanced NSCLC
Martin Reck, LungClinic Grosshansdorf, Germany

11:40 MA 03.07: The Predictive Value of Interferon-? Release Assays (IGRA) for Chemotherapy Response in Advanced Non-Small-Cell Lung Cancer Patients
Hsu-Ching Huang, Taipei Veterans General Hospital, Taiwan

11:45 MA 03.08: Discussant – MA 03.05, MA 03.06, MA 03.07
Ikuo Sekine, Faculty of Medicine, University of Tsukuba, Japan

12:00 MA 03.09: The Cost and the Benefit: Front-Line Immunotherapy for Non-Small Cell Lung Cancer
Christine M. Bestvina, University of Chicago Medicine, USA

12:05 MA 03.10: Prognostic Factors in NSCLC Patients Treated with a Fourth-Line Therapy
Vincent Leroy, Lille University Hospital, France

12:10 MA 03.11: Targeting CDCA3 Enhances Sensitivity to Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer
Mark N. Adams, Institute of Health and Biomedical Innovation, Australia

12:15 MA 03.12: Discussant – MA 03.09, MA 03.10, MA 03.11
Mary O’Brien, Royal Marsden Hospital, UK

11:00 – 12:30 MA 04: Advocacy: Listen to the Patients
TRACK: PATIENT ADVOCACY
ROOM: 313 + 314
CHAIRS: RUDOLF M. HUBER, AUSTRIA & CSABA L. DÉGI, ROMANIA

11:00 MA 04.01: Prospective Comparative Evaluation of Patient and Caregiver Perspectives on a Multidisciplinary Model of Lung Cancer Care
Matthew P. Smeltzer, University of Memphis School of Public Health, USA

11:05 MA 04.02: Assessing the Psychosocial Needs of Newly Diagnosed NSCLC Patients: Identifying the Population Most At-Risk
Bonnie Leung, British Columbia Cancer Agency, Canada

11:10 MA 04.03: Physician Empathy and Sensitivity to a Patient’s Emotional Journey Can Be Critical to Patient Optimism and Empowerment
Danielle Hicks, Lung Cancer Foundation, USA

11:15 MA 04.04: Discussant – MA 04.01, MA 04.02, MA 04.03
Kathy Weber, Mednax, Inc, USA

11:30 MA 04.05: The Impact of the Meso Foundation on Advocacy Efforts for Funding Mesothelioma Research
Melinda Kotizan, Mesothelioma Applied Research Foundation, USA
13:00 – 14:00  EXH 01: Thermo Fisher: Next Generation Sequencing – Changing Paradigm in NSCLC Patient Management

**TRACK:** EXHIBIT SHOWCASE SESSION

**ROOM:** EXHIBIT SHOWCASE THEATER, EXHIBIT HALL (HALL B + C)

As number of targeted therapies in NSCLC is rapidly increasing, simultaneous testing for multiple biomarkers is becoming progressively important to ensure a timely diagnosis and start of treatment.1 Next Generation Sequencing (NGS) technology has been significantly advancing cancer research for some time and now is finally ready for a daily routine patient testing. Objective of this session is to:

- Explain basic science and principle of NGS and its application in NSCLC patient testing
- Introduce the first NGS in vitro diagnostic (IVD) test for NSCLC, simultaneously delivering multiple biomarker results for multiple targeted therapies – Oncomine Dx Target Test
- Give forum for multiple stakeholders – clinicians, laboratories and patients – discussion

14:30 – 15:30  Networking Opportunity & Poster Presenters Present for P1 Posters

**ROOM:** F201 + F202 (ANNEX HALL)

**Refreshments will be provided**

**P1.01** Advanced NSCLC

**P1.02** Biology/Pathology

**P1.03** Chemotherapy/Targeted Therapy

**P1.04** Clinical Design, Statistics and Clinical Trials

**P1.05** Early Stage NSCLC

**P1.06** Epidemiology/Primary Prevention/Tobacco Control and Cessation

**P1.07** Immunology and Immunotherapy

**P1.08** Locally Advanced NSCLC

**P1.09** Mesothelioma

**P1.10** Nursing/Palliative Care/Ethics

**P1.11** Patient Advocacy

**P1.12** Pulmonology/Endoscopy

**P1.13** Radiology/Staging/Screening

---

11:35  MA 04.06: Developing a Lung Cancer Clinical Quality Registry Framework to Collect Longitudinal Patient-Reported Outcomes

Mary Duffy, Peter MacCallum Cancer Centre, Australia

11:40  MA 04.07: Understanding Patient Barriers to Utilization of Low Dose CT Lung Cancer Screening

Cherie Parungo Erkmen, Temple University Hospital, USA

11:45  MA 04.08: Discussant – MA 04.05, MA 04.06, MA 04.07

Andrea Katalin Borondy Kitts, Lahey Hospital & Medical Center, USA

12:00  MA 04.09: A Study on the Damage of Passive Smoking to Japanese Lung Cancer Patients

Kazuo Hasegawa, Japan Lung Cancer Alliance, Japan

12:05  MA 04.10: An Assessment of the Willingness to Provide Serial Bio-Specimens: Experience from an Irish Tertiary Cancer Centre

Anne-Marie Baird, St. James’s Hospital & Trinity College Dublin, Ireland


Angela Meredith Criswell, Lung Cancer Alliance, USA

12:15  MA 04.12: Discussant – MA 04.09, MA 04.10, MA 04.11

Sita Andarini, Faculty of Medicine, Universitas Indonesia, Persahabatan Hospital, Indonesia

12:45 – 14:15  ISS 06: Maximizing Clinical Benefit from TKIs in the Treatment of Advanced NSCLC – Boehringer Ingelheim Pharma GmbH & Co. KG

**TRACK:** INDUSTRY SUPPORTED SYMPOSIUM

**ROOM:** MAIN HALL

**CHAIRS:** TETSUYA MITSUDOMI, JAPAN

**Lunch boxes provided**

12:45  ISS 06.01: Meeting Welcome and Introductions

Tetsuya Mitsudomi, Kindai University Faculty of Medicine, Japan

12:50  ISS 06.02: Efficacy of EGFR TKIs in NSCLC Patients With Uncommon EGFR Mutations

Terufumi Kato, Kanagawa Cancer Center, Japan

13:10  ISS 06.03: Considerations for Choosing TKIs for Squamous NSCLC in the Era of Immunotherapy: Which Patients Could Benefit?

Glenwood Goss, Ottawa Regional Cancer Centre, Canada

13:30  ISS 06.04: Emerging Algorithm for Optimal Sequencing of EGFR TKIs in EGFR Mutation-Positive NSCLC

Keunchil Park, Samsung Med Ctr, Sungkyunkwan University School of Medicine, Korea

13:50  ISS 06.05: Panel Discussion: Carrying the Data into the Clinic: TKI Sequencing Decisions for EGFR Mutation-Positive NSCLC Patients

Terufumi Kato, Kanagawa Cancer Center, Japan, Glenwood Goss, Ottawa Regional Cancer Centre, Canada, Keunchil Park, Samsung Med Ctr, Sungkyunkwan University School of Medicine, Korea

14:10  ISS 06.06: Meeting Close

Tetsuya Mitsudomi, Kindai University Faculty of Medicine, Japan
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:45 – 17:30</td>
<td><strong>MS 05: Clinical Issues of Immune Checkpoint Inhibitors</strong></td>
</tr>
<tr>
<td></td>
<td><strong>TRACK:</strong> IMMUNOLOGY AND IMMUNOTHERAPY</td>
</tr>
<tr>
<td></td>
<td><strong>ROOM:</strong> MAIN HALL</td>
</tr>
<tr>
<td></td>
<td><strong>CHAIRS:</strong> LUISE. RAEZ, USA &amp; NICO VAN ZANDWJIK, AUSTRALIA</td>
</tr>
<tr>
<td>15:45</td>
<td><strong>MS 05.01: How to Evaluate the Efficacy of IO?</strong></td>
</tr>
<tr>
<td></td>
<td>Frances A. Shepherd, Princess Margaret Cancer Centre, Canada</td>
</tr>
<tr>
<td>16:00</td>
<td><strong>MS 05.02: First-line versus Second-Line Anti-PD-(L)1 Therapy for Patients with Positive PD-L1 Expression</strong></td>
</tr>
<tr>
<td></td>
<td>Fabrice Barlesi, Aix Marseille University, France</td>
</tr>
<tr>
<td>16:15</td>
<td><strong>MS 05.03: Rational IO/IO Combinations</strong></td>
</tr>
<tr>
<td></td>
<td>Tony Mok, Chinese University of Hong Kong, Hong Kong</td>
</tr>
<tr>
<td>16:30</td>
<td><strong>MS 05.04: Practical Approach to Combination of Chemotherapy with IO</strong></td>
</tr>
<tr>
<td></td>
<td>Yuichiro Ohe, National Cancer Center Hospital, Japan</td>
</tr>
<tr>
<td>16:45</td>
<td><strong>MS 05.05: Continuation of Immunotherapy in Post-Progressive Disease</strong></td>
</tr>
<tr>
<td></td>
<td>David R. Gandara, UC Davis Comprehensive Cancer Center, USA</td>
</tr>
<tr>
<td>17:00</td>
<td><strong>MS 05.06: Brain Metastasis: Rationale and Efficacy with IO</strong></td>
</tr>
<tr>
<td></td>
<td>Ignacio Gil-Bazo, Clinica Universidad de Navarra, Spain</td>
</tr>
<tr>
<td>17:15</td>
<td><strong>Question and Answer Session</strong></td>
</tr>
<tr>
<td>15:45 – 17:30</td>
<td><strong>MS 06: Combined Modality Treatment for Thymic and Pleural Malignancy</strong></td>
</tr>
<tr>
<td></td>
<td><strong>TRACK:</strong> THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES</td>
</tr>
<tr>
<td></td>
<td><strong>ROOM:</strong> F201 + F202 (ANNEX HALL)</td>
</tr>
<tr>
<td></td>
<td><strong>CHAIRS:</strong> OSCAR ARRIETA, MEXICO &amp; SCOTT SWANSON, USA</td>
</tr>
<tr>
<td>15:45</td>
<td><strong>MS 06.01: Proposal of Change for Future Staging System for Thymic Tumor</strong></td>
</tr>
<tr>
<td></td>
<td>Menoshin Okumura, Osaka Univeristy Graduate School of Medicine, Japan</td>
</tr>
<tr>
<td>16:00</td>
<td><strong>MS 06.02: Is There a Role for Minimally Invasive Surgery in Locally Advanced Thymic Tumors?</strong></td>
</tr>
<tr>
<td></td>
<td>Wentao Fang, Shanghai Chest Hospital, China</td>
</tr>
<tr>
<td>16:15</td>
<td><strong>MS 06.03: PD vs. EPP in the Treatment of MPM</strong></td>
</tr>
<tr>
<td></td>
<td>David Rice, UT MD Anderson Cancer Center, USA</td>
</tr>
<tr>
<td>16:30</td>
<td><strong>MS 06.04: The Effect of the Timing of Chemotherapy: Induction vs Adjuvant after PD or EPP</strong></td>
</tr>
<tr>
<td></td>
<td>David Waller, St Bartholomew’s Hospital, London, UK</td>
</tr>
<tr>
<td>16:45</td>
<td><strong>MS 06.05: The Use of Adjuvant IMRT after Pleurectomy/Decortication</strong></td>
</tr>
<tr>
<td></td>
<td>Andreas Rimner, Memorial Sloan-Kettering Cancer Center, USA</td>
</tr>
<tr>
<td>17:00</td>
<td><strong>MS 06.06: Chemotherapy for Thymic and Mesothelial Tumors</strong></td>
</tr>
<tr>
<td></td>
<td>Miyako Satouchi, Hyogo Cancer Center, Japan</td>
</tr>
<tr>
<td>17:15</td>
<td><strong>Question and Answer Session</strong></td>
</tr>
<tr>
<td>15:45 – 17:30</td>
<td><strong>MS 07: Neuroendocrine Tumors other than SCLC: Pathology to Patient Management</strong></td>
</tr>
<tr>
<td></td>
<td><strong>TRACK:</strong> SCLC/NEUROENDOCRINE TUMORS</td>
</tr>
<tr>
<td></td>
<td><strong>ROOM:</strong> F203 + F204 (ANNEX HALL)</td>
</tr>
<tr>
<td></td>
<td><strong>CHAIRS:</strong> CARLOS BARRIOS, BRAZIL &amp; SANG-WE KIM, KOREA</td>
</tr>
<tr>
<td>15:45</td>
<td><strong>MS 07.01: Pathology of Neuroendocrine Tumors other than SCLC</strong></td>
</tr>
<tr>
<td></td>
<td>Mary Beth Beasley, Mount Sinai Medical Center, USA</td>
</tr>
<tr>
<td>16:00</td>
<td><strong>MS 07.02: Novel Chemotherapy for LCNEC</strong></td>
</tr>
<tr>
<td></td>
<td>Seiji Niho, National Cancer Center Hospital East, Japan</td>
</tr>
<tr>
<td>16:15</td>
<td><strong>MS 07.03: Novel Systemic Therapy for Carcinoid of the Lung</strong></td>
</tr>
<tr>
<td></td>
<td>Primo Lara, University of California Davis Comprehensive Cancer Center, USA</td>
</tr>
<tr>
<td>16:30</td>
<td><strong>MS 07.04: Surgical Treatment for Neuroendocrine Tumors other than SCLC</strong></td>
</tr>
<tr>
<td></td>
<td>Akira Iyoda, Toho University School of Medicine, Japan</td>
</tr>
<tr>
<td>16:45</td>
<td><strong>MS 07.05: ESTS Registration for Neuroendocrine Tumors</strong></td>
</tr>
<tr>
<td></td>
<td>Pier Luigi Filosso, University of Torino Italy, Italy</td>
</tr>
<tr>
<td>17:00</td>
<td><strong>MS 07.06: Which Chemotherapy or Targeted Therapy is Better for Treatment of LCNEC Patients: SCLC-based versus Non-SCLC-based Regimens?</strong></td>
</tr>
<tr>
<td></td>
<td>Sumitra Thongprasert, Bangkok Hospital Chiang Mai, Thailand</td>
</tr>
<tr>
<td>17:15</td>
<td><strong>Question and Answer Session</strong></td>
</tr>
<tr>
<td>15:45 – 17:30</td>
<td><strong>MS 08: Novel Treatment for Mesotheiloma</strong></td>
</tr>
<tr>
<td></td>
<td><strong>TRACK:</strong> MESOTHELIOMA</td>
</tr>
<tr>
<td></td>
<td><strong>ROOM:</strong> 316</td>
</tr>
<tr>
<td></td>
<td><strong>CHAIRS:</strong> PAUL BAAS, NETHERLANDS &amp; TAKASHI NAKANO, JAPAN</td>
</tr>
<tr>
<td>15:45</td>
<td><strong>MS 08.01: Today’s Challenges in MPM Care</strong></td>
</tr>
<tr>
<td></td>
<td>Walter Weder, University Hospital Zurich, Switzerland</td>
</tr>
<tr>
<td>16:00</td>
<td><strong>MS 08.02: Current Role of RT in MPM</strong></td>
</tr>
<tr>
<td></td>
<td>Anna Wrona, Medical University of Gdansk, Poland</td>
</tr>
<tr>
<td>16:15</td>
<td><strong>MS 08.03: Basic Science and Surgical Advances in MPM</strong></td>
</tr>
<tr>
<td></td>
<td>Raphael Bueno, Brigham and Women’s Hospital, USA</td>
</tr>
<tr>
<td>16:30</td>
<td><strong>MS 08.04: Immunotherapy in MPM</strong></td>
</tr>
<tr>
<td></td>
<td>Anna Nowak, University of Western Australia, Australia</td>
</tr>
<tr>
<td>16:45</td>
<td><strong>MS 08.05: New Biological Insights</strong></td>
</tr>
<tr>
<td></td>
<td>Yoshitaka Sekido, Aichi Cancer Center Research Institute, Japan</td>
</tr>
</tbody>
</table>
17:00  MS 08.06: Molecularly Stratified Therapy
Hedy Lee Kindler, University of Chicago, USA

17:15  MS 08.07: Achieving Equitable Access to Novel Treatments for all Patients
Liz Darlison, University Hospitals of Leicester, UK

17:25  Question and Answer Session

15:45 – 17:30  MS 09: Global Perspectives in Eliminating the Major Cause of Lung Cancer

TRACK:  EPIDEMIOLOGY/PRIMARY PREVENTION/TOBACCO CONTROL AND CESSATION
ROOM:  315
CHAIRS:  CAROLYN DRESLER, USA & WILLIAM K. EVANS, USA

15:45  MS 09.01: Global Tobacco Control
Emily Stone, St. Vincent’s Hospital Sydney, Australia

16:00  MS 09.02: FCTC Implementation around the World
Geoffrey Fong, University of Waterloo, Canada

16:15  MS 09.03: Cost Effectiveness of Smoking Cessation
Hong Gwan Seo, National Cancer Center, Korea

16:30  MS 09.04: Nicotine Dependence and Cessation in Lung Cancer Patients
Matthew A. Steliga, University of Arkansas for Medical Sciences, USA

16:45  MS 09.05: Holding the Tobacco Industry Accountable; Discussion about iQOS
Yumiko Mochizuki, National Cancer Center, Japan

17:00  MS 09.06: Tobacco Industry Interference in Low and Middle Income Countries
Nise Yamaguchi, Hospital Albert Einstein, Brazil

17:15  MS 09.07: Implementation of Smoking Cessation Strategies
Stella Bialous, UCSF School of Nursing, USA

17:05  MS 10.05: Immunotherapy: The Latest
Beth Eaby-Sandy, Abramson Cancer Center, University of Pennsylvania, USA

17:25  Question and Answer Session

15:45 – 17:30  MS 10: Evidence Based Care: Interpreting the Research and Enhancing Practice

TRACK:  NURSING/PALLIATIVE CARE/ETHICS
ROOM:  F205 + F206 (ANNEX HALL)
CHAIRS:  CAITLIN BRODERICK, AUSTRALIA & PIPPA LABUC, UK

15:45  MS 10.01: Radiotherapy Management
Mary Duffy, Peter MacCallum Cancer Centre, Australia

16:05  MS 10.02: Interpreting Published Research
Angela Mary Tod, University of Sheffield, UK

16:25  MS 10.03: Community Outreach – Engaging in Primary Care
Lavinia Dobrea, St. Joseph Hospital, USA

16:45  MS 10.04: Pre-Operative Support
Melissa Culligan, University of Maryland Medical Center – Thoracic Surgery, USA

15:45 – 17:30  ES 03: Current Topics for Nurses & Allied Health

TRACK:  NURSING/PALLIATIVE CARE/ETHICS
ROOM:  313 + 314
CHAIRS:  ANNE FRASER, NEW ZEALAND & SUE KIM, KOREA

15:45  ES 03.01: IASLC Immunotherapy Guidelines
Kimberly Ann Rohan, Edward Cancer Center, USA

16:05  ES 03.02: Pulmonary Rehabilitation
Catherine L. Granger, The University of Melbourne, Australia

16:25  ES 03.03: Allied Health: The Missing Link in Comprehensive Cancer Care
Kahren White, Private Practice, Australia

16:45  ES 03.04: Mesothelioma: Beyond the Basics
Mary Hesdorffer, Mesothelioma Applied Research Foundation, USA

17:05  ES 03.05: Case Presentation
Yun Hee Ham, Samsung Medical Center, Korea

17:25  Question and Answer Session
15:45 – 17:30  OA 04: Surgery from Minimal to Radical

TRACK: SURGERY
ROOM: 311 + 312
CHAIRS: JANG-MING LEE, TAIWAN & ANDREW CHANG, USA

15:45  OA 04.01: Randomised Trial of Systematic Lymph Node Dissection versus Bilateral Mediastinal Lymphadenectomy in Patients with Non-Small Cell Carcinoma
Jaroslaw Kudzdał, Jagiellonian University, John Paul II Hospital, Poland

15:55  OA 04.02: Feasibility of Pulmonary Resection Following Definitive Chemoradiotherapy for Primary Lung Carcinoma
Yasuhiro Hida, Hokkaido University Hospital, Japan

16:05  OA 04.03: Primary Tumor Resection versus Maintenance Therapy for Patients with Oligometastatic Non-Small Cell Lung Cancer
Xiaozheng Kang, Peking University Cancer Hospital, China

16:15  OA 04.04: Discussant – OA 04.01, OA 04.02, OA 04.03
Hiroyasu Yokomise, Kagawa University Hospital, Japan

16:30  OA 04.05: Intermediate Results of ICG Anatomical Segmentectomy Based on the Virtual Segmentectomy Simulation
Yasu Seine, Tokyo Women’s Medical University Yachiyo Medical Center, Japan

16:40  OA 04.06: Surgeon Practices for Post Resection Lung Cancer Surveillance: Comparisons of STS and ESTS Members
Leah Backhus, Stanford University School of Medicine, USA

16:50  OA 04.07: Initial Results of Tubeless Single-Port Thoracoscopic Surgery for Pulmonary Tumor
Chao-Yu Liu, Far Eastern Memorial Hospital, Taiwan

17:00  OA 04.08: Is Lobe-Specific Lymph Node Dissection in Clinical N0-1 Non-Small Cell Lung Cancer Adequate for Pathological Nodal Staging
Aphi Chantraworasin, Chiang Mai University, Thailand

17:10  OA 04.09: Discussant – OA 04.05, OA 04.06, OA 04.07, OA 04.08
Anthony Kim, University of Cincinnati, USA

15:45 – 17:30  OA 05: Next Generation TKI

TRACK: ADVANCED NSCLC
CHEMOTHERAPY/TARGETED THERAPY
ROOM: 301 + 302
CHAIRS: JAMES CHIH-HSIN YANG, TAIWAN & FIONA BLACKHALL, UK

15:45  OA 05.01: First-Line Dacomitinib versus Gefitinib in Advanced Non-Small-Cell Lung Cancer with EGFR Mutation Subgroups
Yi-Long Wu, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

15:55  OA 05.02: Osimertinib vs SoC EGFR-TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA): Plasma ctDNA Analysis
Jhannelle Etaine Gray, H. Lee Moffitt Cancer Center & Research Institute, USA

16:05  OA 05.03: Clinical Activity of ASP8273 in Asian Non-Small Cell Lung Cancer Patients with EGFR Activating and T790M Mutations
Keuchil Park, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea

16:15  OA 05.04: Discussant – OA 05.01, OA 05.02, OA 05.03
Mark G. Kris, Memorial Sloan Kettering Cancer Center, USA

16:30  OA 05.05: Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Updated Efficacy and Safety Results From ALTA, a Randomized Phase 2 Trial
Myung-Ju Ahn, Samsung Medical Center, Korea

16:40  OA 05.06: Phase 2 Study of Lorlatinib in Patients with Advanced ALK+/ROS1+ Non-Small-Cell Lung Cancer
Ben J. Solomon, Peter MacCallum Cancer Centre, Australia

15:45 – 17:30  OA 06: Global Tobacco Control and Epidemiology I

TRACK: EPIDEMIOLOGY/PRIMARY PREVENTION/TOBACCO CONTROL AND CESSATION
ROOM: 511 + 512
CHAIRS: GÁBOR KOVÁCS, HUNGARY & YUN FAN, CHINA

15:45  OA 06.01: Costs and Cost-Effectiveness of Smoking Cessation Within an Organized CT Lung Cancer (LC) Screening Program
William Kenneth Evans, McMaster University, Canada

15:55  OA 06.02: Final Report of the INHERIT EGFR Study – 33 Unrelated Kindreds Carrying Germline EGFR Mutations
Geoffrey R. Oxnard, Dana-Farber Cancer Institute, USA

16:05  OA 06.03: Comorbidity and Competing Causes of Death attenuate outcomes in the NLST.
Robert P. Young, University of Auckland, New Zealand

16:15  OA 06.04: Discussant – OA 06.01, OA 06.02, OA 06.03
Anthonie Van Der Wekken, University Medical Centre Groningen, Netherlands

16:30  OA 06.05: Socioeconomic Factors Affecting Outcomes in Non-Small Cell Lung Cancer (NSCLC): A Large Population-Based Analysis
Yanyan Lou, Mayo Clinic, USA

16:40  OA 06.06: Chr15q25 Locus Confers Risk of Lung Cancer, COPD and Smoking: Triple Whammy Effect in the ACRIN NLST Sub-Study (N=9,270)
Raewyn J. Hopkins, University of Auckland, New Zealand
16:50 OA 06.07: Survival Trends Among Non-Small Cell Lung Cancer (NSCLC) Patients Over A Decade: Impact of Initial Therapy at Academic Centers
Bhagirathbhai Dholaria, Mayo Clinic, USA

17:00 OA 06.08: Is Lung Cancer Screening Associated with a Negative Psychological Impact?
Ben Young, University of Nottingham, UK

17:10 OA 06.09: Discussant – OA 06.05, OA 06.06, OA 06.07, OA 06.08
Norihiko Ikeda, Tokyo Medical University, Japan

15:45 – 17:30 OA 07: Biomarker for Lung Cancer
TRACK: BIOLOGY/PATHOLOGY
ROOM: 503
CHAIRS: PHILIP C. MACK, USA & SHINICHI TOYOOKA, JAPAN

15:45 OA 07.01: A Prospective Study of Perioperative Rapid Clearance of Circulating Tumor DNA in R0 Resected Non-Small Cell Lung Cancer Patients
Kezhong Chen, Peking University People’s Hospital, China

15:55 OA 07.02: Characteristics of Lung Cancer Cell-Free Tumor DNA (cfDNA) Shedding and Correlation with Tumor Burden as Measured by RECIST
Vincent K. Lam, The University of Texas MD Anderson Cancer Center, USA

16:05 OA 07.03: Circulating Tumor DNA Mutant Allele Frequency and Tumor Burden as Biomarkers for Response to Immune Checkpoint Blockade
Young Kwang Chae, Developmental Therapeutics Program of the Division of Hematology Oncology Robert H. Lurie Comprehensive Cancer Center of Northwestern University, USA

16:15 OA 07.04: Discussant – OA 07.01, OA 07.02, OA 07.03
Balazs Halmos, Albert Einstein/Montefiore Cancer Center, USA

16:30 OA 07.05: Serial Biopsies in Patients with EGFR-Mutant NSCLC Highlight the Spatial and Temporal Heterogeneity of Resistance Mechanisms
Zofia Piotrowska, Massachusetts General Hospital, USA

16:40 OA 07.06: Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Naive Lesions
Kenichi Suda, University of Colorado Anschutz Medical Campus, USA

16:50 OA 07.07: Inhibition of the Novel Oncogene ELF3 Abolishes Lung Adenocarcinoma Growth
Katey S.S. Enfield, British Columbia Cancer Research Centre, Canada

17:00 OA 07.08: Clinical Potential of Sputum in Detecting Driver Mutations in Patients with Non-Small Cell Lung Cancer: A Preliminary Study
Vanessa Karen De Sá, AC Camargo Cancer Center, Brazil

17:10 OA 07.09: Discussant – OA 07.05, OA 07.06, OA 07.07, OA 07.08
Iver Petersen, SRH Wald-Klinikum, Germany

15:45 – 17:30 MA 05: Immuno-Oncology: Novel Biomarker Candidates
TRACK: IMMUNOLOGY AND IMMUNOTHERAPY
ROOM: 303 + 304
CHAIR: YOICHI NAKANISHI, JAPAN

15:45 MA 05.01: Integrating INDEL Mutations into Neoantigen Prediction in Lung Cancer: Developing Personalized Cancer Vaccines
Yanyan Lou, Mayo Clinic, USA

15:50 MA 05.02: STK11/LKB1 Loss of Function Genomic Alterations Predict Primary Resistance to PD-1/PD-L1 Axis Blockade in KRAS-Mutant NSCLC
Ferdinandos Skoulidis, The University of Texas M. D. Anderson Cancer Center, USA

15:55 MA 05.03: The Early Monitoring of Derived Neutrophil-To Lymphocyte Ratio (dNLR) Could Be a Surrogate Marker of Benefit of Immunotherapy in NSCLC
Laura Mezquita, Gustave Roussy, France

16:00 MA 05.04: Distinct Immunosuppressive Microenvironment Determines Poor Prognosis of Nonsmokers with Adenocarcinoma of Non-Small Cell Lung Cancer
Tomonari Kinoshita, Keio University School of Medicine, Japan

16:05 MA 05.05: Discussant – MA 05.01, MA 05.02, MA 05.03, MA 05.04
Laura Q. Chow, University of Washington, USA

16:20 MA 05.06: Comparison Study of PD-L1 Immunohistochemistry Assays with 22C3 and 28-8: Analysis on Surgical Specimens of NSCLC.
Toshinori Saito, Kansai Medical University Hospital, Japan

16:25 MA 05.07: Whole Body PD-1 and PD-L1 PET in Pts with NSCLC
Anna-Larissa Nadia Niemeijer, VU University Medical Center, Netherlands

16:30 MA 05.08: Very Early Response of Circulating Tumor Derived DNA Predict the Efficacy of Treatment by Nivolumab in Patients with Non-Small Cell Lung Cancer
Yuki Iijima, Yamanashi Prefectural Central Hospital, Japan

16:35 MA 05.09: Pre-Existing Immunity Measured by Teff Gene Expression in Tumor Tissue is Associated with Atezolizumab Efficacy in NSCLC
Marcin Kowanetz, Genentech, Inc., USA

16:40 MA 05.10: Discussant – MA 05.06, MA 05.07, MA 05.08, MA 05.09
David Rimn, Yale University School of Medicine, USA

16:55 MA 05.11: Endothelial Adhesion Molecule Overexpression Correlates to Decreased CD8 T Cells and Increased B/Treg Cells in Lung Cancer
Young Kwang Chae, Robert H Lurie Comprehensive Cancer Center of Northwestern University, USA

17:00 MA 05.12: Oncogenic Drivers Induce Production of CCL5 to Recruit Regulatory T-Cells Early in Lung Cancer Progression
William W. Lockwood, British Columbia Cancer Research Centre, Canada

17:05 MA 05.13: Scavenger Receptor MARCO Defines a Targetable Tumor-Associated Macrophage Subset in Lung Cancer
Linnea La Fleur, Uppsala University, Sweden
17:10 MA 05.14: Differential Expression of IFN-Stimulating DNA Sensors STING and cGAS in Lung Cancer Subtypes
Charles Caldwell Jr, University of Colorado, USA

17:15 MA 05.15: Discussant – MA 05.11, MA 05.12, MA 05.13, MA 05.14
Hiroyuki Suzuki, Fukushima Medical University, Japan

16:55 MA 06.11: Distinct Mutational Landscape and Evolutionary Trajectories of Brain Metastasis and Liver Metastasis in Lung Adenocarcinoma
Tao Jiang, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

17:00 MA 06.12: Genomic Rearrangements of Lung Adenocarcinomas with Fusion Driver Gene Seongyeol Park, Korea Advanced Institute of Science and Technology, Korea

17:05 MA 06.13: Direct Metabolomic Profiling of Lung Cancers Elizabeth Starren, Imperial College London and the Royal Brompton and Harefield NHS Trust, UK

17:10 MA 06.14: Oncogenic SOS1 Mutations in Lung Adenocarcinoma Diana Cai, Dana-Farber Cancer Institute, USA

17:15 MA 06.15: Discussant – MA 06.11, MA 06.12, MA 06.13, MA 06.14
Akihiko Yoshida, National Cancer Center, Japan

15:45 – 17:30 MA 06: Lung Cancer Biology I
TRACK: BIOLOGY/PATHOLOGY
ROOM: 501
CHAIRS: NORIKO MOTOI, JAPAN & KEITH M. KERR, UK

17:45 – 19:15 ISS 07: The Evolving I-O Treatment Landscape in Thoracic Cancers: Clinical Updates and Future Directions – Bristol-Myers Squibb
TRACK: INDUSTRY SUPPORTED SYMPOSIUM
ROOM: MAIN HALL
CHAIRS: DANIEL TAN, SINGAPORE

15:45 MA 06.01: Cancer Testis Antigens and Mutational Load in Relation to the Immune Landscape of Non-Small Cell Lung Cancer
Patrick Micke, Uppsala University, Sweden

15:50 MA 06.02: Cytology and Surgical Pathology Specimens are Comparable Testing Substrates for PD-L1 Immunohistochemistry in Lung Cancer Paul Andrew Vanderlaan, Beth Israel Deaconess Medical Center, Harvard Medical School, USA

15:55 MA 06.03: Programmed Death-Ligand 1 (PD-L1) Expression in Clinical Practice: Comparison of Temporally or Spatially Separated Test Results Charuhas Deshpande, University of Pennsylvania, USA

16:00 MA 06.04: Development of Next-Generation Sequencing Based Cancer Panel and Its Clinical Implications in Lung Cancer Yoohwa Hwang, Seoul National University Borame Hospital, Korea

16:05 MA 06.05: Discussant – MA 06.01, MA 06.02, MA 06.03, MA 06.04 Giuseppe Giaccone, Georgetown University, USA

16:20 MA 06.06: Assessment of RANK Prevalence and Clinical Significance in the NSCLC European Thoracic Oncology Platform Lungscape Cohort Erik Thunnissen, VU University Medical Center, Netherlands

16:25 MA 06.07: JAK Pseudokinase Domain Variants Highlight nRTK nsSNPs Identified with Next-Generation Sequencing in NSCLC Patients Matthew K. Stein, West Cancer Center, University of Tennessee Health Science Center, USA

16:30 MA 06.08: Lung Cancer Patients with Germline Mutation: A Retrospective Study Sandipkumar Patel, Ohio State University Comprehensive Cancer Center, USA

16:35 MA 06.09: Detection of EGFR T790M Mutations by Four Testing Platforms in ctDNA from Chinese Patients with Advanced NSCLC Xu-Chao Zhang, Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangdong Academy of Medical Sciences, China

16:40 MA 06.10: Discussant – MA 06.06, MA 06.07, MA 06.08, MA 06.09
Kenzo Soejima, Keio University School of Medicine, Japan

16:05 MA 06.15: Discussant – MA 06.11, MA 06.12, MA 06.13, MA 06.14
Akihiko Yoshida, National Cancer Center, Japan
19:15 – 20:30  WS 05: superDimension™ Electromagnetic Navigation Bronchoscopy - Bridging the Diagnostic and Therapeutic Domains in Lung Cancer - Medtronic (Sign Up Required)

TRACK: PULMONOLOGY/ENDOSCOPY
ROOM: 315

19:15  WS 05.01: Update on Global NAVIGATE Trial (first 1000 patients)

19:30  WS 05.02: Optimizing the Diagnostic Procedure
Christopher W. Towe, University Hospitals Cleveland Medical Center and Case Western Reserve School of Medicine, USA

19:50  WS 05.03: superDimension™ Beyond the Diagnosis
Mark R. Bowling, East Carolina University, USA

20:10  WS 05.04: Question and Answer Session

19:30 – 20:30  Joint IASLC Foundation – JLCS Concert with Ms. Suwanai and the Tokyo City Philharmonic Orchestra (Ticketed Event)

MONDAY, OCTOBER 16, 2017
19:30–20:30

Minatomirai Hall, Yokohama
Across from PACIFICO Yokohama

Ticket Price: 50 USD

Tickets available at Registration
Limited seats available.
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 – 08:00</td>
<td>ISS 08: Optimising the Continuum of Care for Patients with Oncogenic Driven NSCLC – Pfizer Oncology</td>
</tr>
<tr>
<td></td>
<td>TRACK: INDUSTRY SUPPORTED SYMPOSIUM</td>
</tr>
<tr>
<td></td>
<td>ROOM: F201 + F202 (ANNEX HALL)</td>
</tr>
<tr>
<td></td>
<td>CHAIR: YASUSHI GOTO, JAPAN</td>
</tr>
<tr>
<td></td>
<td>Continental Breakfast provided</td>
</tr>
<tr>
<td>07:00</td>
<td>ISS 08.01: Welcome and Introduction</td>
</tr>
<tr>
<td></td>
<td>Yasushi Goto, National Cancer Center Japan, Japan</td>
</tr>
<tr>
<td>07:10</td>
<td>ISS 08.02: Building on Experience and Driving Precision Medicine in ALK+ &amp; ROS1+ NSCLC</td>
</tr>
<tr>
<td></td>
<td>Nicolas Girard, Hospices Civils de Lyon, France</td>
</tr>
<tr>
<td>07:35</td>
<td>ISS 08.03: Resistance to ALK and ROS1 Inhibitors: Addressing the Clinical Impact</td>
</tr>
<tr>
<td></td>
<td>Justin F. Gainor, Massachusetts General Hospital, USA</td>
</tr>
<tr>
<td>07:50</td>
<td>ISS 08.04: Panel Discussion</td>
</tr>
<tr>
<td></td>
<td>Yasushi Goto, National Cancer Center Japan, Japan, Nicolas Girard, Hospices Civils de Lyon, France, Justin F. Gainor, Massachusetts General Hospital, USA</td>
</tr>
<tr>
<td>08:00</td>
<td>ISS 08.05 Meeting Close</td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 – 08:00</td>
<td>ISS 09: The Evolution of Targetable Oncogenic Drivers in NSCLC: Novel Treatment Paradigms – Novartis</td>
</tr>
<tr>
<td></td>
<td>TRACK: INDUSTRY SUPPORTED SYMPOSIUM</td>
</tr>
<tr>
<td></td>
<td>ROOM: F203 + F204 (ANNEX HALL)</td>
</tr>
<tr>
<td></td>
<td>CHAIR: SOLANGE PETERS, SWITZERLAND</td>
</tr>
<tr>
<td></td>
<td>Continental Breakfast provided</td>
</tr>
<tr>
<td>07:00</td>
<td>ISS 09.01: Welcome and Introduction</td>
</tr>
<tr>
<td></td>
<td>Solange Peters, Lausanne University Hospital CHUV, Switzerland</td>
</tr>
<tr>
<td>07:05</td>
<td>ISS 09.02: NSCLC as a Model for Precision Oncology</td>
</tr>
<tr>
<td></td>
<td>Ben J. Solomon, Peter MacCallum Cancer Centre, Australia</td>
</tr>
<tr>
<td>07:20</td>
<td>ISS 09.03: Management of ALK+ NSCLC: A Rapidly-changing Landscape</td>
</tr>
<tr>
<td></td>
<td>Solange Peters, Lausanne University Hospital CHUV, Switzerland</td>
</tr>
<tr>
<td>07:35</td>
<td>ISS 09.04: Progress in the Treatment of BRAF-Mutated NSCLC: Where Are We Now?</td>
</tr>
<tr>
<td></td>
<td>David Planchard, Gustave Roussy, France</td>
</tr>
<tr>
<td>07:50</td>
<td>ISS 09.05: Expert Panel Q&amp;A (Including Brief Summary and Close)</td>
</tr>
<tr>
<td></td>
<td>Solange Peters, Lausanne University Hospital CHUV, Switzerland, Ben J. Solomon, Peter MacCallum Cancer Centre, Australia, David Planchard, Gustave Roussy, France</td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 – 08:00</td>
<td>SH 01: WCLC 2017 Highlights of the Previous Day</td>
</tr>
<tr>
<td></td>
<td>TRACK: ADVANCED NSCLC, CLINICAL DESIGN, STATISTICS AND CLINICAL TRIALS, IMMUNOLOGY AND IMMUNOTHERAPY, PATIENT ADVOCACY, SURGERY, BIOLOGY/PATHOLOGY, EPIDEMIOLOGY/PRIMARY PREVENTION/TOBACCO CONTROL AND SMOKELESS CESSATION</td>
</tr>
<tr>
<td></td>
<td>ROOM: 502</td>
</tr>
<tr>
<td>07:00</td>
<td>SH 01.01: Advanced NSCLC, Clinical Design, Statistics and Clinical Trials, Immunology and Immunotherapy and Patient Advocacy</td>
</tr>
<tr>
<td></td>
<td>Suresh S. Ramalingam, Winship Cancer Institute of Emory University, USA</td>
</tr>
</tbody>
</table>
07:20 SH 01.02: Surgery
Masafumi Kawamura, Teikyo University, School of Medicine, Japan

07:40 SH 01.03: Biology/Pathology and Epidemiology/Primary Prevention/Tobacco Control and Cessation
Yuichi Takiguchi, Chiba University Hospital, Japan

07:00 – 08:00 MTE 11: How to Write a Scientific Paper (Sign Up Required)
TRACK: EDUCATION/PUBLICATION/CAREER DEVELOPMENT
ROOM: 511 + 512
07:00 MTE 11.01: How to Write a Scientific Paper that will be Accepted
Alex Adjei, Roswell Park Cancer Institute, USA

07:00 – 08:00 MTE 12: Oncology Nursing (Sign Up Required)
TRACK: NURSING/PALLIATIVE CARE/ETHICS
ROOM: 316
07:00 MTE 12.01: Peripheral Neuropathy in Lung Cancer Patients
Alex Molassiotis, The Hong Kong Polytechnic University, Hong Kong
07:30 MTE 12.02: Advance Care Planning: The Pros and Cons
Patsy Yates, QLD University of Technology, School of Nursing, Australia

07:00 – 08:00 MTE 13: Malignant Pleural Mesothelioma: State of the Art (Sign Up Required)
TRACK: MESOTHELIOMA
ROOM: 501
07:00 MTE 13.01: Surgery for Malignant Pleural Mesothelioma
Scott Swanson, Brigham and Women’s Hospital, Harvard Medical School, USA
07:30 MTE 13.02: Systemic Treatments for Malignant Pleural Mesothelioma
Shirish M. Gadgeel, Karmanos Cancer Institute/Wayne State University, USA

07:00 – 08:00 MTE 14: Imaging of Lung Cancer (Sign Up Required)
TRACK: RADIOLOGY/STAGING/SCREENING
ROOM: F205 + F206 (ANNEX HALL)
07:00 MTE 14.01: Computed Tomographic Features of Small Pulmonary Nodules: A Follow-Up Study
Masahiko Kusumoto, National Cancer Center Hospital East, Japan
07:30 MTE 14.02: Diagnostic Intervention for Lung Cancer
David F. Yankelevitz, Icahn School of Medicine at Mount Sinai, USA

07:00 – 08:00 MTE 15: Biomarkers for Immune Checkpoint Inhibitors (Sign Up Required)
TRACK: IMMUNOLOGY AND IMMUNOTHERAPY
ROOM: 301 + 302
07:00 MTE 15.01: Mechanisms of Resistance in IO
Roy S. Herbst, Yale School of Medicine, Yale Cancer Center, Smilow Cancer Hospital at Yale-New Haven, USA
07:30 MTE 15.02: Fast and Deeper Responders with IO: How to Select Them?
Hossein Borghaei, Fox Chase Cancer Center, USA

07:00 – 08:00 MTE 16: Technical Issues after Neoadjuvant Chemoradiation – Surgeon’s Perspective (Sign Up Required)
TRACK: SURGERY
ROOM: 311 + 312
07:00 MTE 16.01: Difficulties of Surgery After Induction of Chemoradiotherapy
Eric Vallieres, Swedish Medical Center and Cancer Institute, USA
07:30 MTE 16.02: Surgery for Stage IIIA NSCLC – Surgeon’s Perspective
Gail Elizabeth Darling, University of Toronto, Canada
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00</td>
<td>MTE 17: Neuroendocrine Tumor (Sign Up Required)</td>
</tr>
<tr>
<td></td>
<td>TRACK: SCLC/NEUROENDOCRINE TUMORS</td>
</tr>
<tr>
<td></td>
<td>ROOM: 418</td>
</tr>
<tr>
<td>07:00</td>
<td>MTE 17.01: Pathological Features of Neuroendocrine Tumors</td>
</tr>
<tr>
<td></td>
<td>Yuichi Ishikawa, Japanese Foundation for Cancer Research, Japan</td>
</tr>
<tr>
<td>07:30</td>
<td>MTE 17.02: Surgical Strategy for the Treatment of Neuroendocrine Tumors</td>
</tr>
<tr>
<td></td>
<td>Enrico Ruffini, University of Torino, Italy</td>
</tr>
<tr>
<td>07:00</td>
<td>MTE 18: Treatment for Squamous Cell Carcinoma (Sign Up Required)</td>
</tr>
<tr>
<td></td>
<td>TRACK: ADVANCED NSCLC</td>
</tr>
<tr>
<td></td>
<td>ROOM: 313 + 314</td>
</tr>
<tr>
<td>07:00</td>
<td>MTE 18.01: Treatment for Squamous Cell Carcinoma</td>
</tr>
<tr>
<td></td>
<td>Paul K. Paik, Memorial Sloan Kettering Cancer Center, USA</td>
</tr>
<tr>
<td>07:00</td>
<td>MTE 19: Laser Therapy for Early Stage and Airway Obstruction (Sign Up Required)</td>
</tr>
<tr>
<td></td>
<td>TRACK: PULMONOLOGY/ENDOSCOPY</td>
</tr>
<tr>
<td></td>
<td>ROOM: 317</td>
</tr>
<tr>
<td>07:00</td>
<td>MTE 19.01: Laser Therapy for Airway Obstruction</td>
</tr>
<tr>
<td></td>
<td>Kenneth Kazuto Sakata, Mayo Clinic, USA</td>
</tr>
<tr>
<td>07:30</td>
<td>MTE 19.02: Ablative Therapy for Early Stage Lung Cancer</td>
</tr>
<tr>
<td></td>
<td>Antoni Rosell, Hospital Universitari de Bellvitge, Spain</td>
</tr>
<tr>
<td>07:00</td>
<td>MTE 20: Liquid Biopsy (Sign Up Required)</td>
</tr>
<tr>
<td></td>
<td>TRACK: BIOLOGY/PATHOLOGY</td>
</tr>
<tr>
<td></td>
<td>ROOM: 303 + 304</td>
</tr>
<tr>
<td>07:00</td>
<td>MTE 20.01: Recent Advances in Liquid Biopsy</td>
</tr>
<tr>
<td></td>
<td>Daniel Shao Weng Tan, National Cancer Centre Singapore, Singapore</td>
</tr>
<tr>
<td>07:30</td>
<td>MTE 20.02: Recent Advances in Liquid Biopsy</td>
</tr>
<tr>
<td></td>
<td>Geoffrey R. Oxnard, Dana-Farber Cancer Institute, USA</td>
</tr>
<tr>
<td>07:00</td>
<td>MTE 21: Search for Novel Driver Mutations (Sign Up Required)</td>
</tr>
<tr>
<td></td>
<td>TRACK: CHEMOTHERAPY/TARGETED THERAPY</td>
</tr>
<tr>
<td></td>
<td>ROOM: 315</td>
</tr>
<tr>
<td>07:00</td>
<td>MTE 21.01: Novel Driver Mutations for Lung Cancer</td>
</tr>
<tr>
<td></td>
<td>Koichi Goto, National Cancer Center Hospital East, Japan</td>
</tr>
<tr>
<td>07:30</td>
<td>MTE 21.02: New Molecular Diagnosis Platforms for Clinicians</td>
</tr>
<tr>
<td></td>
<td>Marc Ladanyi, MSKCC, USA</td>
</tr>
</tbody>
</table>

### 08:15 - 09:45 PL 02: Presidential Symposium (incl. Top 3 Abstracts)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15</td>
<td>PL 02.01: Introduction and Welcome</td>
</tr>
<tr>
<td>08:20</td>
<td>PL 02.02: Patient-Reported Outcomes with Durvalumab after Chemoradiation in Locally Advanced, Unresectable NSCLC: Data from PACIFIC</td>
</tr>
<tr>
<td></td>
<td>Rina Hui, Westmead Hospital and the University of Sydney, Australia</td>
</tr>
<tr>
<td>08:30</td>
<td>PL 02.03: Discussant - PL 02.02</td>
</tr>
<tr>
<td></td>
<td>Michael Boyer, Chris O’Brien Lifehouse, Australia</td>
</tr>
<tr>
<td>08:40</td>
<td>PL 02.04: SCAT Ph III Trial: Adjuvant CT Based on BRCA1 Levels in NSCLC N+ Resected Patients. Final Survival Results a Spanish Lung Cancer Group Trial</td>
</tr>
<tr>
<td></td>
<td>Bartomeu Massuti, Alicante University Hospital, Spain</td>
</tr>
<tr>
<td>08:50</td>
<td>PL 02.05: Discussant - PL 02.04</td>
</tr>
<tr>
<td></td>
<td>Joan Schiller, Inova Schar Cancer Institute, USA</td>
</tr>
<tr>
<td>09:00</td>
<td>PL 02.06: The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for R Status Descriptors for Non-Small Cell Lung Cancer</td>
</tr>
<tr>
<td></td>
<td>John G. Edwards, University of Sheffield, UK</td>
</tr>
<tr>
<td>09:10</td>
<td>PL 02.07: Discussant - PL 02.06</td>
</tr>
<tr>
<td></td>
<td>Kemp Kernstine, University of Texas Southwestern, USA</td>
</tr>
<tr>
<td>09:20</td>
<td>PL 02.08: James Cox Lectureship Award Presentation</td>
</tr>
<tr>
<td></td>
<td>James D. Cox, The University of Texas MD Anderson Cancer Center, USA</td>
</tr>
</tbody>
</table>

### 10:00 - 10:45 Press Conference

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00</td>
<td>Press Conference</td>
</tr>
<tr>
<td></td>
<td>ROOM: 418</td>
</tr>
<tr>
<td></td>
<td>‣ For information on topics and speakers, please visit the Press &amp; Media page on the Conference website at: wclc2017.iaslc.org/press-media/press-media/</td>
</tr>
</tbody>
</table>

### 10:00 - 10:45 Networking Opportunity & Poster Presenters Present for P2 Posters

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00</td>
<td>Networking Opportunity</td>
</tr>
<tr>
<td></td>
<td>‣ Refreshments provided</td>
</tr>
<tr>
<td></td>
<td>EXHIBIT HALL (HALL B + C)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2.01</td>
<td>Advanced NSCLC</td>
</tr>
<tr>
<td>P2.02</td>
<td>Biology/Pathology</td>
</tr>
<tr>
<td>P2.03</td>
<td>Chemotherapy/Targeted Therapy</td>
</tr>
<tr>
<td>P2.04</td>
<td>Clinical Design, Statistics and Clinical Trials</td>
</tr>
<tr>
<td>Time</td>
<td>Session Description</td>
</tr>
<tr>
<td>-------</td>
<td>-------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>11:00</td>
<td>MS 11: Combined Modality Treatment for Superior Sulcus Tumors</td>
</tr>
<tr>
<td>11:00</td>
<td>Preoperative Chemoradiotherapy Followed by Surgical Resection</td>
</tr>
<tr>
<td>11:15</td>
<td>Problems in the Management of Superior Sulcus Tumor</td>
</tr>
<tr>
<td>11:30</td>
<td>Surgical Approaches in Superior Sulcus Tumor</td>
</tr>
<tr>
<td>11:45</td>
<td>Radiation Therapy for Superior Sulcus Tumor</td>
</tr>
<tr>
<td>12:00</td>
<td>Definitive Chemoradiotherapy in Superior Sulcus Tumor</td>
</tr>
<tr>
<td>12:15</td>
<td>Question and Answer Session</td>
</tr>
</tbody>
</table>
11:00 – 12:30  MS 14: QOL Evaluation in Practice from the Viewpoint of Physicians and Nurses

TRACK: NURSING/PALLIATIVE CARE/ETHICS
ROOM: 315
CHAIRS: QING ZHOU, CHINA & BETH EABY-SANDY, USA

11:00  MS 14.01: Elements to Reach the Treatment Goal of Palliation
Christian Klaus Manegold, Medical Faculty Mannheim, University of Heidelberg, Germany

11:15  MS 14.02: Dimensions of Quality of Life in Lung Cancer
Marianne Davies, Yale University, USA

11:30  MS 14.03: Estimating Prognosis – How Accurate Can We Be?
Kunihiko Kobayashi, Saitama Medical University International Medical Center, Japan

11:45  MS 14.04: Whole Person Care
Caitlin Broderick, W A Cancer and Palliative Care Network, Australia

12:00  MS 14.05: Quality of Life in Women with Lung Cancer and Effect of Inner Strength in Mood and QOL
Eunjung Ryu, Chung-Ang University, Korea

12:15 Question and Answer Session

11:00 – 12:30  ES 04: Biology of Lung Cancer

TRACK: BIOLOGY/PATHOLOGY
ROOM: F201 + F202 (ANNEX HALL)
CHAIRS: VERA L. CAPELOZZI, BRAZIL & AKIHIKO GEMMA, JAPAN

11:00  ES 04.01: Novel Targetable Oncogenes in Lung Cancer
Takashi Kohno, National Cancer Center Research Institute, Japan

11:20  ES 04.02: Resistance Mechanism in TKI
Jürgen Wolf, Center for Integrated Oncology Koeln, University Hospital Cologne, Germany

11:40  ES 04.03: Tumor Heterogeneity
Jianjun Zhang, The University of Texas MD Anderson Cancer Center, USA

12:00  ES 04.04: Exploiting Synthetic Lethality in Lung Cancer Therapy
David P. Carbone, The Ohio State Wexner Medical Center, USA

12:20 Question and Answer Session

11:00 – 12:30  PC 02: Is Radiotherapy Necessary for Extensive SCLC? (Thoracic Radiation/PCI)

TRACK: SCLC/NEUROENDOCRINE TUMORS
ROOM: F203 + F204 (ANNEX HALL)
CHAIRS: JENS BENN SORESEN, DENMARK & YOUNG-TAEK OH, KOREA

11:00  PC 02.01: Thoracic Radiation – YES
Ritsuko Komaki, MD Anderson Cancer Center, USA

11:20  PC 02.02: Thoracic Radiation – NO
Sue S. Yom, UCSF, USA

11:40  PC 02.03: PCI---YES
Andrea Bezjak, Princess Margaret Cancer Centre, Canada

12:00  PC 02.04: PCI---NO
Takashi Seto, National Kyushu Cancer Center, Japan

12:20 Question and Answer Session
11:00 – 12:30  OA 09:  EGFR TKI Resistance

**TRACK:** ADVANCED NSCLC CHEMOTHERAPY/TARGETED THERAPY  
**ROOM:** 301 + 302  
**CHAIRS:** THANYANAN REUNGWETWATTANA, THAILAND & LECIA V. SEQUIST, USA

11:00  OA 09.01: Characterizing the Genomic Landscape of EGFR C797S in Lung Cancer Using ctDNA Next-Generation Sequencing  
Zofia Pietrowska, Massachusetts General Hospital, USA

11:10  OA 09.02: Osimertinib Resistance Mediated by Loss of EGFR T790M Is Associated with Early Resistance and Competing Resistance Mechanisms  
Geoffrey R. Oxnard, Dana-Farber Cancer Institute, USA

11:20  OA 09.03: TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI  
Myung-Ju Ahn, Samsung Medical Center, Korea

11:30  OA 09.04: Discussant – OA 09.01, OA 09.02, OA 09.03  
Hatim Husain, University of California San Diego, USA

11:45  OA 09.05: Identification of Novel Potentially Targetable Genomic Alterations in Paired Tumors with Acquired EGFR TKI Resistance by NGS  
Jacqueline Ponville Robichaux, University of Texas MD Anderson Cancer Center, USA

11:55  OA 09.06: A Phase Ib Trial of Savolitinib plus Gefitinib for Chinese Patients with EGFR-Mutant MET-Amplified Advanced NSCLC  
Jin – Ji Yang, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, China

12:05  OA 09.07: Clonality of c-MET Copy Number Gain as a Determinant of Primary TKI Resistance in EGFR-Mutant NSCLC  
Gillianne Lai, National Cancer Centre Singapore, Singapore

12:15  OA 09.08: Discussant – OA 09.05, OA 09.06, OA 09.07  
Howard L. West, Swedish Cancer Institute, USA
11:00 – 12:30 MA 09: The Current Status of Radiation Oncology

**TRACK:** RADIOTHERAPY
**LOCALLY ADVANCED NSCLC**
**ROOM:** 316
**CHAIRS:** TOMOKI KIMURA, JAPAN
& YONG CHAN AHN, KOREA

11:00 MA 09.01: A Propensity-Matched Analysis of Lobectomy and Stereotactic Body Radiotherapy for Early Stage Non-Small Cell Lung Cancer
Yaping Xu, Zhejiang Cancer Hospital, China

11:05 MA 09.02: Ultra-Central Tumours Treated with Stereotactic Body Radiotherapy: A Single Institutional Experience
Meredith Elana Giuliani, University of Toronto and Princess Margaret Cancer Centre, Canada

11:10 MA 09.03: Discussant – MA 09.01, MA 09.02
Takafumi Komiyama, University of Yamanashi School of Medicine, Japan

11:25 MA 09.04: Increasingly Abnormal Pre-Treatment Diffusion Capacity Is Associated with Greater Local Failure After Lung SBRT
Gregory M.M. Videtic, Cleveland Clinic, USA

11:30 MA 09.05: Evidence in Favor of or against the Use of TKIs with Concurrent Cranial Radiotherapy in Patients with NSCLC and CNS Involvement
Giannis Mountzios, University of Athens School of Medicine, Greece

11:35 MA 09.06: Pulmonary Oligometastases Treated by Stereotactic Body Radiation Therapy (SBRT): A Nationwide Survey of 1,378 Patients
Yuzuru Niibe, Toho University Omori Medical Center, Japan

11:40 MA 09.07: Discussant – MA 09.04, MA 09.05, MA 09.06
Gerard G. Hanna, Queen’s University of Belfast, UK

11:55 MA 09.08: Receipt of Chest Radiation and Immune-Related Pneumonitis in Patients with NSCLC Treated with Anti-PD-1/PD-L1
Jarushka Naidoo, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, USA

12:00 MA 09.09: Isotoxic Dose-Escalated Radiotherapy (RT) in Non-Small Cell Lung Cancer (NSCLC) with Deep Inspiration Breath Hold (DIBH)
Hannah Bainbridge, The Royal Marsden Hospital, NHS Foundation Trust, UK

12:05 MA 09.10: Toward a Radiological Scoring System of Radiotherapy-Induced Lung Damage
Catarina Veiga, University College London, UK

12:10 MA 09.11: Isotoxic Intensity Modulated Radiotherapy (IMRT) in Stage III Non-Small Cell Lung Cancer (NSCLC) – a Feasibility Study
Kate Haslett, The Christie NHS Foundation Trust, UK

12:15 MA 09.12: Discussant – MA 09.08, MA 09.09, MA 09.10, MA 09.11
Cecile Le Pechoux, Gustave Roussy, France

11:00 – 12:30 MA 10: Immunotherapy I

**TRACK:** IMMUNOLOGY AND IMMUNOTHERAPY
**ADVANCED NSCLC**
**ROOM:** 303 + 304
**CHAIRS:** SHUHANG WANG, CHINA
& ROBERT PIRKER, AUSTRIA

11:00 MA 10.01: Durvalumab + Tremelimumab with Platinum-Doublets in Non-Small Cell Lung Cancer: Canadian Cancer Trials Group Study IND.226
Desiree Hao, University of Calgary & Tom Baker Cancer Centre, Canada

11:05 MA 10.02: Nab-Paclitaxel + Durvalumab as Second- or Third-Line Treatment of Advanced NSCLC: Results from ABOUND.2L+
Ramaswamy Govindan, Washington University School of Medicine, USA

11:10 MA 10.03: 3-Year Survival and Duration of Response in Randomized Phase II Study of Atezolizumab vs Docetaxel in 2L/3L NSCLC (POPLAR)
Keunchil Park, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea

11:15 MA 10.04: Discussant – MA 10.01, MA 10.02, MA 10.03
Wan-Teck Lim, National Cancer Centre, Singapore

11:30 MA 10.05: Improved Outcome for Immune Checkpoint Inhibitors (ICI) in Patients Previously Treated with Bavituximab in the SUNRISE Trial
Michael Boyer, Chris O’Brien Lifehouse, Australia

11:35 MA 10.06: Real-World Results in Non-Squamous Non-Small Cell Lung Cancer Patients: Italian Nivolumab Expanded Access Programme
Francesco Grossi, Ospedale Policlinico San Martino, Italy

11:40 MA 10.07: Elderly Lung Cancer Patients on Immunotherapy: Preliminary Results from the ELDERS Study
Fabio Gomes, The Christie NHS Foundation Trust, UK

11:45 MA 10.08: Discussant – MA 10.05, MA 10.06, MA 10.07
Hidehito Horinouchi, National Cancer Center Hospital, Japan

12:00 MA 10.09: Increased T Follicular Helper Cell Infiltration in Lung Adenocarcinoma Tertiary Lymphoid Organs
Erin Anne Marshall, BC Cancer Research Centre, Canada

12:05 MA 10.10: Tumor Draining Lymph Node Immuno-phenotype Corresponds with Primary Tumor Characteristics in Patients with Non-Small Cell Lung Cancer
Daniel H. Sterman, NYU Langone Medical Center, USA

12:10 MA 10.11: Hyperprogressive Disease (HPD) Is Frequent in Non-Small Cell Lung Cancer (NSCLC) Patients (Pts) Treated with Anti PD1/PD-L1 Agents (IO)
Roberto Ferrara, Medical Oncology Gustave Roussy, France

David E. Gerber, UT Southwestern, USA
11:00 – 12:30 MA 11: Emerging Diagnostic/Biomarkers in NSCLC

TRACK: ADVANCED NSCLC CHEMOTHERAPY/TARGETED THERAPY
ROOM: 313 + 314
CHAIRS: MOHAMED IBRAHIM ABDUL WAHID, MALAYSIA & MARTIN RECK, GERMANY

11:00 MA 11.01: Liquid Biopsies for Monitoring BRAF Mutation (V600E) in Advanced BRAF (V600E) Non-Small Cell Lung Cancer (NSCLC)
Laura Mezquita, Gustave Roussy, France

11:05 MA 11.02: Circulating Tumour DNA in Early Stage NSCLC: High Sensitivity Analysis in Low Burden Disease. LUCID Study Update
Robert Campbell Rintoul, Papworth Hospital NHS Foundation Trust, UK

11:10 MA 11.03: Gefitinib as First-Line Treatment of Plasma CIDEA EGFR Mutation-Positive NSCLC Detected by DdPCR: BENEFIT Study (CTONG1405)
Jie Wang, Cancer Institute/Hospital, Chinese Academy of Medical Sciences, China

11:15 MA 11.04: Discussant – MA 11.01, MA 11.02, MA 11.03
Hye Ryun Kim, Yonsei Cancer Center, Korea

11:30 MA 11.05: Targeted DNA- and RNA-Based Next-Generation Sequencing for Identifying MET Exon 14 Alterations in Pulmonary Sarcomatoid Carcinoma
Gang Cheng, Novogene Co., Ltd., China

11:35 MA 11.06: Retrospective Analysis of NSCLC Testing in Low Tumor Content Samples: Single-Gene Tests, NGS, & the Oncomine™ Dx Target Test
Tiffany M. Yu, Quorum Consulting, Inc., USA

11:40 MA 11.07: Exosomes-Transmitted MicroRNAs Promote EGFR-TKIs Resistance in NSCLC by Activating PI3K/AKT Signaling Pathway
Xiaobing Liu, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

11:45 MA 11.08: Discussant – MA 11.05, MA 11.06, MA 11.07
Justin F. Gainor, Massachusetts General Hospital, USA

12:00 MA 11.09: Real World Data of Rebiopsy, Mutation Status, and Its Association with Plasma Genotyping after EGFR TKI Failure in NSCLC
Min Hee Hong, Yonsei Cancer Center, Korea

12:05 MA 11.10: EGFR TKI Treatment Induces Active Deamination of 5-Methylcytosine and Leads to Acquired T790M Resistant Mutation
Khaled A. Hassan, University of Michigan, USA

12:10 MA 11.11: Italian Nivolumab Expanded Access Program in Non-Squamous NSCLC Patients: Results in Never Smokers and EGFR Positive Patients
Marina Chiara Garassino, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy

Nicolas Girard, Hospices Civils de Lyon, France

11:00 – 12:30 MA 12: Circumventing EGFR Resistance

TRACK: ADVANCED NSCLC CHEMOTHERAPY/TARGETED THERAPY
ROOM: F205 + F206 (ANNEX HALL)
CHAIR: WAN LING TAN, SINGAPORE

11:00 MA 12.01: A Phase Ib Study of the Combination of Afatinib and Ruxolitinib in EGFR Mutant NSCLC Progressed on EGFR-TKI: An Updated Analysis
Ji Soo Park, Yonsei Cancer Center, Korea

11:05 MA 12.02: Phase I/II Study of S49076, a MET/AXL/FGFR Inhibitor, Combined with Gefitinib in NSCLC Patients Progressing on EGFR TKI
Gee-Chen Chang, Taichung Veterans General Hospital, Taiwan

11:10 MA 12.03: Kinase Fusions as Recurrent Mechanisms of Acquired Resistance in EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)
Sai-Hong Ignatius Ou, University of California at Irvine School of Medicine, Chao Comprehensive Cancer Center, USA

11:15 MA 12.04: Discussant – MA 12.01, MA 12.02, MA 12.03
Miguel-Angel Molina-Vila, Pangaea Oncology, Spain

11:30 MA 12.05: Genomic Profiling of EGFR T790M Mutated Non-Small Cell Lung Cancer to Evaluate the Mechanisms of Resistance to Osimertinib
Sonam Puri, H.Lee Moffitt Cancer Center/University of South Florida, USA

11:35 MA 12.06: Using Population Dynamics Mathematical Modeling to Optimize an Intermittent Dosing Regimen for Osimertinib in EGFR-Mutant NSCLC
Xiuning Le, Beth Israel Deaconess Medical Center, USA

11:40 MA 12.07: Adjusted Indirect Comparison of Osimertinib to Chemotherapy in NSCLC Patients with EGFRm T790M Who Progressed after EGFR-TKI
Christopher Hoyle, AstraZeneca, UK

11:45 MA 12.08: Discussant – MA 12.05, MA 12.06, MA 12.07
Dae Ho Lee, University of Ulsan College of Medicine, Asan Medical Center, Korea

12:00 MA 12.09: EGFR T790M Co-Exist with Sensitive Mutation in the Same Cell Group in Lung Adenocarcinoma Patients
Xiaohua Shi, Peking Union Medical College Hospital, China

12:05 MA 12.10: Clinical Utility of Plasma EGFR T790M Mutation Detection in Advanced Non-Small Cell Lung Cancer Patients According to RECIST Criteria
Kenneth O’Byrne, Princess Alexandra Hospital, Australia

12:10 MA 12.11: The Alteration of T790M Prevalence Between 19 Deletions and L858R in NSCLC After EGFR-TKIs Therapy, a Meta-Analysis
Hengrui Liang, The First Affiliated Hospital of Guangzhou Medical University, China


TRACK:  INDUSTRY SUPPORTED SYMPOSIUM
ROOM:  MAIN HALL
CHAIR:  SURESH S. RAMALINGAM, USA

Lunch boxes provided

12:45  ISS 10.01: Welcome and Introductions
Suresh S. Ramalingam, Winship Cancer Institute of Emory University, USA

12:50  ISS 10.02: The Evolving Treatment Algorithm in EGFR-Mutated NSCLC
Rolf A. Stahel, University Hospital Zurich, Switzerland

13:05  ISS 10.03: Diagnosis and Management on the Frontline
Suresh S. Ramalingam, Winship Cancer Institute of Emory University, USA

13:20  ISS 10.04: Case Examples of Second-Line Management
Heather A. Wakelee, Stanford Cancer Center, USA

13:35  ISS 10.05: Sequencing Therapy to Improve Outcomes
Lecia V. Sequist, Massachusetts General Hospital, USA

13:50  ISS 10.06: Concluding Remarks
Suresh S. Ramalingam, Winship Cancer Institute of Emory University, USA

13:55  ISS 10.07: Question and Answer Session
Suresh S. Ramalingam, Winship Cancer Institute of Emory University, USA
Rolf A. Stahel, University Hospital Zurich, Switzerland
Heather A. Wakelee, Stanford Cancer Center, USA
Lecia V. Sequist, Massachusetts General Hospital, USA

14:30 – 15:30  JTO: Meet the JTO Editor

TRACK:  EDUCATION/PUBLICATION/CAREER DEVELOPMENT
ROOM:  S11 + S12

14:30  JTO 01: Meet the JTO Editor
Alex Adjei, Roswell Park Cancer Institute, USA

Networking Opportunity & Poster Presenters Present for P2 Posters

EXHIBIT HALL (HALL B + C)

Refreshments provided

15:45 – 17:30  MS 15: Molecular Testing

TRACK:  BIOLOGY/PATHOLOGY
ROOM:  301 + 302
CHAIRS:  JIN SOO LEE, KOREA & IVER PETERSEN, GERMANY

15:45  MS 15.01: Overview of Updated CAP/IASLC/AMP Molecular Testing Guideline
Neal Lindeman, Brigham and Women’s Hospital, USA

16:05  MS 15.02: Molecular Testing Using NGS
Ignacio I. Wistuba, The University of Texas MD Anderson Cancer Center, USA

16:25  MS 15.03: Molecular Testing Using Blood (Liquid Biopsy)
Lecia Sequist, Massachusetts General Hospital, USA

16:45  MS 15.04: Molecular Testing Using Cytology Specimens
Lukas Bubendorf, University Hospital Basel, Switzerland

17:05  MS 15.05: Clinical Samples for Molecular Testing
Heather Wakelee, Stanford Cancer Center, USA

17:25  Question and Answer Session

15:45 – 17:30  MS 16: Future Direction of Chemoradiotherapy for Inoperable Non-Small Cell Lung Cancer

TRACK:  RADIOTHERAPY
CHEMOTHERAPY/TARGETED THERAPY
ROOM:  502
CHAIRS:  YUKO NAKAYAMA, JAPAN & CECILE LE PECHOUX, FRANCE

15:45  MS 16.01: Is the Dose Escalation Possible?
Jeffrey Bradley, Washington University School of Medicine, USA

16:05  MS 16.02: Selection of Chemotherapeutic Agents
Nobuyuki Yamamoto, Wakayama Medical University, Japan
16:25  MS 16.03: Management According to the Histologic Subtypes  
Kazushige Hayakawa, Kitasato Univ. School of Medicine, Japan

16:45  MS 16.04: Future Direction of Immuno-Radiotherapy  
Wilfried Eberhardt, University of Duisburg-Essen, Germany

17:05  MS 16.05: High-Dose Boost Radiation Using SBRT/IMRT  
James D. Cox, The University of Texas MD Anderson Cancer Center, USA

17:25  Question and Answer Session

15:45 – 17:30  MS 17: Lessons Learned from Negative Trials  
TRACK: CLINICAL DESIGN, STATISTICS AND CLINICAL TRIALS  
ROOM: 303 + 304  
CHAIRS: VIROTE SRIURANPONG, THAILAND & JOHAN F. VANSTEENKISTE, BELGIUM

15:45  MS 17.01: PROCLAIM  
Anthony Brade, Princess Margaret Hospital, Canada

15:55  MS 17.02: MAGRIT  
Johan F. Vansteenkiste, University Hospital KU Leuven, Belgium

16:05  MS 17.03: Is There Such a Thing as a ‘Negative’ Trial?  
Lucinda Jane Billingham, University of Birmingham, UK

16:30  MS 17.04: MET-Lung: A Phase III Trial of Onartuzumab (METMab) Plus Erlotinib vs Erlotinib in Previously Treated Stage IIIb or IV NSCLC  
Karen Kelly, UC Davis Comprehensive Cancer Center, USA

16:40  MS 17.05: CheckMate026  
David P. Carbone, The Ohio State Wexner Medical Center, USA

16:50  MS 17.06: Avoiding Phase II-III Attrition: Enhanced Biomarkers, Better Drugs or Improved Trial Design?  
John Crowley, Cancer Research And Biostatistics, USA

17:15  Question and Answer Session

15:45 – 17:30  MS 18: Biomarker for Anti-PD-L1 Therapy  
TRACK: IMMUNOLOGY AND IMMUNOTHERAPY  
ROOM: MAIN HALL  
CHAIRS: YUICHI ISHIKAWA, JAPAN & SANJA DACIC, USA

15:45  MS 18.01: How to Select and Set up a IHC Platform for PD-L1 Expression  
Reinhard Büttner, University Hospital Cologne, Germany

16:00  MS 18.02: An Update on the BLUEPRINT and Related Projects  
Fred R. Hirsch, Univ. of Colorado Cancer Center, USA

16:15  MS 18.03: Potential Application of Molecular Genomic for Immunotherapy  
Rolf A. Stahel, University Hospital Zurich, Switzerland

16:30  MS 18.04: PD-L1 Expression in Early Stage Lung Cancer  
Jin-Haeng Chung, Seoul National University Bundang Hospital, Korea

16:45  MS 18.05: Liquid Biopsy Biomarkers in IO: Is There Room?  
Christian Rolfo, Antwerp University Hospital, Belgium

17:00  MS 18.06: Future Perspectives of Biomarkers for Anti PD-1/PD-L1 Therapy  
Julie R. Brahmer, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, USA

17:15  Question and Answer Session

15:45 – 17:30  MS 19: Elevating the Lung Cancer Voice: Raising Awareness and Creating Community  
TRACK: PATIENT ADVOCACY  
ROOM: 315  
CHAIRS: TOSHIYUKI SAWA, JAPAN & ANDREJA CIRILA ŠKUFCA SMRDEL, SLOVENIA

15:45  MS 19.01: Transformative Science in the Community  
Jim Baranski, Lung Cancer Foundation of America, USA

16:05  MS 19.02: Lung Cancer Awareness Month: Unity through IASLC – Organizer Perspective  
Kristin Richeimer, IASLC, USA

16:25  MS 19.03: The ROS1der Story: How a Group of Patients, Doctors and Advocates Launched an International Research Effort  
Lisa Goldman, Patient Advocate/Self, USA

16:45  MS 19.04: Shine a Light on Lung Cancer: The Evolution  
Alana Shea Boyd, Lung Cancer Alliance, USA

17:05  MS 19.05: “How to Beauty Your Day”: Looking Good, Feeling Better – An Italian Approach  
Stefania Vallone, Women Against Lung Cancer in Europe (WALCE Onlus), Italy

17:25  Question and Answer Session

15:45 – 17:30  ES 05: Surgical Skills  
TRACK: SURGERY  
ROOM: 503  
CHAIRS: KOHEI YOKOI, JAPAN & YOUNG MOG SHIM, KOREA

15:45  ES 05.01: Strategy for N2 NSCLC  
Joe B. Putnam, Baptist MD Anderson Cancer Center, USA

16:00  ES 05.02: Superior Sulcus Tumor  
Valerie W. Rusch, Memorial Sloan-Kettering Cancer Center, USA

16:15  ES 05.03: Management of Early Stage Lung Cancer  
Norihiko Ikeda, Tokyo Medical University, Japan

16:30  ES 05.04: Minimally Invasive Surgery for Lung Cancer, including Robotics  
Giulia Veronesi, Humanitas Research Hospital, Italy

16:45  ES 05.05: Lung Cancer Surgery for High Risk Patients  
Claudio Suarez Cruzat, Clinica Santa Maria, Chile

17:00  ES 05.06: Salvage Surgery  
Hans Hoffmann, Thoraxklinik, University of Heidelberg, Germany

17:15  Question and Answer Session
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:20</td>
<td>MA 07.06: Detection of Mechanisms of Resistance to ALK Inhibitors in Routine Practice: A Retrospective Study</td>
<td>Philippe Jamme, Institut de biologie, France</td>
</tr>
<tr>
<td>16:25</td>
<td>MA 07.07: Clinical Outcomes and ALK Resistance Mutations in ALK+ Non-Small Cell Lung Cancer According to EML4-ALK Variant</td>
<td>Jessica Jiyeong Lin, Massachusetts General Hospital, USA</td>
</tr>
<tr>
<td>16:30</td>
<td>MA 07.08: Clinical Implications of ALK Resistance Mutations: Institutional Experience and Launch of Remote Participation Study</td>
<td>Pablo Martinez, Dana-Farber Cancer Institute, USA</td>
</tr>
<tr>
<td>16:35</td>
<td>MA 07.09: ALK/ROS1/TRK Inhibitor TPX-0005 Effectively Overcomes Clinical Resistance Solvent Front Mutations</td>
<td>J. Jean Cui, TP Therapeutics, Inc., USA</td>
</tr>
<tr>
<td>16:40</td>
<td>MA 07.10: Discussant – MA 07.06, MA 07.07, MA 07.08, MA 07.09</td>
<td>Takashi Seto, National Kyushu Cancer Center, Japan</td>
</tr>
<tr>
<td>16:55</td>
<td>MA 07.11: A Phase II Study of Trastuzumab Emtansine in HER2-positive Non-Small-Cell-Lung Cancer</td>
<td>Daijiro Harada, Shikoku Cancer Center, Japan</td>
</tr>
<tr>
<td>17:00</td>
<td>MA 07.12: Short-Term Culture of Patient Derived Tumor Organoids Identify Neratinib/Trastuzumab as an Effective Combination in HER2 Mutant Lung Cancer</td>
<td>Elena Ivanova, Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, USA</td>
</tr>
<tr>
<td>17:05</td>
<td>MA 07.13: NGS Sequencing Based Liquid / Tissue biopsy Identified Coexistence of HER2 Amplification and Mutation in Advanced NSCLC Patients</td>
<td>Rongrong Chen, Geneplus-Beijing, China</td>
</tr>
<tr>
<td>17:10</td>
<td>MA 07.14: Change in Practice Patterns from an Online NSCLC Treatment Decision Support Tool</td>
<td>David R. Gandara, UC Davis Comprehensive Cancer Center, USA</td>
</tr>
<tr>
<td>17:15</td>
<td>MA 07.15: Discussant – MA 07.11, MA 07.12, MA 07.13, MA 07.14</td>
<td>Chia-Chi Lin, National Taiwan University Hospital, Taiwan</td>
</tr>
<tr>
<td>15:45</td>
<td>ES 06: Communication Skills in the End of Life/ Symptom Management in Lung Cancer</td>
<td></td>
</tr>
<tr>
<td>15:45</td>
<td>ES 06.01: Advanced Directives – Are They Useful?</td>
<td>Maiko Fujimori, National Center for Neurology &amp; Psychiatry, Japan</td>
</tr>
<tr>
<td>15:45</td>
<td>ES 06.02: Discussing Advance Care Plans – What Do You Say?</td>
<td>Florian Strasser, Cantonal Hospital, Switzerland</td>
</tr>
<tr>
<td>15:45</td>
<td>ES 06.03: Palliative Management of Dyspnea</td>
<td>Keiko Tanaka, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan</td>
</tr>
<tr>
<td>15:45</td>
<td>ES 06.04: The Lung Cancer Patient, the Nurse and the Rehabilitation Opportunities in Denmark</td>
<td>Marianne Cumberland, University of Copenhagen, Rigshospitalet, Denmark</td>
</tr>
<tr>
<td>15:45</td>
<td>ES 06.05: Approach to Malignant Pleural Effusions</td>
<td>Peter Goldstraw, National Heart and Lung Institute, Imperial College, UK</td>
</tr>
<tr>
<td>15:45</td>
<td>ES 06.06: Dignity Conserving Therapy</td>
<td>Natasha B. Leigl, Princess Margaret Cancer Centre, Canada</td>
</tr>
<tr>
<td>15:45</td>
<td>ES 06.01: Patients with ALK IHC-Positive/FISH-Negative NSCLC Benefit from ALK TKI Treatment: Response Data from the Global ALEX Trial</td>
<td>Tony Mok, State Key Laboratory of South China, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong</td>
</tr>
<tr>
<td>15:45</td>
<td>ES 06.02: Response to Ensartinib in TKI Naïve ALK+ NSCLC Patients</td>
<td>Heather A. Wakelee, Stanford University School of Medicine, USA</td>
</tr>
<tr>
<td>15:45</td>
<td>MA 07: ALK, ROS and HER2</td>
<td></td>
</tr>
<tr>
<td>15:45</td>
<td>MA 07.01: Patients with ALK IHC-Positive/FISH-Negative NSCLC Benefit from ALK TKI Treatment: Response Data from the Global ALEX Trial</td>
<td>Tony Mok, State Key Laboratory of South China, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong</td>
</tr>
<tr>
<td>15:45</td>
<td>MA 07.02: Response to Ensartinib in TKI Naïve ALK+ NSCLC Patients</td>
<td>Heather A. Wakelee, Stanford University School of Medicine, USA</td>
</tr>
<tr>
<td>15:45</td>
<td>MA 07.03: Incidence, Predictors and Prognostic Significance of Thromboembolic Events in Patients with Advanced Alk-Rearranged NSCLCs</td>
<td>Jon Zugazagoitia, Hospital U. 12 Octubre, Spain</td>
</tr>
<tr>
<td>15:45</td>
<td>MA 07.04: Clinical Impact of Crizotinib on Brain Metastases in Patients with Advanced ROS1-Rearranged Non-Small Cell Lung Cancer</td>
<td>Shun Lu, Shanghai Chest Hospital, China</td>
</tr>
<tr>
<td>15:45</td>
<td>MA 07.05: Discussant – MA 07.01, MA 07.02, MA 07.03, MA 07.04</td>
<td>Neal Ready, Duke University Medical Center, USA</td>
</tr>
<tr>
<td>15:45</td>
<td>ES 06.01: Advanced Directives – Are They Useful?</td>
<td>Maiko Fujimori, National Center for Neurology &amp; Psychiatry, Japan</td>
</tr>
<tr>
<td>15:45</td>
<td>ES 06.02: Discussing Advance Care Plans – What Do You Say?</td>
<td>Florian Strasser, Cantonal Hospital, Switzerland</td>
</tr>
<tr>
<td>15:45</td>
<td>ES 06.03: Palliative Management of Dyspnea</td>
<td>Keiko Tanaka, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan</td>
</tr>
<tr>
<td>15:45</td>
<td>ES 06.04: The Lung Cancer Patient, the Nurse and the Rehabilitation Opportunities in Denmark</td>
<td>Marianne Cumberland, University of Copenhagen, Rigshospitalet, Denmark</td>
</tr>
<tr>
<td>15:45</td>
<td>ES 06.05: Approach to Malignant Pleural Effusions</td>
<td>Peter Goldstraw, National Heart and Lung Institute, Imperial College, UK</td>
</tr>
<tr>
<td>15:45</td>
<td>ES 06.06: Dignity Conserving Therapy</td>
<td>Natasha B. Leigl, Princess Margaret Cancer Centre, Canada</td>
</tr>
<tr>
<td>15:45</td>
<td>MA 07: ALK, ROS and HER2</td>
<td></td>
</tr>
<tr>
<td>15:45</td>
<td>MA 07.01: Patients with ALK IHC-Positive/FISH-Negative NSCLC Benefit from ALK TKI Treatment: Response Data from the Global ALEX Trial</td>
<td>Tony Mok, State Key Laboratory of South China, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong</td>
</tr>
<tr>
<td>15:45</td>
<td>MA 07.02: Response to Ensartinib in TKI Naïve ALK+ NSCLC Patients</td>
<td>Heather A. Wakelee, Stanford University School of Medicine, USA</td>
</tr>
<tr>
<td>15:45</td>
<td>MA 07.03: Incidence, Predictors and Prognostic Significance of Thromboembolic Events in Patients with Advanced Alk-Rearranged NSCLCs</td>
<td>Jon Zugazagoitia, Hospital U. 12 Octubre, Spain</td>
</tr>
<tr>
<td>15:45</td>
<td>MA 07.04: Clinical Impact of Crizotinib on Brain Metastases in Patients with Advanced ROS1-Rearranged Non-Small Cell Lung Cancer</td>
<td>Shun Lu, Shanghai Chest Hospital, China</td>
</tr>
<tr>
<td>15:45</td>
<td>MA 07.05: Discussant – MA 07.01, MA 07.02, MA 07.03, MA 07.04</td>
<td>Neal Ready, Duke University Medical Center, USA</td>
</tr>
</tbody>
</table>
16:00 MA 13.04: Adjuvant Systemic Therapy in Patients with Early-Stage Non-Small Cell Lung Cancer (NSCLC) Treated with Stereotactic Body Radiation Therapy Vinicius Ernani, Fred and Pamela Buffett Cancer Center-University of Nebraska Medical Center, USA

16:05 MA 13.05: Discussant – MA 13.01, MA 13.02, MA 13.03, MA 13.04 Shinichi Toyooka, Okayama University Graduate School of Medicine, Japan

16:20 MA 13.06: New Risk Factors for Overall Survival After SBRT in Early Stage NSCLC: A Role of RT Plan Optimization Feng-Ming (Spring) Kong, Indiana University School of Medicine, USA

16:25 MA 13.08: Long Term Follow-up on NRG Oncology RT0915 (NCCTG N0927): a Randomized Phase II Study of 2 SBRT Schedules for Lung Cancer Gregory M.M. Videtic, Cleveland Clinic, USA

16:30 MA 13.09: Toxicity and Second Primary Lung Cancers in Late Survivors Following Lung SBRT Meredith Elana Guiulani, University of Toronto and Princess Margaret Cancer Center, Canada

16:35 MA 13.10: Discussant – MA 13.06, MA 13.08, MA 13.09 Hong-Gyun Wu, Seoul National University College of Medicine, Korea

16:50 MA 13.11: Clinical Significance of Lobar and Segmental Lymph Node Metastasis in cTINOMO Lung Adenocarcinoma Fei Xiao, National Clinical Research Center for Respiratory Diseases, Center for Respiratory Diseases, China-Japan Friendship Hospital, China

16:55 MA 13.12: Wedge Resection and Segmentectomy Are Associated with Comparable Outcomes for Patients with Less Than 2cm Non-Small Cell Lung Cancer Kamran Ali, Seoul National University Bundang Hospital, Korea

17:00 MA 13.13: Spread through Air Spaces Is a Prognostic Factor in Wedge Resection of Non-Small Cell Lung Cancer Satoshi Shiono, Yamagata Prefectural Central Hospital, Japan

17:05 MA 13.14: Surgical Outcomes and Survival Analysis Following Second Pulmonary Resection for Non-Small Cell Lung Cancer Yusuke Takahashi, Memorial Sloan Kettering Cancer Center, USA


17:25 Question and Answer Session

15:45 – 16:00 MA 13.04: Influence of Early Lung Cancer Screening Programme on Treated Patients’ Profile and Activity of Thoracic Surgery Department Bartosz Kubisa, Pomeranian Medical University of Szczecin, Poland

15:50 MA 14.02: Simulation of the Four Rounds of NELSON Lung Cancer Screening Triage Algorithm Takashi Hayashi, Median Technologies, France

16:00 MA 14.04: Therapeutic Response Assessment of NSCLC Patients Treated with Apatinib: A Radiomics Approach Based on CT Texture Features Qiong Zhao, First Affiliated Hospital, Zhejiang University, China

16:05 MA 15.05: Discussant – MA 15.01, MA 15.02, MA 15.03, MA 15.04 Edward F. Patz, Duke University, USA

16:20 MA 15.06: Population Based Cohort Study to Evaluate Lung Cancer Screening Using Low Dose CT in Hitachi City Takeshi Nawa, Hitachi General Hospital, Hitachi, Ltd, Japan

16:25 MA 15.07: Randomized Lung Cancer Screening with Low-Dose CT in China: A Specific Risk-Based Screening for Chinese Population Baohui Han, Shanghai Chest Hospital, China

16:30 MA 15.08: Hematology/Oncology Providers’ Practices and Attitudes of Lung Cancer Screening And Tobacco Cessation at an Academic Medical Center and VA Jennifer Lewis, Vanderbilt University Medical Center, USA

16:35 MA 15.09: Impact of Lung Cancer Perceived Risk, Screening Eligibility and Worry on LDCT Screening Preference – Challenges for Engaging Patients at High Risk Katharine See, Royal Melbourne Hospital, Australia

16:40 MA 15.10: Discussant – MA 15.06, MA 15.07, MA 15.08, MA 15.09 Helmut Prosch, Medical University of Vienna, Austria

16:55 MA 15.11: Malignancy Risk Prediction of Pulmonary Nodule in Lung Cancer Screening – Diameter Or Volumetric Measurement Ren Yuan, BC Cancer Agency, Canada

17:00 MA 15.12: Detecting Epidermal Growth Factor Receptor Mutation Status in Patients with Lung Adenocarcinoma Using Radiomics and Random Forest Tianying Jia, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

17:05 MA 15.13: Nodule Size Isn’t Everything: Imaging Features Other Than Size Contribute to AI Based Risk Stratification of Solid Nodules Timor Kadir, Optellum Ltd., UK
15:45 – 17:30 | MA 15: Lung Cancer Biology II

**TRACK:** Biology/Pathology  
**ROOM:** 501  
**CHAIRS:** HIROTOSHI AKITA, JAPAN  
& LUCIANO MUTTI, UK

15:45 | MA 15.01: LungBEAM: A Prospective Multicenter Trial to Monitor EGFR Mutations Using BEAMing Technology in Stage IV NSCLC Patients  
Pilar Garrido, Hospital Universitario Ramón y Cajal, Spain

15:50 | MA 15.02: Plasma CfDNA next Generation Sequencing in Non-Small Cell Lung Cancer: Clinical Outcomes and Comparison to Tissue  
Luis E. Raza, Memorial Cancer Institute, USA

15:55 | MA 15.03: Distribution of Circulating Tumor DNA in Lung Cancer: Analysis of Primary Lesion, Pulmonary Vein, Bone Marrow and Pripheral Blood  
Taichiro Goto, Yamanashi Central Hospital, Japan

16:00 | MA 15.04: Detection of ALK Rearrangements in Non-Small-Cell Lung Cancer (NSCLC) Patients by Liquid Biopsy  
Dongmei Lin, Beijing Cancer Hospital, China

16:05 | MA 15.05: Discussant – MA 15.01, MA 15.02, MA 15.03, MA 15.04  
Montse Sanchez-Cespedes, Bellvitge Biomedical Research Institute, Spain

16:20 | MA 15.06: ERBB Receptor Feedback Inhibitor-1 Alterations in Non-Small Cell Lung Cancer  
Jeffrey G. Schneider, NYU Winthrop Hospital, USA

16:25 | MA 15.07: Consistency Analysis of Mutations in Tumor Tissue and Circulating Cell-Free DNA in Lung Cancer Patients Through next Generation Sequencing  
Geng Tian, Shenzhen Second People’s Hospital, China

16:30 | MA 15.08: Safety and Efficacy of Osimertinib in Treating an EGFR-Mutant Lung Cancer Patient with a Germline EGFR T790M Mutation  
Tianhong Li, University of California Davis Comprehensive Cancer Center, USA

16:35 | MA 15.09: Circumferential Distribution and Distance from Main Tumor of Tumor Spread Through Air Spaces (STAS) Are Prognostic  
Koji Kameda, Memorial Sloan Kettering Cancer Center, USA

16:40 | MA 15.10: Discussant – MA 15.06, MA 15.07, MA 15.08, MA 15.09  
Natasha Rekhtman, Memorial Sloan Kettering Cancer Center, USA

16:55 | MA 15.11: CCNE1, PTGS2, TGFA and WISP2 Predict Benefit from Bevacizumab and Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (SAKK19/09)  
Sacha I. Rothschild, University Hospital Basel, Switzerland

17:00 | MA 15.12: Expanding the Lung Small RNA Transcriptome: Discovery of Unannotated microRNAs with Roles in Development and Tumourigenesis  
Brenda C. Minatel, British Columbia Cancer Research Centre, Canada

17:05 | MA 15.13: The Transfer of Exogenous UCHL-1 via Mesenchymal Lung Cancer Exosomes to Mediate Phenotypic Alterations of Recipients  
Yoshihisa Shimada, UT Southwestern Medical Center, USA
16:35 MA 16.09: Discussant – MA 16.06, MA 16.07, MA 16.08
Takashi Ohtsuka, Keio University, Japan

16:50 MA 16.10: Treatment Outcomes of Primary Malignant Germ Cell Tumors of the Mediastinum
Tadashi Sakane, Nagoya City University Graduate School of Medical Sciences, Japan

16:55 MA 16.11: Alterations of Notch Pathway among Patients with Adenoid Cystic Carcinoma of the Trachea and Its Impact on Survival
Mian Xie, The First Affiliated Hospital of Guangzhou Medical University, China

17:00 MA 16.12: Prolonged Survival after Pulmonary Metastasectomy for Testicular Germ-cell Tumors in a Single Institution
Jose Francisco Corona-Cruz, Instituto Nacional de Cancerología Mexico, Mexico

17:05 MA 16.13: PD-L1 Expression Is a Prognostic Factor in Patients with Esophageal Squamous Cell Carcinoma Treated with Postoperative Adjuvant Radiotherapy
Yaping Xu, Zhejiang Cancer Hospital, China

17:10 MA 16.14: c-Met in Esophageal Squamous Cell Carcinoma: An Independent Prognostic Factor and Potential Therapeutic Target
Yaping Xu, Zhejiang Cancer Hospital, China

Chang Hyun Kang, Seoul National University Hospital, Korea

15:45 – 17:30 MA 17: Locally Advanced NSCLC

15:45 MA 17.01: Skip N2, an Independent Prognostic Factor of Survival: Analysis of a Favourable N2 Subgroup
Sara Ricciardi, Division of Thoracic Surgery, University Hospital of Pisa, Italy

15:50 MA 17.02: Clinical Impact of the Tumor Immune Microenvironment and Immunoscore in Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer
Wen Feng, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

15:55 MA 17.03: Prognostic Value of the New IASLC/ATS/ERS Lung Adenocarcinoma Classification in Completely Resected Stage IIIA(N2) NSCLC
Qin Zhang, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

16:00 MA 17.04: Initial Surgery in Patients with Clinical N2 Non-Small Cell Lung Cancer: A Multi-Institution Retrospective Study
Tomohiro Maniwa, Yao Municipal Hospital, Japan

16:05 MA 17.05: Discussant – MA 17.01, MA 17.02, MA 17.03, MA 17.04
Jin Seok Ahn, Samsung Medical Center, Korea

16:20 MA 17.06: Safety Data from Randomized Phase II Study of CDDP+S-1 vs CDDP+PEM Combined with TRT for Locally Advanced Non-Squamous NSCLC
Akira Ono, Shizuoka Cancer Center, Japan

16:25 MA 17.07: Veliparib in Combination with Paclitaxel/Carboplatin (P/C)-Based Chemoradiotherapy (CRT) in Patients with Stage III NSCLC
Thomas E. Stinchcombe, Duke University, USA

16:30 MA 17.08: The Validity of TNM Classification After Induction Treatment in Patients with NSCLC: Pulmonary Resection with or Without Induction Treatment
Huseyin Melek, Uludag University, Turkey

16:35 MA 17.09: Discussant – MA 17.06, MA 17.07, MA 17.08
Clarissa Mathias, Núcleo de Oncologia da Bahia, Brazil

16:50 MA 17.10: Toxicity Results from the Randomized Phase III NVALT-11 Study of Prophylactic Cranial Irradiation vs. Observation in Stage III NSCLC
Dirk K. De Ruyscher, Maastricht University Medical Center, Netherlands

16:55 MA 17.11: Prediction of Response to Trimodality Therapy Using CT-Derived Radiomic Features in Stage III Non-Small Cell Lung Cancer (NSCLC)
Vamsidhar Velcheti, Cleveland Clinic, USA

17:00 MA 17.12: Comparison of EORTC, PERCIST, PeteMac & Deauville PET Response Criteria after Radical ChemorT in Non-Small-Cell Lung Cancer
Guy-Anne Turgeon, Peter MacCallum Cancer Centre, Australia

17:05 MA 17.13: Impact of Histologic Subtype of Locally Advanced Lung Adenocarcinoma on Outcomes After Definitive Chemoradiation
Abraham J. Wu, Memorial Sloan Kettering Cancer Center, USA

17:10 MA 17.14: Phase I Trial Evaluating MEK Inhibitor Selumetinib with Concomitant Thoracic Radiotherapy in Non-Small-Cell Lung Cancer
Kate Haslett, The University of Manchester, UK

17:15 MA 17.15: Discussant – MA 17.10, MA 17.11, MA 17.12, MA 17.13, MA 17.14
Olfred Hansen, Odense University Hospital, Denmark

15:45 – 17:30 MA 18: Global Tobacco Control and Epidemiology II

15:45 MA 18.01: Driving Improvements in Cancer Care Ontario’s Smoking Cessation Initiative for Cancer Patients in Ontario, Canada
Meredith Elana Giuliani, University of Toronto and Princess Margaret Cancer Center, Canada

15:50 MA 18.02: Outcomes of Integrating Smoking Cessation Counseling in a Lung Screening Program
Matthew A. Steliga, University of Arkansas for Medical Sciences, USA

15:55 MA 18.03: Role of Electronic Cigarettes in Lung Cancer Prevention Among Smokers
Maciej Lukasz Goniewicz, Roswell Park Cancer Institute, USA
16:00 MA 18.04: Changes in Smoking Behaviour in the Early Cancer Detection Test Lung Cancer Scotland (ECLS) Study
Ben Young, University of Nottingham, UK

16:05 MA 18.05: Discussant – MA 18.01, MA 18.02, MA 18.03, MA 18.04
Emily Stone, St Vincent’s Hospital Sydney, Australia

16:20 MA 18.06: Clinical Prognostic Model for Older Patients with Advanced Non-Small Cell Lung Cancer
Apar Kishor Ganti, VA-Nebraska Western Iowa Health Care System, University of Nebraska Medical Center, USA

16:25 MA 18.07: Disparity in Prognostic Factors After Pulmonary Resection in Non-Small Cell Lung Cancer Between Asian and White Patients
Apichat Tantraworasin, Chiang Mai University, Thailand

16:30 MA 18.08: Assessment of Baseline Symptom Burden in Treatment-Naïve Patients with Lung Cancer
George R. Simon, The University of Texas MD Anderson Cancer Center, USA

16:35 MA 18.09: Enrollment of Minorities, the Elderly, and Women in Lung Cancer Clinical Trials
Narjust Duma, Mayo Clinic, USA

16:40 MA 18.10: Discussant – MA 18.06, MA 18.07, MA 18.08, MA 18.09
Manfred Neuberger, Medical University of Vienna, Austrian Academy of Science, Austria

16:55 MA 18.11: High Incidence of Lung Cancer in Early Stage TCC Patients
Yaakov Tolwin, Tel Aviv University, Israel

17:00 MA 18.12: Quality of Data Informing Epidemiological Studies in Patients with Lung Cancer
Marliese Alexander, Peter MacCallum Cancer Centre, Australia

17:05 MA 18.13: Mutation Profile of EGFR Gene in Chinese Patients with Non-Small-Cell Lung Cancer (NSCLC): An Analysis of 2,666 Cases
Dongmei Lin, Beijing Cancer Hospital, China

17:10 MA 18.14: Non-Small Cell Lung Cancer (NSCLC) Treatment and Survival in Scandinavia: The SCAN-LEAF Study
Simon Ekman, Karolinska University Hospital, Sweden

17:15 MA 18.15: Discussant – MA 18.11, MA 18.12, MA 18.13, MA 18.14
Konstantinos Arnaoutakis, University of Arkansas for Medical Sciences, USA


TRACK: INDUSTRY SUPPORTED SYMPOSIUM
ROOM: MAIN HALL
CHAIRS: FRANCES A. SHEPHERD, CANADA

Snacks and Refreshments provided

17:45 ISS 11.01: Welcome and Introduction
Frances A. Shepherd, Princess Margaret Cancer Centre, Canada

17:50 ISS 11.02: Anti-PD-1 in NSCLC: A Critical Look at the Landscape
Frances A. Shepherd, Princess Margaret Cancer Centre, Canada

18:05 ISS 11.03: PD-1 in Combination or As Monotherapy?
Martin Reck, LungClinic Grosshansdorf, Germany

18:20 ISS 11.04: Future Role for PD-1/L1 in Early-Stage (Non-Metastatic) NSCLC and Other Thoracic Malignancies
Giorgio Scagliotti, University of Torino, Italy

18:45 ISS 11.05: Panel Discussion
Frances A. Shepherd, Princess Margaret Cancer Centre, Canada,
Martin Reck, LungClinic Grosshansdorf, Germany,
Giorgio Scagliotti, University of Torino, Italy

19:10 ISS 11.06: Closing Remarks
Frances A. Shepherd, Princess Margaret Cancer Centre, Canada

19:30 – 22:30 Conference Dinner (Ticketed Event)

ROOM: PLENARY HALL (HALL D)
07:00 – 08:00 SH 03: WCLC 2017 Highlights of the Previous Day

**TRACK:** ADVANCED NSCLC, IMMUNOLOGY AND IMMUNOTHERAPY, EARLY STAGE NSCLC, RADIOLOGY/STAGING/SCREENING, BIOLOGY/PATHOLOGY, EPIDEMIOLOGY/PRIMARY PREVENTION/TOBACCO CONTROL AND CESSATION

**ROOM:** F201 + F202 (ANNEX HALL)

07:00 SH 03.01: Advanced NSCLC and Immunology and Immunotherapy
Nico Van Zandwijk, University of Sydney, Australia

07:20 SH 03.02: Early Stage NSCLC and Radiology/Staging/Screening
Jaroslaw Kuzdzal, Jagiellonian University, Poland

07:40 SH 03.03: Biology/Pathology and Epidemiology/Primary Prevention/TOBACCO Control and Cessation
Anja C. Roden, Mayo Clinic, USA

07:00 – 08:00 SH 04: WCLC 2017 Highlights of the Previous Day

**TRACK:** CHEMOTHERAPY/TARGETED THERAPY, NURSING/PALLIATIVE CARE/ETHICS, SCLC/NEUROENDOCRINE TUMORS, LOCALLY ADVANCED NSCLC, RADIOTHERAPY, BIOLOGY/PATHOLOGY, THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES

**ROOM:** F203 + F204 (ANNEX HALL)

07:00 SH 04.01: Chemotherapy/Targeted Therapy, Nursing/Palliative Care/Ethics, and SCLC/Neuroendocrine Tumors
Paul Baas, Netherlands Cancer Institute, Netherlands

07:20 SH 04.02: Locally Advanced NSCLC and Radiotherapy
Fumihiro Tanaka, University of Occupational and Environmental Health, Japan

07:40 SH 04.03: Biology/Pathology and Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies
Kenzo Hiroshima, Tokyo Women’s Medical University, Japan

07:00 – 08:00 MTE 22: Management of Elderly Patients with Lung Cancer (Sign Up Required)

**TRACK:** NURSING/PALLIATIVE CARE/ETHICS

**ROOM:** 303 + 304

07:00 MTE 22.01: Any Differences in the Management of Elderly Patients with Lung Cancer between East and West?
Kwun M. Fong, The Prince Charles Hospital UQ Thoracic Research Centre, Australia

07:30 MTE 22.02: Treatment Options in Advanced Non-Small Cell Lung Cancer (NSCLC) in the Elderly: An Evolving Landscape
Corey J. Langer, Abramson Cancer Center, University of Pennsylvania, USA

07:00 – 08:00 MTE 23: Mediastinal Tumors including Thymic Tumors, Lymphoma, Germ Cell Tumors: Biopsy, Diagnosis and Treatment (Sign Up Required)

**TRACK:** THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES

**ROOM:** 311 + 312

07:00 MTE 23.01: Thymic Neoplasms
Frank Detterbeck, Yale University School of Medicine, USA
07:30 MTE 23.02: Mediastinal Germ Cell Tumor
Lawrence Einhorn, Indiana University, USA

07:00 – 08:00 MTE 24: Basic Cytology for Clinicians (Sign Up Required)
TRACK: BIOLOGY/PATHOLOGY
ROOM: 313 + 314

07:00 MTE 24.01: Diagnostic Value and Limitation of Cytology
Kim Geisinger, The University of Mississippi Medical Center, USA

07:30 MTE 24.02: Novel Techniques of Cytological Diagnosis
Spasenija Savic, Universitaetsspital Basel, Switzerland

07:00 – 08:00 MTE 25: Tobacco Control – Practical Issues (Sign Up Required)
TRACK: EPIDEMIOLOGY/PRIMARY PREVENTION/TOBACCO CONTROL AND CESSATION
ROOM: 316

07:00 MTE 25.01: Smoking after Diagnosis of Cancer
Jacek Jassem, Medical University of Gdansk, Poland

07:30 MTE 25.02: What Physicians and Scientists Can Do in Tobacco Control Action
Yumiko Mochizuki, National Cancer Center, Japan

07:00 – 08:00 MTE 26: Clinical Trial Design for Novel Treatment (Sign Up Required)
TRACK: CLINICAL DESIGN, STATISTICS AND CLINICAL TRIALS
ROOM: 315

07:00 MTE 26.01: Contemporary Trial Design Considerations in the Era of Immuno-oncology
Mary Redman, Fred Hutchinson Cancer Research Center, USA

07:00 – 08:00 MTE 27: CT Screening for Lung Cancer (Sign Up Required)
TRACK: RADIOLOGY/STAGING/SCREENING
ROOM: 501

07:00 MTE 27.01: Who Should be Screened for Lung Cancer?
Jim Jett, National Jewish Health, USA

07:30 MTE 27.02: Pulmonary Nodule Guidelines: How Do We Decide Between the IELCAP, ACCP, NCCN, Fleischner Society, BTS, and Lung-RADS?
Jim Mo Goo, Seoul National Univ Hospital, Korea

07:00 – 08:00 MTE 28: Immunotherapy for Earlier Stage NSCLC (Sign Up Required)
TRACK: IMMUNOLOGY AND IMMUNOTHERAPY
ROOM: 301 + 302

07:00 MTE 28.01: Rationale for IO in Treatment of Early Stage NSCLC
Patrick M. Forde, Johns Hopkins University, USA

07:30 MTE 28.02: Pros and Cons of IO in Early Stage NSCLC
Edward Brian Garon, UCLA Medical Center, USA

07:00 – 08:00 MTE 29: Stereotactic Body Radiation Therapy for Early Stage Lung Cancer (Sign Up Required)
TRACK: RADIOTHERAPY
ROOM: 502

07:00 MTE 29.01: Update and Overview of SBRT for Early Stage Lung Cancer
Yasushi Nagata, Hiroshima University, Graduate School of Medical Sciences, Japan

07:00 – 08:00 MTE 30: Surgery after Concurrent Chemoradiotherapy (Sign Up Required)
TRACK: SURGERY
ROOM: 503

07:00 MTE 30.01: Surgery after Concurrent Chemoradiotherapy
Gustavo Lyons, Buenos Aires British Hospital, Argentina

07:00 – 08:00 MTE 31: Perspectives of Anti-Angiogenesis (Sign Up Required)
TRACK: CHEMOTHERAPY/TARGETED THERAPY
ROOM: 418

07:00 MTE 31.01: Perspectives of Anti-Angiogenesis
John V. Heymach, The University of Texas MD Anderson Cancer Center, USA
08:15 – 09:45  PL 03: Immunology in Lung Cancer Update 2017

TRACK: IMMUNOLOGY AND IMMUNOTHERAPY
ROOM: PLENARY HALL (HALL D)
CHAIRS: DAVID P. CARBONE, USA & KEUNCHIL PARK, KOREA

08:15  PL 03.01: Serendipities of Acquired Immunity
Tasuku Honjo, Graduate School of Medicine Kyoto University, Japan

08:45  PL 03.02: Biomarkers in Immunooncology Therapy
Naiyer Rizvi, Columbia University Medical Center, USA

09:05  PL 03.03: Blueprint 2: PD-L1 Immunohistochemistry Comparability Study in Real-Life, Clinical Samples
Ming Sound Tsao, University Health Network and Princess Margaret Cancer Centre, Canada

09:25  PL 03.04: Current Status and Future of Immunotherapy in Lung Cancer
Martin Reck, LungenClinic Grosshansdorf, Germany

10:00 – 10:45  Press Conference
ROOM: 418
For information on topics and speakers, please visit the Press & Media page on the Conference website at: wclc2017.iaslc.org/press-media/press-media/

10:00 – 10:45  Networking Opportunity & Poster Presenters Present for P3 Posters
EXHIBIT HALL (HALL B + C)
Refreshments provided

10:00 – 10:45  Networking Opportunity & Poster Presenters Present for P3 Posters
EXHIBIT HALL (HALL B + C)
Refreshments provided

10:00 – 10:45  Networking Opportunity & Poster Presenters Present for P3 Posters
EXHIBIT HALL (HALL B + C)
Refreshments provided

P3.01  Advanced NSCLC
P3.02  Biology/Pathology
P3.03  Chemotherapy/Targeted Therapy
P3.04  Clinical Design, Statistics and Clinical Trials
P3.05  Early Stage NSCLC
P3.06  Epidemiology/Primary Prevention/ Tobacco Control and Cessation
P3.07  Immunology and Immunotherapy
P3.08  Locally Advanced NSCLC
P3.09  Mesothelioma
P3.10  Nursing/Palliative Care/Ethics
P3.11  Patient Advocacy
P3.12  Pulmonology/Endoscopy
P3.13  Radiology/Staging/Screening
P3.14  Radiotherapy

11:00 – 12:30  MS 20: Value-based Management for Special Populations

TRACK: NURSING/PALLIATIVE CARE/ETHICS
ROOM: 501
CHAIRS: JIE WANG, CHINA & ELISABETH QUOIX, FRANCE

11:00  MS 20.01: When is a Treatment Considered Futile?
Vera Hirsh, McGill University, Royal Victoria Hospital, Canada

11:20  MS 20.02: Value-Based Judgment in Advanced NSCLC: The European Perspective
Robert Pirker, Medical University of Vienna, Austria

11:40  MS 20.03: What Do Patients Want at the End of Life? – East vs West
Hiroaki Okamoto, Yokohama Municipal Citizen’s Hospital, Japan

12:00  MS 20.04: Treatment of Fragile Patients with Advanced NSCLC: Futile or Fertile?
Byoung Chul Cho, Yonsei Cancer Center, Korea

12:20  Question and Answer Session

11:00 – 12:30  MS 21: Being Mortal: Learning from ZEN

TRACK: NURSING/PALLIATIVE CARE/ETHICS
ROOM: 316
CHAIRS: MEREDITH CUMMINS, AUSTRALIA & KAORU KUBOTA, JAPAN

11:00  MS 21.01: Spirituality in Asia
Nanrei Yokota, Engakuji Temple, Japan

11:40  MS 21.02: Meditation: From the Temples to the Clinic
Alejandro Chaoul, MD Anderson Cancer Center, USA

12:00  MS 21.03: Self-Care: “Provider, Heal Thyself”
Maria Ftanou, Peter MacCallum Cancer Institute, Australia

12:20  Question and Answer Session

11:00 – 12:30  MS 22: The Cost of Lung Cancer

TRACK: EPIDEMIOLOGY/PRIMARY PREVENTION/TOBACCO CONTROL AND CESSATION
ROOM: 502
CHAIRS: RONAN J. KELLY, USA & TOMOTAKA SOBUE, JAPAN

11:00  MS 22.01: Spirituality in Asia
Nanrei Yokota, Engakuji Temple, Japan

11:40  MS 22.02: Meditation: From the Temples to the Clinic
Alejandro Chaoul, MD Anderson Cancer Center, USA

12:00  MS 22.03: Self-Care: “Provider, Heal Thyself”
Maria Ftanou, Peter MacCallum Cancer Institute, Australia

12:20  Question and Answer Session

11:00 – 12:30  MS 23: The Economic Burden of Lung Cancer

TRACK: EPIDEMIOLOGY/PRIMARY PREVENTION/TOBACCO CONTROL AND CESSATION
ROOM: 502
CHAIRS: RONAN J. KELLY, USA & TOMOTAKA SOBUE, JAPAN

11:00  MS 23.01: The Economic Burden of Lung Cancer
Natasha B. Leighl, Princess Margaret Cancer Centre, Canada
11:00 – 12:30 ES 08: Molecular Diagnostics and Targeted Therapy

**TRACK:** CHEMOTHERAPY/TARGETED THERAPY
**ROOM:** MAIN HALL
**CHAIRS:** KWUN M. FONG, AUSTRALIA & DAVID PLANCHARD, FRANCE

11:00 **ES 08.01:** Overview of Diagnostics and Pathology
Tetsuya Mitsudomi, Kindai University Faculty of Medicine, Japan

11:15 **ES 08.02:** Update of the Management of EGFR-Positive NSCLC
James Chih-Hsin Yang, National Taiwan University, Taiwan

11:30 **ES 08.03:** Update of the Management of ALK-Positive NSCLC
D. Ross Camidge, University of Colorado, USA

11:45 **ES 08.04:** Emerging Target Therapy in NSCLC
Enriqueta Felip, Hospital Universitari Vall d’Hebron, Spain

12:00 **ES 08.05:** Oncogenomics for Clinicians
Matthew Meyerson, Dana Farber Cancer Institute, Broad Institute of Harvard and MIT, and Massachusetts General Hospital, USA

12:15 Question and Answer Session

11:00 – 12:30 GR 03: Treatment Options for Early Stage Lung Cancer Patients with Limited Pulmonary Reserve

**TRACK:** EARLY STAGE NSCLC
**ROOM:** F205 + F206 (ANNEX HALL)
**CHAIRS:** ALEXANDER V. LOUIE, CANADA & ICHIRO YOSHINO, JAPAN

11:00 **GR 03.01:** Case Study
Alexander Vincent Louie, London Regional Cancer Program, Canada

11:20 **GR 03.02:** Alectinib First
Kazuhiko Nakagawa, Kindai University Faculty of Medicine, Japan

11:40 **GR 03.03:** Liquid Biopsy
Heather A. Wakelee, Stanford University, USA

12:00 **GR 03.04:** Tissues Biopsy
Keith M. Kerr, University of Aberdeen, School of Medicine and Dentistry, USA

12:15 Question and Answer Session

11:00 – 12:30 ES 07: Recent Advances in Diagnostics and Interventional Bronchoscopy

**TRACK:** PULMONOLOGY/ENDOSCOPY
**ROOM:** 503
**CHAIRS:** STEPHEN LAM, CANADA & NORIAKI KURIMOTO, JAPAN

11:00 **ES 07.01:** Endoscopic Staging of Lung Cancer
Kazuhiro Yasufuku, University Health Network, Canada

11:20 **ES 07.02:** Guided Bronchoscopy for Peripheral Lung Nodules
Takehiro Izumo, Japanese Red Cross Medical Center, Japan

11:40 **ES 07.03:** Bronchoscopic Management of Central Airway Obstruction
Hojoong Kim, Samsung Medical Center, Korea

12:00 **ES 07.04:** Endoscopic Options for Solitary Pulmonary Nodules
Stephen Lam, British Columbia Cancer Agency, Canada

12:20 Question and Answer Session
11:00 – 12:30  OA 10: Liquid Biopsy for Genomic Alterations

**TRACK:** ADVANCED NSCLC  
**ROOM:** F201 + F202 (ANNEX HALL)  
**CHAIRS:** PASI A. JÄNNE, USA  
& ADRIAN G. SACHER, USA

11:00  OA 10.01: Detection of EGFR Mutations From Plasma ctDNA in the Osimertinib Phase III trial (AURA3): Comparison of Three Plasma Assays
Myung-Ju Ahn, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea

11:10  OA 10.02: Unique Genetic Profiles from Circulating Cell-Free DNA of Cerebrospinal Fluid in Leptomeningeal Metastases of EGFR Mutant NSCLC
Benyuan Jiang, Guangdong Lung Cancer Institute, China

11:20  OA 10.03: Liquid Biopsy in the Lung Cancer Clinic: A Prospective Study of Plasma DNA next Generation Sequencing to Guide Matched Therapy
Joshua K. Sabari, Memorial Sloan Kettering Cancer Center, USA

11:30  OA 10.04: Discussant – OA 10.01, OA 10.02, OA 10.03
Christina S. Baik, University of Washington, Seattle Cancer Care Alliance, USA

11:45  OA 10.05: Non-Invasive Molecular Profiling in NSCLC by Targeted and Whole Exome Analysis of Plasma cfDNA
Dana W.Y. Tsui, Memorial Sloan Kettering Cancer Center, USA

11:55  OA 10.06: Longitudinal Mutation Monitoring in Plasma by Deep Sequencing as a Potential Predictor of Disease Progression in NSCLC
John Jiang, Roche Sequencing Solutions, USA

12:05  OA 10.07: Genomic Profile of Cell-Free DNA from Sputum, Plasma, Urine and Tumor Tissue and Correlation with Clinical Effect in Advanced NSCLC
Zhen Wu, Department of Respiratory medicine, Chinese PLA General Hospital, China

12:15  OA 10.08: Discussant – OA 10.05, OA 10.06, OA 10.07
Naoko Aragane, Saga University, Japan

11:00 – 12:30  OA 11: Reducing Burden: Patient-Centered Care

**TRACK:** NURSING/PALLIATIVE CARE/ETHICS PATIENT ADVOCACY  
**ROOM:** 313 + 314  
**CHAIRS:** BETH IVIMEY, AUSTRALIA  
& ERIC BERNICKER, USA

11:00  OA 11.01: Impact of Tobacco Smoking on the Humanistic and Financial Burden of Advanced Non-Small Cell Lung Cancer (A-NSCLC)
Oana Chirita, Bristol-Myers Squibb, UK

11:10  OA 11.02: Exercise Improves Functional Capacity in Patients with Advance Stage Lung Cancer
Morten Quist, Rigshospitalet, University of Copenhagen, Denmark

11:20  OA 11.03: Reducing Lung Cancer Mortality in Disparate Populations through Cancer-Community Awareness Access Research and Education (C-CARE)
Lovoria B. Williams, Augusta University, USA

11:30  OA 11.04: Effect of Early Palliative Care on Aggressiveness of Cancer Care near End of Life in Lung Cancer Patient
Wandee Chanprasertpiyo, Ramathibodi Hospital, Mahidol University, Thailand

11:40  OA 11.05: Discussant – OA 11.01, OA 11.02, OA 11.03, OA 11.04
Jin Soo Lee, National Cancer Center, Korea

11:55  OA 11.06: Lung Cancer Diagnosis and Assessment as a System Design Problem: Creating an Award Winning Program with Patient Advocates as Co-Designers
Jason Pantarotto, University of Ottawa / The Ottawa Hospital, Canada

12:05  OA 11.07: Enhancing Lung Cancer (LC) Care in the Community Setting Through a Patient Advocacy ‘Centers of Excellence’ (COE) Program
Luis E. Raez, Memorial Cancer Institute, USA

12:15  OA 11.08: Discussant – OA 11.06, OA 11.07
Kazuo Hasegawa, Japan Lung Cancer Alliance, Japan

11:00 – 12:30  OA 12: Emerging Genomic Targets

**TRACK:** ADVANCED NSCLC CHEMOTHERAPY/TARGETED THERAPY  
**ROOM:** F203 + F204 (ANNEX HALL)  
**CHAIRS:** HIROTOSHI AKITA, JAPAN  
& MAURICE PÉROL, FRANCE

11:00  OA 12.01: The Preclinical and Clinical Activity of Poziotinib, a Potent, Selective Inhibitor of EGFR Exon 20 Mutant NSCLC
John V. Heymach, The University of Texas MD Anderson Cancer Center, USA

11:10  OA 12.02: Final Results of a Phase 2 Study of the hsp90 Inhibitor Luminespib (AUY922) in NSCLC Patients Harboring EGFR Exon 20 Insertions
Zofia Piotrowska, Massachusetts General Hospital, USA

11:20  OA 12.03: Clinical Features of Advanced Lung Cancer Harboring HER2 Aberrations: A Large Prospective Cohort Study (HER2-CS STUDY)
Shinobu Hosokawa, Japanese Red Cross Okayama Hospital, Japan

11:30  OA 12.04: Discussant – OA 12.01, OA 12.02, OA 12.03
Rina Hui, Westmead Hospital and the University of Sydney, Australia

11:45  OA 12.05: Spectrum of 1,014 Somatic BRAF Alterations Detected in Cell-Free DNA of Patients with Advanced Non-Small Cell Lung Cancer
Trever G. Bivona, UC San Francisco, USA

11:55  OA 12.06: Plasma Genomic Profiling and Outcomes of Patients with MET Exon 14-Altered NSCLCs Treated with Crizotinib on PROFILE 1001
Alexander Drilon, Memorial Sloan Kettering Cancer Center, USA

12:05  OA 12.07: LOXO-292, a Potent, Highly Selective RET Inhibitor, in MKI-Resistant RET Fusion-Positive Lung Cancer Patients with and without Brain Metastases
Vamsidhar Velcheti, Cleveland Clinic, USA

WEDNESDAY, OCTOBER 18, 2017  |  SCIENTIFIC PROGRAM

www.IASLC.org

Onsite Program  / IASLC 18th World Conference on Lung Cancer
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:10</td>
<td>OA 12.08</td>
<td>Genomic Analysis of Non-Small Cell Lung Cancer (NSCLC) Cases with Focal and Non-Focal MET Amplification</td>
<td>Sai-Hong Ignatious Ou, University of California at Irvine School of Medicine, Chao Family Comprehensive Cancer Center, USA</td>
</tr>
<tr>
<td>11:20</td>
<td>OA 12.09</td>
<td>Discussant – OA 12.05, OA 12.06, OA 12.07, OA 12.08</td>
<td>Julien Mazieres, Toulouse University Hospital, France</td>
</tr>
<tr>
<td>11:10</td>
<td>OA 14.02</td>
<td>Rethinking Progression-Free Survival (PFS) as a Clinical Trials Surrogate for Overall Survival (OS)</td>
<td>David James Stewart, University of Ottawa, Canada</td>
</tr>
<tr>
<td>11:20</td>
<td>OA 14.03</td>
<td>Ontario’s Bundled Payment System for Systemic Therapy Supports Lung Cancer Trials</td>
<td>William Kenneth Evans, Cancer Care Ontario, Canada</td>
</tr>
<tr>
<td>11:30</td>
<td>OA 14.04</td>
<td>Discussant – OA 14.01, OA 14.02, OA 14.03</td>
<td>George R. Simon, MD Anderson Cancer Center, USA</td>
</tr>
<tr>
<td>11:45</td>
<td>OA 14.05</td>
<td>Phase 2 Basket Trial of Ado-Trastuzumab Emtansine in Patients with HER2 Mutant or Amplified Lung Cancers</td>
<td>Bob T. Li, Memorial Sloan Kettering Cancer Center, USA</td>
</tr>
<tr>
<td>11:55</td>
<td>OA 14.06</td>
<td>Entrectinib in Patients with Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)</td>
<td>Myung-Ju Ahn, Samsung Medical Center, Korea</td>
</tr>
<tr>
<td>12:10</td>
<td>MA 19.01</td>
<td>A Phase II Study of Nivolumab: A Multicenter, Open-Label, Single Arm Study in Malignant Pleural Mesothelioma (MERIT)</td>
<td>Yasushi Goto, National Cancer Center Hospital, Japan</td>
</tr>
<tr>
<td>12:20</td>
<td>MA 19.02</td>
<td>Tremelimumab plus Durvalumab in First- or Second-Line Mesothelioma Patients: Final Analysis of the NIBIT-MESO-1 Study</td>
<td>Luana Calabro, Center for Immuno-Oncology, University Hospital of Siena, Italy</td>
</tr>
<tr>
<td>12:10</td>
<td>OA 14.01</td>
<td>The Impact of Measurement Variability on Response Categorization in Oncology Trials</td>
<td>Soon Ho Yoon, Seoul National University College of Medicine, Korea</td>
</tr>
<tr>
<td>12:20</td>
<td>OA 14.02</td>
<td>Genomic Analysis of Non-Small Cell Lung Cancer (NSCLC) Cases with Focal and Non-Focal MET Amplification</td>
<td>Sai-Hong Ignatious Ou, University of California at Irvine School of Medicine, Chao Family Comprehensive Cancer Center, USA</td>
</tr>
<tr>
<td>12:20</td>
<td>OA 14.03</td>
<td>Ontario’s Bundled Payment System for Systemic Therapy Supports Lung Cancer Trials</td>
<td>William Kenneth Evans, Cancer Care Ontario, Canada</td>
</tr>
<tr>
<td>12:30</td>
<td>OA 14.04</td>
<td>Discussant – OA 14.01, OA 14.02, OA 14.03</td>
<td>George R. Simon, MD Anderson Cancer Center, USA</td>
</tr>
<tr>
<td>12:45</td>
<td>OA 14.05</td>
<td>Phase 2 Basket Trial of Ado-Trastuzumab Emtansine in Patients with HER2 Mutant or Amplified Lung Cancers</td>
<td>Bob T. Li, Memorial Sloan Kettering Cancer Center, USA</td>
</tr>
<tr>
<td>12:55</td>
<td>OA 14.06</td>
<td>Entrectinib in Patients with Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)</td>
<td>Myung-Ju Ahn, Samsung Medical Center, Korea</td>
</tr>
<tr>
<td>12:10</td>
<td>MA 19.01</td>
<td>A Phase II Study of Nivolumab: A Multicenter, Open-Label, Single Arm Study in Malignant Pleural Mesothelioma (MERIT)</td>
<td>Yasushi Goto, National Cancer Center Hospital, Japan</td>
</tr>
<tr>
<td>12:20</td>
<td>MA 19.02</td>
<td>Tremelimumab plus Durvalumab in First- or Second-Line Mesothelioma Patients: Final Analysis of the NIBIT-MESO-1 Study</td>
<td>Luana Calabro, Center for Immuno-Oncology, University Hospital of Siena, Italy</td>
</tr>
<tr>
<td>12:10</td>
<td>OA 14.01</td>
<td>The Impact of Measurement Variability on Response Categorization in Oncology Trials</td>
<td>Soon Ho Yoon, Seoul National University College of Medicine, Korea</td>
</tr>
<tr>
<td>12:20</td>
<td>OA 14.02</td>
<td>Genomic Analysis of Non-Small Cell Lung Cancer (NSCLC) Cases with Focal and Non-Focal MET Amplification</td>
<td>Sai-Hong Ignatious Ou, University of California at Irvine School of Medicine, Chao Family Comprehensive Cancer Center, USA</td>
</tr>
<tr>
<td>12:20</td>
<td>OA 14.03</td>
<td>Ontario’s Bundled Payment System for Systemic Therapy Supports Lung Cancer Trials</td>
<td>William Kenneth Evans, Cancer Care Ontario, Canada</td>
</tr>
<tr>
<td>12:30</td>
<td>OA 14.04</td>
<td>Discussant – OA 14.01, OA 14.02, OA 14.03</td>
<td>George R. Simon, MD Anderson Cancer Center, USA</td>
</tr>
<tr>
<td>12:45</td>
<td>OA 14.05</td>
<td>Phase 2 Basket Trial of Ado-Trastuzumab Emtansine in Patients with HER2 Mutant or Amplified Lung Cancers</td>
<td>Bob T. Li, Memorial Sloan Kettering Cancer Center, USA</td>
</tr>
<tr>
<td>12:55</td>
<td>OA 14.06</td>
<td>Entrectinib in Patients with Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)</td>
<td>Myung-Ju Ahn, Samsung Medical Center, Korea</td>
</tr>
</tbody>
</table>

**11:00 – 12:30**

**OA 14:** New Paradigms in Clinical Trials

**Track:** CLINICAL DESIGN, STATISTICS AND CLINICAL TRIALS

**Room:** 311 + 312

**Chairs:** ALEX ADJEI, USA & EUN KYUNG CHO, KOREA

**11:00 OA 14.01:** The Impact of Measurement Variability on Response Categorization in Oncology Trials

Soon Ho Yoon, Seoul National University College of Medicine, Korea
Onsite Program  / IASLC 18th World Conference on Lung Cancer
WWW.IASLC.ORG
WEDNESDAY, OCTOBER 18, 2017  |  SCIENTIFIC PROGRAM

11:45  MA 19.08: Discussant – MA 19.05, MA 19.06, MA 19.07
Yoshitaka Sekido, Aichi Cancer Center Research Institute, Japan

12:00  MA 19.09: The Role of Neoadjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma
David Harpole, Duke Medical Center, USA

12:05  MA 19.10: Comparative Value of MR and CT for Tumor Volumetric and Clinical Staging of Malignant Pleural Mesothelioma
Ritu R. Gill, Brigham and Women’s Hospital, USA

Walter Weder, University Hospital Zurich, Switzerland

12:25  Question and Answer Session

12:45 – 14:15  ISS 12: SCLC Biomarker Testing Symposium – AbbVie

12:45  Lunch boxes provided

12:45  ISS 12.01: Welcome & Introductions
Koichi Goto, National Cancer Center Hospital East, Japan

12:55  ISS 12.02: Opportunities & Challenges in SCLC Patient Care
Benjamin Besse, Gustave Roussy, France

13:15  ISS 12.03: Novel Therapeutics in SCLC & the Changing Treatment Landscape
Maya Gottfried, Mer Medical Center, Israel

13:45  ISS 12.04: Incorporating Biomarker Testing & Targeted Therapies into the SCLC Treatment Paradigm
Wilfried Eberhardt, University of Essen, Germany

14:15  ISS 12.06: Adjourn

14:30 – 15:30  ® Networking Opportunity
& Poster Presenters Present for P3 Posters


14:30  Lunch boxes provided

14:30  MS 23.01: What Type of Lung Cancer Cannot be Resected?
Marc De Perrot, University Health Network, Canada

14:50  MS 23.02: When Do Surgeons Quit Resection During Surgery?
Jessica Donington, NYU Langone Medical Center, USA

15:10  MS 23.03: What is Resectable N2 Disease, and What is Unresectable N2 Disease: A Medical Oncologist’s Viewpoint
Hidehito Horinouchi, National Cancer Center Hospital, Japan

15:30  MS 23.04: What is Resectable N2 Disease, and What is Unresectable N2 Disease: A Radiation Oncologist’s Viewpoint
Walter John Curran, Jr., Winship Cancer Institute, USA

15:50  MS 23.05: What is Resectable N2 Disease, and What is Unresectable N2 Disease: A Surgeon’s Viewpoint
Jhingook Kim, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea

16:10  Question and Answer Session

14:30 – 16:15  MS 24: Management of GGO-Containing Nodule

14:30  Lunch boxes provided

14:30  MS 24.01: Natural History of GGO-Containing Tumors
Ryutaro Kakinuma, Tokyo General Hospital, Japan

14:50  MS 24.02: What Type of Surgery Should be Selected for GGO-Containing Tumors?
Paul De Leyn, University Hospitals Leuven, Belgium
15:10 MS 24.03: When to Operate GGO-Containing Tumors?
David Harpole, Duke University, USA

15:30 MS 24.04: Possibility of Radiotherapy for GGO-Containing Tumors
Hiroshi Onishi, University of Yamanashi, Japan

15:50 MS 24.05: Possibility of Chemotherapy for GGO-Containing Tumors
Pieter E. Postmus, Clatterbridge Cancer Centre, UK

16:10 Question and Answer Session

14:30 – 16:15 MS 25: Novel Molecular Targets (KRAS/MET/Novel Fusions): Druggable or Not?
TRACK: CHEMOTHERAPY/TARGETED THERAPY
ROOM: MAIN HALL
CHAIRS: RAFAEL ROSELL, SPAIN & ISAMU OKAMOTO, JAPAN

14:30 MS 25.01: Discovery of Novel Molecular Targets
Pasi A. Janne, Dana-Farber Cancer Institute, USA

14:50 MS 25.02: KRAS-Targeted Therapy or Angiogenesis: Still a Viable Target?
Ravi Salgia, City of Hope National Medical Center, USA

15:10 MS 25.03: MET-Related Molecular Targets
Alexander Drilon, Memorial Sloan Kettering Cancer Center, USA

15:30 MS 25.04: FGFR-Related Novel Molecular Targets
Kazuto Nishio, Kinkai University School of Medicine, Japan

15:50 MS 25.05: Novel Fusions
Robert C. Doebele, University of Colorado Anschutz Medical Campus, USA

16:10 Question and Answer Session

14:30 – 16:15 MS 26: Re-Modeling Microenvironment Mimicking Human Cancer
TRACK: BIOLOGY/PATHOLOGY
ROOM: 502
CHAIRS: PAN CHYR YANG, TAIWAN & CELINE MASCAUX, FRANCE

14:30 MS 26.01: Cancer Stem Cell
Hideyuki Saya, Institute for Advanced Medical Research, School of Medicine, Keio University, Japan

14:50 MS 26.02: Innate Immune Microenvironment
Ruben Pio, CIMA-University of Navarra, Spain

15:10 MS 26.03: Animal Model
Kwok-Kin Wong, NYU Langone Health Perlmutter Cancer Center, USA

15:30 MS 26.04: PDx Model
John Poirier, Memorial Sloan Kettering Cancer Center, USA

15:50 MS 26.05: In Vitro Model of Early Progression in SCLC
Kwon-Sik Park, University of Virginia, USA

16:10 Question and Answer Session

14:30 – 16:15 MS 27: Engaging Patients in Research: Best Practices
TRACK: PATIENT ADVOCACY
ROOM: 311+312
CHAIRS: SHANI SHILO, ISRAEL & JANE KERR, AUSTRALIA

14:30 MS 27.01: The Multi-Centre Clinical Trials Network (MCTN): Matching Lung Cancer Patients to Trials in Australia
Nick Pavlakis, Royak North Shore Hospital, Australia

14:50 MS 27.02: LungMATCH: Developing a Patient-Friendly, Personalized Education and Navigation Program to Increase Participation in Clinical Research
Jennifer C. King, Lung Cancer Alliance, USA

15:10 MS 27.03: Lung Cancer Registry: Using Patient Data to Improve Outcomes and Quality of Life
David LeDuc, Addario Lung Cancer Foundation, USA

15:30 MS 27.04: Approaches to Patient-Centric Clinical Trials: Sharing Challenges and Lessons Learned
Ingeborg Beunders, Focus Patient Ltd., Austria

15:50 MS 27.05: Screening Veterans: Opportunity and Challenge
Chris Draft, The Chris Draft Family Foundation, USA

16:10 Question and Answer Session

14:30 – 16:15 ES 09: Recent Progress in the Management of Small Cell Lung Cancer
TRACK: SCLC/NEUROENDOCRINE TUMORS
ROOM: 501
CHAIRS: DAVID S. ETTINGER, USA & KENNETH O’BYRNE, AUSTRALIA

14:30 ES 09.01: Genomics and Translational Research
Charles M. Rudin, Memorial Sloan Kettering Cancer Center, USA

14:45 ES 09.02: Cytotoxic Chemotherapy
Yoichi Nakanishi, Kyushu University, Japan

15:00 ES 09.03: Immunotherapy
Caicun Zhou, Shanghai Pulmonary Hospital, Tongji University, China

15:15 ES 09.04: Novel Agents for SCLC
Se-Hoon Lee, Samsung Medical Center, Korea

15:30 ES 09.05: Management of Paraneoplastic Syndromes in SCLC
Lucio Crinò, Medical Oncology- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Italy

15:45 ES 09.06: NCI’s Small Cell Lung Cancer Consortium: New Answers to Old Questions
Peter Ujhazy, National Cancer Institute, USA

16:00 Question and Answer Session
14:30 – 16:15  ES 10: Radiation Treatment Update

**TRACK:** RADIOTherapy
**ROOM:** F201 + F202 (ANNEX HALL)
**CHAIRS:** Zhongxing Liao, USA & Fiona Mc Donald, UK

**14:30 ES 10.01: SBRT**
Billy Loo, Stanford University, USA

**14:50 ES 10.02: IMRT**
Francoise Mornex, Centre Hospitalier Lyon-Sud, France

**15:10 ES 10.03: Proton Therapy**
Yong Chan Ahn, Samsung Medical Center, Korea

**15:30 ES 10.04: Carbon-ion Therapy**
Yuko Nakayama, National Center Hospital, Japan

**15:50 ES 10.05: RT and Targeted Therapies**
Rafał Dziadziuszko, Medical University of Gdańsk, Poland

16:10 Question and Answer Session

14:30 – 16:15  OA 15: Diagnostic Radiology, Staging and Screening for Lung Cancer II

**TRACK:** RADIOLOGY/STAGING/SCREENING
**ROOM:** 303 + 304
**CHAIRS:** Yukitoshi Satoh, Japan & Jin Mo Goo, Korea

**14:30 OA 15.01: Lung Cancer Screening: Participant Selection by Risk Model – the Pan-Canadian Study**
Stephen Lam, BC Cancer Agency, Canada

**14:40 OA 15.02: Benefits, Harms, and Economic Efficiency of Low-Dose CT Lung Cancer Screening Strategies in a Population-Based Setting**
Alexander Kuhlmann, Leibniz Universität Hannover, Germany

**14:50 OA 15.03: Gene-Based Risk Stratification of NLST-ACRIN Screening Participants Identifies The "Sweet Spot" of Screening (N=10,054)**
Robert P. Young, University of Auckland, New Zealand

**15:00 OA 15.04: Community-Based Lung Cancer Screening, Targeting High-Risk Ever Smokers in Deprived Areas of Manchester: an NHS Implementation Project**
Haval Balata, University Hospital of South Manchester, UK

**15:10 OA 15.05: Discussant – OA 15.01, OA 15.02, OA 15.03, OA 15.04**
David F. Yankelevitz, Icahn School of Medicine at Mount Sinai, USA

**15:25 OA 15.06: Management of Nonresolving New Solid Nodules after Initial Detection in Incidence Rounds of CT Lung Cancer Screening**
Joan E. Walter, University of Groningen, University Medical Center Groningen, Netherlands

**15:35 OA 15.07: Value of Nodule Characteristics in Risk-Stratification of New Incident Nodules Detected in CT Lung Cancer Screening**
Joan E. Walter, University of Groningen, University Medical Center Groningen, Netherlands

15:45 OA 15.08: Thoroughness of Staging and the Outcomes of Surgical Resection Outcomes in Potentially Curable Non-Small Cell Lung Cancer (NSCLC)
Matthew P. Smetzer, University of Memphis School of Public Health, USA

15:55 OA 15.09: Discussant – OA 15.06, OA 15.07, OA 15.08
John Field, The University of Liverpool, UK

14:30 – 16:15  OA 16: Treatment Strategies and Follow Up

**TRACK:** EARLYSTAGE NSCLC
**ROOM:** 315
**CHAIRS:** Jun Nakajima, Japan & Todd Demmy, USA

**14:30 OA 16.01: Stereotactic Ablative Radiotherapy Versus Surgery in Early Lung Cancer: A Meta-analysis of Propensity Score-Adjusted Studies**
Hanbo Chen, London Health Sciences Centre, Canada

**14:40 OA 16.02: Risk of Recurrence in Stage I Adenocarcinoma of the Lung: A Multi-Institutional Study on Interaction with Type of Surgery and Type of Nodal Staging**
Francesco Guerrera, University of Torino, Italy

**14:50 OA 16.03: Recurrences and 2Nd Primary Cancers in the IFCT-0302 Trial Assessing a CT-Scan-Based Follow-Up after Lung Cancer Surgery**
Virginie Westeel, Centre Hospitalier Universitaire de Besançon, Hôpital Minjoz, France

**15:00 OA 16.04: Efficacy and Safety of Erlotinib vs Vinorelbine/Cisplatin as Adjuvant Therapy for Stage IIIA EGFR Mutant NSCLC Patients**
Dongsheng Yue, Tianjin Medical University Cancer Institute and Hospital, China

**15:25 OA 16.05: Risk of Recurrence in Stage I Adenocarcinoma of the Lung: A Multi-Institutional Study on Interaction with Type of Surgery and Type of Nodal Staging**
Francesco Guerrera, University of Torino, Italy

15:50 OA 16.06: Mediastinal Staging by Videomediastinoscopy in Clinical N1 Non-Small Cell Lung Cancer: A Prospective Multicentre Study
Herbert Decaluwe, University Hospitals Leuven, Belgium

15:55 OA 16.07: Radiological Feature on TSCT for Predicting a Pathological Less-Invasive Lung Cancer According to the 8th TNM Classification
Shinya Katsumata, National Cancer Center Hospital East, Japan

15:50 OA 16.08: A Modified Pathological N1 Classification Strategy Based on Systematic Dissection of N1 Nodes from Level 10 to 14 for Non-Small Cell Lung Cancer
Wu Nan, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), China
14:30 – 16:15  OA 17: Immunotherapy II

**TRACK:** ADVANCED NSCLC IMMUNOLOGY AND IMMUNOTHERAPY  
**ROOM:** 301 + 302  
**CHAIRS:** ANNE TSAO, USA & YUI CHIRO OHE, JAPAN

14:30  OA 17.01: Pemetrexed-Carboplatin Plus Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC: KEYNOTE-021 Cohort G Update  
Hossein Borghaei, Fox Chase Cancer Center, USA

14:40  OA 17.02: Updated Efficacy Results From the BIRCH Study: First-Line Atezolizumab Therapy in PD-L1–Selected Patients With Advanced NSCLC  
Enric Cancreny, Catalan Institute of Oncology Badalona—Germans Trias I Pujol Hospital Badalona, Spain

14:50  OA 17.03: First-Line Nivolumab plus Platinum-Based Doublet Chemotherapy for Advanced NSCLC: CheckMate 012 3-Year Update  
Rosalyn J. Juergens, Juravinski Cancer Centre at McMaster University, Canada

15:00  OA 17.04: Discussant – OA 17.01, OA 17.02, OA 17.03  
Martin Schuler, University Hospital Essen, Germany

15:15  OA 17.05: IFTC-1502 CLINICO: Real-Life Experience with Nivolumab in 600 Patients (Pts) with Advanced Non-Small Cell Lung Cancer (NSCLC)  
Nicolas Girard, Institut Curie, France

15:25  OA 17.06: Updated Analysis of KEYNOTE-024: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced NSCLC With PD-L1 TPS ≥50%  
Julie R. Brahmer, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, USA

15:35  OA 17.07: Long-Term Survival in Atezolizumab-Treated Patients with 2L+ NSCLC from Ph III Randomized OAK Study  
Miyako Satouchi, Hyogo Cancer Center, Japan

15:45  OA 17.08: Phase II Study of Pembrolizumab for Oligometastatic Non-Small Cell Lung Cancer (NSCLC): Following Completion of Locally Ablative Therapy (LAT)  
Joshua Michael Baum, Perelman School of Medicine at the University of Pennsylvania, USA

15:55  OA 17.09: Discussant – OA 17.05, OA 17.06, OA 17.07, OA 17.08  
Penelope Bradbury, University Hospital Network, Princess Margaret Cancer Centre, Canada

14:30 – 16:15  MA 20: Recent Advances in Pulmonology/Endoscopy

**TRACK:** PULMONOLOGY/ENDOSCOPY  
**ROOM:** F205 + F206 (ANNEX HALL)  
**CHAIRS:** CHOON-TAEK LEE, KOREA & SHINJI SASADA, JAPAN

14:30  MA 20.01: Fiducial Marker Placement Using Electromagnetic Navigation Bronchoscopy in the Prospective, Multicenter NAVIGATE Study  
Mark R. Bowling, East Carolina University, USA

14:40  MA 20.02: Pleural Dye Marking of Lung Nodules by Electromagnetic Navigation Bronchoscopy in the Prospective, Multicenter NAVIGATE Study  
Mark R. Bowling, East Carolina University, USA

14:50  MA 20.03: Safety of Electromagnetic Navigation Bronchoscopy in Patients with COPD: Results from the NAVIGATE Study  
Mark R. Bowling, East Carolina University, USA

14:50  OA 18.03: Genomic Profiling Reveals Hedgehog Pathway Alterations in Vismodegib Sensitive Lung Squamous Cell Carcinoma  
Siraj M. Ali, Foundation Medicine, USA

15:00  OA 18.04: Whole Genome Tumor-Normal Sequencing Reveals Potential False Positives Versus Standard CGP Sequencing in Patients with NSCLC  
Sandeep Bobby Reddy, Nant Health, USA

15:10  OA 18.05: Discussant – OA 18.01, OA 18.02, OA 18.03, OA 18.04  
Maria E. Arcila, Memorial Sloan Kettering Cancer Center, USA

15:25  OA 18.06: Three-Dimensional Assessment of Spread Through Air Spaces in Lung Adenocarcinoma: Insights and Implications  
Yukako Yagi, Memorial Sloan Kettering Cancer Center, USA

15:35  OA 18.07: 3D Low-Attachment Culture: A Putative Model for STAS And “Floating” Cancer Cells  
Toshiro Niki, Jichi Medical University, Japan

15:45  OA 18.08: FLI1 Circular RNAs Promote Metastasis of Small Cell Lung Cancer Cells by Direct Binding to miR-584-3p  
Jiuwei Cui, The First Hospital of Jilin University, China

15:55  OA 18.09: Discussant – OA 18.06, OA 18.07, OA 18.08  
Alain Borczuk, Albert Einstein College of Medicine/Montefiore Medical Center, USA

14:30 – 16:15  OA 17: Lung Cancer Pathology and Genetics

**TRACK:** BIOLOGY/PATHOLOGY  
**ROOM:** 316  
**CHAIRS:** GEORGE R. SIMON, USA & YOON-LA CHOI, KOREA

14:30  OA 18.01: Paired Tumor-Normal Next-Generation Sequencing (NGS) to Identify Pathogenic / Likely Pathogenic Germline Mutations in Lung Cancer Patients  
Rongrong Chen, Geneplus-Beijing, China

14:40  OA 18.02: The Landscape of Alteration of DNA Integrity-Related Genes and Their Association with Tumor Mutation Burden in Non-Small Cell Lung Cancer  
Michael F. Sharpnack, The Ohio State University, USA

15:00  OA 18.04: Whole Genome Tumor-Normal Sequencing Reveals Potential False Positives Versus Standard CGP Sequencing in Patients with NSCLC  
Sandeep Bobby Reddy, Nant Health, USA

15:10  OA 18.05: Discussant – OA 18.01, OA 18.02, OA 18.03, OA 18.04  
Maria E. Arcila, Memorial Sloan Kettering Cancer Center, USA

15:25  OA 18.06: Three-Dimensional Assessment of Spread Through Air Spaces in Lung Adenocarcinoma: Insights and Implications  
Yukako Yagi, Memorial Sloan Kettering Cancer Center, USA

15:35  OA 18.07: 3D Low-Attachment Culture: A Putative Model for STAS And “Floating” Cancer Cells  
Toshiro Niki, Jichi Medical University, Japan

15:45  OA 18.08: FLI1 Circular RNAs Promote Metastasis of Small Cell Lung Cancer Cells by Direct Binding to miR-584-3p  
Jiuwei Cui, The First Hospital of Jilin University, China

15:55  OA 18.09: Discussant – OA 18.06, OA 18.07, OA 18.08  
Alain Borczuk, Albert Einstein College of Medicine/Montefiore Medical Center, USA

14:30 – 16:15  MA 20: Recent Advances in Pulmonology/Endoscopy

**TRACK:** PULMONOLOGY/ENDOSCOPY  
**ROOM:** F205 + F206 (ANNEX HALL)  
**CHAIRS:** CHOON-TAEK LEE, KOREA & SHINJI SASADA, JAPAN

14:30  MA 20.01: Fiducial Marker Placement Using Electromagnetic Navigation Bronchoscopy in the Prospective, Multicenter NAVIGATE Study  
Mark R. Bowling, East Carolina University, USA

14:40  MA 20.02: Pleural Dye Marking of Lung Nodules by Electromagnetic Navigation Bronchoscopy in the Prospective, Multicenter NAVIGATE Study  
Mark R. Bowling, East Carolina University, USA

14:50  MA 20.03: Safety of Electromagnetic Navigation Bronchoscopy in Patients with COPD: Results from the NAVIGATE Study  
Mark R. Bowling, East Carolina University, USA

14:50  OA 18.03: Genomic Profiling Reveals Hedgehog Pathway Alterations in Vismodegib Sensitive Lung Squamous Cell Carcinoma  
Siraj M. Ali, Foundation Medicine, USA

15:00  OA 18.04: Whole Genome Tumor-Normal Sequencing Reveals Potential False Positives Versus Standard CGP Sequencing in Patients with NSCLC  
Sandeep Bobby Reddy, Nant Health, USA

15:10  OA 18.05: Discussant – OA 18.01, OA 18.02, OA 18.03, OA 18.04  
Maria E. Arcila, Memorial Sloan Kettering Cancer Center, USA

15:25  OA 18.06: Three-Dimensional Assessment of Spread Through Air Spaces in Lung Adenocarcinoma: Insights and Implications  
Yukako Yagi, Memorial Sloan Kettering Cancer Center, USA

15:35  OA 18.07: 3D Low-Attachment Culture: A Putative Model for STAS And “Floating” Cancer Cells  
Toshiro Niki, Jichi Medical University, Japan

15:45  OA 18.08: FLI1 Circular RNAs Promote Metastasis of Small Cell Lung Cancer Cells by Direct Binding to miR-584-3p  
Jiuwei Cui, The First Hospital of Jilin University, China

15:55  OA 18.09: Discussant – OA 18.06, OA 18.07, OA 18.08  
Alain Borczuk, Albert Einstein College of Medicine/Montefiore Medical Center, USA
15:10 MA 20.07: Endobronchial Ultrasound Elastography: Mediastinal Staging in Non-Small Cell Lung Cancer and Technical Factors
Lokesh Yagnik, Fiona Stanley Hospital, Australia

15:15 MA 20.08: Classification of Confocal Endomicroscopy Patterns for Diagnosis of Lung Cancer
Antoni Rosell, Hospital Universitari de Bellvitge, Spain

15:20 MA 20.09: Accuracy & Utility of Systematic Mediastinal LN Staging via EBUS-TBNA in cN0/N1 NSCLC: Systematic Review & Meta-Analysis
Daniel P. Steinfort, Royal Melbourne Hospital, Australia

15:25 MA 20.10: Discussant – MA 20.06, MA 20.07, MA 20.08, MA 20.09
Jitsuo Usuda, Nippon Medical School, Japan

15:40 MA 20.11: Chronic Obstructive Pulmonary Disease Prevalence in a Lung Cancer Screening Population
John R. Goffin, McMaster University, Canada

15:45 MA 20.12: Longitudinal Evaluation of Pulmonary Function in Patients with Advanced NSCLC Treated with Concurrent Chemo-Radiotherapy
Marisol Arroyo Hernandez, Instituto Nacional de Cancerologia, Mexico

15:50 MA 20.13: ctDNA: Tumor-Derived DNA from Pleural Effusion Supernatant as a Promising Source for NGS-Based Mutation Profiling in Lung Cancer
Lin Tong, Shanghai Respiratory Research Institute, China

15:55 MA 20.14: Genotyping of Lung Cancer Using Cell-Free DNA (cfDNA) from Cytologic Supernatant (CSN)
Nicolas Marie Guibert, Dana Farber Cancer Institute, USA

16:00 MA 20.15: Discussant – MA 20.11, MA 20.12, MA 20.13, MA 20.14
Virginie Westeel, Jean-Minjoz Hospital, France

16:30 – 17:45 PL 04: Closing Plenary:
Where We Are Now, and Where We Will Be in 10 Years
ROOM: MAIN HALL
CHAIRS: HARUBUMI KATO, JAPAN & RAFAEL ROSELL, SPAIN

16:30 PL 04.01: Where We Are Now, and Where We Will Be in 10 Years: From North American Perspective
Paul A. Bunn, Jr., University of Colorado Denver Medical Campus, USA

16:50 PL 04.02: Where We Are Now, and Where We Will Be in 10 Years: From Asian Perspective
Nagahiro Saijo, Tokyo Medical University, Kinki University School Medicine, Japan

17:10 PL 04.03: Where We Are Now, and Where We Will Be in 10 Years: From European Perspective
Giorgio Vittorio Scagliotti, University of Torino, Italy

17:30 PL 04.04: WCLC 2018 – Welcome to Toronto
Andrea Bezjak, Princess Margaret Cancer Centre, Canada,
Gail Elizabeth Darling, University of Toronto, Canada,
Natasha B. Leighl, Princess Margaret Cancer Centre, Canada,
Frances A. Shepherd, Princess Margaret Cancer Centre, Canada
## POSTER SESSIONS

<table>
<thead>
<tr>
<th>Session</th>
<th>Date</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poster Session 1</td>
<td>Monday, October 16</td>
<td>124</td>
</tr>
<tr>
<td>At a Glance</td>
<td>124</td>
<td></td>
</tr>
<tr>
<td>In Detail</td>
<td>125</td>
<td></td>
</tr>
<tr>
<td>Poster Session 2</td>
<td>Tuesday, October 17</td>
<td>139</td>
</tr>
<tr>
<td>At a Glance</td>
<td>139</td>
<td></td>
</tr>
<tr>
<td>In Detail</td>
<td>140</td>
<td></td>
</tr>
<tr>
<td>Poster Session 3</td>
<td>Wednesday, October 18</td>
<td>154</td>
</tr>
<tr>
<td>At a Glance</td>
<td>154</td>
<td></td>
</tr>
<tr>
<td>In Detail</td>
<td>155</td>
<td></td>
</tr>
</tbody>
</table>
## POSTER SESSIONS | MONDAY, OCTOBER 16

### POSTERS AT A GLANCE

**Monday, October 16 | Poster Session 1**

<table>
<thead>
<tr>
<th>P1.01 ADVANCED NSCLC</th>
<th>P1.07 IMMUNOLOGY AND IMMUNOTHERAPY</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1.01-001 – P1.01-023 ALK</td>
<td>P1.07-001 – P1.07-044a IMMUNOTHERAPY (BIOMARKERS)</td>
</tr>
<tr>
<td>P1.01-024 – P1.01-045 BIOMARKERS</td>
<td></td>
</tr>
<tr>
<td>P1.01-046 – P1.01-049 EGFR</td>
<td>P1.08 LOCALLY ADVANCED NSCLC</td>
</tr>
<tr>
<td>P1.01-050 – P1.01-066 IMMUNOTHERAPY</td>
<td></td>
</tr>
<tr>
<td>P1.01-067 – P1.01-070 MISCELLANEOUS</td>
<td>P1.09 MESOTHELIOMA</td>
</tr>
<tr>
<td>P1.01-071 – P1.01-078a PRECLINICAL</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.02 BIOLOGY/PATHOLOGY</th>
<th>P1.08 LOCALLY ADVANCED NSCLC</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1.02-001 – P1.02-006 MISCELLANEOUS</td>
<td></td>
</tr>
<tr>
<td>P1.02-007 – P1.02-013 MISMATCH REPAIR AND MUTATION LOADS</td>
<td></td>
</tr>
<tr>
<td>P1.02-014 – P1.02-039 MORPHOLOGY</td>
<td></td>
</tr>
<tr>
<td>P1.02-040 – P1.02-059 OTHER MUTATIONS IN THORACIC MALIGNANCIES</td>
<td></td>
</tr>
<tr>
<td>P1.02-060 – P1.02-064 PROTEINS IN LUNG CANCER AND PROTEOMICS</td>
<td></td>
</tr>
<tr>
<td>P1.02-065 – P1.02-067 STEM CELLS IN LUNG CANCER</td>
<td></td>
</tr>
<tr>
<td>P1.02-068 – P1.02-071 TARGETS FOR TREATMENT PREDICTION</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.03 CHEMOTHERAPY/TARGETED THERAPY</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>P1.03-001 – P1.03-013 ALK</td>
<td>P1.10 NURSING/PALLIATIVE CARE/ETHICS</td>
</tr>
<tr>
<td>P1.03-014 – P1.03-049 CHEMOTHERAPY</td>
<td></td>
</tr>
<tr>
<td>P1.03-050 – P1.03-053 MISCELLANEOUS</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.04 CLINICAL DESIGN, STATISTICS AND CLINICAL TRIALS</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>P1.05 EARLY STAGE NSCLC</td>
<td></td>
</tr>
<tr>
<td>P1.05-001 – P1.05-012 MISCELLANEOUS</td>
<td></td>
</tr>
<tr>
<td>P1.05-013 – P1.05-015 NEOADJUVANT AND ADJUVANT CHEMOTHERAPY</td>
<td></td>
</tr>
<tr>
<td>P1.05-016 – P1.05-022a RECURRENCE</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.06 EPIDEMIOLOGY/PRIMARY PREVENTION/TOBACCO CONTROL AND CESSATION</th>
<th>P1.14 RADIOTHERAPY</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1.06-001 – P1.06-024 EPIDEMIOLOGY</td>
<td>P1.15 SCLC/NEUROENDOCRINE TUMORS</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.07 IMMUNOLOGY AND IMMUNOTHERAPY</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>P1.07-001 – P1.07-044a IMMUNOTHERAPY (BIOMARKERS)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.08 LOCALLY ADVANCED NSCLC</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>P1.09 MESOTHELIOMA</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.10 NURSING/PALLIATIVE CARE/ETHICS</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>P1.11 PATIENT ADVOCACY</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.11 PATIENT ADVOCACY</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>P1.12 PULMONOLOGY/ENDOSCOPY</td>
<td></td>
</tr>
<tr>
<td>P1.12-001 – P1.12-009 THERAPEUTIC ENDOSCOPY</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.13 RADIOLOGY/STAGING/SCREENING</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>P1.13-001 – P1.13-011 STAGING</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.14 RADIOTHERAPY</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>P1.15 SCLC/NEUROENDOCRINE TUMORS</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.15 SCLC/NEUROENDOCRINE TUMORS</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>P1.16 SURGERY</td>
<td></td>
</tr>
<tr>
<td>P1.16-001 – P1.16-028 MINIMAL INVASIVE SURGERY</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.16 SURGERY</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>P1.17 THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES</td>
<td></td>
</tr>
<tr>
<td>P1.17-001 – P1.17-019 THYMOMA</td>
<td></td>
</tr>
</tbody>
</table>
POSTERS IN DETAIL

Monday, October 16 | Poster Session 1

P.01.006: Effect of EML-Alk Fusion Variant and Fusion Abundance on the Efficacy of Crizotinib in Non-Small Cell Lung Cancer
Tang Feng Lv, Jinling Hospital, China

P.01.007: ALK Testing Trends and Patterns Among Community Practices in the United States
Peter B. Illei, Johns Hopkins University School of Medicine, USA

P.01.008: Real-World Patient Characteristics, Testing and Treatment Patterns of ALK+ NSCLC
Matthew A. Gubens, University of California, USA

P.01.009: Clinically Primary and Secondary Resistance to ALK Inhibitors in ALK-Positive Advanced Non-Small-Cell Lung Cancer
Jin Kang, Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

P.01.010: Circulating Cell-Free DNA of Cerebrospinal Fluid May Function as Liquid Biopsy for Leptomeningeal Metastases of ALK Rearrangement NSCLC
Yangli Li, Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

P.01.011: Pattern of Care and Survival of ALK Rearranged Non-Small-Cell Lung Cancer in Two Australian Referral Centres
Malinda Itchins, University of Sydney, Australia

P.01.012: Ceritinib in Anaplastic Lymphoma Kinase (ALK)+ NSCLC Patients Pretreated With Only Crizotinib: ASCEND-1 Subgroup Analysis
Alice Shaw, Massachusetts General Hospital, USA

P.01.013: Patient-Reported Outcomes and Safety from the Phase III ALUR Study of Alectinib vs Chemotherapy in Pre-Treated ALK+ NSCLC
Julien Mazieres, Toulouse University Hospital, France

P.01.014: Feasibility of Liquid Biopsy Using Plasma and Platelets for Detection of ALK Rearrangements in Non-Small Cell Lung Cancer
Cheol-Kyu Park, Chonnam National University Cancer Hospital, Korea

P.01.015: Crizotinib in ROS1 Rearranged or MET Deregulated Non-Small-Cell Lung Cancer (NSCLC): Final Results of the METROS Trial
Lorenza Landi, OncO Immunology Department, AUSL della Romagna, Italy

P.01.016: Next-Generation Sequencing Shows Mechanisms of Intrinsic Resistance in ALK-Positive NSCLC Patients Treated with Crizotinib
Ben J. Solomon, Peter MacCallum Cancer Centre, Australia

P.01.017: ALK-Rearranged May Promote VTE by Increasing the Expression of TF in Advanced Lung Adenocarcinoma
Qiming Wang, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, China

P.01.018: Acquired Resistance to Crizotinib in Advanced NSCLC with De Novo MET Overexpression
Anna Li, Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

P.01.019: ALK+ Non-Small Cell Lung Cancer Treated with First Line Crizotinib: Patient Characteristics, Treatment Patterns, and Survival
Claudio Martin, Fleming Institute, Argentina

P.01.020: Translocation ALK/EML4+ in Non-Squamous NSCLC Population and Crizotinib: What Can We Tell?
Ana Barroso, Centro Hospitalar Vila Nova de Gaia/Espinho, Portugal

P.01.021: FISH and IHC Discordance in ALK Rearranged Non Small Cell Lung Cancer
Akhil Kapoor, Tata Memorial Hospital, India

P.01.022: Prediction of Central Nervous System Progression During Crizotinib Treatment in ALK+ NSCLC Among Hispanics
Andrés F. Cardona, Foundation for Clinical and Applied Cancer Research - FICMAC, Colombia

P.01.023: ALK-Positive NSCLC: A TMH Experience
Vikas Taleja, Tata Memorial Hospital, India

P.01.024: Biomarkers

P.01.024: Plasma Circulating cfDNA as a Potential Biomarker in Clinical Management of NSCLC: Experience of Tata Memorial Hospital, India
Anuradha Choughule, Tata Memorial Hospital, India

P.01.025: Biomarker Testing in Advanced NSCLC: A Simulation-Based Assessment of Medical Oncologists
Tara Herrmann, Medscape Education, USA

P.01.026: Circulating miR-206 in Advanced Stage Lung Cancer Patients and Its Association with Cancer Cachexia
Noorwati Sutandyo, Dharmas National Cancer Hospital, Indonesia

WWW.IASLC.ORG

Onsite Program / IASLC 18th World Conference on Lung Cancer 125
P1.01-027: Combination of Biomarker and Clinicopathologic Characters May Circle out Beneficiaries through Second-Line Immuno-therapy: A Meta Analyse
Si-Yang Liu, Guangdong Lung Cancer Institute; Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

P1.01-028: Characteristics of Cell Free DNA in Lung Cancer Patients
Tonomori Abe, Saga University, Japan

P1.01-029: Lymphocyte Monocyte Ratio as a Prognostic Factor in Non Small Cell Lung Cancer
Tarkan Yetisgyit, Namik Kemal University Hospital, Turkey

P1.01-030: Predictive Biomarkers in Non-SmallCell Carcinoma and Their Clinical Association
Anurag Mehta, RGCI&RC, India

P1.01-031: Utilization and Timing of Foundation Medicine (FMI) Testing in U.S. Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients
Lisa Wang, Genentech, Inc, USA

P1.01-032: Detection of EGFR, ALK and Other Driver Oncogenes from Plasma cfDNA by Single Molecule Amplification and Re-se-queencing Technology (cSMART)
Tony Mok, The Chinese University of Hong Kong, Hong Kong

P1.01-033: Thrombogenic Biomarkers in Patients with NSCLC and Their Clinical Association
Luciene Schluckebier, Fundação do Câncer, de Oncologia Torácica - GBOT, Brazil

P1.01-034: Cerebrospinal Fluid and Plasma Tumor DNA Profiling Reveals Heterogeneity of CNS Metastasis in Patients with Non-Small-Cell Lung Cancer
Panwen Tian, Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, China

P1.01-035: A Next Generation Sequencing and Characteristics Based Model for Predict Clinical Benefit of Advanced NSCLC Patients
Yongchang Zhang, Hunan Cancer Hospital, China

P1.01-036: Identifying and Addressing Gaps in Molecular Testing for Patients with Lung Cancer
Jennifer C. King, Lung Cancer Alliance, USA

P1.01-037: Circulating Tumor DNA Clearance During Treatment Associates with Improved Progression-Free Survival
Shun Lu, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

P1.01-038: Identification and Characterization of Circulating Tumor Cells from Lung Cancer Patients for Selecting Target Anticancer Drugs for Relapse
Bong-Seog Kim, Veterans Health Service Medical Center, Korea

P1.01-039: Survival Impact of Next-Generation Sequencing in Lung Cancer
Smadar Geva, Thoracic Cancer Service, Davidoff Cancer Center, Rabin Medical Center, Israel

P1.01-040: Clinical Utility of Plasma-Based NGS for Advanced-Stage NSCLC Patients with Insufficient or Unavailable Tumor Tissue
Pilar Garrido, Hospital Universitario Ramón y Cajal, Spain

P1.01-041: Role of Re-Biopsy During Disease Progression Non-Small Cell Lung Cancer for Acquired Resistance Analysis and Directing Oncology Treatments
Masatoshi Kakhana, Tokyo Medical University, Japan

P1.01-042: Dynamic ctDNA Assay by Next Generation Sequencing to Guide Targeted Therapy in Advanced Non-Small Cell Lung Cancer
Xiaochun Zhang, The Affiliated Hospital of Qingdao University, China

P1.01-043: Molecular Testing for Non-Small Cell Lung Cancer in Latin American Ana Caroline Zimmer Gelatti, Grupo Brasileiro de Oncologia Torácica - GBOT, Brazil

P1.01-044: Detection of Circulating Tumor Cells Is Associated with Disease Burden in Patients with Advanced Non-Small Cell Lung Cancer
Kostas Syrigos, University of Athens, Greece

P1.01-045: Companion Diagnostic Tests for EGFR, ALK and ROS-1 vs NGS in Advanced NSCLC Patients - Which Is the Best in Terms of Cost and Effective?
Luciene Schluckebier, Fundação do Câncer, Brazil

P1.01-046 – P1.01-049

P1.01-046: The Feasibility of Osimertinib Treatment on Brain Metastases in NSCLC Patients After 1st Generation EGFR-TKI Resistance: A Preliminary Study
Lucheng Zhu, Hangzhou First People’s Hospital, Nanjing Medical University, China

P1.01-047: Analysis of EGFR Mutation Status in CSF and Blood in Lung Adenocarcinoma Patients with EGFR Mutation and CNS Metastasis
Qiming Wang, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, China

P1.01-048: Clinical Impact of EGFR Mutation on Brain Metastasis in NSCLC Patients: A Meta-Regression Analysis
Chien-Chung Lin, National Cheng Kung University Hospital, Taiwan

P1.01-049: Conformity of EGFR Mutation Status Between Blood Plasma and Tumor Tissue Samples Among NSCLC Adenocarcinoma Patients, at Dr. H. A. Rotinsulu Lung Hospital. A Preliminary Study
Reza Kurniawan Tanuwidjaja, RS Paru Dr. H. A. Rotinsulu, Indonesia

P1.01-050 – P1.01-066

P1.01-050: Cost-Effectiveness of PDL1 Based Test-And-Treat Strategy with Pembrolizumab as the 1st Line Treatment for NSCLC in Hong Kong
Herbert H. Loong, The Chinese University of Hong Kong, Hong Kong

P1.01-051: Nivolumab Versus Chemotherapy as Post-Platinum Therapy for Advanced Non–Small Cell Lung Cancer in a Real-world Setting
Edward Brian Garon, Santa Monica Hematology Oncology, USA

P1.01-052: Patient-Reported Outcomes (PROs) in OAK: A Phase III Study of Atezolizumab vs Docetaxel in Non–Small-Cell Lung Cancer (NSCLC)
Rodolfo Bondoni, Georgia Cancer Specialists and Northside Hospital Cancer Institute, USA

P1.01-053: Italian Nivolumab Expanded Access Programme (EAP): Data from Patients with Advanced Non-Squamous NSCLC and Brain Metastases
Lucio Crinò, Medical Oncology- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Italy

P1.01-054: PD-L1 Expression in Patients with Non–Small Cell Lung Cancer According to Underlying Pulmonary Disease: A Retrospective Study
Sayaka Ohara, NTT Medical Center Tokyo, Japan

P1.01-055: Spectrum of Early Progression in Advanced NSCLC Patients Treated with PD-1 Inhibitors: Identifying Markers for Poor Outcome
Mizuki Nishino, Dana-Farber Cancer Institute, USA

P1.01-056: Quality of Life and Clinical Outcomes of Nivolumab as 2+ Line Treatment in Advanced Refractory NSCLC Pts: Interim Analysis
Tatiana I. Ionova, Multinational Center for Scientific Research and Comprehensive Oncological Service “La Princesa”, Spain

P1.01-057: Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
José Miguel Sánchez-Torres, Hospital Universitario Ramón y Cajal, Spain

P1.01-058: Real World Data with Nivolumab: Experience in Argentina
Claudio Martin, Department of Clinical Oncology, Instituto Alexander Fleming, Argentina
MONDAY, OCTOBER 16 | POSTER SESSIONS

P1.01-059: Combination Pembrolizumab and Low Dose Weekly Carboplatin/Paclitaxel for Patients with Recurrent/Metastatic NSCLC and PS of 2
Tamjeed Ahmed, Wake Forest Comprehensive Cancer Center, USA

P1.01-060: Nivolumab after Progression to Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer (NSCLC)
Mariana López Flores, Complejo Asistencial Universitario de León, Spain

P1.01-061: The Efficacy and Safety of Anti-PD-1 in the Treatment of Non-Small Cell Lung Cancer (NSCLC): Systematic Review
Mingyi Di, Peking Union Medical College Hospital, China

P1.01-062: KRAS Mutations (KRAS-Mut) and antiPD1/PD1L Therapy in a Cohort of Lung Cancer (LC) Patients (P): Experience from a Single Institution
Enric Carcereny, Catalan Institute of Oncology-Hospital Germans Trias i Pujol, Spain

P1.01-063: Are the Real World Patients with Advanced Non-Small Cell Lung Cancer Represented in Phase III Immunotherapy Trials?
Ana Caroline Zimmer Gelatti, Grupo Brasileiro de Oncologia Toracica (GBOT), Brazil

P1.01-064: Efficacy and Tolerability of Nivolumab in Elderly Patients with Advanced Non-Small Cell Lung Cancer
Kohei Yamane, Tottori University Hospital, Japan

P1.01-065: Treatment Beyond Progression with Nivolumab in Patients with Advanced Non-Squamous NSCLC: Results from the Italian Expanded Access Program
Enrico Cortesi, Policlinico Umberto I, Italy

P1.01-066: PDL-1 Expression of Tumor Cell, Macrophage, and Immune Cells on Pleural Effusion
Yen-Han Tseng, Taipei Veterans General Hospital, Taiwan

P1.01-067 – P1.01-070 MISCELLANEOUS

P1.01-067: Characteristics and Survival Rate of Non-Small Cell Lung Cancer in Patients 45 Years of Age or Younger
Noorwati Sutandyo, Dharmas National Cancer Hospital, Indonesia

P1.01-068: Impact of Case-Based CME on Physician Performance in the Diagnosis and Management of NSCLC
Martin P. Barr, St. James’s Hospital & Trinity College Dublin, Ireland

P1.01-069: Clinical Experience with IBM Watson for Oncology (WFO) Cognitive System for Lung Cancer Treatment in China
Xiaohua Zhang, The Affiliated Hospital of Qingdao University, China

P1.01-070: BIW-8962, an Anti-GM2 Ganglioside Monoclonal Antibody, in Advanced/Recurrent Lung Cancer: A Phase I/II Study
Joo-Hang Kim, Yonsei Cancer Center, Korea

P1.01-071 – P1.01-078a PRECLINICAL

P1.01-071: High Dose IV AA Synergy with mEHT in Patients with Stage III-IV NSCLC: A Phase I Study
Junwen Ou, Clifford Hospital, China

P1.01-072: Epithelial-To-Mesenchymal Transition (EMT) in Lung Cancer: Classic Reproduction
Huibin Liu, Affiliated Hospital of Xining Medical University, Xuzhou, China

P1.01-073: Over-Expression of GGPPs Contributes to Tumor Metastasis and Correlates with Poor Prognosis of Lung Adenocarcinoma
Qingdong Song, Jinling Hospital, China

P1.01-074: Exosomal RNA-Profilng of Lung Pleural Effusions Identifies Adenocarcinoma Patients through Elevated miR-200 Expression
Per Hydbring, Karolinska Institutet, Sweden

P1.01-075: Simultaneous Multiplex Profiling of Gene Fusions, METEx4 Mutations and Immune Genes in Advanced NSCLC by NCounter Technology
Noemi Reguart, Hospital Clinic, Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain

P1.01-076: Comparison of PANA MutypeR and PNA Clamping for Detecting KRAS Mutations in Tumor Tissue, Cell Block and Pleural Effusion from Cancer
Chan Kwon Park, The Catholic University of Korea, Korea

P1.01-077: Oncogenic Potential of a Novel HER2 755PL In-Frame (HER2PL) Mutation in Lung Adenocarcinoma
Anya Maan-Yuh Lin, Institute of Pharmacology, National Yang-Ming University, Taiwan

P1.01-078: Longitudinal Studies of Quality of Life in Advanced Non-Small Cell Lung Cancer Patients Undergoing First-Line Target Therapy
Lin Zhi Xuan, Chi Mei Medical Center, Liouying, Taiwan

P1.01-078a: The Construction and Clinical Application of an Integrated Microfluidic Device for CTCs Detection in Patients with NSCLC
Qi Wang, The Second Affiliated Hospital, Dalian Medical University, China

P1.01-079: Over-Expression of GGPPs Contributes to Tumor Metastasis and Correlates with Poor Prognosis of Lung Adenocarcinoma
Qingdong Song, Jinling Hospital, China

P1.01-080: Expression of Mismatch Repair Proteins Associates with Survival and Reproduction of Cardiac Damage by NAD-Modulation
Yen-Han Tseng, Taipei Veterans General Hospital, Taiwan

P1.01-081: TP53 and DNA-Repair Gene Polymorphisms as Risk Factors for the Development of Advanced Lung Adenocarcinoma in Serbia
Jelena Spasic, Institute for Oncology and Radiology of Serbia, Serbia

P1.01-082: Expression of Mismatch Repair Proteins Associates with Survival and Response to EGFR Tyrosine Kinase Inhibitors in Lung Adenocarcinoma Patients
Hsiang-Ling Ho, Taipei Veterans General Hospital, Taiwan

P1.01-083: Accumulation of Mutations in Background Normal Lung Tissue Constitutes a Major Lung Cancer Risk
Emi Kubo, National Cancer Center Japan, Japan

P1.02 BIOLOGY/PATHOLOGY

P1.02-001 – P1.02-006 MISCELLANEOUS

P1.02-001: SLFN11 Expression in Early Stage Non-Small Cell Lung Cancer Predicts Benefit from Adjuvant Chemotherapy with Taxane and Platinum
Vamsidhar Velcheti, Cleveland Clinic, USA

P1.02-002: Diagnostic Utility of MUC4 Expression to Differentiate Epithelioid Mesothelioma from Lung Adenocarcinoma and Squamous Cell Carcinoma
Vishwa Jeet Amatya, Graduate School of Biomedical & Health Sciences, Hiroshima University, Japan

P1.02-003: Prevention of Adriamycin-induced Cardiac Damage by NAD-Modulation: Prevention of Adriamycin-induced Cardiac Damage by NAD-Modulation
Sei-Hoon Yang, Wonkwang University Hospital, Korea

P1.02-004: Long Non-Coding RNA XLOC_000990 Promotes Lung Cancer Migration Through Modulation of mir-4505
Bin Zhang, Tianjin Medical University Cancer Institute and Hospital, China

P1.02-005: Solving the Interfering Problem of Tissue Embedding OCT Compound in Activity Based Multiplex Profiling of Tyrosine Kinase Substrates
Sven Hilinger, University Hospital, Switzerland

P1.02-006: Arsenic Promotes Persistent Alterations in the Lung PiRNA Transcriptome to Target Epigenetic Pathways
Victor D. Martinez, BC Cancer Research Centre, Canada

P1.02-007 – P1.02-013 MISMATCH REPAIR AND MUTATION LOADS

P1.02-007: TP53 and DNA-Repair Gene Polymorphisms as Risk Factors for the Development of Advanced Lung Adenocarcinoma in Serbia
Jelena Spasic, Institute for Oncology and Radiology of Serbia, Serbia

P1.02-008: Expression of Mismatch Repair Proteins Associates with Survival and Response to EGFR Tyrosine Kinase Inhibitors in Lung Adenocarcinoma Patients
Hsiang-Ling Ho, Taipei Veterans General Hospital, Taiwan

P1.02-009: Accumulation of Mutations in Background Normal Lung Tissue Constitutes a Major Lung Cancer Risk
Emi Kubo, National Cancer Center Japan, Japan

P1.02-010: Novel Role of hSSB2 in the Base Excision Repair Pathway (BER)
Mark Adams, Queensland University of Technology, Australia

P1.02-011: XRCG6BP1: A Key Player in the DNA Repair of Cisplatin Resistant NSCLC Cells
Martin P. Barr, St. James’s Hospital & Trinity College Dublin, Ireland

P1.02-012: Profiling DNA Repair in Lung Cancer
Alexander Dobrovic, Olivia Newton-John Cancer Research Institute, Australia
P1.02-013: ATM Mutation as a Predictor for Mutation Burden in NSCLC
D. Gwyn Bebb, University of Calgary, Canada

P1.02-014 – P1.02-039
MORPHOLOGY

P1.02-014: TGFalpha Promotes Growth of Lung Tumors Carrying EGFR Mutation but not KRAS Mutation in Transgenic Mouse Models in Vivo
Koichi Tomoshige, Cincinnati Children’s Hospital Medical Center, USA

P1.02-015: Comparison of Study Models of Lung Cancer
Yoshito Yamada, University Hospital Zurich, Switzerland

P1.02-016: Establishment of Lung Adenocarcinoma Organoid Cultures
Hirotugu Notsuda, University Health Network, Canada

P1.02-017: Freely Floating Cancer Cells in Lymph Node Sinuses of Hilar Lymph Node Positive Lung Cancer Patients
Yusuke Nakamura, Tokai University Hachioji Hospital, Japan

P1.02-018: Number of Cancer Cells in Lung Adenocarcinoma Specimen - Correlation with Noguchi's Classification, WHO Pathologic Type, and Prognosis
Takahiro Inoue, Dokkyo Medical University, Japan

P1.02-019: Dual Role of Notch in Lung Cancer
Sara Siciripi-Yao, The Ohio State University, USA

P1.02-020: Acinar-Predominant Pattern Correlates with Poorer Prognosis in Invasive Mucinous Adenocarcinoma of the Lung
Gengpeng Lin, The First Affiliated Hospital of Sun Yat-sen University, China

P1.02-021: Can 18F-FDG PET/CT Predict the Pathological Necrosis and Microvessel Density in Lung Adenocarcinomas
Young Wha Koh, Ajou University School of Medicine, Korea

P1.02-022: Spontaneous Regression of Primary Pulmonary Synovial Sarcoma: A Case Report
Naoko Miyata, Tokyo Medical University Hachioji Medical Center, Japan

P1.02-023: TGF-β Signaling Mediated by Fibroblasts is Associated with the Histological Subtypes of Lung Adenocarcinoma
Ryo Sato, Keio University, Japan

P1.02-024: Correlation of Maximall Tumor Diameter between Pathology Specimen and CT in Nonsmall Cell Lung Cancer: A Pilot Study
Hee Sungr Park, Gangnam Severance Hospital, Korea

P1.02-025: A Case of Primary Peripheral Epithelial–Myoepithelial Carcinoma of the Lung
Daisuke Eriguchi, Tokyo Medical University Hachioji Medical Center, Japan

P1.02-026: The Characteristics of Lymph Node Metastasis in Resected Adenocarcinoma of Lung Cancer
Xuuy Cai, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, China

P1.02-027: Minute Pulmonary Meningothelial-Like Nodules Presenting as Multiple Ground-Glass Density Nodules (GGNs): A Case Report
Yeon Bi Han, Department of Pathology Seoul National University Bundang Hospital, Korea

P1.02-028: Pathways Involved in Early Stage Lung Cancers
Vilde D. Haakensen, Oslo University Hospital, Norway

P1.02-029: Pulmonary Adenofibroma with Cystic Change: A Case Report
Eunhyang Park, Seoul National University Bundang Hospital, Korea

P1.02-030: The Effect of Chronic Obstructive Pulmonary Disease on the Tumor Stroma in Non-Small Cell Lung Cancer
Yasuhiro Ohshio, Shiga University of Medical Science, Japan

P1.02-031: Clinicopathological Study of 16 Cases with Pulmonary Pleomorphic Carcinoma
Fumi Ohawa, Maebashi Red Cross Hospital, Japan

P1.02-032: Clinicopathological Profile of Invasive Mucinous Adenocarcinoma Based on Evaluation of Invasive Components
Yuichi Mitsu, Osaka General Medical Center, Japan

P1.02-033: Differentiating of Cytomorphological Characteristics in Non-Small Cell Lung Cancer Predicts Value of Radiologic Features
Korin University School of Medicine, Japan

P1.02-034: Non-Invasive Qualitative Diagnosis of Lung Cancer Enabled by Spectrum Analysis of Ultrasound
Takashi Anayama, Kochi Medical School, Kochi University, Japan

P1.02-035: Human Papillomavirus Infection in Lung Squamous Cell Carcinoma and Correlation to p16 INK4a Expression from an Argentine Population
Valeria Cecilia Denninghoff, Centro de Educación Médica e Investigaciones Clínicas (CEMIC-CONICET), Argentina

P1.02-036: Fine Needle Aspiration as a Diagnostic Tool in Lung Cancer: Worth Pursuing?
Luiz H. Araujo, Instituto Nacional de Cancer (INCA), Brazil

P1.02-037: Pulmonary Carcinoid Tumors: A Prognostic Implications of Ki-67 Proliferative Index
Renata Langfort, National Institute of Tuberculosis and Lung Diseases, Poland

P1.02-038: Bilateral Combined Lymphangiomyomatosis and Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia with Typical Carcinoids
Jan Hinrich Von Der Thuesen, Erasmus MC, Netherlands

P1.02-039: Main Bronchus Location Is a Predictor for Metastasis and Prognosis in Lung Adenocarcinoma: A Large North American Cohort Analysis
Lin Yang, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, China

P1.02-040 – P1.02-059
OTHER MUTATIONS IN THORACIC MALIGNANCIES

P1.02-040: Genetic Risk Evaluation in Families with Lung Cancer History in High Lung Cancer Mortality Region of Xuanwei, China
Madhita Kanwal, Kunming Institute of Zoology, Chinese Academy of Sciences, China

P1.02-041: Mutation of SWI/SNF Complex Genes Is Frequent in Poorly Differenitated, Mesenchymal-Like Lung Cancer without Major Driver Mutation
Toshiyoshi Yoshimoto, Jichi Medical University, Japan

P1.02-042: Circadian Clock Gene Per2 Over-Expression Inhibits Tumor Progression in Human Non-Small Cell Lung Cancer
Li Qiang, Sichuan Cancer Hospital-Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, China

P1.02-043: A Comparison of Consistency of Detecting BRAF Gene Mutations in Peripheral Blood and Tumor Tissue of Non-Small-Cell Lung Cancer Patients
Gang Chen, Fujian Provincial Cancer Hospital, China

P1.02-044: Relationship between RET Rearrangement and Thymidylate Synthase mRNA Expression in Non-Small Cell Lung Cancer Tissues
Gang Chen, Fujian Provincial Cancer Hospital, China

P1.02-045: PIK3CA Mutations in Chinese Patients with Non-Small-Cell Lung Cancer
Meiyu Fang, Zhejiang Cancer Hospital, China

P1.02-046: Mutational Subtypes and Prognosis of Non-Small-Cell Lung Cancer Harboring HER2 Mutations
Gang Chen, Fujian Provincial Cancer Hospital, China

P1.02-047: Mutational Features and Prognosis of Non-Small-Cell Lung Cancer Harboring RAS Mutations
Meiyu Fang, Zhejiang Cancer Hospital, China
**P1.02-048**: Somatic Mutation Analysis of RB1 Gene in Chinese Non-Small Cell Lung Cancer Patients
Meiyu Fang, Zhejiang Cancer Hospital, China

**P1.02-049**: Detection of CDKN2A Gene Mutations in Patients with Non-Small Cell Lung Cancer Patients
Meiyu Fang, Zhejiang Cancer Hospital, China

**P1.02-050**: Pan-Can Analysis of miRNAs at the Imprinted Chromosome 14q32 Locus Reveals a Unique Pattern of Deregulation in NSCLC
Jhon Ralph Enterina, British Columbia Cancer Research Centre, Canada

**P1.02-051**: Ultra-Deep Sequencing Depicts the Genomic Landscape of Ground-Glass Nodules in Early Stage Lung Adenocarcinoma
Hongwei Duan, Beijing Institute of Genomics, Chinese Academy of Sciences, University of Chinese Academy of Sciences, China

**P1.02-052**: Identification of DAB2 and Intelectin-1 as Novel Positive Immunohistochemical Markers of Epithelioid Mesothelioma
Masatugu Kuraoka, Hiroshima University Graduate School of Biomedical and Health Sciences, Japan

**P1.02-053**: A New Strategy of Adjuvant Chemotherapy for Lung Cancer Based on the Expression of Anti-Aging Gene Klotho
Kyo shiro Takegahara, Nippon Medical School Hospital, Japan

**P1.02-054**: The Molecular Characterisation of Lung Adenocarcinoma Subgroups
Elizabeth Starren, Imperial College London and the Royal Brompton and Harefield NHS Trust, UK

**P1.02-055**: Genotyping Squamous Cell Lung Carcinoma Among Hispanics (Geno1.1-CLI-CAp)
Andrés P. Cardona, Foundation for Clinical and Applied Cancer Research - FICMAC, Colombia

**P1.02-056**: BRAF Non-V600E Mutations Recurrently Found in Non-Small Cell Lung Cancer in Chinese Patients
Meiyu Fang, Zhejiang Cancer Hospital, China

**P1.02-057**: Analysis of C-MET Amplification Non-Small Cell Lung Cancer Cell Blocks from Pleural Effusion
Gang Chen, Fujian Provincial Cancer Hospital, China

**P1.02-058**: Molecular Characteristics and Outcome of Chinese Patients with Non-Small Cell Lung Cancer Harboring NFE2L2 Mutations
Gang Chen, Fujian Provincial Cancer Hospital, China

**P1.02-059**: Molecular Characteristics of SMARCA4 Mutations Detection in Chinese Non-Small Cell Lung Cancer Patients
Gang Chen, Fujian Provincial Cancer Hospital, China

**P1.02-060**: Podoplanin Expression in Cancer-associated Fibroblasts Predicts Poor Prognosis in Patients with Squamous Cell Carcinoma of the Lung
Yoo Hei Yurugi, Tottori University, Faculty of Medicine, Japan

**P1.02-061**: Podoplanin Expression in Cancer-Associated Fibroblasts Predicts Unfavorable Prognosis in Patients with Stage IA Adenocarcinoma
Yasuki Kubouchi, Tottori University, Faculty of Medicine, Japan

**P1.02-062**: Ring Finger Protein 38 Promote Non-Small Cell Lung Cancer Progression by Endowing Cell EMT Phenotype
Jian-Yong Ding, Zhongshan Hospital, Fudan University, China

**P1.02-063**: Tumor Heterogeneity Analyses by Integrated Proteo-Genomics of Thoracic Tumors from Sequential Biopsies and Warm Autopsies
Udayan Guha, Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, NCI, NIH, USA

**P1.02-064**: Proteomic Analysis of Exosome Purified Using a Novel Reagent
Ayako Kurimoto, Fujirebio Inc., Japan

**P1.02-065** – **P1.02-067**: STEM CELLS IN LUNG CANCER

**P1.02-065**: Histone Deacetylase Inhibition Alters Stem Cell Phenotype in Gefitinib-Resistant Lung Cancer Cells with EGFR Mutation
Fariz Nurwidy, Universitas Indonesia, Indonesia

**P1.02-066**: Cancer Stem Cells in Pulmonary High Grade Neuroendocrine Carcinoma: a Series of 23 Cases from Eastern India Prasanta Rabhab Mohapatra, All India Institute of Medical Sciences, India

**P1.02-067**: FGFI and IGF1 Co-Stimulation Promoted the Amplification and Cancer Stemness of Lung Cancer Cells under 3D Culture Condition
Ru Zhang, Tianjin Medical University Cancer Institute & Hospital, China

**P1.02-068** – **P1.02-071**: TARGETS FOR TREATMENT PREDICTION

**P1.02-068**: Effects of Pirfenidone Targeting EMT and Tumor-Stroma Interaction as Novel Treatment for Non-Small Cell Lung Cancer
Ayako Fujiiwara, Osaka National Hospital, Japan

**P1.02-069**: Pemetrexed-Resistant Non-Small Cell Lung Cancer Cell Lines Have Novel Drug-Resistant Mechanisms
Ryosuke Tanino, Shimane University, Japan

**P1.02-070**: Identification of Lung Cancer Specific Differentially Methylated Regions Using Genome-Wide DNA Methylation Study
Yoonki Hong, Kangwon National University Hospital, Korea

**P1.02-071**: SFN Stabilizes Oncoproteins through Binding with SKP1 to Block SCFFBW7 Ubiquituting Ligase
Jeongmin Hong, University of Tsukuba, Japan

**P1.03 CHEMOTHERAPY/TARGETED THERAPY**

**P1.03-001** – **P1.03-013**: ALK

**P1.03-001**: Verification and Implementation of the VENTANA Anti-ALK D5F3 Antibody in Detecting ALK Rearrangement in NSCLC
Haider Al-Najjar, Central Manchester University Hospitals NHS Foundation Trust, UK

**P1.03-002**: Crizotinib-Associated Toxic Epidermal Necrolysis in an ALK-Positive Advanced NSCLC Patient
Shao Yu Yang, Hangzhou First People’s Hospital, China

**P1.03-003**: Clinical Implications of an Analysis of Crizotinib Pharmacokinetics Co-Administered with Dexamethasone in Patients with NSCLC
Swan Lin, University of California, San Diego, USA

**P1.03-004**: Alectinib for Patients with ALK Rearrangement–Positive Non-Small Cell Lung Cancer and a Poor Performance Status
Hirotsugu Kenmotsu, Shizuoka Cancer Center, Japan

**P1.03-005**: Phase 2 Study of Ceritinib in Patients with ALK+ NSCLC with Prior Alectinib Treatment in Japan: ASCEND-9
Hidehito Horinouchi, National Cancer Center Hospital, Japan

**P1.03-006**: Clinicopathological Features and Poor Outcome for ALK Inhibitors of Squamous Cell Lung Cancer with ALK-Rearrangement
Hiroaki Motomura, Juntendo University Faculty of Medicine & Graduate School of Medicine, Japan

**P1.03-007**: A Real-World Study of Clinicopathological Characteristics and Survival Outcome in Advanced ALK-Positive Non-Small-Cell Lung Cancer
Xiao Hu, Zhejiang Cancer Hospital, China

**P1.03-008**: Analysis of Data on Interstitial Lung Disease Onset and Its Risk Following Treatment of ALK-positive NSCLC with Xalkori
Akihiko Gemma, Graduate School of Medicine, Nippon Medical School, Japan
P1.03-009: A Lung Adenocarcinoma with a STRN-ALK Rearrangement Was Poorly Responsive to Alectinib Treatment
Yuko Iida, Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Japan

P1.03-010: Efficacy and Safety of Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors in ALK-Positive Non-Small Cell Lung Cancer
Reina Imase, Hiratsuka Kyosai Hospital, Japan

P1.03-011: Clinical Outcomes Correlated with Percentage of Positive Anaplastic-Lymphoma Kinase Cells Tested by PISH Analysis in NSCLC
Katy Louise Clarke, Leeds Cancer Centre, UK

P1.03-012: Using Computational Modeling to Simulate Clinical Response of ALK Inhibitors to G1202R ALK and Possible Mechanisms of Resistance
Chien-Ting Liu, Kaohsiung Chang Gung Memorial Hospital, Taiwan

P1.03-013: Monitoring of ALK Fusions and Mutations in Advanced ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Laura Mezquita, Gustave Roussy, France

P1.03-014 – P1.03-049

CHEMOTHERAPY

P1.03-014: Saline Alone vs Saline plus Mannitol Hydration for the Prevention of Acute Cisplatin Nephrotoxicity: A Randomized Trial
Wilfred Dela Cruz, San Antonio Military Medical Center, USA

P1.03-015: The Relationship between the UGT1A1*27 and UGT1A1*7 Genetic Polymorphisms and Irinotecan-Related Toxicities in Patients with Lung Cancer
Minoru Fukuda, Nagasaki University Hospital, Japan

P1.03-016: Video-Theracoscopic Pulmonary Resection Avoids Delay and Increase Adjuvant Chemotherapy Compliance for Non-Small Cell Lung Carcinoma
Akin Ozturk, Suvreyapasa Thoracic and Thoracic Surgery Training and Research Hospital, Turkey

P1.03-017: Benzyl Isothiocyanate Induces Protective Autophagy in Human Lung Cancer Cells through Endoplasmic Reticulum Stress-Mediated Mechanism
Ke Xu, Tianjin Medical University General Hospital, China

P1.03-018: Effectiveness of Supportive Care Drugs in Lung Cancer Patients Undergoing 1st Line Chemotherapy in a Resource Limited Setting
Digambar Behera, Postgraduate Institute of Medical Education and Research (PGIMER), India

P1.03-019: Soraphoridine Inhibits Lung Cancer Cell Proliferation through Activating Hippo Signaling and P53 Pathway
Jiangping Xiong, The First Affiliated Hospital of Nanchang University, China

P1.03-020: Detection of Hypoxia Using EF5 PET/CT in 10 Patients with Advanced NSCLC Receiving Chemotherapy with and without Bevacizumab
Frederic Lacroix-Poisson, BC Cancer Agency, Canada

P1.03-021: A Prospective Observational Study to Evaluate Incidence of Thromboembolic Events during Platinum Based Chemotherapy in Lung Cancer
Vikas Talreja, Tata Memorial Hospital, India

P1.03-022: A Phase 1B Study of TRC105 in Combination with Paclitaxel/Carboplatin and Bevacizumab in Patients with Stage 4 Non-Squamous Cell Lung Cancer
Francisco Robert, University of Alabama - Birmingham, USA

P1.03-023: The Real-World Practice of Bevacizumab Plus Chemotherapy in Stage IV Adenocarcinoma: A Single Institute Experience
Yen-Hao Chen, Kaohsiung Chang Gung Memorial Hospital, Taiwan

P1.03-024: Efficacy of Carboplatin-Vinorelbine in Advanced NSCLC Patients at Perusahaan Hospital, Jakarta - Indonesia
Putu Ayu Diah, Department of Pulmonology and Respiratory Medicine, Indonesia

P1.03-025: Combination Therapy with Carboplatin and Hypericin Synergistically Enhances Suppression of Benzo[a]Pyrene Induced Lung Cancer
Sang Haak Lee, St. Paul’s Hospital, Catholic University of Korea, Korea

P1.03-026: Interim Results of a Phase I Study of Nivolumab plus Nab-Paclitaxel/Carboplatin in Patients with NSCLC
Jonathan W. Goldman, University of California at Los Angeles, USA

P1.03-027: Randomized Phase 2 Study Comparing CBDA+PTX+BEV and CDDP+PEM+BEV in Treatment-Naive Advanced Non-Sq NSCLC (CLEAR Study)
Shinji Atagi, National Hospital Organization Kinki-chuo Chest Medical Center, Japan

P1.03-028: A Phase II Trial of Alumim-Bound Paclitaxel and Gemcitabine in Patients with Untreated Stage IV Squamous Cell Lung Cancers
Paul K. Paik, Memorial Sloan Kettering Cancer Center, USA

P1.03-029: Study of Plasma Homocysteine as a Marker of Toxicity and Depression in Patients Treated with Pemetrexed-Based Chemotherapy
Mary O’Brien, Royal Marsden Hospital NHS Foundation Trust, UK

P1.03-030: Prognostic Impact of the Presence of COPD in Patients with NSCLC under Cisplatin for Completely Resected Non-Small Cell Lung Cancer
Koji Teramoto, Shiga University of Medical Science, Japan

P1.03-031: Adherence and Feasibility of 2 Treatment Schedules of S-1 as Adjuvant Chemotherapy in Completely Resected Lung Cancer
Takaharu Kiriyabashi, Division of Chest Surgery (Ohashi), Toho University School of Medicine, Japan

P1.03-032: Observation of Durative Infusion Endostar Combined with Chemotherapy Within Vascular Normalization Period in Advanced NSCLC
Chen Tian, Jiangsu Cancer Hospital, China

P1.03-033: Long-Term Outcome of Histoculture Drug Response Assay Guided Adjuvant Chemotherapy in Patients with Non-Small Cell Lung Cancer
Yoshimitsu Hirai, Wakayama Medical University, Japan

P1.03-034: Therapeutic Effect of Novel Leucyl-IRNA Synthetase Inhibitor, B1206, in Non-Small Cell Lung Cancer
Eun Young Kim, Yonsei University College of Medicine, Korea

P1.03-035: Efficacy of Nintedanib and Docetaxel in Combination with the Nutraceutical Use of Silibinin in Advanced NSCLC
Joaquim Bosch Barrera, Catalan Institute of Oncology. Hospital Universitari Dr. Josep Trueta, Spain

P1.03-036: Adjuvant Chemotherapy with Uracil-Tegafur for Pathological T1aN0M0 Lung Adenocarcinoma with Lymphatic Vessel Invasion
Yoshitaka Kitamura, Hyogo Cancer Center, Japan

P1.03-037: A Phase II Study of Adjuvant Chemotherapy with Docetaxel plus Nedaplatin for Completely Resected Non-Small Cell Lung Cancer
Koji Teramoto, Shiga University of Medical Science, Japan

P1.03-038: A Phase I Trial of Aflatinib and Bevacizumab in Untreated Patients with Advanced NSCLC Harboring EGFR-Mutations: OLCSLG1404
Shouchi Kyayama, NHO Iwakuni Clinical Center, Japan

P1.03-039: Therapeutic Inhibition of the Cancer Stem Cell Marker, ALDH1, a Promising Mechanism by Which Cisplatin Sensitivity Can Be Restored in NSCLC
Martin P. Barr, St. James’s Hospital & Trinity College Dublin, Ireland

P1.03-040: Smokers Having Activating EGFR Mutant Non-Small Cell Lung Cancer Might Benefit from EGFR-TKI Treatment - Single Center Experience
Perran Fulden Yumuk, Marmara University Medical School, Marmara University Pendik Training & Research Hospital, Turkey

P1.03-041: Exploitation of the Cancer Stem Cell Marker ALDH1 Within the Vitamin a/ Retinoic Acid Axis Promotes Re-Sensitisation of Cisplatin Resistant NSCLC
Martin P. Barr, St. James’s Hospital & Trinity College Dublin, Ireland
P1.03-042: BB608, a Small Molecule Stemness Inhibitor, Circumvents Cisplatin Resistance in NSCLC
Martin P. Barr, St. James’s Hospital & Trinity College Dublin, Ireland

P1.03-043: 30-Day Mortality Following Systemic Anti-Cancer Treatment for NSCLC at a Single Canadian Cancer Centre
Gwyn Bebb, Alberta Health Services, Canada

P1.03-044: Exploratory Analysis of Lung Cancer Patients in a Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) plus Gemcitabine
Lyudmila Bazhenova, University of California San Diego, Moores Cancer Center, USA

P1.03-045: HER-2 Mutation Is Not a Prognostic Factor Treated with First-Line Platinum-Based Chemotherapy Small Cell Lung Cancer Patients: The ARPA Study
Enrica Capelletto, Department of Oncology, University of Turin, Italy

P1.03-046: A Retrospective Analysis of Correlation Between Cytokines in TME and Therapeutic Effect of Advanced Lung Cancer Chemotherapy in China
Chunxiu Su, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

P1.03-047: Carboplatin/Weekly Nab-PTX in Elderly Patients with Previously Untreated Advanced Squamous NSCLC Selected Based on MNA-SF
So Takata, Osaka Habikino Medical Center, Japan

P1.03-048: miR-34a and the Micromanagement of Cancer Stemness and Resistance in NSCLC. Does It Hold Therapeutic Benefit? Martin P. Barr, St. James’s Hospital & Trinity College Dublin, Ireland

P1.03-049: Phase II Study of S-1 plus Bevacizumab Combination Therapy for Patients Previously Treated for Non-Squamous Non-Small Cell Lung Cancer
Kentaro Masuhiro, Osaka Habikino Medical Center, Japan

P1.03-050: Clinical Consequences, Quality of Life, and Management of Neutropenic NSCLC Patients in the REVEL Trial
David S. Ettinger, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, USA

P1.03-051: Development of a Novel Microfluidic Device for Studying the Chemotaxis Mechanism of Bacterial Cancer Targeting Qi Wang, The Second Affiliated Hospital of Dalian Medical University, China

P1.03-052: Comparing EGFR-TKI with EGFR-TKI plus Chemotherapy as 1st Line Treatment in Advanced NSCLC Patients with Both Mutated EGFR and Bim Polymorphism
Yayi He, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

P1.03-053: Taiwan Real World Efficacy of 1st Line EGFR TKIs Treatment in EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
Chih-Yen Tu, China Medical University, Taiwan

P1.03-054: Exploratory Analysis of Lung Cancer Patients in a Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) plus Gemcitabine
Lyudmila Bazhenova, University of California San Diego, Moores Cancer Center, USA

P1.03-055: Osimertinib with Ramucirumab or Necitumumab in Advanced T790M-positive EGFR-Mutant NSCLC: Preliminary Ph1 Study Results
Helena Yu, Memorial Sloan Kettering Cancer Center, USA

P1.03-056: Phase Ib Study of Nivolumab and Velparib in Advanced Solid Tumors and Lymphoma with and without Alterations in Selected DNA Repair Genes
Wade Thomas Iams, McGaw Medical Center of Northwestern University, USA

P1.03-057: Phase 2 Study of Nivolumab and Metformin in Advanced Non-Small Cell Lung Cancer with and without Prior Treatment with PD-1/PD-L1 Inhibitors
Wade Thomas Iams, McGaw Medical Center of Northwestern University, USA

P1.03-058: Rovalpituzumab Tesirine vs Topotecan in Patients with Advanced Small Cell Lung Cancer Following 1st Line Chemotherapy
Philip Komarnitsky, AbbVie Inc., USA

P1.03-059: Rovalpituzumab Tesirine Maintenance Therapy Following 1st Line Platinum-Based Chemotherapy Small Cell Lung Cancer
Philip Komarnitsky, AbbVie Inc., USA

P1.03-060: POSEIDON: A Phase 3 Study of First-Line Durvalumab ± Tremelimumab + Chemotherapy vs Chemotherapy Alone in Metastatic NSCLC
Tony Mok, The Chinese University of Hong Kong, Hong Kong

P1.03-061: The First Study of BBSKE in Non-Small Cell Lung Cancer Treated Patients With Non-Small Cell Lung Cancer in Asia
Shun Lu, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

P1.03-062: Development of Novel Blood-Based Biomarker Assays in 1L Advanced/Metastatic NSCLC: Blood First Assay Screening Trial (BFAST)
Tony Mok, Chinese University of Hong Kong, Hong Kong

P1.03-063: Phase 1b Multi-Indication Study of the Antibody Drug Conjugate Anetumab Radvansine in Patients with Mesothelin-Expressing Advanced or Recurrent Malignancies
Alex Adjei, Mayo Clinic, USA

P1.04 – P1.04-042 CLINICAL DESIGN, STATISTICS AND CLINICAL TRIALS

P1.04-001: Osimertinib with Ramucirumab or Necitumumab in Advanced T790M-positive EGFR-Mutant NSCLC: Preliminary Ph1 Study Results
Helena Yu, Memorial Sloan Kettering Cancer Center, USA

P1.04-002: Tolerability of Osimertinib and Its Impact on Quality of Life in Advanced Non-Small Cell Lung Cancer Patients: The ARPA Study
Enrica Capelletto, Department of Oncology, University of Turin, Italy

P1.04-003: The International Lung Screen Trial: A Multi-Centre Study to Evaluate LDCT Screening Selection Criteria and Nodule Management
Kuan Pin Lim, Sir Charles Gairdner Hospital, Australia

P1.04-004: Phase I/ib Study of Nivolumab and Velparib in Advanced Solid Tumors and Lymphoma with and without Alterations in Selected DNA Repair Genes
Wade Thomas Iams, McGaw Medical Center of Northwestern University, USA

P1.04-005: Phase 2 Study of Nivolumab and Metformin in Advanced Non-Small Cell Lung Cancer with and without Prior Treatment with PD-1/PD-L1 Inhibitors
Wade Thomas Iams, McGaw Medical Center of Northwestern University, USA

P1.04-006: Rovalpituzumab Tesirine vs Topotecan in Patients with Advanced Small Cell Lung Cancer Following 1st Line Chemotherapy
Philip Komarnitsky, AbbVie Inc., USA

P1.04-007: Rovalpituzumab Tesirine Maintenance Therapy Following 1st Line Platinum-Based Chemotherapy Small Cell Lung Cancer
Philip Komarnitsky, AbbVie Inc., USA

P1.04-008: POSEIDON: A Phase 3 Study of First-Line Durvalumab ± Tremelimumab + Chemotherapy vs Chemotherapy Alone in Metastatic NSCLC
Tony Mok, The Chinese University of Hong Kong, Hong Kong

P1.04-009: The First Study of BBSKE in Non-Small Cell Lung Cancer Treated Patients With Non-Small Cell Lung Cancer in Asia
Shun Lu, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

P1.04-010: CheckMate 870: An Open-label Safety Study of Nivolumab in Previously Treated Patients With Non-Small Cell Lung Cancer in Asia
Shun Lu, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

P1.04-011: Development of Novel Blood-Based Biomarker Assays in 1L Advanced/Metastatic NSCLC: Blood First Assay Screening Trial (BFAST)
Tony Mok, Chinese University of Hong Kong, Hong Kong

P1.04-012: A Phase 1b Dose-Escalation Study of TRC105 in Combination with Nivolumab in Patients with Metastatic Non-Small Cell Lung Cancer
Francisco Robert, University of Alabama - Birmingham, USA

P1.04-013: Phase 1b Multi-Indication Study of the Antibody Drug Conjugate Anetumab Radvansine in Patients with Mesothelin-Expressing Advanced or Recurrent Malignancies
Alex Adjei, Mayo Clinic, USA

P1.05 – P1.05-001 EARLY STAGE NSCLC

P1.05-001: Microwave Ablation plus Recombinant Human Endostatin (Endostar) versus Microwave Ablation Alone in Inoperable Stage I Non Small Lung Cancer
Guanghui Huang, Shandong Provincial Hospital Affiliated to Shandong University, China

P1.05-002: Characteristics and Prognosis of Ground Glass Opacity Predominant Primary Lung Cancer Larger Than 3.0 Cm on Thin-Section Computed Tomography
Shigeki Suzuki, National Cancer Center Hospital, Japan

P1.05-003: Impact of Coexisting Pulmonary Diseases on Oncological Outcomes of Patients with pStage I Non-Small Cell Lung Cancer
Hiroyuki Tao, Yamaguchi Ube Medical Center, Japan

P1.05-004: Adenocarcinoma Subtyping of Early Stage Lung Cancer in a Danish Cohort
Petrine laier Sonne, Odense University Hospital, Denmark

P1.05-005: Percutaneous Cryoablation for Lung Cancer Patients with Idiopathic Pulmonary Fibrosis
Takashi Ohtsuka, Keio University, School of Medicine, Japan

P1.05-006: Clinicopathological Features of Small-Sized Peripheral Squamous Cell Lung Cancer
Takayuki Kosaka, Gunma University Graduate School of Medicine, Japan
Posters

Monday, October 16 | Poster Sessions

P1.06-017: Lung Cancer Detection Rates for National Comprehensive Cancer Network Group 2 High Risk Individuals
Andrea Katalin Borody Kitts, Lahey Hospital & Medical Center, USA

P1.06-018: EGFR Mutations and ALK Gene Rearrangements: Changing Patterns of Molecular Testing in Brazil
Gilberto Lopes, Sylvester Comprehensive Cancer Center at the University of Miami, USA

P1.06-019: The Association Between HPV Presence and EGFR Mutations in Asian Patients with NSCLC: A Meta-Analysis
Hengrui Liang, The First Affiliated Hospital of Guangzhou Medical University, China

P1.06-020: Unequal Access to Health Care System Have a Higher Impact in Upgrading Staging for 8th TNM Ed
Maria Teresa Ruiz Tsukazan, Hospital São Lucas da PUCRS, Brazil

P1.06-021: Lung Cancer Among Women Assisted in an Argentinian University Institution
Carolina Gabay, Instituto de Oncología Angel H.Rofo, University of Buenos Aires, Argentina

P1.06-022: Prognostic Value of NLRI in Overall Survival of Patients with Advanced Lung Cancer
Claudio Flores, Oncosalud - AUNA, Peru

P1.06-023: Spatio-Temporal Distribution of Lung Cancer Mortality Rate in Peru: 2005-2014
Claudio J. Flores, Oncosalud - AUNA, Peru

P1.06-024: Outcome of Non-Small Cell Lung Cancer Patients Treated in the Private Health Care in Brazil
Luiz H. Araujo, Américas Centro de Oncologia Integradra, Brazil

P1.07 IMMUNOLOGY AND IMMUNOTHERAPY

P1.07-001 – P1.07-044a
IMMUNOTHERAPY (BIOMARKERS)

P1.07-001: Clinical Value of Expression of PD-L1 and CD8 of 58 Cases with NSCLC
Hongnian Wu, Fuzhou Lung Hospital, China

P1.07-002: The Expression of PD-L1 Protein and CD8 of 58 Cases with NSCLC: A Comprehensive Analysis of Systemic Inflammatory Markers
Haiyue Wang, Peking University Cancer Hospital, China

P1.07-003: Cytolytic Tests with Hyperimmune Patient Sera Is a Good Prognostic Tool in Rachotumomab Immunotherapy in Advanced Non-Small Cell Lung Cancer
Necdet Ismail Hakk Uskent, Anadolu Health Science Center, Turkey

P1.07-004: Predictive Biomarkers of Response to Nivolumab in Non–Small Cell Lung Cancer: A Multicenter Retrospective Cohort Study
Yuki Kataoka, Hyogo Prefectural Amagasaki General Medical Center, Japan

P1.07-005: A Systematic and Genome-Wide Correlation Analysis of PD-L1 Expression and Common NSCLC Driver Genes Xiaoshun Shi, State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, China

P1.07-006: Altered Expression of Programmed Death-1 Receptor (PD-1) and Its Ligand PD-L1, PD-L2 after Neo-Adjuvant Chemotherapy in Lung Cancer
Wenyu Sun, The First Hospital of Jinlin University, China

P1.07-007: Interleukin-17A Promotes Lung Tumor Progression Through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade.
Esra A. Akbay, University of Texas Southwestern Medical Center at Dallas, USA

P1.07-008: Microbiome & Immunotherapy: Antibiotic Use Is Associated with Inferior Survival for Lung Cancer Patients Receiving PD-1 Inhibitors
Jonathan R. Thompson, Medical College of Wisconsin, USA

P1.07-009: PD-L1 Expression in Circulating Tumor Cells and Response to PD-1 Inhibitor Treatment in Non-Small Cell Lung Cancer Patients
Nicolas Guibert, Centre Hospitalier Universitaire, France

P1.07-010: Peripheral Blood Markers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab
Junko Tanizaki, Kindai University Faculty of Medicine, Japan

P1.07-011: PD-L1 Expression and CD8+ T Cell Infiltration Associate with the Prognosis of Pulmonary Neuroendocrine Tumor
Haiyue Wang, Peking University Cancer Hospital, China

P1.07-012: Prediction Sensitivity of PD-1 Checkpoint Blockade Using Pathological Tissues Specimens by Novel Computerized Analysis System
Akira Saito, Tokyo Medical University, Japan

P1.07-013: Detection of Genomic Alterations in Plasma Circulating Tumor DNA in Patients with Metabolically Active Lung Cancers
Tianhong Li, Veterans Affairs Northern California Health Care System, USA

P1.07-014: Association of Preoperative Serum CRP with PD-L1 Expression in NSCLC: A Comprehensive Analysis of Systemic Inflammatory Markers
Takaki Akamine, Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Japan

P1.07-015: Interferon-Gamma (INFgamma) as a Biomarker to Guide Immune Checkpoint Blockade (ICB) in Cancer Therapy
Niki Karachalios, Instituto Oncologico Dr Rosell (IOR), Hospital Universitario Sagrat Cor, Spain

P1.07-016: Comparison of PD-L1 Immunohistochemical Staining between EBUS-TBNA and Resected Non–Small Cell Lung Cancer Specimens
Kenneth Kazuto Sakata, Mayo Clinic, USA

P1.07-017: Assessment of Cancer Immunity Status in Each Patient Using Immunogram
Takahiro Karasaki, The University of Tokyo Hospital, Japan

P1.07-018: A Meta-Analysis of PD-L1 Expression as a Biomarker of PD-L1 Blockade in Advanced Non Small Cell Lung Cancer
Johnathan Man, Westmead Hospital, Australia

P1.07-019: Immune Cell Infiltrates in Non-Small Cell Lung Cancer
Rudolf M. Huber, Ludwig Maximilian University of Munich and Thoracic Oncology Centre Munich, Germany

P1.07-020: Autoantibody Profiles of Cancer-Testis Genes in Non-Small Cell Lung Cancer
Dijana Djureinovic, Uppsala University, Sweden

P1.07-021: Multiplex Immune Profiling Identifies Prognostic Importance of the Spatial Co-Localization of Immune Cells in NSCLC
Arthur Mesheyuevski, Uppsala University, Sweden

P1.07-022: Routine PD-L1 Immunohistochemistry Testing by 22C3 in a Canadian Reference Testing Centre
Ming Sound Tsoa, University Health Network, Canada

P1.07-023: The Correlation Between BT-H4 Expression and Survival of Non–Small Cell Lung Cancer Patients Treated with Nivolumab
Francesco Grossi, Ospedale Policlinico San Martino, Italy

P1.07-024: ISEND May Predict Clinical Outcomes for Advanced NSCLC Patients on PD-1/PD-L1 Inhibitors but Not Chemotherapies or Targeted Kinase Inhibitors
Wungki Park, University of Miami, Sylvester Comprehensive Cancer Center, USA

P1.07-025: Correlating ISEND and Tumor Mutation Burden (TMB) with Clinical Outcomes of Advanced Non-Small Cell Lung Cancer (NSCLC) Patients on Nivolumab
Wungki Park, University of Miami, Sylvester Comprehensive Cancer Center, USA

P1.07-026: Predicting Tumor Mutational Burden (TMB) and Tumor Necrotizing Burden (TNB) of East Asian ANSCLC Patients by a Targeted Genomic Profiling
Lukin Chen, Sun Yet-Sen University Cancer Center, China
P1.07-027: PD-L1 Expression Analysis in African American (AA) and Hispanic Lung Cancer Patients at a Minority-Based Academic Cancer Center
Elaine Shum, Montefiore-Einstein Center for Cancer Care, USA

P1.07-028: Determination of Soluble PD-L1 as a Potential Biomarker for Anti-PD(L)1 Therapy in Non-Small Cell Lung Cancer (NSCLC)
Margarita Majem Tarruella, Hospital de la Santa Creu i Sant Pau, Spain

P1.07-029: Correlation Study Between Plasma sPD-L1 and the Efficacy and Progression of Patients with Non-Small Cell Lung Cancer
Xiaoyan Kang, Shaxi Cancer Hospital, China

P1.07-030: Prognostic Impact of PD-L1 Expression in Correlation with HLA Class I Expression Status in Adenocarcinoma of the Lung
Kazue Yoneda, University of Occupational and Environmental Health, Japan

P1.07-031: Autoantibodies Associated with Risk of Subclinical Autoimmunity and Immune-Related Adverse Events from Checkpoint Inhibitor Therapy
David E. Gerber, UT Southwestern, USA

P1.07-032: 28-Color, 30 Parameter Flow Cytometry to Dissect the Complex Heterogeneity of Tumor Infiltrating T Cells in Lung Cancer
Pier Luigi Novellis, Humanitas Clinical and Research Center, Italy

P1.07-033: Differential Expression of Immune Inhibitory Markers in Association with the Immune Microenvironment in Resected Lung Adenocarcinomas
Mingjuan Lisa Zhang, Massachusetts General Hospital, USA

P1.07-034: Pretreatment Neutrophil & Platelet Count as a Predictor for Unfavorable Clinical Outcome in Non-Small Cell Lung Cancer (NSCLC)
Sarita Agte, Northwestern University, USA

P1.07-035: Lymphocytes and Neutrophils Count After Two Cycles and TTF1 Expression as Early Outcome Predictors During Immunotherapy
Iosune Baraibar, Clinica Universidad de Navarra, Spain

P1.07-036: LC-HRMS Metabolomics Profiling in Advanced NSCLC Treated with Anti PD-1 Agents. Metabolic Features at Diagnosis and at Response Evaluation
Ana Laura Ortega Granados, Complejo Hospitalario de Jaén, Spain

P1.07-037: Testing the Positive and Negative Immune Checkpoint on PBMCs of Patients from Initiatory to Terminative Treatment of Anti PD-1 Antibody
Wushuang Du, Chinese PLA General Hospital, China

P1.07-038: The Potential Clinical Application of Comprehensive Genomic Profiling in Targeted Therapy and Immunotherapy of Lung Cancer
Mingwu Chen, The First Affiliated Hospital of Guangxi Medical University, China

P1.07-039: Blood Biomarkers Correlate with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Anti PD-1 Antibodies
Yanyan Lou, Mayo Clinic, USA

P1.07-040: Prognosis-Relevant Subgroups in NSCLC According to Granulocytic Myeloid-Derived Suppressor Cell Frequency and Cytokine Levels
Oscar Arrieta, Instituto Nacional de Canceroología, Mexico

P1.07-041: CD47 Expression and Prognosis in a Cohort of Patients with Lung Adenocarcinoma (NSCLC)
Oscar Arrieta, Instituto Nacional de Canceroología, Mexico

P1.07-042: PD-L1 and CD8 Expression in EGFR-Mutant or ALK-Rearranged Patients with Lung Cancer
Yi-Long Wu, Guangdon Lung Cancer Institute, China

P1.07-043: Barrier Molecule Overexpression is Associated with Increased CD8 T Cells and Decreased B/Treg Cells in Human Lung Cancer
Wosyoung Monica Choi, Robert H Lurie Comprehensive Cancer Center of Northwestern University, USA

P1.07-044: The Impact of Neutrophil/Lymphocyte Ratio as the Predictive Marker to Anti-PD-1 Antibody Treatment in NSCLC Patients
Keiko Tanimura, Kyoto Prefectural University, Japan

P1.07-044a: Comparison of Tumor Mutational Burden (TMB) Derived from Whole Exome and Large Panel Sequencing in Lung Cancer
Gang Cheng, Novogene Co., Ltd, China

P1.07-045: Adjuvant Chemoradiotherapy vs. Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer
Jong-Mu Sun, Samsung Medical Center, Korea

P1.08-004: Preoperative Analysis of 18FDG-PET Features May Predict Loco-Regional Invasiveness in NSCLC
Pietro Bertolgi, Sacro Cuore-Don Calabria Research Hospital and Cancer Care Centre, Italy

P1.08-006: Phase I/II Study of Carboplatin, nab-paclitaxel, and Concurrent Radiation Therapy for Patients with Locally Advanced NSCLC
Yuko Kawano, Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Japan

P1.08-007: Surgery versus Concurrent Chemoradiotherapy for Resectable Clinical N1A-N2 NSCLC: A Propensity Score Matched Analysis
Xin Sun, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, China

P1.08-008: Chemoradiotherapy in the Regime of Accelerated Fractionation in the Treatment of Lung Cancer
Yury Ragulin, Medical Radiological Research Center, Russia

P1.08-009: Neutrophilia as Prognostic Biomarker in Locally Advanced Stage Iii Lung Cancer
Angela Botticella, Gustave Roussy, France

P1.08-010: Unsuspected N2 Disease in Patients Undergoing Surgery for Non-Small Cell Lung Cancer: Role of Extent and Location of the Lymph Node Metastasis
Saana Andersson, Heart and Lung Center, Helsinki University Hospital, Finland

P1.08-001: Surgical versus Non-Surgical Treatments for Resectable Stage III NSCLC: A Systematic Review and Meta-Analysis
Wee Yao Koh, National University Cancer Institute Singapore, Singapore

P1.08-002: Blood Supply to the Tumor Does Not Predict the Effect of Induction Therapy in Patients with Locally Advanced Lung Cancer
Koji Kawaguchi, Nagoya University, Japan

P1.08-003: Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable, Stage III Non-Small Cell Lung Cancer: A Phase I Study
Kristin A. Higgins, Winship Cancer Institute, Emory University, USA

P1.08-004: Adjuvant Chemoradiotherapy vs. Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer
Jong-Mu Sun, Samsung Medical Center, Korea

P1.09-001: Multiplexed Biomarker Strategies Based on Targeted Proteomics for Detection of Malignant Pleural Mesothelioma in Blood Fernando Ceriello, The Ohio State University Medical Center, USA

P1.09-002: Cellular Noise and Positional Effects Determine the Cell Stem State in Malignant Mesothelioma
Walter Blum, UMR-1162, France

P1.09-003: Malignant Mesothelioma Versus Synovial Sarcoma: An Analysis of 19 Cases with Molecular Diagnosis
Sonja Klebe, Flinders University, Australia

P1.09-004: YB-1 Suppresses mir-137 via a Feed Forward Loop, Increasing YB-1 Levels, Migration and Invasion in Malignant Mesothelioma Karin Schelch, Asbestos Diseases Research Institute, Australia
**POSTER SESSIONS | MONDAY, OCTOBER 16**

**P1.13-002: New Clinical T Classification Is Associated with Pathological Stage I Invasive Adenocarcinoma with Solid Histologic Subtype**
Yukata Sawai, The University of Tokyo, Japan

**P1.13-003: Recurrence Dynamics in Resected Pathological Stage I Lung Adenocarcinoma Depend on the IASLC/ATS/ERS Histological Subtype**
Yusuke Takahashi, Memorial Sloan Kettering Cancer Center, USA

**P1.13-004: The Role of Lymph Node Staging by EBUS-TBNA in Stereotactic Body Radiation Therapy for patients with Non-Small Cell Lung Cancer.**
Kohei Hashimoto, University of Toronto, Canada

**P1.13-005: Is Tumor Size for the T4 Descriptor in Lung Cancer Staging Appropriate?**
Junji Ichinose, Cancer Institute Hospital, Japan

**P1.13-006: The Value of F-18 FDG PET/CT-guided EBUS-TBNA in Nodal Staging of NSCLC.**
Sung Yong Lee, College of Medicine, Korea University, Korea

**P1.13-007: Is Central Lung Tumor Location Really Predictive for Occult Mediastinal Nodal Disease in (Suspected) NSCLC Staged cN0 on PET-CT?**
Herbert Decaluwe, University Hospitals Leuven, Belgium

**P1.13-008: Evaluation of Clinical Associated Factors for Lung Adenocarcinoma by TNM 8th Edition with Unexpected N2 disease**
Yoshiteru Kidokoro, Tottori University, Japan

**P1.13-009: Macroscopic and Microscopic Lymphatic Remodeling Caused by VEGF-C and the Key Role in Lymphatic Metastasis of Non-Small Cell Lung Cancer**
Hiromitsu Takizawa, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan

**P1.13-010: Is MRI Brain Mandatory in All Patients with Early Stage NSCLC?**
George Karmundackal, Tata Memorial Hospital, India

**P1.13-011: Prospective Cohort Study of Patterns of Staging and Treatment Selection with or Without Multidisciplinary (MD) Care**
Raymond Osarogiagbon, Baptist Cancer Hospital, India

**P1.13-012: Hypofractionated Simultaneous Integrated Boost IMRT Concurrent with Chemotherapy Improved Loco-Regional Control in Locally Advanced NSCLC**
Hui Liu, Sun Yat-sen University Cancer Center, China

**P1.14-001: The Feasibility of Predicting Radiation Pneumonitis Using Equivalent Uniform Dose (LEUD) in Volumetric-Modulated Arc**
Xiaodong Li, Zhejiang University, China

**P1.14-002: Comparison Between Stereotactic and Conventional Radiotherapy for Solitary Lung Tumors After Resection of Lung Cancer**
Shigeo Takahashi, Kagawa University Hospital, Japan

**P1.14-003: Anesthesia Allows Safe Administration of SBRT for Early Stage Lung Cancer Patients with Advanced Cognitive Impairments**
Gregory M.M. Videtic, Cleveland Clinic, USA

Liang Wang, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, China

**P1.14-005: Development of a Novel Spacer to Reduce Mediastinal Organ Toxicity from Stereotactic Body Radiotherapy**
Yusuke Muranishi, Kyoto University, Japan

**P1.14-006: Carbon-Ion Radiotherapy for Isolated Lymph Node Metastasis from Lung Cancer Using a Regimen of 12 Fractions during 3 Weeks**
Katsuyuki Shirai, Gunma University Heavy Ion Medical Center, Japan

**P1.14-007: Mesenchymal Stem Cells Labeled with Fluorescent Magnetic Nanoparticles for Targeted Imaging and Hyperthermia Therapy of Lung Cancer**
Runlei Hu, Hangzhou First People’s Hospital, China

**P1.14-008: Elevated Platelet Levels Affect Prognosis in Patients with NSCLC Treated with Curatively Intended Chemoradiotherapy**
Georg Holgersson, Gavle Hospital, Sweden

**P1.14-009: Comparison of Dosimetric Parameters and Outcome in Non-Small Cell Lung Cancer Patients Having 3D Conformal or VMAT Plans**
Nur Abdul Satar, St Bartholomew’s Hospital, UK

**P1.14-010: SGA Could Be a Predictive Factor for Radiation Pneumonitis in Lung Cancer Patients Treated by Concurrent Chemoradiotherapy**
Hui Liu, Sun Yat-sen University Cancer Center, China

**P1.14-011: An Esophagus-Sparing Technique to Limit Radiation Esophagitis in Locally Advanced NSCLC Treated by SIB-IMRT and Concurrent Chemotherapy**
Hui Liu, Sun Yat-sen University Cancer Center, China

**P1.14-012: High Dose Radiotherapy (74Gy) Improved Local Progression Free Survival in Patients with Inoperable Stage III NSCLC**
Young Il Kim, Chungnam National University Hospital, Korea

Iulian Badragan, BC Cancer Agency, Canada

**P1.14-014: Local Recurrence Rate and Timing after Stereotactic Body Radiotherapy for Lung Cancer: Need for Long-term Follow-up**
Takashi Shintani, Kyoto University Graduate School of Medicine, Japan

**P1.14-015: Assessing the Feasibility of FLT-PET for Evaluation of Non-Small Cell Lung Cancer (NSCLC) Treated with Stereotactic Body Radiotherapy (SBRT)**
Meredith Elena Giuliani, University of Toronto and Princess Margaret Cancer Center, Canada

**P1.14-016: Impact of Systematic EBUS-TBNA Mediastinal Staging on Radical Radiotherapy Planning in NSCLC**
Nicholas Hardcastle, Peter MacCallum Cancer Centre, Australia

**P1.14-017: Survival by Response to RapidPlanTM Models for Radical Lung Planning**
Timothy Mitchell, Beatson West Of Scotland Cancer Center, UK

**P1.15 SCLC/NEUROENDOCRINE TUMORS**

**P1.15-001: Iplimumab Increases Th1/Th2 and Inflammatory Cytokines Counteracting Chemotherapy Effects in Small Cell Lung Cancer**
Edurne Arriola, Hospital del Mar, Spain

**P1.15-002: A Retrospective Study of Amrubicin Monotherapy for the Treatment of Relapsed Small Cell Lung Cancer in Elderly Patients**
Hiroiuki Minemura, Fukushima Medical University, Japan

**P1.15-003: Survival by Response to First-line Platinum-Based Therapy Among Patients With Extensive Disease Small Cell Lung Cancer**
Yong Yuan, Bristol-Myers Squibb, USA

**P1.15-004: An Open-Label, Multitumor Phase II Basket Study of Olaparib and Durvalumab (MEDIOLA): Results in Patients with Relapsed SCLC**
Matthew G. Krebs, The University of Manchester and The Christie NHS Foundation Trust, UK

**P1.15-005: Relationship Between MYC Family Status and Sensitivity to Aurora Kinase Inhibitors in Neuroendocrine and Other Lung Cancer Cell Lines**
Tomohiro Hanuki, University of Texas Southwestern Medical Center, USA
P1.15-006: Enriched Environment and Anti-Depressants Enhance Platinum Chemosensitivity of Small Cell Lung Cancer
Qiming Wang, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, China

P1.15-007: Randomized Phase III Trial of Enoxaparin in Addition to Standard Treatment in Small Cell Lung Cancer: The RASTEN Trial
Emelie Gezelius, Lund University Cancer Center, Sweden

P1.15-008: Clinical Features and Gene Mutation Profiling of Pulmonary Carcinoid Tumors
Xiongfei Li, Tianjin Medical University General Hospital, China

P1.15-009: Safety and Efficacy of Nab-Paclitaxel Monotherapy as 2nd or Later Line Treatment in Pts with Extensive SCLC, a Phase II Single Arm Study (NCT02262897)
Shengxiang Ren, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Tongji University Cancer Institute, China

P1.15-010: Small Cell Lung Cancer: Experience of a Portuguese District Hospital
Margarida Felizardo, Hospital Beatriz Angelo, Portugal

P1.15-011: Longitudinal Mutation Monitoring in Plasma Without Matching Tumor Tissue by Deep Sequencing in Small Cell Lung Cancer (SCLC)
André Rosenthal, Roche Sequencing Solutions, USA

P1.15-012: Clinical Prognostic Factors of Elderly Patients with Extensive Stage Small Cell Lung Cancer in Korea
Jung Sun Kim, Korea University Medical Center, Korea

P1.15-013: Small Cell Lung Cancer. Methodology and Preliminary Results by the Small Cell Study
Ángeles Rodríguez, Pontevedra Hospital, Galicia, Spain

P1.15-014: Can Limited Resection Be Accepted as an Alternative Treatment Option for Patients with Early-Stage Small Cell Lung Cancer?
Takamasa Koga, National Hospital Organization Minami-kyushu Hospital, Japan

P1.15-015: Prognostic Implication of the FEV1/FVC Ratio in Limited-Stage Small Cell Lung Cancer
Young-Taek Oh, Ajou University School of Medicine, Korea

P1.15-016: The Study of Population Pharmacokinetics and Individualized Dosage of Lobaplatin-Based Regimens in Elderly Patients with Small Cell Lung Cancer
Ying Cheng, Jilin Provincial Cancer Hospital, China

P1.15-017: Adoption of Prophylactic Cranial Irradiation for Extensive Stage Small Cell Lung Cancer: A Population Based Outcomes Study
Swee Peng Yap, National Cancer Centre Singapore, Singapore

P1.16-001: Characteristics of Resected Lung Cancer in Patients Aged under 60: A Single-Center Experience
Jeong Su Cho, Pusan National University Hospital, Korea

P1.16-002: Management of Local Recurrence after Segmentectomy for Stage IA Lung Cancer
Takeshi Mori, Kumamoto University Hospital, Japan

P1.16-003: Learning Curve for Adoption of Robotic Lobectomy for Early Stage Non-Small Cell Lung Cancer by a Thoracic Surgeon Experienced in Open Lobectomy
Shea Gallagher, University of California, USA

P1.16-004: Intubated Versus Non-intubated Anesthesia for Lung Cancer VATS in Octogenarians
Nenad Ilic, University Surgical Hospital, Croatia

P1.16-005: Comparison Sublobar vs Lobar Resection in Early Stage Lung Cancer in Octogenarian Patients
Shea Gallagher, University of California, USA

P1.16-006: Less Is More: video Assisted Thoracic Surgery (VATS) vs Open Thoracotomy in the Management of Resectable Lung Cancer
Shagufa Shaheen, Loma Linda University Medical Center, USA

P1.16-007: Mobile Computed Tomography in Video-Assisted Thoracoscopic Surgery for Ground-Glass Opacity Lung Nodules
Kouhei Tajima, Kiyu Kosei General hospital, Japan

P1.16-008: Near-Infrared Fluorescence-Guided Pulmonary Segmentectomy Following Endobronchial Indocyanine Green Injection
Hironobu Wada, Chiba University Graduate School of Medicine, Japan

Alan D L Sihoe, The University of Hong Kong Shenzhen Hospital, China

P1.16-010: Development of a Novel Surgical Marking Method Using Low Power Laser Light
Keishi Ohtani, Tokyo Medical University, Japan

P1.16-011: The Role of 3D-CT in Patients with Pulmonary Malignancies Undergoing Segmentectomy
Ali Amiravie, P. Hertzen Research Institute of Oncology, Russia

P1.16-012: Application of Fluorescent and Iodized Dual Marker for Pre-Operative Localization and Image-Guided Surgery of Pulmonary Nodule
Jiyun Rho, Korea University Guro Hospital, Korea

P1.16-013: Video-Assisted Thoracoscopic Surgery (VATS) versus Thoracotomy in Locally-Advanced Lung Cancers - a Meta-Analysis
Gerald Sng, National Cancer Centre Singapore, Singapore

P1.16-014: The Efficacy of Thoracoscopic Right Upper Lobectomy Using Fissureless Technique in Patients with Dense Fissures
Hitoshi Iga, Maebashi Red Cross Hospital, Japan

P1.16-015: miMRST Thoracotomy Cures Aged, Sickly Weak and/or Cardiopulmonary Dysfunction Patients with Lung Cancer
Jun Zhang, China Medical University Lung Cancer Center, The First Hospital of China Medical University, China

P1.16-016: Comparing Safety and Effectiveness of Image-Guided VATS Versus Conventional VATS for Small or Deep Pulmonary Nodules
Yin Kai Chao, Chang Gung Memorial Hospital, Taiwan

P1.16-017: Middle Term Survival Outcome of Single Port Video Assisted Thoracoscopic Anatomic Lung Resection: Two Center Experience
Ching Meng Wu, Chang Gung Memorial Hospital, Taiwan

P1.16-018: Intraoperative Detection of Tumor Resection Margin via Inhalation of Fluorescent Imaging Agents
Yu Hua Quan, Korea University Guro Hospital, Korea

P1.16-019: Three Dimensional CT Angio-Bronchography Doesn’t Contribute to the Shortening of the Operation Time in Segmentectomy
Hirono Horii, Saitama-City Hospital, Japan

P1.16-020: Outcomes of Pulmonary Metastectomy in Hepatocellular Carcinoma According to Approach Method-Thoracoscopic Versus Open Approach
Hyong Soo Kim, Asan Medical Center, University of Ulsan College of Medicine, Korea

P1.16-021: Mittern Oncologic Outcomes of Single Port Thoracoscopic Lobectomy for Lung Cancer by Propensity Matched Analysis
Kook Nam Han, Korea University Guro Hospital, Korea
P1.16-022: Incorporating Robotics to the Surgical Treatment of Thoracic Neoplasms: 5-Year Experience at an Academic Center Dao Minh Nguyen, University of Miami, USA

P1.16-023: A Useful and Safe Method of Intraoperative Localization of Small-Sized Peripheral Pulmonary Lesions Yujiro Kubo, Iwakuni Clinical Center, Japan

P1.16-024: A Case of Bronchial Atresia Treated with Complete Thoracoscopic-Assisted Right S6 Segmentectomy Using Fluorescence Navigation Motootsugu Watanabe, Iwakuni Clinical Center, Japan

P1.16-025: Safety of Simultaneous TEVAR and Combined Aortic Wall Resection at the Time of Lung Resection for T4 Lung Cancer Infiltrating the Aorta Masanori Tsuchida, Niigata University Graduate School of Medical and Dental Sciences, Japan

P1.16-026: Multimodal Image-Guided VATS Resection of Sub-Centimeter Pulmonary Nodules by Cone Beam CT and Bronchoscopic NIR Fluorescence Marking Takashi Anayama, Kochi Medical School, Kochi University, Japan

P1.16-027: Robotic Surgery, VATS, and Open Surgery for Early Stage Lung Cancer: Comparison of Costs and Outcomes at a Single Institute Pierluigi Novellis, Humanitas Clinical and Research Center, Italy

P1.16-028: Is Video-Assisted Thoracic Surgery a Safer Procedure for Lung Cancer Patients? Maria Teresa Ruiz Tsukazan, Hospital São Lucas da PUCRS, Brazil

P1.17 THYMIC MALIGNANCIES/ ESPEROGEAL CANCER/OTHER THORACIC MALIGNANCIES

P1.17-001 – P1.17-019 THYMOMA

P1.17-001: The Optimal First-Line Treatment for Advanced Thymic Carcinomas Xue Yang, Peking University Cancer Hospital and Institute, China

P1.17-002: Clinicopathological Significance of Epithelial Mesenchymal Transition in Thymic Cancer Yasushi Shintani, Osaka University Graduate School of Medicine, Japan

P1.17-003: Identification of Differentially Expressed Genes between Thymoma and Paraneoplastic Thymic Tissue Lei Yu, Beijing Tongren Hospital, Capital Medical University, China

P1.17-004: Extrapleural Pneumonectomy for Patients with Stage IVa Thymoma: Pathological Evaluation of Disseminated Pleural Nodules Shota Nakamura, Nagoya University Graduate School of Medicine, Japan

P1.17-005: Pure Red Cell Aplasia Associated with Thymoma: A Report of a Single-Center Experience Satoru Moriyama, Nagoya City University Graduate School of Medical Sciences, Japan

P1.17-006: Radiographic Assessment for Tumor Responses of Thymic Carcinoma Using the ITMIG Modified Criteria Taiki Hakozaki, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan

P1.17-007: Platinum Based Chemotherapy in Locally Advanced Non-Metastatic Thymic Carcinoma Tahir Mehmood, Northwest General Hospital and Research Centre, Pakistan

P1.17-008: Clinical and Oncological Outcomes on Resected Thymomas over a Decade at the National Cancer Institute at Mexico City Francisco Corona Cruz, National Cancer Institute, Mexico

P1.17-009: Clinical Significance of Preoperative Neutrophil-Lymphocyte Ratio in Patients with Thymic Epithelial Tumor Undergoing Surgery Satoru Okada, Kyoto Prefectural University of Medicine, Japan

P1.17-010: The Diagnostic Value of Serum Cytokeratin Fragment 19 (CYFRA21-1) for Thymic Squamous Cell Carcinoma Haruhioko Shiya, Hokkaido University Hospital, Japan

P1.17-011: Efficacy and Toxicities of Gemcitabine and Cisplatin Combination Chemotherapy in Advanced Thymoma and Thymic Carcinoma Jian Fang, Peking University Cancer Hospital and Institute, China

P1.17-012: Thymic Neoplasms: The Experience of a Cancer Institute Rita Vitorino, Instituto Português de Oncologia de Lisboa Francisco Gentil, Portugal

P1.17-013: Prognostic Impact of Programmed Cell Death-1 (PD-1) and PD–Ligand 1 (PD-L1) Expression in Thymic Cancer Soichiro Funaki, Osaka University Graduate School of Medicine, Japan

P1.17-014: Platinum Rechallenge in Advanced Thymic Epithelial Tumors: Still an Option in the Age of Target Therapy? A Monocentric Experience Margaret Ottaviano, CRTR Rare Tumours Reference Center, Italy

P1.17-015: Long Acting Octreotide plus Prednisone in Advanced Thymic Epithelial Tumors: A Real Life Clinical Experience Margaret Ottaviano, CRTR Rare Tumours Reference Center, Italy

P1.17-016: Immunohistochemical Markers as Prognostic Factors in Malignant Thymic Epithelial Tumors Yoshito Yamada, University Hospital Zürich, Switzerland

P1.17-017: Usefulness of FDG-PET for Differentiating Thymic Epithelial Tumors from Malignant Lymphomas Hiroyuki Sakamaki, Keio University, School of Medicine, Japan

P1.17-018: Distribution of Ectopic Thymus in Chinese Patients: A Preliminary Study Jian-Yong Ding, Zhongshan Hospital, Fudan University, China

P1.17-019: B7-H3 Protein Expression in Thymic Epithelial Tumour Subtypes and Its Association with PD-L1 and Clinical Characteristics Spyridon Gennatas, Imperial College, London, UK

P1.17-020: The Role of Surgery in Malignant Thymic Tumors Yutaka Sakamoto, National Cancer Center Research Institute, Japan

P1.17-021: A Case of Bronchial Atresia Treated with Complete Thoracoscopic-Assisted Right S6 Segmentectomy Using Fluorescence Navigation Motootsugu Watanabe, Iwakuni Clinical Center, Japan

P1.17-022: Safety of Simultaneous TEVAR and Combined Aortic Wall Resection at the Time of Lung Resection for T4 Lung Cancer Infiltrating the Aorta Masanori Tsuchida, Niigata University Graduate School of Medical and Dental Sciences, Japan

P1.17-023: Multimodal Image-Guided VATS Resection of Sub-Centimeter Pulmonary Nodules by Cone Beam CT and Bronchoscopic NIR Fluorescence Marking Takashi Anayama, Kochi Medical School, Kochi University, Japan

P1.17-024: Robotic Surgery, VATS, and Open Surgery for Early Stage Lung Cancer: Comparison of Costs and Outcomes at a Single Institute Pierluigi Novellis, Humanitas Clinical and Research Center, Italy


P1.17-026: The Optimal First-Line Treatment for Advanced Thymic Carcinomas Xue Yang, Peking University Cancer Hospital and Institute, China

P1.17-027: Clinicopathological Significance of Epithelial Mesenchymal Transition in Thymic Cancer Yasushi Shintani, Osaka University Graduate School of Medicine, Japan

P1.17-028: Identification of Differentially Expressed Genes between Thymoma and Paraneoplastic Thymic Tissue Lei Yu, Beijing Tongren Hospital, Capital Medical University, China

P1.17-029: Extrapleural Pneumonectomy for Patients with Stage IVa Thymoma: Pathological Evaluation of Disseminated Pleural Nodules Shota Nakamura, Nagoya University Graduate School of Medicine, Japan

P1.17-030: Pure Red Cell Aplasia Associated with Thymoma: A Report of a Single-Center Experience Satoru Moriyama, Nagoya City University Graduate School of Medical Sciences, Japan

P1.17-031: Radiographic Assessment for Tumor Responses of Thymic Carcinoma Using the ITMIG Modified Criteria Taiki Hakozaki, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan

P1.17-032: Platinum Based Chemotherapy in Locally Advanced Non-Metastatic Thymic Carcinoma Tahir Mehmood, Northwest General Hospital and Research Centre, Pakistan

P1.17-033: Clinical and Oncological Outcomes on Resected Thymomas over a Decade at the National Cancer Institute at Mexico City Francisco Corona Cruz, National Cancer Institute, Mexico

P1.17-034: Clinical Significance of Preoperative Neutrophil-Lymphocyte Ratio in Patients with Thymic Epithelial Tumor Undergoing Surgery Satoru Okada, Kyoto Prefectural University of Medicine, Japan

P1.17-035: The Diagnostic Value of Serum Cytokeratin Fragment 19 (CYFRA21-1) for Thymic Squamous Cell Carcinoma Haruhioko Shiya, Hokkaido University Hospital, Japan

P1.17-036: Efficacy and Toxicities of Gemcitabine and Cisplatin Combination Chemotherapy in Advanced Thymoma and Thymic Carcinoma Jian Fang, Peking University Cancer Hospital and Institute, China

P1.17-037: Thymic Neoplasms: The Experience of a Cancer Institute Rita Vitorino, Instituto Português de Oncologia de Lisboa Francisco Gentil, Portugal

P1.17-038: Prognostic Impact of Programmed Cell Death-1 (PD-1) and PD–Ligand 1 (PD-L1) Expression in Thymic Cancer Soichiro Funaki, Osaka University Graduate School of Medicine, Japan

P1.17-039: Platinum Rechallenge in Advanced Thymic Epithelial Tumors: Still an Option in the Age of Target Therapy? A Monocentric Experience Margaret Ottaviano, CRTR Rare Tumours Reference Center, Italy

P1.17-040: Long Acting Octreotide plus Prednisone in Advanced Thymic Epithelial Tumors: A Real Life Clinical Experience Margaret Ottaviano, CRTR Rare Tumours Reference Center, Italy

P1.17-041: Immunohistochemical Markers as Prognostic Factors in Malignant Thymic Epithelial Tumors Yoshito Yamada, University Hospital Zürich, Switzerland

P1.17-042: Usefulness of FDG-PET for Differentiating Thymic Epithelial Tumors from Malignant Lymphomas Hiroyuki Sakamaki, Keio University, School of Medicine, Japan

P1.17-043: Distribution of Ectopic Thymus in Chinese Patients: A Preliminary Study Jian-Yong Ding, Zhongshan Hospital, Fudan University, China

P1.17-044: B7-H3 Protein Expression in Thymic Epithelial Tumour Subtypes and Its Association with PD-L1 and Clinical Characteristics Spyridon Gennatas, Imperial College, London, UK
POSTERS AT A GLANCE

Tuesday, October 17 | Poster Session 2

P2.01  ADVANCED NSCLC
P2.01-001 – P2.01-058a  CHEMOTHERAPY
P2.01-059 – P2.01-075a  MISCELLANEOUS

P2.02  BIOLOGY/PATHOLOGY
P2.02-001 – P2.02-024  GENOMICS
P2.02-025 – P2.02-049  IMMUNE MECHANISMS IN THORACIC CANCER AND TARGETED THERAPY
P2.02-050 – P2.02-073  MARKER FOR PROGNOSIS, PREDICTION

P2.03  CHEMOTHERAPY/TARGETED THERAPY
P2.03-001 – P2.03-058a  EGFR

P2.04  CLINICAL DESIGN, STATISTICS AND CLINICAL TRIALS

P2.05  EARLY STAGE NSCLC
P2.05-001 – P2.05-009  SBRT
P2.05-010 – P2.05-021  SURGERY

P2.06  EPIDEMIOLOGY/PRIMARY PREVENTION/TOBACCO CONTROL AND CESSATION
P2.06-001 – P2.06-011  PREVENTION

P2.07  IMMUNOLOGY AND IMMUNOTHERAPY
P2.07-001 – P2.07-062c  IMMUNOTHERAPY (CLINICAL)

P2.08  LOCALLY ADVANCED NSCLC

P2.09  MESOTHELIOMA

P2.10  NURSING/PALLIATIVE CARE/ETHICS

P2.11  PATIENT ADVOCACY

P2.12  PULMONOLOGY/ENDOSCOPY
P2.12-001 – P2.12-006  DIAGNOSTIC ENDOSCOPY

P2.13  RADIOLOGY/STAGING/SCREENING
P2.13-001 – P2.13-026a  SCREENING

P2.14  RADIOTHERAPY

P2.15  SCLC/NEUROENDOCRINE TUMORS

P2.16  SURGERY

P2.17  THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES
**Tuesday, October 17 | Poster Session 2**

**P2.01-001: Serum Albumin Level Predicts the Survival Benefit of Chemotherapy in Elderly Advanced NSCLC Patients with Poor Performance Status**  
Satoshi Ikeda, Kanagawa Cardiovascular and Respiratory Center, Japan

**P2.01-002: Survival of Patients with Advanced Non-Small Cell Lung Cancer at Single Institute in Eastern Thailand, 2013-2016**  
Sittith Sukauachai, Chonburi Cancer Hospital, Thailand

**P2.01-003: Does Astragalus Membranaceus Root Extract Have Any Survival Benefit for Metastatic Non-Small Cell Lung Cancer?**  
Adnan Aydiner, Istanbul University, Institute of Oncology, Turkey

**P2.01-004: Safety and Efficacy of Nab-Paclitaxel plus Carboplatin in Elderly Patients with NSCLC (ABOUND.70+)**  
Corey J. Langer, Abramson Cancer Center, University of Pennsylvania, USA

**P2.01-005: A Randomized Phase II Trial of Erlotinib vs S-1 in Patients with NSCLC as Third- or Fourth-Line Therapy (HOT1002)**  
Yasutaka Kawai, Oji General Hospital, Japan

**P2.01-006: Effect of Maintenance Using Pemetrexed with and without Bevacizumab in Patients Advanced Lung Cancer in Non-Small Cells**  
Mayra Galeana Hernandez, Hospital Central Militar, Mexico

**P2.01-007: Molecular Characterization of Non-Small Cell Lung Cancers (NSCLC) in Young Patients from an Argentine Population**  
Velia Cecilia Denninghoff, Centro de Educación Médica e Investigaciones Clínicas (CEMIC-CONICET), Argentina

**P2.01-008: Combination of Bevacizumab with Conventional Chemotherapy Shows Better Prognosis in Patients with Lung Cancer with Liver Metastases**  
Kim Ki-Up, Soon Chun Hyang University Hospital, Korea

**P2.01-009: The Efficacy of Bevacizumab Adding in Standard First Line Chemotherapy and Maintenance Treatment in Advanced NSCLC: A Network Meta-Analysis**  
Voralak Vichapat, Mahidol University, Thailand

**P2.01-010: Risk Score for Predicting Acute Exacerbation from Chemotherapy in Lung Cancer Associated with Interstitial Pneumonia**  
Kazutoshi Isobe, Toho University School of Medicine, Japan

**P2.01-011: The Efficiency and Safety of Apatinib plus S-1 as Second-Line or Laterline Chemotherapy for Advanced Squamous Cell Lung Carcinoma**  
Qingming Shi, Anhui Chest Hospital, China

**P2.01-012: Impact of Brain Metastases on the Humanistic Burden Incurred by Patients with Advanced Non-Small Cell Lung Cancer (A-NSCLC)**  
Kana Chirita, Bristol-Myers Squibb, UK

**P2.01-013: Nab-Paclitaxel/Carboplatin in Elderly Patients with NSCLC (ABOUND.70+): Analysis of Safety and Quality of Life (QoL) by Cycle**  
Corey J. Langer, Abramson Cancer Center, University of Pennsylvania, USA

**P2.01-014: ABOUND.PS2: Safety and Efficacy of Nab-Paclitaxel-Based Therapy in Patients with NSCLC and ECOG PS 2**  
Ajeet Gajra, University of New York, USA

**P2.01-015: Longitudinal Assessment of Performance Status (PS) in Patients with NSCLC and ECOG PS 2 on Nab-Paclitaxel-Based Therapy**  
Nagla Abdel Karim, University of Cincinnati Medical Center, USA

**P2.01-016: Prognostic Impact of a New Score Using Neutrophil-To-Lymphocyte Ratios in the Serum and Malignant Pleural Effusion in Lung Cancer Patients**  
Yixiang Zhu, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China

**P2.01-017: Study on the Effect of Apatinib Salvage Treatment of Advanced Non-Small Cell Lung Cancer**  
Yoshimasa Tokunaga, Kochi Health Sciences Center, Japan

**P2.01-018: Risk Factors in Patients with Pathological N1 or N2 Non-Small Cell Lung Cancer**  
Meiyu Fang, Zhejiang Cancer Hospital, China

**P2.01-019: The Necessity of Contrast-enhanced CT before CT-Guided Percutaneous Transthoracic Needle Biopsy for Lung Lesions**  
Tang Feng Lv, Jinling Hospital, China

**P2.01-020: Continuous Intravenous Infusion Endostar Combined with Pemetrexed plus Cisplatin in Chinese Treatment-Naive Metastatic Non-Squamous NSCLC**  
Li Chen, The First Affiliated Hospital of Nanchang University, China

**P2.01-021: Efficacy of Single-Agent Chemotherapy after Exposure to Nivolumab in Advanced Non-Small Cell Lung Cancer**  
Yuto Yasuda, Kyoto University, Japan

**P2.01-022: Nintedanib/Docetaxel Efficacy in Advanced Lung Adenocarcinoma Treated with 1L Chemotherapy/2L Immunotherapy in Nintedanib NPU**  
Jesus Corral, Hospital Virgen del Rocío-Oncoavance, Spain

**P2.01-023: Reasons for Withholding Systemic Therapy in Stage IV NSCLC: Comparison of Years 2004 to 2007 and 2010 to 2013**  
Gouri Shankar Bhattacharyya, Fortis Hospital, Anandapur, India

**P2.01-024: Prognostic Value of Body Fat Mass Ratio in Lung Cancer Patients**  
Abdurrahman Isikdogan, Dicle University Diyarbakir, Turkey

**P2.01-025: Evaluation of Calculating Carboxyhemoglobin Dosage in Carboplatin-Pemetrexed Therapy in Chinese Patients with Advanced NSCLC**  
Yixiang Zhu, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China

**P2.01-026: Distribution of Metastatic Disease in Survival Outliers with Stage IV Non-Small Cell Lung Cancer**  
P. Gwyn Bebb, University of Calgary, Canada
P2.01-027: Clinical Significance of Topoisomerase-II Expression in Patients with Non-Small Cell Lung Cancer Treated with Amrubicin
Reiko Sakurai, Gunma University Hospital, Japan

P2.01-028: Clinical Correlation between CTCs Enumeration Based on New Detection Method and Chemotherapy Efficacy in Human Advanced Lung Cancer
Honglei Chen, Wuhan University, China

P2.01-029: Real World Report of Clinical Outcomes of Bevacizumab in First-Line or Later-Line Treatment for Patients with Advanced NSCLC
Yalei Wang, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, China

P2.01-030: Real World Study of Bevacizumab-Contained Regimen as First Line Therapy in Chinese Patients with Advanced NSCLC
Yuxin Mu, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China

P2.01-031: Use of Geriatric Assessment (GA) in Clinical Practice for Stage IV Non-Small Cell Lung Cancer (NSCLC). The GIDO Experience
Regina Gironés, Hospital Lluís Alcanyís, Spain

P2.01-032: A Randomized Phase II Trial of Selumetinib + Platinum-pemetrexed (Pem-c) in Kras Wildtype (Wt)/Unknown NSCLC: CCTG Ind219
Barbara Melosky, British Columbia Cancer Agency, Canada

P2.01-033: Leptomeningeal Metastasis from Non-Small Cell Lung Cancer: A Single Center Experience in Chinese Patients
Junling Li, Cancer Institute and Hospital, Chinese Academy of Medical Sciences Peking Union Medical College, China

P2.01-034: Phase I/II Trial of Weekly Nab-Paclitaxel as 2nd or 3rd Line Treatment in NSCLC Without Driver Mutations. (GLCSTG3003)
Kenichiro Kudo, National Hospital Organization Ikawuni Clinical Center, Japan

P2.01-035: Phase II Study: Weekly Docetaxel as First Line Chemotherapy for Elderly Patients with Squamous-Cell Non-Small-Cell Lung Cancer
Kyung Ho Kang, College of Medicine, Korea University, Korea

P2.01-036: Symptom Trajectories During Chemotherapy Predict Overall Survival in Patients with Advanced Non-Small Cell Lung Cancer
Quling Shi, University of Texas MD Anderson Cancer Center, USA

P2.01-037: Clinical Impact of Interstitial Lung Disease on Advanced Non-Small Cell Lung Cancer
Hajime Oi, Tosei General Hospital, Japan

P2.01-038: Determinants of Frailty and Treatment Toxicity in Non-Small Cell Lung Cancer Patient
Marie-Eve Boucher, Institut Gustave Roussy, France

P2.01-039: Erythropoiesis-Stimulating Agents for Chemotherapy-Induced Anemia in Lung Cancer: Efficacy, Toxicity and Effect on Survival
Kostas Syringos, University of Athens, Greece

P2.01-040: Pemetrexed plus Platinum Chemotherapy with or Without Immunotherapy in Non-Squamous NSCLC: Descriptive Safety Analysis
Vassiliki A. Papadimitrakopoulou, MD Anderson Cancer Center, USA

P2.01-041: Pemetrexed plus Platinum Chemotherapy with or Without ImmunoResponse of Bevacizumab plus Cisplatin for the Non-Squamous Non-Small-Cell Lung Cancer Patients with Malignant Pleural EffusionTherapy in Non-Squamous NSCLC: Descriptive Safety Analysis
Xue Li, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China

P2.01-042: Perioperative Chemotherapy with Pemetrexed and Cisplatin for Pulmonary LCNEC: A Case Report and Literature Review
Hong Tang, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, China

P2.01-043: PD-L1 Expression, EGFR and KRAS Mutations in First-Line Therapy (1L) for Non-Small Cell Lung Cancer (NSCLC) Patients
James Rigas, AstraZeneca, USA

P2.01-044: The Correlation Between One Year Survival and the Affecting Factors of Lung Cancer Patients at Dr. Moewardi Hospital Surakarta
Ana Rima, Moewardi Hospital, Indonesia

P2.01-045: The Efficiency of Apatinib plus S-1 as Laterline Chemotherapy for Advanced Non-Small-Cell Lung Cancer
Zhiyong Wu, PLA General Hospital, China

P2.01-046: Clinical Characteristics of Survival with De Novo Versus Relapsed Metastatic Non-Small Cell Lung Cancer
Gwyn Bebb, Alberta Health Services, Canada

P2.01-047: A Phase 1 Trial of Dose Escalated BGB324 in Combination with Docetaxel for Previously Treated Advanced NSCLC
David E. Gerber, UT Southwestern, USA

P2.01-048: Early Changes in Body Composition in Metastatic Non-Small-Cell Lung Cancer (NSCLC) Are Predictive for Poor Overall Survival
Anne-Marie C. Dingemans, Maastricht University Medical Center, Netherlands

P2.01-049: Long Progression Free Survival and Overall Survival in Advanced NSCLC Patients with EGFR Mutation and Complete Response with TKI Treatment
Omar Macedo-Pérez, Instituto Nacional de Cancerología, Mexico

P2.01-050: Predicting Risk of Hospitalization in Patients with NSCLC Receiving Chemotherapy Using the LCS3 3-Item Global Index (3-IGI)
Richard J. Gralla, Albert Einstein College of Medicine, USA

P2.01-051: Randomized Study of Pemetrexed Versus Erlotinib as Maintenance Therapy in Metastatic/Locally Advanced EGFR Mutation Negative NSCLC
Vikas Talreja, Tata Memorial Hospital, India

P2.01-052: Does Radiomics Improves the Survival Prediction in Non Small Cell Lung Cancer?
Ravindra Patil, University of Maastricht, Netherlands

P2.01-053: Outcome of Clinical Management of Elderly and Younger Patients with NSCLC Inside a Private Institution (Onco-land-AUNA)
Jose Maria Gutierrez Castañeda, Oncosalud, Peru

P2.01-054: Inclusion of Central Nervous System Metastasis in Lung Cancer Early Phase Clinical Trials
Narjus Durna, Mayo Clinic, USA

P2.01-055: Examining Metabolomics as a Prognostic Marker in Metastatic Non-Small Cell Lung Cancer Patients Undergoing First-Line Chemotherapy
Desiree Hao, University of Calgary & Tom Baker Cancer Centre, Canada

P2.01-056: Use of Cell-Free Circulating RNA (cfRNA) Expression of PD-L1 and ERCC1 in Plasma to Monitor Response to Therapy in NSCLC
Luis E. Raez, Memorial Cancer Institute, USA

P2.01-057: Activity of Pemetrexed on Wild-Type and Unknown Status EGFR Genes with Brain Metastases from Non-Small Cell Lung Cancer
Yun Fan, Zhejiang Cancer Hospital, China

P2.01-058: Pharmacokinetic Parameter Variability of Docetaxel between Individuals and Its Relationship with Hematological Toxicity
Qisen Guo, Shandong Cancer Hospital, China

P2.01-059a: Dose Serum Lactate Dehydrogenase Have a Significant Prognostic Value in Lung Cancer?
Sharareh Seifi, National Institute of Tuberculosis and Lung Disease (NRITLD), Iran
P2.01-059 – P2.01-075a

**MISCELLANEOUS**

P2.01-059: Breast Metastasis from Pulmonary Cancer: A Case Report. University Hospital "Shefket Ndroqi" Tirana Albania 2008 Fadil Gradica, University Hospital Shefket Ndroqi, Albania

P2.01-060: Outcomes Following Gamma Knife Radiosurgery in Patients with Non-Small Cell Lung Cancer with Brain Metastases. Oliver Coen, Leeds Cancer Centre, UK

P2.01-061: Mode of Lung and Airway Metastasis of NSCLC: Review of Chest CT Findings Mr. Young Kim, Asan Medical Center, Korea

P2.01-062: Primary Lung Adenocarcinoma in the Young with Multiple Metastases: An Autopsy Report of 2 Cases. Randall Santos Arias, Philippine Heart Center, Philippines

P2.01-063: Outcomes of Patients with Oligometastatic Non-Small Cell Lung Cancer Who Were Treated with Radical Treatment Ahmet Bilici, Istanbul Medipol University, Medical Faculty, Department of Medical Oncology, Turkey

P2.01-064: Co-Existing Mutations and Their Clinical Implications in Non-Small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01). Bo Mi Ku, Samsung Biomedical Research Institute, Samsung Medical Center, Korea

P2.01-065: Clinico-Radiological and Pathological Evaluation of Lung Adenocarcinoma with Infiltration on the Computed Tomography of the Chest. Asuka Okada, Saiseikai Suita Hospital, Japan

P2.01-066: Targeted Therapy for Lung Cancer: Liquid Biopsy or Tumor Sampling? A Case-Control Study. Zhen-Yu Ding, West China Hospital, Sichuan University, China

P2.01-067: Treatment of the Patients with Oncological Emergencies with Massive Pleural Effusion at the First Hospital Visit. Kazuhiro Ito, Kyoto Yamashiro Medical Center, Japan

P2.01-068: Lobectomy Improve the Survival of Non-Small Cell Lung Cancer Patients with Occult Malignant Pleural Disease First Detected at Thoracotomy. Shaoei Li, Peking University Cancer Hospital & Institute, China

P2.01-069: Radiologists’ Considerations to Determine the Origin of Tumor on Chest CT: Lung vs Mediastinum. Junghwa Choi, Uijeongbu St. Mary’s Hospital, Korea

P2.01-070: FAACCT- Anorexia Cachexia Scale: Cut-Off Value for the Anorexia Diagnosis in NSCLC Patients. Jenny Turcott, Instituto Nacional de Cancerologia, Mexico

P2.01-071: Efficacy of Thoracic Radiotherapy in Oligometastatic Non-Small-Cell Lung Cancer Harboring Wild-Type EGFR After First-Line Chemotherapy. Congying Xie, the 1st Affiliated Hospital of Wenzhou Medical University, China

P2.01-072: Local Management of Oligometastasis in Non-Small Cell Lung Cancer (NSCLC). Margarita Majem Tarruella, Hospital de la Santa Creu i Sant Pau, Spain

P2.01-073: Prognostic Factors Analysis of Non-Small Cell Lung Cancer with Brain Metastases. Jiancheng Li, Fujian Cancer Hospital, China

P2.01-074: Wait and See: A Favorable Alternative for R-M1a and S-M1a NSCLC Patients. Ying Chen, Guangdong Lung Cancer Institute, China

P2.01-075: Genomic Changes and Clinical Characteristics Associated with Wood-Smoke Exposure in Patients with Non-Small Cell Lung Cancer. Norma Yanet Hernandez-Pedro, Instituto Nacional de Cancerologia, Mexico

P2.01-075a: Incidence of Hippocampal Metastases in Non-Small Cell Lung Cancer. Sophia Ly, Princess Alexandra Hospital, Australia

P2.02 - BIOLOGY/PATHOLOGY

P2.02-001 – P2.02-024

**GENOMICS**

P2.02-001: Detection of Gene Fusions in NSCLC Using NGS Fusion Assay. Yoon-La Choi, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea


P2.02-003: A Practical Prognostic IncRNA Signature for Lung Squamous Cell Carcinoma. Xiaoshun Shi, State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, China

P2.02-004: Gene Mutational Feature in Lung Enteric Adenocarcinoma by the Next Generation Sequencing. Gang Chen, Fujian Provincial Cancer Hospital, China

P2.02-005: 13 Cases of Molecular Features Analysis in Pulmonary Mucoepidermoid Carcinoma. Gang Chen, Fujian Provincial Cancer Hospital, China

P2.02-006: NovelSV: Identify and Parse the Pattern of Chromosomal Structural Variation. Gang Chen, Fujian Provincial Cancer Hospital, China

P2.02-007: Molecular Spectrum of STK11 Gene Mutations in Patients with Non-Small-Cell Lung Cancer in Chinese Patients. Gang Chen, Fujian Provincial Cancer Hospital, China

P2.02-008: Small-Expression Cancer-Associated Fibroblast Induce Epithelial-Mesenchymal Transition of Lungcancer Cells through miR-33b. Min Li, Xiangya Hospital, The Central South University, China

P2.02-009: Metabolic Analysis in Lung Cancer. Nashiro Kajiwara, Tokyo Medical University, Japan

P2.02-010: Oncogenic Role of PKP1 in Non-Small-Cell Lung Cancer. Pedro P. Medina, University of Granada, Spain

P2.02-011: Clinical and Molecular Features of Lung Cancers with Increased FGFR1 mRNA and/or Gene Copy Number. Terry L. Ng, University of Colorado Cancer Center, USA

P2.02-012: The Epigenetic Role of LSD1+8a in Small Cell Lung Cancer. Aditya Wirawan, Juntendo University Graduate School of Medicine, Japan

P2.02-013: Investigation of Genomic and TCR Repertoire Evolution of AAH, AIS, MIA to Invasive Lung Adenocarcinoma by Multi-region Exome and TCR Sequencing. Jianjun Zhang, The University of Texas MD Anderson Cancer Center, USA

P2.02-014: Simultaneous Gene Profiling of Advanced NSCLC: Single-Molecule Quantification of DNA and RNA by nCounter3D Technology. Cristina Teixidó, Hospital Clinic, Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain

P2.02-015: Mutation Patterns in a Swedish Non-Small Cell Lung Cancer Cohort. Linnea La Fleur, Uppsala University, Sweden

P2.02-016: Pulmonary Sarcomas: A Comprehensive Genomic Profiling Study. Jeffrey S. Ross, Albany Medical College, USA

P2.02-018: Genomic Profiling of Driver Gene Mutations in 498 Chinese NSCLC Patients
Minghui Wang, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, China

P2.02-019: Utility of Circulating Tumor DNA (ctDNA) in Prognostication of Lung Cancer vs. Other Cancer Types
Francisco III Maramara Heraldo, University of the Philippines, Philippines

P2.02-020: Molecular Characteristics of Patients with PTEN Mutations in Chinese Non-Small Cell Lung Cancer
Meiyu Fang, Zhejiang Cancer Hospital, China

P2.02-021: Prevalence of PTPRD Gene Mutations in Chinese Non-Small Cell Lung Cancer Patients
Meiyu Fang, Zhejiang Cancer Hospital, China

P2.02-022: Alternative Regulation of Cancer-Associated Genes through Modulation of Long Non-Coding RNAs
Adam Patrick Sage, British Columbia Cancer Research Centre, Canada

P2.02-023: Targeted Gene Expression Profiling to Evaluate Minimal Diagnostic FFPE-Biopsies from NSCLC Patients
Erik Thunnissen, VU University Medical Center de La Princesa, Spain

P2.02-025: Histological Difference of Non-Small-Cell Lung Cancer
José Miguel Sánchez-Torres, Hospital Universitario Sagrat Cor, Spain

P2.02-026: Impact of PD-L1 Expression on 18F-FDG-PET in Pulmonary Squamous Cell Carcinoma
Norimitsu Kasahara, Gunma University Graduate School of Medicine, Japan

P2.02-027: Are Inflammatory Markers Predictive of Nivolumab Efficacy in Advanced Non-Small-Cell Lung Cancer (NSCLC)?
Eun Su Park, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Korea

P2.02-028: Prognostic Value of Cox-2 Expression Differing on CD8+ T Lymphocytes and PD-L1 Expression in Resected Lung Adenocarcinoma
Katsuhiko Shimizu, Kawasaki Medical School, Japan

P2.02-029: Morphologic Features of Lung Adenocarcinoma Expressing PD-L1 Protein in Small Biopsy Specimens
Sanja Dacic, University of Pittsburgh Medical School, USA

P2.02-030: Bavituximab in Combination With Nivolumab Enhances Tumor Immune Response in a 3D Ex Vivo System of Lung Cancer Patients
Jinghui Wang, Beijing Chest Hospital, China

P2.02-031: Relationship between PD-L1 Expression and EGFR/HER2 Signaling in Non-Small-Cell Lung Cancer
Riki Okita, Kawasaki Medical School, Japan

P2.02-032: Interplaying between Gamma-H2AX and Autophagy in A549 Cells Treated with Cisplatin and Etoposide
Jong Wook Shin, Chung-Ang University Hospital, Korea

P2.02-033: The Association of PD-L1 Expression with Clinical Characteristics and EGFR and ALK Status in Lung Adenocarcinoma
Jinghui Wang, Beijing Chest Hospital, China

P2.02-034: PD-L1 Expression Can Be a Prognostic Marker in EGFR Mutant NSCLC Patients Treated with Erlotinib
Niki Karachaliou, Instituto Oncoligico Dr Rosell (IOR), Hospital Universitario Sagrat Cor, Spain

P2.02-035: PD-L1 IHC Test on Cytological Cell Block Specimen; Potential Utility and Practical Issues
Michiko Sugiyama, National Cancer Center Hospital, Japan

P2.02-036: The Expression Pattern of CD26/DPP4 in Human Lung Cancer
Naohiro Kobayashi, University of Tsukuba, Japan

P2.02-037: CD14+ Cell Tumor Microenvironment: Network Analysis of Lung Cancers Concerning Immunogenomic Profiling of Non-Small Cell Lung Cancer Samples
Minghui Wang, Sun Yat-Sen Memorial Hospital, China

P2.02-038: Imaging Platform for the Quantification of Cell-Cell Spatial Organization within the Tumour-Immune Microenvironment
Jane Sze Yin Sui, St. James’s Hospital, Ireland

P2.02-039: Spatial Heterogeneity of Immunological Markers Between Cores and Complete NSCLC Sections Using Multiplex Quantitative Immunofluorescence in Lung Cancer: Clinical Implications
Erik Thunnissen, VU University Medical Center, Netherlands

P2.02-040: Cytology Cell Block Is Suitable for Immunohistochemical Testing for PD-L1 Inhibitors
Sanja Dacic, University of Pittsburgh Medical School, USA

P2.02-041: Update on Prospective Immunogenomic Profiling of Non-Small Cell Lung Cancer (ICON Project)
Jianjun Zhang, MD Anderson, USA

P2.02-042: Clinical Significance of the Tumor Expression of PD-L1 Using Four Immunohistochemistry Assays in Non-Small Cell Lung Cancer. Multicentre Study
Cristian Ortiz, Villalón, Karolinska University Hospital, Sweden

P2.02-043: Multicentre Assessment of PD-L1 Immunohistochemistry: Challenges for Establishing the Concordance Between Four Different Antibodies
Eun Su Park, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Korea

P2.02-044: Pulmonary Findings in 7 Autopsy Cases of Patients Treated with Immune Checkpoint Inhibitors
Eun Su Park, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Korea

P2.02-045: PD-L1 Assessment in Cytology Samples
Peter B. Iller, Johns Hopkins University School of Medicine, USA

P2.02-046: Assessment of PD1 and Immunoprofiling Using Multiplex Quantitative Immunofluorescence in Lung Cancer: Clinical Implications
Jane Sze Yin Sui, St. James’s Hospital, Ireland

P2.02-047: Comparison of PD-L1 Immunochemistry Assays and Response to PD-L1 Inhibitors
Sanja Dacic, University of Pittsburgh Medical School, USA

P2.02-048: Survival Correlation Between TP53 Gene and PD-L1 Tumour Expression in Resected Non-Small Cell Lung Carcinoma
Jane Sze Yin Sui, St. James’s Hospital, Ireland

P2.02-049: Immunohistochemical Approach in Predicting Primary Lung Cancer Outcome: A Single Center Study
Gurukri Kamiljonovna Botiralieva, National Cancer Research Center, Uzbekistan

P2.02-050: Weighted Genes Co-expression Network Analysis of Lung Cancers Concerning Patients Overall Survival and Cancer Stage
Haolong Qi, Chinese University of Hong Kong, Hong Kong

P2.02-051: Bevacizumab Prevents Growth of Established Non-Small Cell Lung Cancer Brain Metastases in Hematogenous Brain Metastasis Model
Jong Wook Shin, Chung-Ang University Hospital, Korea

P2.02-052: A Clinically-Validated Universal Companion Diagnostic Platform for Cancer Patient Care
James Sun, Foundation Medicine, USA
POSTER SESSIONS | TUESDAY, OCTOBER 17

**P2.02-053: The Prognostic Value of 18 Circulating Markers of Inflammation, Endothelial Activation and Extraglomerular Matrix Remodelling in Non-Small Cell Lung Cancer Patients**
Janna Berg, Vestfold Hospital Trust, Norway

**P2.02-054: Thymidylate Synthase Promotes Epithelial-To-Mesenchymal Transition and Aggressiveness in NSCLC**
Paolo Ceppi, IZKF Erlangen, Germany

**P2.02-055: Stratifin Regulates Stabilization of Receptor Tyrosine Kinases via Activation of Ubiquitin-Specific Protease 8 in Lung Adenocarcinoma**
Aya Shiba, University of Tsukuba, Japan

**P2.02-056: Regulatory Variants in Cancer-Related Pathway Genes Predict Survival of Patients with Surgically Resected Non-Small Cell Lung Cancer**
Eungbae Lee, Kyungpook National University Medical Center, Korea

**P2.02-057: Expression of MGAT4a and MGAT5 Are Correlated with Poorer Outcome in Advanced Lung Adenocarcinoma**
Yoko Nakanishi, Nihon University School of Medicine, Japan

**P2.02-058: Endogenous Arginase 2 as a Biomarker for PEGylated Arginase 1 Treatment in Squamous Cell Lung Carcinoma Xenograft Models**
Sze Kwan Lam, The University of Hong Kong, Hong Kong

**P2.02-059: Genomic Mutation Patterns Detected with Cancer Panel Can Predict Postoperative Prognosis in Clinical Stage I Adenocarcinoma**
Kwanyong Hyn, Seoul National University Hospital, Korea

**P2.02-060: Prognostic Significance of EDIL3 Expression and Correlation with Mesenchymal Phenotype and Microvessel Density in Lung Adenocarcinoma**
Young Wha Kho, Ajou University School of Medicine, Korea

**P2.02-061: Two Novel Protein-Based Prognostic Signatures Improve Risk Stratification of Early Lung ADC and SCC Patients**
Luis M. Montuenga, CIMA-University of Navarra, IDISNA, CIBERONC, Spain

**P2.02-062: The MicroRNAs Associated with Recurrence and Metastasis of Stage I Lung Adenocarcinoma**
Yanning Gao, Cancer Hospital, Peking Union Medical College, China

**P2.02-063: Oncogenic microRNAs Associated with Poor Prognosis Are Up-Regulated on the Amplicon in Squamous Cell Lung Carcinoma**
Sana Yokoi, Chiba Cancer Center Research Institute, Japan

**P2.02-064: A Novel 5-miR Signature Shows Potential as a Diagnostic Tool and as a Predictive Biomarker of Cisplatin Response in NSCLC**
Martin P. Barr, St. James’s Hospital & Trinity College Dublin, Ireland

**P2.02-065: RanBP9 is a Novel Prognostic and Predictive Biomarker for NSCLC and Affects Cellular Response to Cisplatin and PARP Inhibitors**
Anna Tessler, The Ohio State University, USA

**P2.02-066: Identification of Crucial Gene Targets in the in Situ Environment of Cancer by Google Network Ranking**
Victor Ponten, Uppsala University, Sweden

**P2.02-067: LKB1 Loss Is Associated with DNA Hypomethylation in Human Lung Adenocarcinoma**
Michael John Koenig, The Ohio State University, USA

**P2.02-068: BRG1 and p53 Expression in Resected Stage I – III Non-Small Cell Lung Cancer**
Gwyn Bebb, University of Calgary and Alberta Health Services, Canada

**P2.02-069: Targeting Neuropilin-1 in NSCLC**
Martin P. Barr, St James’s Hospital & Trinity College Dublin, Ireland

**P2.02-070: C-MET as a Biomarker in Patients with Surgically Resected Non-Small Cell Lung Cancer**
Georgios Tsakonas, Karolinska Institutet, Sweden

**P2.02-071: Prospective Molecular Study of 22 Genes by NGS in Patients with Non-Small Cell Lung Cancer (NSCLC) in Argentina: A Single Institution Experience**
Valeria Cecilia Denninghoff, Centro de Educacion Medica e Investigaciones Clinicas (CEMIC-CONICET), Argentina

**P2.02-072: Reliability of Small Biopsy Samples for Tumor PD-L1 Expression in Non-small-cell Lung Cancer**
Akihito Tsunoda, St. Marianna University School Of Medicine, Japan

**P2.02-073: Cytoplasmic Mislocalization of ECT2 Protein Is Associated with Poor Prognosis in Lung Adenocarcinoma**
Zeinab Kosibaty, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Japan

**P2.02-074: C-MET as a Biomarker in Patients with Surgically Resected Non-Small Cell Lung Cancer**
Gwyn Bebb, University of Calgary and Alberta Health Services, Canada

**P2.03 CHEMOTHERAPY/ TARGETED THERAPY**

**P2.03-001 – P2.03-058a EGFR**

**P2.03-001: Survivors and Adverse Events After First-Line Targeted Therapy for Advanced Non-Small Cell Lung Cancer Patients in Taiwan**
Lin Zhi Xuan, Chi Mei Medical Center, Taiwan
P2.03-014: A Phase I Study of Afatinib for Patients Aged 75 or Older with Advanced NSCLC Harboring EGFR Mutations
Hisashi Tanaka, Hiroasaki University, Japan

P2.03-015: Efficacy of EGFR-TKIs for EGFR Mutant NSCLC Patients with Central Nervous System Metastases: A Retrospective Analysis
Kenichi Koyama, Niigata Cancer Center Hospital, Japan

P2.03-016: Clinical Utility of Liquid Biopsy for Detecting EGFR T790M Mutation Is Very Limited
Tomohiro Sakamoto, Tottori University Hospital, Japan

P2.03-017: Clinical Features and Treatment with Afatinib in Patients with Squamous Cell Lung Cancer with Sensitive EGFR Mutations
Yuri Taniguchi, NTT Medical Center Tokyo, Japan

P2.03-018: Diagnostic Yield of Fine-Needle Aspiration and Core-Needle Biopsy in Assessment of EGFR and ALK Mutation Status in Non-Small Cell Lung Cancer
Jin-Hyoung Kang, Seoul St. Mary’s Hospital, Korea

P2.03-019: Sizing Capillary Electrophoresis with PCR to Detect Various EGFR Exon 19 Deletions in Non-Small Cell Lung Cancer
Eiji Nakajima, Tokyo Medical University Ibaraki Medical Center, Japan

P2.03-020: Pemetrexed Continuation Maintenance versus Conventional Platinum-based Doublet Chemotherapy in EGFR-negative Lung Adenocarcinoma: Retrospective Analysis
Seung Hyeun Lee, Kyung Hee University Medical Center, Korea

P2.03-021: A Phase I Study Evaluating the Combination of Afatinib, Carboplatin and Pemetrexed after Failure of 1st Generation EGFR-TKIs
Ou Yamaguchi, Saitama Medical University International Medical Center, Japan

P2.03-022: Impact of EGFR Mutation on Clinical Outcome of Nintedanib plus Docetaxel in Previously Treated Non-Small Cell Lung Cancer (NSCLC)
Jin-Hyoung Kang, Seoul St. Mary’s Hospital, Korea

P2.03-023: Characteristics of NSCLC Patients Treated in First Line Treatment with Tyrosine Kinase Inhibitors (TKI) - Real Data from the Czech Republic
Jana Skrnickova, University Hospital Brno and Faculty of Medicine, Masaryk University, Czech Republic

P2.03-024: Phase II Trial of AZD9291 in Second-Line Treatment after Acquired Resistance with T790M Mutation Detected From Circulating Tumor DNA
Young-Chul Kim, Chonnam National University Hwasun Hospital, Korea

P2.03-025: Prevalence of EGFR T790M Mutation in NSCLC Patients after Afatinib Failure, and Subsequent Response to Osimertinib
Maximilian Johannes Hochmair, Department of Respiratory and Critical Care Medicine, and Ludwig Boltzmann Institute of COPD and Respiratory Epidemiology, Otto Wagner Hospital, Austria

P2.03-026: Managing EGFR T790M Mutation in Advanced Non-Small Cell Lung Cancers in Thailand
Thongbiway Prempree, Chularat Hospital, Thailand

P2.03-027: Comparative Longitudinal Toxicity Analysis of EGFR Mutated NSCLC Treated with Either Pemetrexed Carboplatin or Gefitinib
Mansi Sharma, Tata Memorial Hospital, India

P2.03-028: Third Generation EGFR Inhibitor AST2818 (Afatinib) in NSCLC Patients with EGFR T790M Mutation: A Phase 1/2 Multi-Center Clinical Trial
Yuanki Shi, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China

P2.03-029: A Case of a Patient Harboring an EGFR Insertion of Exon 20 and Long Lasting Clinical Response to Afatinib
Ana Caroline Zimmer Gelatti, Hospital do Câncer Mãe de Deus, Brazil

P2.03-030: Cumulative Smoking Dose Affects the Clinical Outcomes of EGFR-Mutated Lung Adenocarcinoma Patients Treated with EGFR-TKIs
In Ae Kim, Konkuk University Medical Center, Korea

P2.03-031: Efficacy of Gefitinib and Radiotherapy Combination in Lung Adenocarcinoma
Elisia Syahruddin, Persahabatan National Respiratory Referral Hospital, Indonesia

P2.03-032: Efficacy and Safety of Osimertinib as Third-Line or Later Therapy for T790M-Positive Advanced Non-Small Cell Lung Cancer
Hiroyuki Shimada, Hiratsuka Kyosai Hospital, Japan

P2.03-033: Propensity Score-Adjusted Survival Analysis of Non-Small Cell Lung Cancer Patients with Acquired Resistance to EGFR-TKI
Sho Watanabe, National Center for Global Health and Medicine, Japan

P2.03-034: EGFR Exon 19 Deletion Is Associated with Favorable Overall Survival After First-Line Icotinib Therapy in Advanced NSCLC Patients
Xiaochun Zhang, The Affiliated Hospital of Qingdao University, China

P2.03-035: Osimertinib in Relapsed EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases: Results from the TREM-Study
Inger Johanne Zwicky Eide, Oslo University Hospital, Norway

P2.03-036: Comparing the Efficacy/Toxicity of Osimertinib and First Line EGFR-TKI by Individual Patient Analysis
Shoko Narita, National Cancer Center Hospital, Japan

P2.03-037: Osimertinib in Relapsed EGFR-Mutated, T790M-Negative Non-Small Cell Lung Cancer (NSCLC) Patients: Results from the TREM-Study
Inger Johanne Zwicky Eide, Oslo University Hospital, Norway

P2.03-038: Early Serum Tumor Markers After 14 Days of Tyrosine Kinase Inhibitor Target Therapy Predicts Outcomes in Patients with Lung Adenocarcinoma
Kuo-Yang Huang, Yuanlin Christian Hospital, Taiwan

P2.03-039: Compassionate Use of Osimertinib: Argentine Experience
Jose Nicolas Minatta, Hospital Italiano, Argentina

P2.03-040: EGFR T790M Mutation Detection and Osimertinib Treatment Response Evaluation by Liquid Biopsy in Advanced NSCLC Patients
Chenguang Li, Tianjin Medical University Cancer Institute and Hospital, China

P2.03-041: The Concentration of Avitinib in Cerebrospinal Fluid and Its Efficacy and Safety in NSCLC Patients with T790M Mutation
Haping Wang, Peking Union Medical College Hospital, China

P2.03-042: EGFR Mutation and Erlotinib Efficacy in Turkish Oncoregistry
Mahmut Gumus, Istanbul Medeniyet University, Turkey

P2.03-043: A Phase I Study of Erlotinib and Momeolotinib for TKI-Naïve EGFR-Mutated Metastatic Non-Small Cell Lung Cancer Sukhmani Kaur Paddd, Stanford Cancer Institute/Stanford University School of Medicine, USA

P2.03-044: OSCILLATE - Phase 2 Trial of Alternating Osimertinib with Gefitinib in Patients with EGFR-T790M Mutation Positive Advanced NSCLC
Ben J. Solomon, Peter MacCallum Cancer Centre, Australia

P2.03-045: Updated Results of Phase II, Liquid Biopsy Study in EGFR Mutated NSCLC Patients Treated with Afatinib (WJOG 81H1LTR)
Hitoshi Hayashi, Kindai University Faculty of Medicine, Japan
P2.03-048: Mixed Response of Non-Small Cell Lung Cancer Harboring the EGFR T790M Mutation to Osimertinib
Songtao Xu, Zhongshan Hospital Fudan University, China

P2.03-049: Pulmonary Adenoid Cystic Carcinoma with EGFR Activating Mutation and Responds Well with Tyrosine Kinase Inhibitor Jamal Zaini, Faculty of Medicine Universitas Indonesia - Persahabatan National Respiratory Referral Hospital, Indonesia

P2.03-050: The Efficacy of EGFR Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer Harboring G719X Mutation Hanping Wang, Peking Union Medical College Hospital, China

P2.03-051: The Impact of EGFR Mutations, Treatment with ITKs in Non Small Cell Lung Cancer Patients Teresa García Manrique, Hospital Virgen del Rocio, Spain

P2.03-052: Local Ablative Therapy for Oligoprogressive, EGFR-Mutant, Non-Small Cell Lung Cancer (NSCLC) After Treatment with Osimertinib Udayan Guha, Thoracic and Gastrointestinal Oncology Branch, National Cancer Institute, USA

P2.03-053: A Five-Year Audit of EGFR and ALK Testing at a Tertiary Care Centre in North India: More Sensitive Methods Do Make a Difference! Valliappan Muthu, Postgraduate Institute of Medical Education and Research (PGIMER), India

P2.03-054: EGFR Mutation with Acquired C-MET Positive Reveals Potential Immuno-therapeutic Vulnerabilities Shan Su, Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

P2.03-055: Comparison of Aftatinib Versus Erlotinib for Advanced Non-Small-Cell Lung Cancer Patients with Resistance to EGFR-TKI Yuichi Sakamori, Graduate School of Medicine, Kyoto University, Japan

P2.03-056: Primary Double EGFR Mutations T790M and Mutation in Exon 19 or 21 in Slovakian NSCLC Patients - Updated Survival Data Peter Berzince, specialised Hospital of St Zoerardus Zobor, Slovakia

P2.04 CLINICAL DESIGN, STATISTICS AND CLINICAL TRIALS

P2.04-001: BALTIC: A Phase 2, Open-Label Study of Novel Combinations of Immunotherapies or DDR Inhibitors in Platinum-Refractory ED-SCLC Ihor Vynnychchenko, Sumy State University, Ukraine

P2.04-002: CASPIAN: Phase 3 Study of First-Line Durvalumab ± Tremelimumab + Platinum-Based Chemotherapy vs Chemotherapy Alone in ED-SCLC Luis Paz-Ares, Hospital Universitario 12 de Octubre, Spain

P2.04-003: Phase II Trial of X-396 (Ensartinib) for Chinese Patients with ALK (+) Non–Small-Cell Lung Cancer Who Progressed on Crizotinib Li Zhang, Sun Yat-sen University Cancer Center, China

P2.04-004: I-Power010: A Phase III Study of Atezolizumab vs Best Supportive Care Following Adjuvant Chemotherapy in Completely Resected NSCLC Enriqueta Felip, Vall d’Hebron University Hospital, Spain

P2.04-005: GEOMETRY Mono-1: Phase II, Multicenter Study of MET Inhibitor Capmatinib (INC280) in EGFR WT, MET-Dysregulated Advanced NSCLC Jurgen Wolf, University of Cologne, Germany

P2.04-006: ADARAUR: Phill, Double-Blind, Randomized Study of Osimertinib vs Placebo in EGFR Mutation-Positive NSCLC Post-Tumor Resection Roy S. Herbst, Yale Cancer Center, USA

P2.04-007: KEYNOTE-604: Phase 3 Randomized, Double-Blind Trial of Pembrolizumab/Placebo plus Etoposide/Platinum for Extensive Stage-SCLC Charles M. Rudin, Memorial Sloan Kettering Cancer Center, USA

P2.04-008: ATLANTIS: Phase III Study of PM01183 with Doxorubicin vs. CAV or Topotecan in Small-Cell Lung Cancer After Platinum Therapy Jose Antonio Lopez-Vilarro, PharmaMar, Spain

P2.04-009: Randomized, Single-Blind Phase 1 Study of Pharmacokinetic Equivalence of ABP 215 Relative to Bevacizumab in Japanese Subjects Valdimir Hanes, Amgen, Inc., USA

P2.04-011: The Using of LungCare Electromagnetic Navigated Bronchoscopy System in Lung Lesions, a New Project in China Baohui Han, Shanghai Chest Hospital, China

P2.04-012: First-Line Ensitinib (X396) versus Crizotinib in Advanced ALK-Rearranged NSCLC (eXalt3): A Randomized, Open-Label, Phase 3 Study Yi-Long Wu, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

P2.04-013: ElevatION:NSCLC-101 - A Phase 1b Study of PDR001 Combined with Chemotherapy in PD-L1 Unselected, Metastatic NSCLC Patients Enriqueta Felip, Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Spain

P2.04-014: Computing the Impact of Immunotherapy on NSCLC Landscape: The Advanced Non-Small Cell Lung Cancer Holistic Registry (ANCHoR) George R. Simon, The University of Texas MD Anderson Cancer Center, USA

P2.05 EARLY STAGE NSCLC

P2.05-001 – P2.05-009 SBRT

P2.05-001: Does CGA Impact QoL and Overall Survival in NSCLC Patients Treated with SBRT – Results of a Randomized Pilot Study Stefan Staarup Jeppesen, Odense University Hospital, Denmark

P2.05-002: A Pilot Study on the Safety and the Efficacy of Dose Escalation in Stereotactic Body Radiotherapy for Peripheral Lung Tumor Takamasa Mitsuishi, Kyoto University Graduate School of Medicine, Japan

P2.05-003: Stage by Stage Comparison of Radiotherapy versus Surgery in NSCLC: The Influence of Prognostic Factors on Survival Outcome Sara Moore, British Columbia Cancer Agency, Canada
P2.05-004: Radiotherapy Patterns of Care for Stage I and II Non-Small-Cell Lung Cancer in Sydney, Australia
Andrew Duc Nguyen, University of NSW, Australia

P2.05-005: Proton Beam Therapy for Early Stage Lung Cancer: A Multi-Institutional Retrospective Study in Japan
Kayoko Ohsishi, University of Tsukuba Hospital, Japan

P2.05-006: Credentialing of Radiotherapy Centres in Australasia for a Phase III Clinical Trial on SABR (TROG 09.02 CHISEL)
Nicholas Hardcastle, Peter MacCallum Cancer Centre, Australia

P2.05-007: Stereotactic-Body-Radiotherapy for Early-Lung Cancer: Is FDG-PET/TC a Predictor of Outcome?
Margarita Majem, Hospital de la Santa Creu i Sant Pau, Spain

P2.05-008: Stereotactic Body Radiotherapy (SBRT) for Early Stage I Lung Cancer: A Review from an Oncology Center in Hong Kong
Lim Mei Ying, Princess Margaret Hospital, Hong Kong

P2.05-009: Outcome of Stereotactic Body Radiotherapy for Clinical Stage I Non Small Cell Lung Cancer and CT Findings: Comparison with Surgical Resection
Yuho Maki, Shikoku Cancer Center, Japan

P2.05-010 – P2.05-021 SURGERY

P2.05-010: Changes between Pre- and Post-Operative AICs (Lung) in NSCLC Patients: Predictability of High-Risk Cases with Recurrence
Masahiko Higashiyama, Osaka International Cancer Institute, Japan

P2.05-011: Segmentectomy versus Wedge Resection in Patients with Clinical Stage I Non-Small Cell Lung Cancer Who Were Untfit for Lobectomy
Yasuhiro Tsutani, Hiroshima University, Japan

P2.05-012: Prognostic Factors for Surgically Resected Non-Small Cell Lung Cancer with Cavity Formation
Shunsuke Shigefuku, Tokyo Medical University, Japan

P2.05-013: The Result of Preoperative Lipiodol Markings for 121 Small Pulmonary Nodules in 115 Patients
Hirofumi Suzuki, Saiseikai Suita Hospital, Japan

P2.05-014: Factors Associated with Recovery Time to Predicted FEV1 in Non-Small-Cell Lung Cancer Patients after Lobectomy
Shin Ah Young, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Korea

P2.05-015: Wedge Resection Is Enough for Curing GGO Patients with Minimally Invasive Adenocarcinoma (MIA) of the Lung?
Jun Zhang, China Medical University Lung Cancer Center, The First Hospital of China Medical University, China

P2.05-016: Clinical Importance and Application of New T Descriptors in the 8th TNM Classification for Pathological T0-1 Lung Adenocarcinoma
Masayuki Nakao, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan

P2.05-017: Prognostic Impact of the Clinical T Descriptor in the Eighth Edition of the TNM Staging System of Non-Small Cell Lung Cancer
Tatsuro Okamoto, Oita University Faculty of Medicine, Japan

P2.05-018: Video-Assisted Thoracoscopic Surgery vs Thoracotomy for Early-Stage Non-Small Cell Lung Cancer: Short-Term Outcomes of a Randomized Trial
Dongrong Shi, Lung Cancer Research Institute, Sun Yat-sen University, China

P2.05-019: Overall Survival (OS) of Pathological T1N0 Non-Small Cell Lung Cancer (NSCLC) After Resection.
Etienne Bourdages-Pageau, Laval University, Canada

P2.05-020: Prognostic Factors in Patients with Completely Resected Subsolid Node-Negative Lung Adenocarcinoma of 3cm or Smaller
Jung-Jyh Hung, Taipei Veterans General Hospital and National Yang-Ming University, Taiwan

P2.05-021: Occult Nodal Metastasis Following Lobectomy for Clinical Stage I Lung Adenocarcinoma: Implications for Sublobar Resection
Yusuke Takahashi, Memorial Sloan Kettering Cancer Center, USA

P2.06 EPIDEMIOLOGY/PRIMARY PREVENTION/TOBACCO CONTROL AND CESSATION

P2.06-001 – P2.06-011 PREVENTION

P2.06-001: Circulating Cotinine Concentrations, Self-Reported Smoking, and Lung Cancer Risk in the Lung Cancer Cohort Consortium (LC3)
Tricia L. Larose, Norwegian University of Science and Technology, Norway

P2.06-002: Tobacco Use and Prevalence of Head and Neck Cancers among Malayali Tribes, Yelagiri Hills, Tamil Nadu, India
Deftin Lovelina Francis, Tagore Dental College and Hospital, India

P2.06-003: Retrospective Study of Cerebral Thromboembolism Occurring before and after Detection of Lung Cancer (Trousseau Syndrome)
Kinnosuke Matsumoto, Osaka General Medical Center, Japan

P2.06-004: Role of Polymorphic Variants of BER and DSBP Pathway Genes in Modulating Lung Cancer Susceptibility and Prognosis of North Indian Population
Amrita Singh, Thapar University, India

P2.06-005: An Exploration of Attitudes and Barriers to Uptake of Lung Cancer Screening in at Risk Adults in the United Kingdom
David Raymond Baldwin, Nottingham University Hospitals, UK

P2.06-006: Screening Values of CEA and Cyfra 21-1 for Lung Cancer in Combination with Low Dose CT (LDCT) in High-Risk Populations
Natthaya Triphuridet, Chulabhorn Hospital, Thailand

P2.06-007: Demographic Characteristics of Lung Cancer and Association with Wood Smoke in Mexican Population
Jeronimo Rafael Rodriguez-Cid, Instituto Nacional de Enfermedades Respiratorias, Mexico

P2.06-008: Diagnosis of Incidental Disease in Medicaid Recipients During Lung Cancer Screening
Marisa Bittoni, The Ohio State University Wexner Medical Center, USA

P2.06-009: Trait Elements Affect Lung Cancer Subtypes
RyoSKUe Chiba, Iwate Medical University, Japan

P2.06-010: Association of Vitamin D Receptor BsmI Polymorphism with Lung Cancer Risk: Evidence from a Meta-Analysis
Minhua Shi, the Second Affiliated Hospital of Soochow University, China

P2.06-011: Assessing and Addressing Knowledge Gaps to Improve Lung Cancer Screening Rates
Lawrence Eric Feldman, The University of Illinois Hospital and Health Sciences System, UI Cancer Center, USA

P2.07 IMMUNOLOGY AND IMMUNOTHERAPY

P2.07-001 – P2.07-062C IMMUNOTHERAPY (CLINICAL)

P2.07-001: Clinicopathological Characteristics of NSCLC Patients with Nivolumab-Induced Pneumonitis
Nobuyuki Koyama, Tokyo Medical University Hachioji Medical Center, Japan

P2.07-002: Drug-Related Pneumonitis in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Commercial PD-1 Inhibitors
Mizuki Nishino, Dana-Farber Cancer Institute, USA
POSTER SESSIONS | TUESDAY, OCTOBER 17

P2.07-003: Nivolumab for Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer Hironori Ashinuma, Chiba Cancer Center, Japan

P2.07-004: Immune-Related Adverse Events (irAEs) of Nivolumab Predicts Clinical Benefit in Advanced Lung Cancer Patients Yukihiko Toi, Sendai Kousei Hospital, Japan

P2.07-005: Impact of Baseline Leptomenigeal and Brain Metastases on Immunotherapy Outcomes in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Laura Mezquita, Gustave Roussy, France

P2.07-006: Irinotecan Augmented Anti-Tumor Activity of Anti-PD-L1 through Enhancing CD8 Proliferation Regardless of Its Hematotoxicity Toshiki Iwai, Chugai Pharmaceutical Co., Ltd., Japan

P2.07-007: Retrospective Analysis of Antitumor Effects and Biomarkers of Nivolumab in NSCLC Patients with EGFR Mutations Satoshi Watanabe, Niigata University School of Medical and Dental Sciences, Japan

P2.07-008: Does PD-L1 Expression of the Tumor Predict the Sensitivity of Recurrence to Nivolumab in Patients with NSCLC? Yuki Shinya, Chiba University Graduate School of Medicine, Japan

P2.07-009: Monitoring Nivolumab Binding as a Method to Clarify the Residual Therapeutic Effects in Previously Treated Lung Cancer Patients Akio Osa, Osaka University Graduate School of Medicine, Japan

P2.07-010: Impact of Clinicopathological Features on the Efficacy of PD-1/PD-L1 Inhibitors in Patients with Previously Treated Non-Small Cell Lung Cancer Tao Jiang, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

P2.07-011: Long Follow up from Phase I Study of Nivolumab and Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer Shintaro Kanda, National Cancer Center Hospital, Japan

P2.07-012: Patterns of Response to Nivolumab in Patients with Non-Small Cell Lung Cancer (NSCLC) Martin Früh, Cantonal Hospital St. Gallen, Switzerland

P2.07-013: Efficacy and Safety of Nivolumab in Non-Small Cell Lung Cancer with Preexisting Interstitial Lung Disease Osamu Kanai, National Hospital Organization Kyoto Medical Center, Japan

P2.07-014: Immune Checkpoint Inhibitors for Brain Metastases of Non-Small-Cell Lung Cancer Hironori Ashinuma, Chiba Cancer Center, Japan

P2.07-015: Reviving Chemotherapy Sensitivity after Anti-CCRE mAb (Mom gulizumab) Treatment in Lung Cancer Patients Koji Kurose, Kawasaki Medical School, Japan


P2.07-017: Association between Thyroid Dysfunction and Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Received Nivolumab Tomoko Funazo, Kyoto University, Japan

P2.07-018: Correlation of Clinical Response and XAGE1 Immunity in Lung Adenocarcinoma Yoshihiro Ohue, Kawasaki Medical School, Japan

P2.07-019: Role of Anti-Angiogenesis on the Prognosis in Advanced Non-Small Cell Lung Cancer Who Are Treated with Immunotherapy Takefumi Komiya, Tulane University School of Medicine, USA

P2.07-020: Distinct Immune Status in Patients with Adenocarcinoma and Squamous Cell Carcinoma: Implication for Immunotherapy of NSCLC Nada Hradilova, Sotio a.s., Czech Republic

P2.07-021: A Checkpoint Molecule B7-H3 as a Novel Immune Therapy Target for Non-Small Cell Lung Cancer (NSCLC) Kimio Yonesaka, Kindai University Faculty of Medicine, Japan

P2.07-022: Inflammatory Cytokine Induction after Anti-PD-1 Ab Administration Relates to the Efficacy and Safety in Patients with Non-Small Cell Lung Cancer Yuichi Ozawa, Seirei Mikatahara General Hospital, Japan

P2.07-023: Safety of Immune Checkpoint Inhibitors in Patients with Preexisting Autoimmune Disease Margaux Geier, CHRU Morvan, France

P2.07-024: Real-World Data of Nivolumab for Previously Treated Non-Small Cell Lung Cancer Patients in Japan: A Multicenter Retrospective Cohort Study Dachi Fujimoto, Kobe City Medical Center General Hospital, Japan

P2.07-025: Increased Antitumor Response to Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer Song Ee Park, Samsung Medical Center, Korea

P2.07-026: Nivolumab in Non-Small Cell Lung Cancer (NSCLC): Facing the Reality Sivan Shamai, Tel Aviv Medical Center, Israel

P2.07-027: Efficacy and Safety of Nivolumab Therapy for Advanced NSCLC in the Expanded Access Named Patient Program in Taiwan Bin-Chi Liao, National Taiwan University Hospital, Taiwan

P2.07-028: Efficacy and Safety of Nivolumab in Non-Small Cell Lung Cancer Patients Who Relapse after Thoracic Radiotherapy Teppei Yamaguchi, Aichi Cancer Center Hospital, Japan

P2.07-029: CheckMate 169: Safety/Efficacy of Nivolumab in Canadian Pretreated Advanced NSCLC (including Elderly and PS 2) Patients Rosalyn J. Juergens, Juravinski Cancer Centre, Canada


P2.07-031: Relationship between Clinical Factors and the Expression of Programmed Death Ligand 1 in Lung Cancer Yasuhiro Kato, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan

P2.07-032: Outcomes of Nivolumab in Metastatic NSCLC Patients via the Access Program Across Multiple Tertiary Oncology Centres Kenneth O’Byrne, Princess Alexandra Hospital and Queensland University of Technology, Australia

P2.07-033: Anti-PD1-Induced Rotator Cuff Injury: A Case Series Kenneth O’Byrne, Princess Alexandra Hospital and Queensland University of Technology, Australia

P2.07-034: Health Status in Patients with Small-Cell Lung Cancer Treated with Nivolumab Alone or Combined with Ipilimumab: CheckMate 032 D. Ross Camidge, University of Colorado, USA

P2.07-035: Correlation Between Immune-Related Adverse Events and Efficacy in Non-Small Cell Lung Cancer Treated with Nivolumab Koichi Sato, Third Department of Internal Medicine, Wakayama Medical University, Japan

P2.07-036: Appropriate Use of Immune Checkpoint Inhibitors in Advanced NSCLC: Effectiveness of Unique Case-Based Education on Clinical Decision-Making Tara Herrmann, Medscape Education, USA

P2.07-037: Developing a Predictive Clinical Outcome Model for Advanced Non-Small Cell Lung Cancer Patients Receiving Nivolumab Wungki Park, University of Miami, Sylvester Comprehensive Cancer Center, USA
P2.07-038: Thyroid Dysfunction Arising During KEYNOTE-001 Associated with Improved Efficacy of Pembroliuzumb in NSCLC Patients at UCLA
Aaron Lisberg, University of California, Los Angeles, USA

P2.07-039: Nivolumab Experience in Patients with Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC) in Toledo, Spain
Antonio Irigoyen Medina, Hospital Toledo, Spain

P2.07-040: Pre-Treatment Tumor Volume in Non-Small Cell Lung Cancer (NSCLC) as a Predictor of Response to PD-1 Inhibitors
Misako Nagasaka, Karmanos Cancer Institute/ Wayne State University, USA

P2.07-041: Immuno-Related Cutaneous Adverse Events (irCTAEs) in Patients (P) with Advanced NSCLC: A Single-Institution Prospective Study
Enric Carcereny, Catalan Institute of Oncology-Hospital Germans Trias i Pujol, Spain

P2.07-042: Feasibility Study of Nivolumab and Docetaxel in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer Tsuene Shimokawa, Yokohama Municipal Citizen’s Hospital, Japan

P2.07-043: Efficacy and Safety of Anti-PD-1 Antibody as the First Line Treatment in Elderly Patient with Advanced Lung Squamous Cell Carcinoma: A Case Report
Hua Min Shi, The Second Affiliated Hospital of Soochow University, China

P2.07-044: Thyroid Dysfunction in Advanced NSCLC Patients Treated with Nivolumab out of Clinical Trial: A Real-World Data Analysis
Ramon Palmero, Catalan Institute of Oncology, Spain

P2.07-045: A Retrospective Analysis of Nivolumab-Related Pneumonitis in Non-Small Cell Lung Cancer Patients Shuhei Tsujino, Nagasaki University Hospital, Japan

P2.07-046: Nivolumab Exerts Remarkable Antitumor Activity in NSCLC After an Immune-Modulating Biochemotherapy Regimen
Pierpaolo Correale, Unit of Medical Oncology, Grand Metropolitan Hospital “Bianchi-Melacrido- Morelli”, Reggio Calabria, Italy

P2.07-047: Poor Performance Status and BRAF Mutation Predict Grade 3-5 Immune-Related Adverse Events in Pts with Advanced NSCLC
Yan Wang, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

Inbar Finkel, Belinson Medical Center, Israel

P2.07-049: Early Clinical Predictors of Progressive Disease or Non-Response to PD-1/ PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer
David P. Walder, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, UK

P2.07-050: Impact of Steroid Use for Immune Related Adverse Events on Outcomes in Non-Small Cell Lung Cancer (NSCLC) Treated with Checkpoint Inhibitors
Neil J. Shah, Medstar Georgetown University Hospital, USA

P2.07-051: Immune Checkpoint Associated Cardiotoxicity: An Update
Zin War Mynt, Division of Hematology and Oncology, University of Kentucky, USA

P2.07-052: Detection of KRAS Mutation in Blood Predicts Favorable Response to Immuno-therapy in NSCLC
Martin Frederik Dietrich, Memorial Cancer Institute, USA

P2.07-053: A Case of Small Cell Lung Cancer Complicated During Nivolumab Administration as Second Line Treatment for Squamous Cell Lung Cancer
Tomoki Kimura, Tosei General Hospital, Japan

P2.07-054: Cost-Effectiveness of Pembrolizumab as First-Line Therapy for Advanced Non-Small Cell Lung Cancer
Pedro Aguiar Jr, Faculdade de Medicina do ABC, Brazil

P2.07-055: Indirect Comparison between Immune-Checkpoint Inhibitors for 2nd Line Non-Small Cell Lung Cancer - a Network Meta-Analysis
Pedro Aguiar Jr, Faculdade de Medicina do ABC, Brazil

P2.07-056: SAKK 16/14 – Perioperative Anti-PD-L1 Antibody Durvulamub in Patients with Stage IIA(N2) Non-Small Cell Lung Cancer (NSCLC)
Sacha I. Rothschild, University Hospital Basel, Switzerland

P2.07-057: Anti-PD-1/PD-L1 Antibodies Combine with Chemotherapy or CTLA4 Antibodies for First-Line Treatment of Advanced Lung Cancer
Yun Fan, Zhejiang Cancer Hospital, China

P2.07-058: First-In-Human Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, for Non-Small Cell Lung Carcinoma in Patients with Preexisting Autoimmune Diseases
Tomoki Kimura, Tosei General Hospital, Japan

P2.07-059: Phase I Trial of Gene Mediated Immunotherapy (GMCI) for Malignant Pleural Mesothelioma (MPM)
Daniel H. Sterman, NYU Langone Medical Center, USA

P2.07-060: Response Assessment and Subgroups Analysis According to the Lung Immune Prognostic Index (LIP) for Immunotherapy in Advanced NSCLC Patients
Misako Nagasaka, Karmanos Cancer Institute/ Wayne State University, USA

P2.07-061: Nivolumab in Patients with Non-Small Cell Lung Carcinoma in Patients with Progression to One or More Lines of Chemotherapy in Mexican Population
Jeronimo Rafael Rodriguez-Cid, Instituto Nacional de Enfermedades Respiratorias, Mexico

P2.07-062: Phase II Study of NKT-214 and Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumor Malignancies
Vassiliki A. Papadimtrakopoulou, The University of Texas MD Anderson Cancer Center, USA

P2.07-063: First-In-Human Study of NKTR-214 in Combination with Pembrolizumab in Patients with Previously Treated Advanced Lung Adenocarcinoma
Murray Yule, BerGenBio ASA, Norway

P2.08-001: Hand Grip Strength Is an Independent Prognostic Factor for Mortality in Patients with NSCLC Undergoing Radiotherapy
Chris Burtin, Hasselt University, Belgium

P2.08-002: A Nomogram for Predicting Underlying Beneficiaries for Resectable IIIA/N2 NSCLC Patients
Chao Zhang, Guangdong Lung Cancer Institute, China

P2.08-003: An Audit of Concurrent Chemoradiotherapy for Non-Small Cell Lung Cancer at the Leeds Cancer Centre (LCC)
Kat Louise Clarke, Leeds Cancer Centre, UK

P2.08-004: Pathologic Complete Response as an Independent Prognostic Factor in Patients with Locally Advanced Non-Small Cell Lung Cancer
Waldemar Schreiner, Friedrich-Alexander-University, Germany

P2.08-005: Salvage Lung Surgery Following Definitive Chemoradiation in Locally Advanced Non-Small Cell Lung Cancer
Waldemar Schreiner, Friedrich-Alexander-University, Germany
P2.08-006: Immunological Biomarkers Characterization in Locally Advanced Non-Small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy
Ernest Nadal, Department of Medical Oncology, Catalan Institute of Oncology, Hospital, Spain

P2.08-007: Five-Year Results of Concurrent Chemotherapy and Isotactic Radiotherapy Dose-Escalation with IMRT in Stage III NSCLC (NCT01166204)
Dirk K. De Ruyscher, Maastricht University Medical Center, Netherlands

P2.09 MESOTHELIOMA

P2.09-001: Effects of Tumor Burden Reduction on Survival in Epithelioid Pleural Mesothelioma
Aaron S. Mansfield, Mayo Clinic, USA

P2.09-001a: TNM or Tumor Volume for Predicting Prognosis in Malignant Pleural Mesothelioma: Still an Open Debate
Marina Chiara Garassino, IRCCS Istituto Nazionale dei Tumori, Italy

P2.09-002: Prevalence and Survival of Malignant Pleural Mesothelioma Patients Treated in a Single Brazilian Cancer Center João Navarro Reolon, A.C. Camargo Cancer Center, Brazil

P2.09-003: Dissecting the Immune Environment in Malignant Pleural Mesothelioma: Results from a Prospective Assessment
Silvia Novello, University of Torino, Italy

P2.09-004: PD-L1 Protein Expression Is Negative Prognostic Factor in Malignant Pleural Mesothelioma in Central Europe Luka Brčic, Medical University of Graz, Austria

P2.09-005: The C-reactive Protein/Albumin Ratio Is a Novel Significant Prognostic Factor in Patients with Malignant Pleural Mesothelioma Shinkichi Takamori, Graduate School of Medical Sciences, Kyushu University, Japan

P2.09-005a: Clinical Characteristics of Early Stage, Malignant Pleural Mesothelioma Koizuru Kuriyama, Hyogo College of Medicine, Japan

P2.09-006: FISH Analysis of p16 and BAP1 Immunohistochemistry for the Diagnosis of Mesothelioma Kenzo Hiroshima, Tokyo Women’s Medical University, Japan

P2.09-007: Pleural Biopsy in Patients Suspected of Malignant Pleural Mesothelioma Consecutive 377 Cases Masaki Hashimoto, Hyogo College of Medicine, Japan

P2.09-008: Usefulness of Immunohistochemistry in the Differential Diagnosis of Epithelioid Mesothelioma and Lung Squamous Cell Carcinoma Kei Kushitani, Hiroshima University, Japan

P2.10 NURSING/PALLIATIVE CARE/ETHICS

P2.10-001: Factors Associated with Quality of Life among Patients with Lung Cancer Y.-Lin Wu, National Cheng Kung University, Taiwan

P2.10-002: A Study on the Relation between Gender and Quality of Life for Lung Cancer Patients Y.-Lin Wu, National Cheng Kung University Hospital, Taiwan

P2.10-003: The Deterioration and Prognostic Value of Functional Capacity in Patients with Lung Cancer: A Systematic Review Laerke Winther, University of Copenhagen, Denmark

P2.10-004: Efficacy and Safety of Viscum Album (Helixor M) to Treat Malignant Pleural Effusion in Patients with Advanced Lung Cancer Yun-Gyo Lee, Kangbuk Samsung Hospital, Korea

P2.10-005: Overall Survival of Lung Cancer Patients with Brain Metastases in a Developing Country Tomi Kovacevic, Institute for Pulmonary Diseases of Vojvodina, Faculty of Medicine, University of Novi Sad, Serbia

P2.10-006: Prognostic Factors of Mortality and Recurrence of Malignant Pleural Effusion in High-Risk Tumors According to the LENT Score Study Fernando Conrado Abrão, Hospital Santa Marcelina, Brazil

P2.11 PATIENT ADVOCACY

P2.11-001: Evaluation of a Cultural Notebook of Self-Expression and Follow-Up Among Patients with Lung Cancer in French Polynesia Eric Parrat, CHPI Taaoane, French Polynesia

P2.11-002: To Live and Work with Lung Cancer: Coping Strategies of a Stage 4 Patient Satoko Kono, Japan

P2.12 PULMONOLOGY/ENDOSCOPY

P2.12-001: Early Experience with Radial Endobronchial Ultrasound with Guide Sheath For Diagnosis of Peripheral Pulmonary Lesion Sze Shyang Kho, Sarawak General Hospital, Malaysia

P2.12-002: Radial Probe Endobronchial Ultrasound (EBUS) Guided Transbronchial Cryobiopsy In The Diagnosis of Peripheral Lung Mass Sze Shyang Kho, Sarawak General Hospital, Malaysia

P2.12-003: The History of EBUS TBNA Mark Krasnik, Copenhagen University Hospital Rigshospitalet/Gentofte Hospital, Denmark

P2.12-004: Lung Cancer Detection Rate of Conventional Bronchoscopy Techniques: A Tertiary Hospital Experience June 2011-December 2016 Mario Pasco Bagano, Perpetual Succour Hospital - Cebu Lung Institute, Philippines

P2.12-005: Comparison of Needle Gauge Used to Obtain Specimens During EBUS-TBNA in Patients with Lung Cancer Goohyeon Hong, Dankook University College of Medicine, Korea

P2.12-006: Evaluation of New 25G Needle in EBUS-TBNA Comparing Conventional 22G Needle in Diagnosis for Nodal Metastasis of Lung Cancer Yuchi Sakairi, Chiba University Graduate School of Medicine, Japan

P2.13 RADIOLOGY/STAGING/SCREENING

P2.13-001 – P2.13-026a SCREENING

P2.13-001: Herbal Compound as a Potential Lead Targets Lung Cancer Stem Cells Pei-Jung Lee, National Taiwan University, College of Medicine, Taiwan

P2.13-002: The LungScreen WA Project: Feasibility of LDCT Screening with the PLCOm2012 Risk Model and PanCan Nodule Risk Calculator Kuan Pin Lim, Sir Charles Gardiner Hospital, Australia

P2.13-004: Role of Low-Dose Chest Computed Tomography in Lung Cancer Screening among Never-Smokers Hye-Rin Kang, Seoul National University College of Medicine, Korea

P2.13-005: Early Results of Lung Cancer Screening in an African American Population Cherie Parungo Erkmen, Temple University Hospital, USA

P2.13-006: Enhanced Shared Decision Making in Lung Cancer Screening: Addressing Questions of Willingness and Ability to Undergo Lung Cancer Treatment Cherie Parungo Erkmen, Temple University Hospital, USA

P2.13-007: Relationship of Nodule Count and Lung Cancer Probability in New Nodules Detected after Baseline in CT Lung Cancer Screening Joan E. Walter, University of Groningen, University Medical Center Groningen, Netherlands
P2.13-008: Lung Cancer Screening Improves Mortality: Examining Screening Patterns in an Urban Underserved Community
Haiying Cheng, Albert Einstein College of Medicine/Montefiore Medical Center, USA

P2.13-009: Results of Low-Dose CT Lung Cancer Screening at a Non-University Tertiary Hospital System in Oregon, USA
John R. Handy, Providence Cancer Center, USA

P2.13-010: Five-Year-Long Follow-Up of the Low-Dose Computed Tomography Screening Programme in Gdansk, Poland
Marcin Ostrowski, Medical University of Gdanski, Poland

P2.13-011: Optimal Selection Criteria for LDCT Lung Cancer Screening
Renelle L. Myers, British Columbia Cancer Agency, Canada

P2.13-012: Recruitment for Lung Cancer Screening
Renelle L. Myers, British Columbia Cancer Agency, Canada

P2.13-013: Determination of the Detection Lead Time for Autoantibody Biomarkers in Early Stage Lung Cancer Using the UKCTOCS Cohort
Jim Jett, Oncimmune PLC, USA

P2.13-014: Computed Tomography-Based Radiomic Classifier Distinguishes Malignant from Benign Pulmonary Nodules in the National Lung Screening Trial
Tobias Peikert, Mayo Clinic, USA

P2.13-015: The Primary Care Provider Role in the US Screening Context: Current Practices and Strategies for Physician Engagement
Angela Meredith Criswell, Lung Cancer Alliance, USA

P2.13-016: Self-Reported Program Barriers to Increasing Lung Cancer Screening Rates in the US and Implications for the Screening Community
Angela Meredith Criswell, Lung Cancer Alliance, USA

P2.13-017: Four Years of Data in an Established Low Dose CT (LDCT) Screening Program
Jacob Sands, Lahey Hospital & Medical Center, USA

P2.13-018: Clinical Outcomes Stage I/II Adenocarcinoma Lung Diagnosed by Low Dose CT (LDCT) Screening vs Incidentally Discovered
Jacob Sands, Lahey Hospital & Medical Center, USA

P2.13-019: Attrition Rate in Community-Based Lung Cancer Screening: One and Done
Candice L. Wilshire, Swedish Cancer Institute, USA

P2.13-020: Lung-RADS Used in Lung Cancer Screening: Does Granulomatous Disease Interferes with the Results? Initial Findings at a Brazilian Cancer Center
Fabio Jose Haddad, A.C.Camargo Cancer Center, Brazil

P2.13-021: Community Network Lung Cancer Screening Experience Underrepresents Medically Underserved and Geographically Remote Individuals
Candice Leigh Wilshire, Swedish Medical Center and Cancer Institute, USA

P2.13-022: Lung Nodule Survey: One Pathology, Perspectives from Thoracic Surgeon, Pulmonologist and Radiology Point of View
Maria Teresa Ruiz Tsukazan, Hospital Sao Lucas da PUCRS, Brazil

P2.13-023: Lung Cancer Risk and Eligibility for Lung Cancer Screening in Patients Undergoing Computed Tomography Coronary Angiography
Daniel P. Steinfort, Royal Melbourne Hospital, Australia

P2.13-025: Selecting the Risk Cut off for the LLP Model
Kevin Ten Haaf, Erasmus MC, Netherlands

P2.13-026: Determining the Effect of Screening on Lung Cancer Mortality
Claudia I. Henschke, Icahn School of Medicine at Mount Sinai, USA

P2.13-026a: A Validated Clinical Lung Cancer Risk-Prediction Model for Light-, Heavy- and Ex-Smokers: the Lung-HUNT Model
Oluf Røe, Norwegian University of Science and Technology, Norway

P2.14 RADIOThERAPY

P2.14-001: Mid-Treatment Perfusion PET/CT Is More Effective Than Ventilation PET/CT in Functionally-Adapted Radiotherapy for NSCLC
Rosshini Thomas, Peter MacCallum Cancer Centre, Australia

P2.14-002: Impact of Pre-Existing Cardiac Disease and Heart Doses on Survival in NSCLC Treated with Post-Operative Thoracic Radiotherapy
Chia Ching Lee, National University Cancer Institute Singapore, Singapore

P2.14-003: Clinical Outcomes of SBRT in Inoperable Elderly Patients with NSCLC: Experience from a Developing Country
Fabio Y. Moraes, Hospital Sirio Libanes, Brazil

P2.14-004: Comparable Local Controls after Twice-Daily and Once-Daily Chest Radiotherapy in Extensive Stage Small Cell Lung Cancer
Bo Qiu, Sun Yat-sen University Cancer Center, China

P2.14-005: Determination of Optimal Cut off SUV Threshold for Auto-Contouring of GTV Using PETCT for Early Stage NSCLC
Mangesh Babarao Patil, Tata Memorial Hospital, India

P2.14-006: A Pilot, Randomized Trial of Daily Lisinopril vs Placebo to Prevent Radiation-Induced Pulmonary Distress (Alliance MC1221)
Terence Tai Weng Sia, Mayo Clinic Arizona, USA

P2.14-007: Histological Difference in Outcomes of Definitive Chemoradiotherapy for non-small cell Lung Cancer
Ito Hitoshi, Kyoto Katsura Hospital, Japan

P2.14-008: Partial and Full Arc VMAT in Lung Cancer SBRT with Different Definitions of Internal Target Volume Based on 4D CT
Xiance Jin, The 1st Affiliated Hospital of Wenzhou Medical University, China

Alexander Vincent Louie, London Regional Cancer Program, Canada

P2.14-010: The Time-Weighted Mid- Ventilation Technique: Reducing Planning Target Volumes For Patients Undergoing Lung Stereotactic Body Radiotherapy.
Charlotte Emily Louise Atkinson, St George Cancer Centre, Australia

P2.14-011: Recombinant Human Endostatin (Endostar) Combined with Concurrent Intensity Modulated Radiation Therapy for Elderly Local Advanced NSCLC
Qun Chen, Fuzhou Pulmonary Hospital of Fujian, China

P2.14-012: Clinical Outcomes of the Largest UK Cohort of Cyberknife-Delivered Stereotactic Ablative Body Radiotherapy (SABR) for Primary Lung Cancers
Qamar Ghafoor, Queen Elizabeth Hospital, UK

P2.14-013: Effect of Stereotactic Radiotherapy (SABR) on Pulmonary Function and Quality of Life: Results from a Tertiary Oncology Unit
Qamar Ghafoor, Queen Elizabeth Hospital, UK

P2.14-014: Does Histological Subtype Affect Outcomes in Stereotactic Ablative Body Radiotherapy (SABR) for Lung Tumours? Qamar Ghafoor, University Hospitals Birmingham NHS Foundation Trust, UK

P2.14-015: Outcomes for Stereotactic Ablative Body Radiotherapy (SABR) for Early Primary Lung Cancers: Cyberknife Versus VMAT Platform
Qamar Ghafoor, University Hospitals Birmingham NHS Foundation Trust, UK

P2.14-016: Pulmonary Resection After Curative Intent Chemoradiation for NSCLC
Gamze Cetinkaya, Uludag University, Turkey
P2.14-017: Postoperative Radiotherapy in Completely Resected Stage IIIA-N2 Non-Small Cell Lung Cancer
Sung-Ja Ahn, Chonnam National University Hwasun Hospital, Korea

P2.14-018: Treatment Outcome and Lung Toxicities of Volumetric Modulated Arc Therapy in the Treatment of Inoperable Non-Small-Cell Lung Cancer Patients
Congyong Xie, The 1st Affiliated Hospital of Wenzhou Medical University, China

P2.14-019: Magnetic Resonance (MR)-Guided Adaptive Stereotactic Ablative Radiotherapy for Adrenal Metastases
Suresh Senan, VU University Medical Center, Netherlands

P2.14-020: Clinical Validation of NTCP-Models for Esophageus Toxicity in Non-Small Cell Lung Cancer Patients Treated with Concurrent Chemoradiation
Iris Walraven, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Netherlands

P2.14-020a: Retrospective Research on Radiofrequency Ablation (RFA) for Liver Metastasis Due to NSCLC: A Single Institutional Experience
Kentaro Ito, Matusaka Municipal Hospital, Japan

P2.15 SCLC/NEUROENDOCRINE TUMORS

P2.15-001: NHWD-870, a Novel BET Family Bromodomain Inhibitor Targeting BRD2/3/4, Proved to Be Effective and Promising for Treatment of Small Cell Lung Cancer
Yongchang Zhang, Huanan Cancer Hospital, China

P2.15-002: Pulmonary Large Cell Neuroendocrine Carcinoma (LCNEC): An Experience From Eastern Indian Hospital
Prasanta Raghab Mohapatra, All India Institute of Medical Sciences, India

P2.15-003: A Long Non-Coding RNA HOT-TIP Expression Is Associated with Disease Progression and Predicts Outcome in Small Cell Lung Cancer Patients
Linlang Guo, Zhujiang Hospital, Southern Medical University, China

P2.15-004: Underrepresentation of Elderly Patients with ED-SCLC as Clinical Trial Candidates
Yuki Misumi, Yokohama Municipal Citizen’s Hospital, Japan

P2.15-005: Post-Progression Survival Is Strongly Linked to Overall Survival in Refractory Small-Cell Lung Cancer Patients Who Received Amrubicin
Hisao Imai, Gunma Prefectural Cancer Center, Japan

P2.15-006: The Effects of Pegylated Arginase on Small Cell Lung Cancer in vitro and in vivo
Shi Xu, The University of Hong Kong, Hong Kong

P2.15-007: Extensive Stage Small Cell Lung Cancer: Patterns of Care and Outcomes of a Single Institution over 15 Years
Eunji Hwang, Radiation Oncology Prince of Wales Hospital, Australia

P2.15-008: Genomic Analysis to Assess a Molecular Signature in Japanese Patients with Pulmonary High Grade Neuroendocrine Carcinoma
Hideaki Kojima, Shizuoka Cancer Center, Japan

P2.15-009: Linc00173 Modulates Chemoresistance of Small Cell Lung Cancer by Functioning as a Competing Endogenous RNA to Regulate Etk Expression
Fanrui Zeng, Zhubang Hospital, Southern Medical University, China

P2.15-010: Etk Interacting with PKF2B4 Modulates Chemoresistance of Small Cell Lung Cancer by Regulating Autophagy
Qiongyao Wang, Zhubang Hospital, Southern Medical University, China

P2.15-011: Therapeutic Strategies and Genetic Comparisons in SCLC and LCNEC of the Lung Using Next-Generation Sequencing
Masaki Itô, Hiroshima University Hospital, Japan

P2.15-012: Analysis of Small Cell Lung Cancer with Paraneoplastic Limbic Encephalitis
Minji Di, Peking Union Medical College Hospital, China

P2.15-013: Doxorubicin and Topotecan for Relapsed/Refractory Small Cell Lung Cancer (SCLC): A Phase I Study
Apar Kishor Ganti, VA Nebraska Western Iowa Health Care System and University of Nebraska Medical Center/Fred & Pamela Buffett Cancer Center, USA

P2.15-014: Extensive Stage Small Cell Lung Cancer: Is Primary Growth Factor Support Warranted in Patients Having Doublet Chemotherapy?
Tasha Mackie, Auckland District Health Board, New Zealand

P2.15-015: Negativity for Thyroid Transcription Factor 1 Was Correlated with Less Neuroendocrine Differentiation in Small Cell Lung Cancers
Yuko Iida, Nihon University School of Medicine, Japan

P2.15-016: Clinical Significance of Topoisomerase-II Expression in Patients with Relapsed HGNEC of the Lung Treated with Amrubicin
Yosuke Miura, Department of Respiratory Medicine, Gunma University Graduate School of Medicine, Japan

P2.15-016a: Exploiting G2-M Cell Cycle Checkpoint Dependency in Small Cell Lung Cancer (SCLC) by Targeting Checkpoint Kinase 1 (CHK1)
Triparna Sen, University of Texas MD Anderson Cancer Center, USA

P2.15-017: Postoperative Radiotherapy in Completely Resected Stage IIIA-N2 Non-Small Cell Lung Cancer
Sung-Ja Ahn, Chonnam National University Hwasun Hospital, Korea

P2.15-018: Treatment Outcome and Lung Toxicities of Volumetric Modulated Arc Therapy in the Treatment of Inoperable Non-Small-Cell Lung Cancer Patients
Congyong Xie, The 1st Affiliated Hospital of Wenzhou Medical University, China

P2.15-019: Magnetic Resonance (MR)-Guided Adaptive Stereotactic Ablative Radiotherapy for Adrenal Metastases
Suresh Senan, VU University Medical Center, Netherlands

P2.15-020: Clinical Validation of NTCP-Models for Esophageus Toxicity in Non-Small Cell Lung Cancer Patients Treated with Concurrent Chemoradiation
Iris Walraven, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Netherlands

P2.15-020a: Retrospective Research on Radiofrequency Ablation (RFA) for Liver Metastasis Due to NSCLC: A Single Institutional Experience
Kentaro Ito, Matusaka Municipal Hospital, Japan
P2.16-014: Deconstructing Surgical Decision Making
Rowena Yip, Icahn School of Medicine at Mount Sinai, USA

P2.16-015: Log Data of Digital Drainage System Is a Potential Predictive Factor of Pleurodesis Efficacy for Postoperative Air Leak After Pulmonary Resection
Tomonari Oki, National Cancer Center Hospital East, Japan

P2.16-016: Surgical Treatment of Indeterminate Lung Nodules
Masashi Yanada, Japanese Red Cross Kyoto Daini Hospital, Japan

P2.16-017: Surgical Treatment of Bronchial Carcinoid Tumors: Evaluation of Survival and Prognostic Factors. A Single-Center Experience
Piotr Rudzinski, National Institute of Tuberculosis and Lung Diseases, Poland

P2.16-018: Phrenic Nerve Injury After Lung Surgery: An Underestimated Problem
Luigi Ventura, University Hospital of Parma, Italy

P2.16-019: Improving Survival with a Lymph Node (LN) Collection Kit for Non-Small Cell Lung Cancer (NSCLC) Resections
Raymond U. Osarogiagbon, Baptist Cancer Center, USA

P2.16-020: Surgical Strategy for Synchronous Multiple Lung Cancers with Ground Glass Opacity
Toshihiko Moroga, Fukuoka University Chikushi Hospital, Japan

P2.16-021: Malignant Melanocytic Neoplasm: A Rare Presentation of a Large Mediastinal Mass
Tina Koh, National Cancer Centre, Singapore

P2.16-022: Initiative for Early Lung Cancer Research on Treatment: Pilot Implementation
Claudia I. Henschke, Icahn School of Medicine at Mount Sinai, USA

P2.16-023: Changes of the Pulmonary Artery After Resection of Stage I Lung Cancer
Michael Chung, Mount Sinai Hospital, USA

P2.16-024: Effect of Resection of Stage I Lung Cancer on Lung Volume
Artit Jirapatnakul, Icahn School of Medicine at Mount Sinai, USA

P2.16-025: Accuracy of Multidisciplinary Evaluation of Small Solitary Pulmonary Nodules in a Portuguese Private Hospital
Joao Reis, Hospital da Luz, Portugal

P2.16-026: Surgical Treatment for Metastatic Lung Tumors from Various Sarcomas
Hiromasa Yamamoto, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan

P2.16-027: Comparison of Single Chest Tube Versus Double Chest Tube Drainage After Lung Resection for the Treatment of Non-Small Cell Lung Cancer
Tomasz Gil, Jagiellonian University, John Paul II Hospital, Poland

P2.16-028: Are We Doing the Right Thing? Overall Survival & Intermediate Outcomes Following Lung Metastasectomy
Prakash Balakrishnan, Wellington Regional Hospital, New Zealand

P2.17-001: Pulmonary Inflammatory Myofibroblastic Tumor with TPM4-ALK Translocation
Katsuhiro Okuda, Nagoya City University Graduate School of Medical Sciences, Japan

P2.17-002: Pulmonary and Mediastinal Paragangliomas: Rare Endothoracic Malignancies with Challenging Diagnosis and Treatment
Angela De Palma, University of Bari “Aldo Moro”, Italy

P2.17-003: Is Complete Resection Mandatory for Mediastinal Germ Cell Tumor Which Shows Severe Adhesion to Greater Vessels?
Hiroyuki Ito, Kanagawa Cancer Center, Japan

P2.17-004: Salvage Surgery for Pulmonary Metastases in Patients with Testicular Germ Cell Tumors
Shinji Kikuchi, University of Tsukuba, Japan
# Posters At A Glance

## Wednesday, October 18 | Poster Session 3

### P3.01 Advanced NSCLC
- P3.01-001 – P3.01-076a EGFR
- P3.01-077 – P3.01-088a OTHER GROUPS AND TARGETS

### P3.02 Biology/Pathology
- P3.02-001 – P3.02-014a ANALYSIS OF BODY FLUIDS IN CANCER
- P3.02-015 – P3.02-017 APOPTOSIS IN LUNG CANCER
- P3.02-018 – P3.02-070 DRIVER GENES IN NSCLC, RESISTANCE, AND OTHER
- P3.02-071 – P3.02-097e FUNCTIONAL BIOLOGY IN LUNG CANCER

### P3.03 Chemotherapy/Targeted Therapy

### P3.04 Clinical Design, Statistics and Clinical Trials

### P3.05 Early Stage NSCLC

### P3.06 Epidemiology/Primary Prevention/Tobacco Control and Cessation

### P3.07 Immunology and Immunotherapy

### P3.08 Locally Advanced NSCLC

### P3.09 Mesothelioma

### P3.10 Nursing/Palliative Care/Ethics

### P3.11 Patient Advocacy

### P3.12 Pulmonology/Endoscopy

### P3.13 Radiology/Staging/Screening
- P3.13-001 – P3.13-038a DIAGNOSTIC RADIOLOGY

### P3.14 Radiotherapy

### P3.15 SCLC/Neuroendocrine Tumors

### P3.16 Surgery
- P3.16-001 – P3.16-036 RISK ASSESSMENT AND PROGNOSTIC FACTORS
- P3.16-037 – P3.16-049 SURGERY FOR LOCALLY ADVANCED AND ADVANCED NSCLC
- P3.16-050 – P3.16-053a TRANSLATIONAL STUDIES

### P3.17 Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies
**P3.01 ADVANCED NSCLC**

**P3.01-001 – P3.01-076a**

**EGFR**

**P3.01-001:** Comparisons of Two Plasma EGFR Platforms (ddPCR and Cobas) in Patients with Radiological Metastatic Lung Cancer
Jacky Yu Chung Li, Queen Elizabeth Hospital, Hong Kong

**P3.01-002:** Concurrent EGFR T790M Secondary Mutation and EMT in a Lung Adenocarcinoma Patient with EGFR TKI Drug Resistance
Renwang Liu, Tianjin Medical University General Hospital, China

**P3.01-003:** Study of the Relationship between EGFR Mutation Status and Bone Metastasis in Advanced Lung Adenocarcinoma
Zhao Bing, Affiliated Tumor Hospital of Xijiang Medical University, China

**P3.01-004:** The Underestimated Role of Bronchial Washing Fluid in the Detection of EGFR Mutation from Lung Cancer Patients
Jie Hu, Zhongshan Hospital, China

**P3.01-005:** ASTRIS: A Real World Study of Osimertinib Treatment in Patients with EGFR T790M Positive Advanced NSCLC; Interim Analysis
Sang-We Kim, Asan Medical Center, University of Ulsan College of Medicine, Korea

**P3.01-006:** Osimertinib in Pretreated EGFR T790M-Positive Non-Small Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis
Bin-Chi Liao, National Taiwan University Hospital, Taiwan

**P3.01-007:** Heterogeneous Resistance Mechanisms in Rebiopsies from EGFR-Mutated NSCLC: Transformation to SCLC; FGFR3 and T790M Mutations
Edyta Maria Urbanska, University of Copenhagen, Rigshospitalet, Finsens Center, Denmark

**P3.01-008:** Association between Icotinib Efficacy and Circulating Tumor Cell Levels in Advanced Non-Small Cell Lung Cancer
Meiyu Fang, Zhejiang Cancer Hospital, China

**P3.01-009:** Clinical Efficacy of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 18 E709X Mutations
Meiyu Fang, Zhejiang Cancer Hospital, China

**P3.01-010:** High Probability and Frequency of EGFR Mutations in Non-Small Cell Lung Cancer with Brain Metastases
Xiaohua Liang, Huashan Hospital, China

**P3.01-011:** Comparision of EGFR and ALK-Driven Lung Adenocarcinoma with Brain Metastases for Prognostic Factors in Chinese Patients
Fengnan Wang, The First Affiliated Hospital of Guangzhou Medical University, China

**P3.01-012:** Symptom Impact of First-Line Dacomitinib versus Gefitinib in EGFR-Positive NSCLC: Results from a Randomized Phase 3 Study
Rickard Sandin, Pfizer Oncology, Sweden

**P3.01-013:** CNS Metastases in EGFR Mutation Positive NSCLC: Impact on Health Resource Utilization
Negar Choback, British Columbia Cancer Agency, Canada

**P3.01-015:** Differential Outcomes between First and Second Generation TKIs in Patients with Activating EGFR Mutations in NSCLC
Sally C. Lau, British Columbia Cancer Agency, Canada

**P3.01-016:** Factors Associated with Symptoms Improvement and HRQoL for First-Line EGFR-TKIs in NSCLC: A Multicenter Prospective SMILE Study
Yu-Feng Wei, E-Da Hospital/I-Shou University, Taiwan

**P3.01-017:** Clinical Outcomes of Patients with EGFR T790M + NSCLC on Osimertinib
Wan Ling Tan, National Cancer Centre Singapore, Singapore

**P3.01-018:** Mutation Abundance Affects the Therapeutic Efficacy of EGFR-TKI in Patients with Advanced Lung Adenocarcinoma: A Retrospective Analysis
Huijuan Wang, Henan Cancer Hospital, China

**P3.01-019:** Canadian Multicentre Validation Study of Plasma Circulating Tumour DNA for Epidermal Growth Factor (EGFR) T790M Testing
Ming Sound Tsao, University Health Network Princess Margaret Cancer Centre, Canada

**P3.01-020:** Clinical Features ofPatients with Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations in Brunei
Shir Kiong Lu, The Brunei Cancer Centre, Brunei Darussalam

**P3.01-021:** A Multicenter, Non-Interventional Study on Real World EGFR Testing and in Patients with IIIB/IV NSCLC in Northern China
Ying Cheng, Jilin Provincial Cancer Hospital, China

**P3.01-022:** Prognostic Value of Clinical, Immune and Biochemical Markers in EGFR-Mutant NSCLC Patients Treated with First-Line EGFR TKIs
Isaac Kah Siang Ng, NUS Yong Loo Lin School of Medicine, Singapore

**P3.01-023:** First-line Afatinib for Non-Small Cell Lung Cancer in Real World Practice
Youjin Kim, Samsung Medical Center, Korea

**P3.01-024:** Characterization of PD-L1 Expression and Its Predictive and Prognostic Significance in EGFR-Mutant NSCLC Patients Treated with EGFR-TKIs
Tao Jiang, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

**P3.01-025:** Treatment Outcomes of Advanced Lung Adenocarcinoma with Unknown EGFR Gene Status: A Retrospective Analysis of 140 Patients
Cheng Xiao, The First Affiliated Hospital, School of Medicine, Zhejiang University, China

**P3.01-026:** Analysis of Long-Term Response to First-Line Afatinib in the LUX-Lung 3, 6 and 7 Trials in Advanced EGFRm+ NSCLC
Martin Schuler, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Germany

**P3.01-027:** TET2 Mutation as a Novel Mechanism of Acquired Resistance to EGFR TKIs Identified by a Mutational Profiling Using NGS
Xiao Hu, Zhejiang Cancer Hospital, China

**P3.01-028:** Efficacy of Osimertinib for Brain Metastasis in Advanced NSCLC: Data from Single Center in ASTRIS Trial
Jee Hung Kim, Yonsei Cancer Center, Korea
P3.01-029: Transient Asymptomatic Pulmonary Opacities (TAPOs) during Osimertinib Treatment and Its Clinical Implication
Hansang Lee, Samsung Medical Center, Korea

P3.01-030: CNS Metastases in EGFR Mutation Positive (EGFRm) NSCLC Patients: The Prognostic Relevance of Presenting Symptoms
Negar Chooback, British Columbia Cancer Agency, Canada

P3.01-031: ctDNA Assessment of EGFR Mutation Status in Chinese Patients with Advanced Non-Small-Cell Lung Cancer in Read World Setting
Shirong Zhang, Affiliated Zhongzhou Hospital of Nanjing Medical University, China

P3.01-032: Preliminary study of Lung Cancer Adenocarcinoma with De-novo EGFR T790M Mutation in Persahabatan Hospital-Jakarta, Indonesia.
Hapsari Dewianti, Faculty of Medicine Universitas Indonesia - Persahabatan National Respiratory Referral Hospital, Indonesia

P3.01-033: Detection of Epidermal Growth Factor Receptor Mutations with Plasma Sample Compared with Tumor Tissue Biopsy in Advanced Lung Adenocarcinoma
Taewon Jang, Kosin University Gospel Hospital, Korea

P3.01-034: Liquid Biopsy for EGFR Genotyping Using Cell-Free DNA and Extracellular Vesicular DNA of Pleural Effusion in Pulmonary Adenocarcinoma Patients
Jong Sik Lee, Konkuk University School of Medicine, Korea

P3.01-035: Post-Marketing Observational Study of Japanese Patients with EGFR Mutation-Positive (EGFRm+) NSCLC Treated with Daily Afatinib (Final Report)
Nobuyuki Yamamoto, Wakayama Medical University, Japan

P3.01-036: A Phase IIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: An Interim Analysis
Yi-Long Wu, Guangdong General Hospital and Guangdong Academy of Medical Sciences, China

P3.01-037: Understanding Mechanisms of Resistance to Osimertinib by Circulating Tumor DNA Genotyping in Advanced Non-Small-Cell Lung Cancer
Gang Cheng, Novogene Co., Ltd., China

P3.01-038: Impact on OS and PFS of 2nd and 3rd Generation TKI in EGFR Mt+ and ALK+ Patients: Results of the NOWEL Network
Julia Roeper, Pius Hospital Oldenburg/University of Oldenburg, Germany

P3.01-040: Real-World Management of Patients with EGFR Mutation-Positive NSCLC in the US
Apar Kishor Ganti, VA Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, USA

P3.01-041: The Robustness of Allele-Specific qPCR Assays for Detection of EGFR Mutations in Plasma Cell-Free DNA from NSCLC Patients
Joanna Chorostowska-Wynimko, National Institute of Tuberculosis and Lung Diseases, Poland

P3.01-042: Efficacy & Tolerability of Afatinib in NSCLC Patients Prior Exposure to 1st Generation EGFR TKI: Thailand Multicenter Study
Thanyanan Reungwattana, Ramathibodi Hospital, Thailand

P3.01-043: Impact of ErbB Mutations on Clinical Outcomes in Afatinib- or Erlotinib-Treated Patients with SCC of the Lung
Glenwood Goss, University of Ottawa, Canada

P3.01-044: Erlotinib vs Chemotherapy in EGFR Mut+ NSCLC: OS in Three Phase III Trials Adjusting for Post-Progression Treatment Crossover
Yi-Long Wu, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

P3.01-045: Correlation of EGFR Mutation Detection in ctDNA by Two Different Platforms in Advanced NSCLC Patients from a Single Institution
Naemi Reguair, Hospital Clinic, Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain

P3.01-046: Longitudinal Analysis of Plasma ctDNA in EGFR-Mutant NSCLC: SWOG S1403 Trial of Afatinib with or without Cetuximab
Philip Christopher Mack, UC Davis Comprehensive Cancer Center, USA

P3.01-047: Erlotinib Induced Ectropion Followed by Papulo-Erythematous Skin Rash
Abdolali Shahrasbi, Bouali Hospital, Tehran Medical unit, Azad University, Iran

P3.01-048: CBL Mutations as Potential Mediators of EGFR TKI Resistance Effectively Treated with Sitravatinib
Lyudmila A. Bazhenova, University of California San Diego Moores Cancer Center, USA

P3.01-049: T790M Mutation Detection, Clinical Characteristics and Impact in NSCLC Patients Treated with EGFR Tyrosine Kinase Inhibitors
Júlio Oliveira, Instituto Português de Oncologia do Porto, Portugal

P3.01-050: A Real World Treatment Study of Osimertinib: ASTRIS Study Korean Subgroup Analysis
Byoung Chul Cho, Yonsei Cancer Center, Korea

P3.01-051: Dramatic Response to Afatinib in EGFR-Mutant Lung Adenocarcinomas After Resistance to First-Generation EGFR Inhibitors: A Brief Report
Wen -Feng Li, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, China

P3.01-052: The Prevalence and Genotype Distribution of Dual in Cis EGFR Mutations in Chinese Advanced Non-Small Cell Lung Cancer Patients
Min Li, Xiangya Hospital, Central South University, China

P3.01-053: Detection of Common EGFR Mutation in Cytological Smears Using Reversed Dot Blot (RDB) Hybridization Method
Najmiatul Masykura, Stem-cell and Cancer Institute, Indonesia

P3.01-054: Urinary ct-DNA Testing of EGFR Common Mutation in Non-Small Cell Lung Cancer Patients
Asep Muhammad Ridwanuloh, Indonesian Institute of Sciences, Indonesia

P3.01-055: The Usefulness of Liquid Biopsy for ctDNA in Patients with EGFR-Mutant NSCLC During and After Treatment with EGFR-TKIs
Takuma Yokoyama, Kyorin University Hospital, Japan

P3.01-056: Intracranial Activity of Osimertinib in Naïve EGFRm T790M(-)and Treated EGFRm T790M(+) NSCLC Patients with Asymptomatic Brain Metastases
Nir Peled, Rabin Medical Center, Davidoff Cancer Center, Israel

P3.01-057: Comparison of EGFR Mutations in Matched Tumor Tissues, Cell Blocks, Pleural Effusions and Bloods with NSCLC, by PANA Mutyper and PNA Clamping
Seung Joon Kim, The Cancer Research Institute, College of Medicine, The Catholic University of Korea, Korea

P3.01-058: Impact of Different Timing of Radiotherapy in Patients with Brain Metastases from Epidermal Growth Factor Receptor-Mutant NSCLC
Yaping Xu, Zhejiang Cancer Hospital, China

P3.01-059: First Experience with Osimertinib in Patients with Newly Developed T790M Mutation Previously Treated with EGFR-TKIs in Croatia
Marko Jakopovic, University Hospital Centre Zagreb, Croatia

P3.01-060: The Clinical Utility of ctDNA Gene Analysis in Lung Cancer
Smrada Geva, Thoracic Cancer Service, Davidoff Cancer Center, Rabin Medical Center, Israel

P3.01-061: Endostar Combined with Re-Challenged Gefitinib in Previous Treatment Failed NSCLC: A Retrospective Study
Huijuan Wang, Henan Cancer Hospital, China

P3.01-062: The Perceived Value of Avoiding Biopsy: Patients’ Willingness to Pay for Circulating Tumour DNA T790M Testing
Tristan Alexandra Barnes, Princess Margaret Cancer Centre, Canada
**P3.01-063:** Concomitant EGFR Mutation and ALK Rearrangement in Non-Small-Cell Lung Cancer
Rui-Lian Chen, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, China

**P3.01-064:** Detection of EGFR Mutations in Circulating Tumor DNA Using Plasma Samples: Clinical Validation of Cobas EGFR Mutation Test V2
Hidetoshi Itani, Ise Red Cross Hospital, Japan

**P3.01-065:** Advanced NSCLC with EGFR Mutations in Elderly Patients. Single-Centre Experience
Angel Artal Cortes, Hospital Universitari Miguel Servet, Spain

**P3.01-066:** CNS Metastases of Pulmonary Adenocarcinoma Harboring EGFR-Activating Mutations: a Multidisciplinary Approach, Including EGFR-TKIs
Renata Rodrigues da Cunha Colombo Bonadio, Instituto do Cancer do Estado de Sao Paulo, Brazil

**P3.01-067:** TP53 Mutations Could Involved in EGFR-TKI Primary Resistance in Advanced Non-Small Cell Lung Cancer
Tao Jiang, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

**P3.01-068:** Investigation of Low Plasma/Tissue EGFR Concordance in Russia: Follow-up to the IGNITE Global Diagnostic Study
Brian B. Lentrichia, AstraZeneca Pharmaceuticals, USA

**P3.01-069:** Three Treatments for EGFR-Mutant Non-Small-Cell Lung Cancer with Brain Metastases
Yun Fan, Zhejiang Cancer Hospital, China

**P3.01-070:** A Phase II Study of Fruquintinib in Combination with Gefitinib in Stage IIIb/IV NSCLC Patients Harboring EGFR Activating Mutations
Shun Lu, Shanghai Chest Hospital, China

**P3.01-071:** Randomized Phase 1b/3 Study of Erlotinib + Ramucirumab in Untreated EGFR Mutation-Positive Stage IV NSCLC: Phase 1b Outcomes
Kazuhiko Nakagawa, Kindai University School of Medicine, Japan

**P3.01-072:** Dacomitinib Versus Gefitinib for First-Line Treatment of Advanced EGFR+ NSCLC in Japanese Patients (ARCHER 1050)
Kazuhiko Nakagawa, Kindai University Hospital, Japan

**P3.01-073:** TPX-0005 with an EGFR Tyrosine Kinase Inhibitor (TKI) Overcomes Innate Resistance in EGFR Mutant NSCLC
Rafael Rosell, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Spain

**P3.01-074:** Genomic Analysis of Tumor and Plasma in T790M Mutant Positive EGFR Lung Cancer Patients before and after Osimertinib Treatment
James Chih-Hsin Yang, National Taiwan University, Taiwan

**P3.01-075:** Aftinib Dose Adjustment: Effect on Safety, Efficacy and Patient-Reported Outcomes in the LUX-Lung 3/6 Trials in EGFRm+ NSCLC
Vera Hirsh, McGill University, Canada

**P3.01-076:** QT/WST Analysis to Compare the Benefit of Gefitinib Versus Pemetrexed Platinum for Patients with EGFR Mutated NSCLC
Vijay Patil, Tata Memorial Hospital, India

**P3.01-076a:** Lung Cancer Stem Cell (LCSC) Markers and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Resistance
Shinnosuke Takeomo, Nagasaki Medical Center, Japan

**P3.01-077 – P3.01-088a** OTHER GROUPS AND TARGETS

**P3.01-077:** Effectiveness of Methylnaltrexone Bromide in Opioid-Induced Constipation in Advanced NSCLC Patients
Ioannis Dimitrioulos, Sotiria Hospital for Thoracic Diseases, Greece

**P3.01-078:** Outcome of Stage IIIb Non-Small Cell Lung Cancer (NSCLC) Patients - A Single Tertiary Center Experience
Tahir Mehmood, Northwest General Hospital and Research Centre, Pakistan

**P3.01-079:** Evaluating the Roles of Neoadjuvant and Adjuvant Chemotherapy for Treating Patients with Stage IIIa (N2) Lung Cancer
Luo-Sheng Yong, National Taiwan University, Taiwan

**P3.01-080:** Overall Survival (OS) of Pathological N2 Non-Small Cell Lung Cancer (NSCLC) After Surgical Resection
Etienne Bourdages-Pageau, Laval University, Canada

**P3.01-081:** Overall Survival (OS) of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) After Negative Invasive Mediastinal Staging
Arthur Vieira, Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ), Canada

**P3.01-082:** Surgical Rebiopsy in Advanced Non-Small Cell Lung Cancer Resistant to Previous Chemotherapy
Sumin Shin, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea

**P3.01-083:** Clinical Characteristics and Survival Outcomes for Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Double Mutations
Min Peng, Renmin Hospital of Wuhan University, China

**P3.01-084:** Analysis on ALTER0303 Trial: aCECs Level May Correlate with Metastases Burden and Predict PFS of Alectinib in Advanced NSCLC
Kai Li, Tianjin Medical University Cancer Institute and Hospital, China

**P3.01-085:** A Phase 2 Trial of Apatinib in Advanced Non-Squamous NSCLC: Updated Data and Clinical Benefit of Continuing Apatinib after Initial Progression
Fengying Wu, Shanghai Pulmonary Hospital, Tongji University, China

**P3.01-086:** Biomarker Testing Trends and Treatment Patterns in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients in the United States
Laura Chu, Genentech, USA

**P3.01-087:** Impact Factor Analysis for Efficacy and Prognosis of Alectinib in NSCLC as Second-Line Treatment: Data from Trial ALTER 0303
Kai Li, Tianjin Medical University Cancer Institute and Hospital, China

**P3.01-088:** Molecular Testing and First-Line Treatment of Patients with NSCLC. First Results from the German CRISP Study (AIO-TRK-0315)
Martin Sebastian, University Hospital Frankfurtt, Germany

**P3.01-088a:** Phase II Study of Nab-Paclitaxel in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer: SNIPER Study
Naruo Yoshimura, Graduate School of Medicine, Osaka City University, Japan

**P3.02:** BIOLOGY/PATHOLOGY

**P3.02-001 – P3.02-014** ANALYSIS OF BODY FLUIDS IN CANCER

**P3.02-001:** Clinical Significance of Plasma Epstein-Barr Virus DNA in Pulmonary Lymphoepithelioma-Like Carcinoma (LELC) Patients
Mian Xie, The First Affiliated Hospital of Guangzhou Medical University, China

**P3.02-002:** Liquid and Solid Rebiopsies in EGFR-Mutated NSCLC Patients
Alexis B. Cortot, Lille University Hospital, France

**P3.02-003:** Tissue and Serum Levels of Galectin-3 in NSCLC Patients
Yoko Kataoka, Shiga University of Medical Science, Japan
P3.02-004: Analysis of MET in Liquid Biopsy and Tissue Biopsy in Patients with Advanced NSCLC: Incidence and Pattern
Edgardo S. Santos, Thoracic and Head and Neck Cancer Programs, Eugene M. & Christine E. Lynn Cancer Institute, Florida Atlantic University, Boca Raton, FL, USA

P3.02-005: Applicability of Ion Torrent Colon and Lung Sequencing Panel on Circulating Cell-Free DNA
Christina Dernuth, Aarhus University Hospital, Denmark

P3.02-006: Monitoring Genetic Alterations in Plasma during Anti-Cancer Treatment in Advanced NSCLC (MAGICI-Validation Cohort: Preliminary Results)
Laura Bonanno, 1. Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Italy

P3.02-007: Circulating miRNAs as Prognostic Biomarkers in Resected Early-Stage Non-Small-Cell Lung Cancer
Lucio Crinó, Medical Oncology - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Italy

P3.02-008: Non-Invasive Diagnosis of Solitary Pulmonary Nodules Using High-Throughput Targeted DNA Methylation Sequencing of Circulating Tumor DNA
Wenhua Liang, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, China State Key Laboratory of Respiratory Disease, China

P3.02-009: Mutation Detection in Cell-Free DNA from Patients with Lung Adenocarcinoma by Next-Generation Sequencing
Hana Khairina Putri Faisal, Natural Sciences Graduate School of Biomedical and Health Sciences, Japan

P3.02-010: Significant Increase of Blood Extracellular Vesicles in Pulmonary Vein as Potential Prognostic Biomarker for Lung Cancer Patients
Eeyeon Hyeon Choi, Korea University Guro Hospital, Korea

P3.02-011: A Prospective Study of Serial Circulating Tumor DNA Assessment in Detecting Recurrence of Resected Early-stage Lung Cancer
Hong Kwan Kim, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea

P3.02-012: Liquid Based Cytology (LBC) Specimens Were Useful for EGFR Mutation Test
Tatsuo Ohira, Tokyo Medical University, Japan

P3.02-013: Prognostic Role of Circulating Tumor DNA (ctDNA) and Immune Cell Biomarkers in Non-Small Cell Lung Cancer (NSCLC)
Young Kwang Chae, Robert H Lurie Comprehensive Cancer Center of Northwestern University, USA

P3.02-014: Amplicon-Based Next-Generation Sequencing (NGS) of Plasma Cell-Free DNA (cfDNA) for Detection of Driver and Resistance Mutations in NSCLC
Nicolas Marie Guibert, Dana Farber Cancer Institute, USA

P3.02-015: Diagnosis of Value of FR alpha - CTs Detected by LT-PCR for Lung Cancer in SPN and Tumor Invasiveness in Adenocarcinoma
Qianjun Zhou, Shanghai Chest Hospital, Shanghai Jiaotong University School of Medicine, China

P3.02-016: Correlation of Programmed Cell Death Ligand-1 Messenger RNA and Protein Expression in Non-Small Cell Lung Cancer
Hyun Jung Kwon, Seoul National University Bundang Hospital, Korea

P3.02-017: Apoptosis-Related Protein in Non Small Cell Lung Cancer: Correlation of Clinicopathologic, Molecular Characteristics and Prognosis
Ping-Li Sun, Jinlin University Second Hospital, China

P3.02-018 – P3.02-070 DRIVER GENES IN NSCLC, RESISTANCE, AND OTHER

P3.02-019: Clinical Validation of a Real Time PCR Assay for the Detection of ROS1 Fusion in Chinese Non-Small Cell Lung Cancer
Guanshan Zhu, Amoy Diagnostics Co., Ltd., China

P3.02-020: Comparison of Diagnostic Ability for EGFR Mutation of the Specimen Groups: Histology - Cytology - Plasma
Nguyen Son Lam, Pham Ngoc Thach Hospital, Vietnam

P3.02-021: Secondary EGFR Exon 20 T790M Mutation for Therapy of Non Small Cell Lung Cancer at Phat Ngoc Thach - Ho Chi Minh City - Vietnam
Nguyen Son Lam, Pham Ngoc Thach Hospital, Vietnam

P3.02-022: Protein Tyrosine Phosphatase Interacting Protein S1 Might Improve EGFR-TKI Sensitivity in Non-Small-Cell Lung Cancer
Xing Wang, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), China

P3.02-023: Semaphorin 7A Reduces Response to EGFR-TKI Treatment via Apoptosis in Human Lung Adenocarcinoma
Yuhei Kinehara, Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Japan

P3.02-024: Role of FBXW7 in the Maintenance of Quiescent Cancer Stem Cells Resistant to Gefitinib in EGFR-Mutation-Positive Non-Small Cell Lung Cancer
Mouid Hidayat, Juntendo University Graduate School of Medicine, Japan

P3.02-025: 65 Cases of Molecular Profiling Analysis in Surgical Resected Pulmonary Neuroendocrine Carcinoma
Gang Chen, Fujian Provincial Cancer Hospital, China

P3.02-026: The Study of ROS1 Rearrangement in Advanced Primary Non-Small Cell Lung Cancer and Associated Metastatic Lesions
Gang Chen, Fujian Provincial Cancer Hospital, China

P3.02-027: Lung Adenocarcinoma Patient with EGFR 19 Exon Insert Mutation: I740_K745insIPVAIK and Its Response to Icotinib: A Case Report
Gang Chen, Fujian Provincial Cancer Hospital, China

P3.02-028: 276 Cases of EGFR/ALK Gene Status and Predominant Histologic Subtype in Chinese Surgically Resected Lung Adenocarcinoma
Gang Chen, Fujian Provincial Cancer Hospital, China

P3.02-029: 218 Cases of EGFR/ALK Gene Status Analysis in Chinese Lung Squamous Cell Carcinoma
Gang Chen, Fujian Provincial Cancer Hospital, China

P3.02-030: Inhibitory Effects of Mitochondrial TRAP1 on Gefitinib-Resistance in Non-Small Lung Cancer Cells
Euntaik Jeong, Wonkwang University Hospital, Korea

P3.02-031: Detection of Activating EGFR Mutations and Resistant T790M Mutation from cfDNA in Malignant Pleural Effusion (MPE-DNA)
Kirsty Wai Chung Lee, Chinese University of Hong Kong, Hong Kong
P3.02-032: Spatial Heterogeneity of EGFR and KRAS Variant Allele Frequencies Correlates with Histological Patterns of Lung Adenocarcinomas
Steffen Dietz, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Germany

P3.02-033: Pathological and Molecular Alterations after First and Second Generation EGFR-TKI Therapy in Patients with EGFR-Mutated Lung Adenocarcinomas
Hironori Uruga, Toranomon Hospital, Japan

P3.02-034: Acquired Resistance to Osimertinib by CCDC6-RET Fusion in a Patient with EGFR T790M Mutant Metastatic Lung Adenocarcinoma
Wade Thomas Iams, McGaw Medical Center of Northwestern University, USA

P3.02-035: Mutational Signatures and Their Association with Clinicopathological Features in Lung Adenocarcinoma of Smokers
Takeshi Jimbo, Daiichi-Sankyo Co., Ltd., Japan

P3.02-036: Feasibility Study to Evaluate Patterns of Metastases and Effect of Surgery on Lung Cancer Xenografts with Differing Sensitivity to EGFR TKI
Sabita Jiwani, Tata Memorial Hospital, India

P3.02-038: Diagnosis of Deletemeal Disease and Clonal Heterogeneity with Digital Droplet PCR (ddPCR) in EGFR Mutated NSCLC
Gareth Rivalland, University of Melbourne, Australia

P3.02-039: Acquired Resistance to EGFR-TKI in the Uncommon EGFR Mutation, G719S
P3.02-040: Driver Gene Detection in Chinese NSCLC Patients Using CSMART and Prognosis Analysis
Meiyu Fang, Zhejiang Cancer Hospital, China

P3.02-041: EGFR Amplification Mediated Resistance to TAS121, A Third-Generation EGFR-TKI, in EGFR T790M-Positive Non-Small Cell Lung Cancer
Sho Watanabe, National Cancer Center Hospital, Japan

P3.02-042: DS-1205b, a Novel, Selective, Inhibitor of AXL, Delays the Onset of Resistance and Overcomes Acquired Resistance to EGFR-TKIs
Takeshi Jimbo, Daichi-Sankyo Co., Ltd., Japan

P3.02-043: Clinical and Genetic Features in Lung Adenocarcinoma Without EGFR Mutation and ALK Rearrangement in Taiwan
Tsu-Hui Shiou, Taipei Veterans General Hospital, Taiwan

P3.02-044: Diagnosis and Monitoring of EGFR Mutation Status with cfDNA in Advanced NSCLC: A Prospective Single Institution Study in Asia
Teh-Ying Chou, Taipei Veterans General Hospital, Taiwan

P3.02-045: Prevalence of ALK Gene Abnormalities in Routine Diagnostics of Polish NSCLC Patients
Kamil Wojas-Krawczyk, Medical University of Lublin, Poland

P3.02-046: EGFR-Grb2-GEF100 Complex Promoted Its Invasive and Metastatic Potential via Arf6 Pathway in Lung Adenocarcinoma
Toshi Menju, Graduate School of Medicine, Kyoto University, Japan

P3.02-047: Testing EGFR and ALK in Large Cell Neuroendocrine Carcinoma of the Lung. Looking for Biological Features in Rare Tumors
Teresa García Manrique, Hospital Virgen Macarena, Spain

P3.02-048: Clinicopathologic Characteristics of Non-Small Cell Lung Carcinomas harbouring MET Exon 14 Skipping Mutations
Takeshi Fujii, Toranomon Hospital, Japan

P3.02-049: The Evaluation of Circulating miRNA Expression in Plasma as the Epigenetic Marker of EGFR Mutation Status in NSCLC Patients
Mateusz Florczuk, National Institute of Tuberculosis and Lung Diseases, Poland

P3.02-050: Mechanisms of Acquired Resistance to the ALK Inhibitor Lorlatinib in ALK-Rearranged NSCLC Cell Lines
Anne Tranberg Madsen, Aarhus University Hospital, Denmark

P3.02-051: Low Consistency Between FGFR1 Gene Amplification and Protein Expression in Squamous Cell Lung Cancer (SQCLC)
Joanna Chorostowska-Wynimko, National Institute of Tuberculosis and Lung Diseases, Poland

P3.02-052: Stability of EGFR Mutations in Whole Blood and Plasma in Patients with NSCLC
Johanne Andersen Højbjerg, Aarhus University Hospital, Denmark

P3.02-053: Optimization and Characterization of Assays to Identify Met Exon 14 Skipping in FFPE Embedded NSCLC Samples
Steven G. Gray, Trinity College Dublin, Ireland

P3.02-054: Prognostic Implications of ROS1 Positivity in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Published Literature
Anchit Khanna, Pfizer Oncology, Australia

P3.02-055: Detecting ALK, ROS1 and RET Gene Translocations in Non-Small Cell Lung Cancer (NSCLC) with the NanoString Platform
Hangjun Wang, McGill University Health Center & McGill University, Canada

P3.02-056: EGFR Mutation Profile of NSCLC Patients Tested at the Lung Center of the Philippines
Maria Teresa Alhambra Barzaga, Lung Center of the Philippines, Philippines

P3.02-057: Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples
Kurtis D. Davies, University of Colorado - Anschutz Medical Campus, USA

P3.02-058: Detection of ROS1 Rearrangements in 508 Russian Patients with Non-Small Cell Lung Cancer (NSCLC)
Irina Demidova, Moscow Oncological Hospital 62, Russia

P3.02-059: T790M and C797S as Mechanisms of Acquired Resistance to Dacomitinib in Cell Models
Yosshisai Kobayashi, Kindai University Faculty of Medicine, Japan

P3.02-060: EGFR Mutation Status by Three Sequencing Platforms in 704 Non-Small Cell Lung Cancer (NSCLC) Brazilian Patients
Helano Cario Freitas, A.C. Camargo Cancer Center, Brazil

P3.02-061: An ALK Follow-On Companion Diagnostic Using CGP for Clinical Care of Patients with NSCLC
James Sun, Foundation Medicine, USA

P3.02-062: An EGFR Follow-On Companion Diagnostic for Clinical Care of Patients with NSCLC
James Sun, Foundation Medicine, USA

P3.02-063: EGFR Exon 20 Insertions in Lung Adenocarcinomas: Molecular and Clinicopathologic Characteristics Among Hispanics (Geno1.2-CLiCaP)
Oscar Arrieta, Instituto Nacional de Cancerologia, Mexico

P3.02-064: Epidermal Growth Factor Receptor Gene Mutation in Pleural Lavage Cytology Findings of Primary Lung Adenocarcinoma Cases
Takashi Inoue, Dokkyo Medical University, Japan

P3.02-065: Lung Adenocarcinoma Patient with EGFR Kinase Domain Duplication(KDD) and Its Response to Icotinib: A Case Report
Chunwei Xu, Fujian Provincial Cancer Hospital, China

P3.02-066: Wild-Type KRAS Mediates Growth Inhibition and Resistance to MEK Inhibitors through Dimerization with Mutant KRAS in Lung Adenocarcinoma
Chiara Ambrogio, Dana Farber Cancer Institute, USA

P3.02-067: Lung Cancer with Concurrent EGFR Mutation and ROS1 Rearrangement: A Case Report
Meiyu Fang, Zhejiang Cancer Hospital, China

P3.02-068: 95 Cases of EGFR/ALK Gene Rearrangements in a Cohort of Positive Patient Samples
Kurtis D. Davies, University of Colorado - Anschutz Medical Campus, USA

P3.02-069: 159
P3.02-071: Statics May Improve the Prognosis of Patients with Lung Adenocarcinoma by Supressing Mutant p53-Induced EMT
Shigeto Nishikawa, Graduate School of Medicine, Kyoto University, Japan

P3.02-072: MiR-33b Inhibits Lung Adenocarcinoma Cell Epithelial-Mesenchymal Transition Through ceRNA Regulatory Network
Min Li, Xiangya Hospital Central South University, China

P3.02-073: Stromal Hedgehog Pathway Activation Suppresses Growth and Metastasis of Lung Adenocarcinoma
James Kim, University of Texas Southwestern, USA

P3.02-074: Podoplanin-Positive CAF Is Associated with a Higher Number of Single Nucleotide Variants in Cancer Cells in Lung Adenocarcinoma
Shoko Nakasone, National Cancer Center Hospital East, Japan

P3.02-075: Molecular Disorders of the Genes of Intracellular Signal Pathways in Patients with Non-Small Cell Lung Cancer: Shizuka Shima, Institute of Genetics and Cytology of the National Academy of Sciences of Belarus, Belarus

P3.02-076: Glutaminase Inhibitor CB-839 Radiosensitizes KRAS-Mutant Lung Cancer Cells in a LKB1- and KEAPI/NRF2-Pathway Dependent Manner
Piyada Sitthideatphaiboon, The University of Texas MD Anderson Cancer Center, USA

P3.02-077: Platin Sensitivity and ATM-Deficiency in Non-Small Cell Lung Cancer
D. Gwyn Bebb, University of Calgary, Canada

P3.02-078: Establishing Malignant Pleural Mesothelioma Primary Cell Lines Using the 3D Spheroid Method Produces a Model with Better Tumour Architecture
Yuen Yee Cheng, The University of Sydney, Australia

P3.02-079: A 3-D Spheroid Culture Represents an Improved in Vitro Model of Malignant Pleural Mesothelioma (MPM)
Yuen Yee Cheng, The University of Sydney, Australia

P3.02-080: DNMT3A Defines a Unique Molecular Class of Chinese Non-Small Cell Lung Cancer Patients
Gang Chen, Fujian Provincial Cancer Hospital, China

P3.02-081: Nutritional Status Assessment in Treatment Naïve Patients with Lung Cancer
Sabita Jiwnani, Tata Memorial Hospital, India

P3.02-082: High Mobility Group Box 1 Antagonist Limits Metastatic Seeding in the Lungs via Reduction of Cell-Cel Adhesion
Adi Karsch-Bluman, The Institute for Drug Research, The School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Israel

P3.02-083: DKK1 Promotes Migration and Invasion of Non-Small Cell Lung Cancer via β-Catenin Signaling Pathway
Jinjing Tan, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, China

P3.02-084: FGFR9-FGFR Pathway Induce Neuroendocrine Differentiation in Lung Epithelial Cells
Kota Ishioka, Keio University School of Medicine, Japan

P3.02-085: Sphingosine Kinase 1 (SPHK1) Promotes Proliferation and Survival in Non-Small Cell Lung Cancer
Nanomoto Motono, Kanazawa Medical University, Japan

P3.02-086: MGA Suppresses the MYC Pathway in Lung Adenocarcinoma
Paula Liabata, Bellvitge Biomedical Research Institute, Spain

P3.02-087: Long Noncoding RNA FOXF1-AS1 Regulates Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer Cells
Yongsheong Wang, Nanjing Drum Tower Hospital, Medical School of Nanjing University, China

P3.02-088: Enhanced Glycolysis Is Critical for Maintaining Inactivation of JNK and Stability of EGFR Leading to the Survival of EGFR-Mutant Lung Cancer Cells
Jae Cheol Lee, Asan Medical Center, University of Ulsan College of Medicine, Korea

P3.02-089: Establishment of Highly Metastatic Lung Cancer Cell Sublines in Long-term Three-dimensional Low Attachment Cultures
Tomoyuki Nakano, Jichi Medical University, Japan

P3.02-090: Hypoxia-Induced Modifications of the Small Non-Coding RNA Transcriptome Delineates Risk of Recurrence in Early-Stage Lung Adenocarcinoma
Victor D. Martinez, BC Cancer Research Centre, Canada

P3.02-091: Concurrent Aberrations in G2/M-Phase Transcriptional Programs and Genomic Gatekeepers Highlight Lung Cancer Predisposition in COPD Patients
Enn Anne Marshall, BC Cancer Research Centre, Canada

P3.02-092: CD151-Integrin-C-KIT Axis Plays an Important Role in the Pathogenesis of Non-Small Cell Lung Cancer
Zeyi Liu, Institute of Respiratory Diseases, China

P3.02-093: Knockdown of BRM Causes Epithelial-Mesenchymal Transition in Lung Adenocarcinoma Cell Line H1975
Daisuke Matsubara, Jichi Medical University, Japan

P3.02-094: Identification of Oncofetal piR-NAs in Lung
Brenda C. Minatel, British Columbia Cancer Research Centre, Canada

P3.02-095: Basic Transcription Factor 3 Is Involved in Lung Cancer Growth and Progression
Xiongfei Li, Tianjin Medical University General Hospital, China

P3.02-096: The Interaction Between Mast Cells and Lung Cancer Cells Through Extracellular Vesicles
Smadar Geva, Thoracic Cancer Service, Davidoff Cancer Center, Rabin Medical Center, Israel

P3.02-097: Clinicopathological Features and Genetic Landscape of Pulmonary Large Cell Carcinoma under 2015 WHO Classification of NSCLC
Renwang Liu, Tianjin Medical University General Hospital, China

P3.02-097a: Metabolic Biomarkers in Serum for the Early Diagnosis of Lung Cancer: First Results from the Cancer-Biomarkers in HUNT Initiative
Oluf Røe, Norwegian University of Science and Technology, Norway

P3.02-097b: Significance of PAK1/CREB Pathway in Lung Adenocarcinoma Oncogenesis
Seong Yoon, Pusan National University Yangsan Hospital, Korea

P3.02-097c: Detection of the EGFR P.T7990M Mutation by Different Methods: A Small Comparison Case Study
Hangjun Wang, McGill University Health Center & McGill University, Canada

P3.02-097d: Pulmonary LCNEC Might Be Aggregated With SCC On the Basis of Different Clinical Features, Overall Survival, and Pathogenesis
Ke Chen, Zhongshan Hospital, China

P3.02-097e: Prognostic Importance of Tumor Spread Through Air Spaces in Lymph Node Negative Operated Adenocarcinoma Lung Cancers
Fatih Biricik, Koc University Medicine Faculty, Turkey
POSTER SESSIONS | WEDNESDAY, OCTOBER 18

P3.03 CHEMOTHERAPY/TARGETED THERAPY

P3.03-001: Immunotherapy Toxicity: Are General Practitioner Satisfied About Information Transmitted? A Retrospective Survey Radj Gervas, Centre Francos Baclesses, France

P3.03-002: Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer cells Harboring Ras Mutations Tadaaki Yamada, Kyoto Prefectural University of Medicine, Japan

P3.03-003: ABCB1 3435C≫T Polymorphism Influences the Toxicity and Clinical Outcome of Patients with Taxane-Based Chemotherapy Jia Zhong, Peking University Cancer Hospital & Institute, China

P3.03-004: The Frequency and Clinical Implication of ALK, ROS1, RET and NTRK1 Gene Rearrangements in Adenosquamous Lung Carcinoma Patients Xiaohua Shi, Peking Union Medical College Hospital, China

P3.03-005: Diagnosis and Treatment Analysis of Lung Enteric Adenocarcinoma: a Case Report and Review of the Literature Li Lin, Affiliated Hospital Cancer Center, Academy of Military Medical Sciences, China

P3.03-006: Efficiency of Anlotinib as 3rd Line Treatment in Patients with Different EGFR Gene Status, an Exploratory Subgroup Analysis of ALTER0303 Trial Baohui Han, Shanghai Chest Hospital, China

P3.03-007: LCMC2: Expanded Profiling of Lung Adenocarcinomas Identifies ROS1 and RET Rearrangements and TP53 Mutations as a Negative Prognostic Factor Mark G. Kris, Memorial Sloan Kettering Cancer Center, USA

P3.03-008: Organoid Cultures of Lung Squamous Cell Carcinoma for Drug Screening Ruoshui Shi, Ontario Cancer Institute, Canada

P3.03-009: Concurrent Somatic Mutations in Driver Genes Were Significantly Correlated with Lymph Node Metastasis and Pathological Types in Solid Tumors Yanan Cheng, Tianjin Medical University Cancer Institute and Hospital, China

P3.03-010: Identification of Mechanisms of Drug Resistance in RET-Rearranged Lung Cancer Takashi Nakaoku, National Cancer Center, Research Institute, Japan

P3.03-011: A Report of BRAF V600E Positive Lung Adenocarcinoma Patient Who Respond Well to Pemetrexed Yoshiko Nakagawa, Nihon University School of Medicine, Japan

P3.03-012: The Relationship between Efficacy of Weel Inhibitor AZD1775 and Mutational Status of TP53 in KRAS-Mutant Non-Small Cell Lung Cancer Bo Mi Ku, Samsung Biomedical Research Institute, Samsung Medical Center, Korea

P3.03-013: Identification of Proteasomal Catalytic Subunit PSMA6 as a Therapeutic Target for Lung Cancer through a Pooled shRNA Screen Mitsuhiro Sato, Nagoya University Graduate School of Medicine, Japan

P3.03-014: Tumor Cavitiation in Patients with Primary Lung Cancer Following Apatinib Treatment Man Jiang, The Affiliated Hospital of Qingdao University, China

P3.03-015: ROS-1 Rearranged Non Small Cell Lung Cancer and Crizotinib: An Indian Experience Vikas Talreja, Tata Memorial Hospital, India

P3.03-016: Morphometric Genotyping Identifies Lung Cancer Cells Harboring Target Mutations; Cell-CT® Platform Detects Gene Abnormalities Alan Nelson, VisionGate, USA

P3.03-017: Blood Samples NGS for Baseline Abnormalities for Lung Cancer: Results of a Phase II Study Jun Chen, The Second Affiliated Hospital of Dalian Medical University, China

P3.03-018: Tumor Cavitiation in Lung Metastases in Patients with Solid Tumor Treated with Apatinib Man Jiang, The Affiliated Hospital of Qingdao University, China

P3.03-019: Activity of PARP Inhibitor in NSCLC with Germline and Somatic Mutation and in Silico Chemotherapy Lethality Carmelia Maria Noa Barreto, Avancos em Medicina Instituto, Brazil

P3.03-020: Unique Molecular Profile of NSCLC in Thai Population Narumol Trachu, Mahidol University, Thailand

P3.03-021: In Vitro Pharmacogenomic Platform with a High-Purity Patient-Derived Cell Model Hyun Chang, Catholic Kwandong University International St. Mary’s Hospital, Korea

P3.03-022: Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement but Better Survival Nir Peled, Rabin Medical Center, Israel

P3.03-023: Nintedanib Selectively Inhibits the Activation and Tumor-Promoting Effects of Fibroblast from Lung Adenocarcinoma Patients Noemi Reguart, Hospital Clinic, Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain

P3.03-024: Real-Life Experience and Clinical Characterization of BRAF V600E Mutation in Austrian NSCLC Patients Maximilian Johannes Hochmair, Department of Respiratory and Critical Care Medicine, and Ludwig Boltzmann Institute of COPD and Respiratory Epidemiology, Otto Wagner Hospital, Austria

P3.03-025: Tumor Biomarkers for the Routine Care of Advanced Non-Small-Cell Lung Cancer: A Decade of Experience in Implementing Predictive Genomic Events Paul Andrew Vanderlaan, Beth Israel Deaconess Medical Center, Harvard Medical School, USA

P3.03-026: Cell-CT® Differential Detection of Dysplastic Bronchial Epithelial Cells from Patient Explants Daniel J. Sussman, VisionGate, USA

P3.03-027: LKB1 Loss Is Associated with Resistance to Anti-Angiogenic Therapy in Non-Small Cell Lung Cancer Mouse Models Irene Guijarro, The University of Texas M. D. Anderson Cancer Center, USA

P3.03-028: WINOTHER – a Study of Cancer Therapy Based on Tumor and Normal-Matched Biopsies - the Sheba Medical Center Lung Cancer Experience Amir Onn, Sheba Medical Center, Israel

P3.03-029: ROS1 Alterations in Lung Adenocarcinoma: The Prognostic Role of Rearrangement and Copy Number Variation Jun Chen, The Second Affiliated Hospital of Dalian Medical University, China

P3.03-030: TP53 Alteration, a Potential Primary Cause of Early Progression in EGFR-Mutated NSCLC Patients Treated with First-Line TKI Yun Fan, Zhejiang Cancer Hospital, China

P3.03-031: Response to Crizotinib Can Occur in C-MET Overexpression NSCLC Independent of MET exon14 Alterations After First-Line EGFR-TKI Resistance Yun Fan, Zhejiang Cancer Hospital, China

P3.03-031a: The IGFBP-3 Methylation Status Could Define a New Alternative Schedule for NSCLC Treatment Javier De Castro Carpeño, Hospital Universitario La Paz, IDIPAZ, Spain

P3.03-031b: Results of a Phase II Study of Stereotactic Radiosurgery Followed by Erlotinib for Patients with EGFR Mutation and Progression in 5 or Fewer Sites Jared Weiss, Lineberger Comprehensive Cancer Center, USA

P3.04 CLINICAL DESIGN, STATISTICS AND CLINICAL TRIALS

P3.04-001: Evaluate the Utility of the ProLung China Test in the Diagnosis of Lung Cancer Dawei Yang, Zhongshan Hospital Fudan University, China
P3.04-002: A Randomized Phase II Study of Carboplatin plus Nab-Paclitaxel with or Without Nintedanib for NSCLC with IPF (J-SONIC): Trial in Progress
Kohei Otsubo, Kyushu University, Japan

P3.04-003: Phase II Trial of Atezolizumab Before and After Definitive Chemoradiation for Patients with Unresectable Stage III NSCLC
Helen J. Ross, Mayo Clinic Arizona, USA

P3.04-004: Treatment Rationale and Study Design for the TAKUMI Trial
Kentaro Tanaka, Kyushu University Hospital, Japan

P3.04-005: PD-L1 and Other Immuno-Markers Influenced by Osimertinib Treatment in Advanced Non-Small Cell Lung Cancer Patients (ATHENE Study)
Shun Lu, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

P3.04-006: SYSTEMS-2: Randomised Phase II Trial of Standard Versus Dose Escalated Radiotherapy for Pain in Malignant Pleural Mesothelioma
Miranda Jane Ashton, Beatson West of Scotland Cancer Centre, UK

P3.04-007: A Prospective Study of Apatinib in Advanced Small Cell Lung Cancer Patients Failed from Two or More Lines of Chemotherapy
Yutao Liu, National Cancer Center/Cancer Hospital-Chinese Academy of Medical Sciences & Peking Union Medical College, China

P3.04-008: A Phase 1b/2 Study of Atezolizumab With or Without Daratumumab in Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Rathi N. Pillai, Winship Cancer Institute, Emory University, USA

P3.04-009: Stereotactic Body Radiotherapy to All Sites of Oligometastatic Non-Small Cell Lung Cancer (NSCLC) Combined with Durablemab and Tremelimumab
Ticiana A. Leal, University of Wisconsin Cancer Center, USA

P3.04-010: Validation of a ctDNA Methylation Assay to Differentiate Benign and Malignant Pulmonary Nodules: A Chinese Nationwide Multi-Center Study
Wenhua Liang, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, China State Key Laboratory of Respiratory Disease, China

P3.04-011: A Prospective Study to Optimize the Extent of Pulmonary Resection According to Decision-Making Algorithm in cStage IA NSCLC
Hong Kwan Kim, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea

P3.04-012: Phase 1 Study of the AXL Inhibitor DS-1205c in Combination with Osimertinib in Subjects with Metastatic or Unresectable EGFR-Mutant NSCLC
Pasi A. Jänne, Dana-Farber Cancer Institute, USA

P3.04-013: Phase 1 Study of the Anti-HER3 Antibody Drug Conjugate U3-1402 in Metastatic or Unresectable EGFR-Mutant NSCLC
Pasi A. Jänne, Dana-Farber Cancer Institute, USA

P3.04-013a: CONFIRM: A Phase III Randomized Trial to Evaluate the Efficacy of Nivolumab versus Placebo in Relapsed Mesothelioma
Dean Fennell, University of Leicester & Leicester University Hospitals, UK

P3.05-001: Breath Analysis for Early Detection of Lung Cancer: The LuCID Study
Marc Phillip Van Der Schee, Academic Medical Center, University of Amsterdam, Netherlands

P3.05-002: The Effect of Nodule Size on the Sensitivity of the LuCED® Test for Lung Cancer
Michael Meyer, VisionGate, USA

P3.05-003: Serum Thioredoxin Reductase 1 as a Diagnostic Biomarker for Non-Small Cell Lung Cancer
Xiaozheng Kang, Peking University Cancer Hospital, China

P3.05-004: The Impact of EGFR Mutations on Incidence and Survival of NSCLC Patients with Brain Metastasis: a Single Center Retrospective Study
Wei-Yuan Chang, National Cheng Kung University Hospital, Taiwan

P3.05-005: Hypermethylation of the RASSFIA and SOX1 Genes in Tumor DNA Predicts Unfavorable Overall Survival in Surgically Resected NSCLC Patients
Milica Kontic, Clinic for Pulmonology, Clinical Centre of Serbia, Serbia

P3.05-006: Integrated Genomic Analysis to Assess the Molecular Signature of Japanese Patients with Non-Small Cell Lung Cancer
Mitsuhiko Isaka, Shizuoka Cancer Center, Japan

P3.05-007: Potential of CYFRA 21-1 and HE4 to Detect Recurrence in Patients with Early-Stage Lung Adenocarcinoma
Achim Escherich, Roche Diagnostics International Ltd, Switzerland

P3.05-008: Potential of CYFRA 21-1 and HE4 to Detect Recurrence in Patients with Early-Stage Lung Adenocarcinoma
Achim Escherich, Roche Diagnostics International Ltd, Switzerland

P3.05-009: Hsacirc_0044013: A Potential Novel Diagnostic Biomarker of Lung Adenocarcinoma
Shuzhen Wei, Zhongda Hospital, Southeast University, China

P3.05-010: NOTCH 1 and NOTCH 3 Expressions for Early Stage of Non-Small Cell Lung Cancer
Eun Kyung Cho, Gachon University Gil Medical Center, Korea

P3.05-012: Clinopathological Determinants of Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer
Jong Ho Cho, Sungkyunkwan University School of Medicine, Samsung Medical Center, Korea

P3.06-001: Tobacco Use, Awareness and Oral Health among Kanchipuram Silk Weavers, Tamil Nadu, India
Delfin Lovelina Francis, Tagore Dental College and Hospital, India

P3.06-002: Tobacco Use, Awareness and Oral Health Status among Seafarers in Voc Port, Tuticorin, Tamilnadu, India
Delfin Lovelina Francis, Tagore Dental College and Hospital, India

P3.06-003: What do the Children Think about Smoking and How Are They Helped in Prevention?
Domenico Galetta, Clinical Cancer Center “Giovanni Paolo II”, Italy

P3.06-004: Role Models “a Tool for Effective Tobacco Control Campaign”
Seye O. Omiyera, Youth Action on Tobacco Control and Health, Nigeria

P3.06-005: Informational Needs on Smoking Cessation of Cancer Patients
Meredith Elana Giulian, University of Toronto and Princess Margaret Cancer Center, Canada

P3.06-006: The Government Willingness to Legislate Tobacco Control and Changes on Individual Behavior in Brazil
Ana Paula Leal Teixeira, National Cancer Institute-Ministry of Health, Brazil

P3.06-007: Level of Awareness of Various Aspects of Lung Cancer Among College Students in India: Impact of Cancer Awareness Programs
Abhishek Shankar, All India Institute of Medical Sciences, India

P3.06-008: Lung Cancer Pathways: A Five-Year Program to Reduce Impact Through Epidemiological Modelling and Investment in Prioritized Interventions
Nicole Marion Rankin, The University of Sydney, Australia

P3.06-009: How Does Screening for the Early Detection of Lung Cancer Facilitate Smoking Cessation? A Qualitative Study of Screened Smokers
Ben Young, University of Nottingham, UK
P3.07 IMMUNOLOGY AND IMMUNOTHERAPY

P3.07-001: Overcoming Resistance to Anti-PD Immunotherapy in a Syngeneic Mouse Lung Cancer Model Using Adenovirus-Mediated Gene Therapy
Xiang Yan, Chinese PLA General Hospital, China

P3.07-002: Blocking of ADAM17 Mitigates Kras-Induced Lung Adenocarcinoma Possibly via Inhibition of IL-6 Trans-Signaling
Mohamed I. Saad, Monash University, Australia

P3.07-003: Analysis of Dendritic Cell Derived Exosomes That Suppressed Tumor Growth
Masakatsu Takanashi, Tokyo Medical University, Japan

P3.07-004: GSDMD Is Required for Effector CD8+ T Cell Responses to Lung Cancer Cell Tung Feng Lv, Jinling Hospital, China

P3.07-005: Activation of Toll-like Receptor-2 Promotes Proliferation in Human Lung Adenocarcinoma Cells
Patrick Kohtz, University of Colorado - Denver, USA

P3.07-006: Pemetrexed Exerts Intratumor Efficacy of Immune Checkpoint Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer
Alexander Kuhlmann, Leibniz Universität Hannover, Germany

P3.07-007: Blockade of the Complement C5a/C5aR1 Axis Impairs Lung Cancer Bone Metastasis
Ruben Pio, CIMA-University of Navarra, Idsina, Ciberonc, Spain

P3.07-008: Development of Immunomonitoring Assays for Dendritic Cell-Based Lung Cancer Immunotherapy
Ondrej Palata, Soto a.s., Czech Republic

P3.07-009: PI3K/mTOR Pathway Alterations in Neoplastic Type in Non-Small Cell Lung Cancer
Ondrej Palata, Sotio a.s., Czech Republic

P3.07-010: Hereditary Familial Overlap Syndrome with Multiple Synchronous Lung Tumors
Andrés F. Cardona, Foundation for Clinical and Applied Cancer Research - FICMAC, Colombia

P3.07-011: Investigation of Autologous Tumor-Killing Effect of Effusion-Associated Lymphocytes in Malignant Pleural Effusion of Lung Cancer
Yung-Hung Luo, Taipei Veterans General Hospital, Taiwan

P3.07-012: Nivolumab Versus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer and Liver Metastases
Lucio Crinió, Istituto Scientifico Romagnolo Per lo Studio e la Cura dei Tumori (IRST) IRCSS, Italy

P3.07-013: Cost-Effectiveness of Immune Checkpoint Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer
Alexender Kuhlmann, Leibniz Universitat Hannover, Germany

P3.07-013a: PD-L1 Expression, Using SP142 and 22C3 Antibody Clones, in NSCLC Patients with Known Status of EGFR and ALK Genes
Pawel Krawczyk, Medical University of Lublin, Poland

P3.07-013b: The Comparison Analysis of PD-1 Status Between 22C3 and 28-8 IHC Assay in Clinical Practice: A Single Institutional Experience
Yuki Nakamura, Matsusaka Municipal Hospital, Japan

P3.07-014: Phase II/II Trial of Nab-Paclitaxel or Paclitaxel Plus Carboplatin with Concurrent Radiation for Inoperable Stage IIIA/B NSCLC
Aarón Laine, UT Southwestern Medical Center, USA

P3.07-015: Phase I/II Trial of Nab-Paclitaxel or Paclitaxel Plus Carboplatin with Concurrent Radiation for Inoperable Stage IIIA/B NSCLC
Kazunori Okabe, Yamaguchi Ume Medical Center, Japan

P3.07-016: Treatment Response and Survival Outcomes Are Associated with Histologic Type in Non-Small Cell Lung Cancer Treated with Trinodal Treatment
Hong Kwan Kim, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea

P3.07-017: The Comparison Analysis of PD-1 Status Between 22C3 and 28-8 IHC Assay in Clinical Practice: A Single Institutional Experience
Yuki Nakamura, Matsusaka Municipal Hospital, Japan

P3.08 LOCALLY ADVANCED NSCLC

P3.08-001: Concurrent Chemoradiotherapy with Weekly Carboplatin-Paclitaxel May Be Feasible Option in Inoperable Stage III NSCLC
Fatih Kose, Baskent University, Turkey

P3.08-002: Lymphovascular Invasion Is Not a Postoperative Prognostic Factor for Large-Sized Lung Cancer
Atsushi Tajima, Saiseikai Utsunomiya Hospital, Japan

P3.08-003: Multimodal Treatment in the Initially Inoperable Stage III N2 Non-Small Cell Lung Cancer Patients
Eun Kyo Joong, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Korea

P3.08-004: Phase I/II Trial of Nab-Paclitaxel or Paclitaxel Plus Carboplatin with Concurrent Radiation for Inoperable Stage IIIA/B NSCLC
Kazunori Okabe, Yamaguchi Ume Medical Center, Japan

P3.08-005: Hereditary Familial Overlap Syndrome with Multiple Synchronous Lung Tumors
Andrés F. Cardona, Foundation for Clinical and Applied Cancer Research - FICMAC, Colombia

P3.08-006: Treatment Response and Survival Outcomes Are Associated with Histologic Type in Non-Small Cell Lung Cancer Treated with Trinodal Treatment
Hong Kwan Kim, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea

P3.09 MESOTHELIOMA

P3.09-001: The Dosimetric Advantages of Intensity Modulated Proton Therapy (IMPT) for Mesothelioma after Pleurectomy/Decorticitation
Jean-Claude M. Rwigema, Mayo Clinic Arizona, USA

P3.09-002: Can We Do Better? Feasibility Dosimetric Study for Upfront Radical Radiotherapy in Mesothelioma
Timothy Mitchell, Beatson West of Scotland Cancer Center, UK

P3.09-003: Heart Radiation Dose as a Risk Factor for Dyspnea Worsening After Modality Treatment for NSCLC and MPM: An Exploratory Analysis
Angela Botticella, KU Leuven, Belgium

P3.09-004: Routine Clinical Parameters Can Stratify Survival Characteristics in Mesothelioma Patients Undergoing Surgery
Fraser Brims, Sir Charles Gardiner Hospital, Australia

P3.09-005: The Results of Trinodal Modality Treatment for Malignant Pleural Mesothelioma
Kazunori Okabe, Yamaguchi Ume Medical Center, Japan

P3.09-006: Preoperative Six-Minute Walk Distance and Desaturation in Patients with Malignant Pleural Mesothelioma
Motoki Nagaya, Nagoya University Hospital, Japan

P3.09-007: Thoracic Asymmetry and Its Impact on Survival after Radiation and Surgery for Malignant Pleural Mesothelioma
John Cho, University Hospital Network, Princess Margaret Cancer Centre, Canada

P3.09-008: Role of Surgery in the Multimodal Treatment of Malignant Pleural Mesothelioma
Bub-Se Na, Seoul National University Hospital, Korea

P3.09-009: Fourteen Cases Study of 5 Year Survivors of Malignant Pleural Mesothelioma Following Extrapleural Pneumonectomy
Ayumi Kuroda, Hyogo College of Medicine, Japan

P3.09-010: 18 Years Single Center Experience of Surgical Resection of Malignant Pleural Mesothelioma After Induction Chemotherapy
Michaela B. Kirschner, University Hospital Zurich, Switzerland
P3.10 NURSING/PALLIATIVE CARE/ETHICS

P3.10-001: Prognostic Factors of Survival in Malignant Pleural Effusion
Fernando Conrado Abrão, Hospital Santa Marcelina, Brazil

P3.10-002: Implementing an Innovative Distress/Supportive Care Screening Tool in a Lung Cancer Clinic
Lawrence Eric Feldman, The University of Illinois Hospital and Health Sciences System, UI Cancer Center, USA

P3.10-003: Assessing and Addressing Knowledge Gaps to Improve Lung Cancer Screening Rates
Lawrence Eric Feldman, The University of Illinois Hospital and Health Sciences System, UI Cancer Center, USA

P3.10-004: Immunotheraphy: Emergency Department Provider Needs Assessment Survey
Lavinia Dobrea, St. Joseph Hospital, USA

P3.10-005: National UK Thoracic Surgery PPI Group Identify Key Questions in Routine Clinical Care for Further Research
Amy Kerr, Heart of England NHS Foundation Trust, UK

P3.10-006: The Efficacy of Pistasia Terebinthus Soap in the Treatment of Erlotinib-Induced Skin Toxicity in Non-Small Cell Lung Cancer Patients
Didem Tastekin, Institute of Oncology, Istanbul University, Turkey

P3.10-007: Sudden Death of the Patients with Lung Cancer
Yasushi Nakano, Kawasaki Municipal Ida Hospital, Japan

P3.12 PULMONOLOGY/ENDOSCOPY

P3.12-001: Lung Cancer in Patients with Interstitial Lung Disease: Clinical Characteristics and Impact on Survival
Shunsaku Hayai, Tosei General Hospital, Japan

P3.12-002: Patients with Malignant Pleural Effusion who Succeeded Pleurodesis have a Longer Survival Rate - a 10-year Follow-up
Li-Han Hsu, Sun Yat-Sen Cancer Center, Taiwan

P3.12-003: Optimised Inhaler Therapy Is Superior to Supportive Care Alone for Dyspnoea in Patients with Coexisting COPD and Lung Cancer
David Peter Walder, Institution for Cancer Research, UK

P3.12-004: Maitdiong on the Prevention and Treatment of Radiation Pneumonitis in Mice C57BL/6
Jiancheng Li, Fujian Cancer Hospital, China

P3.12-004a: The Demonstration of the Possibility of the Mediastinal Mass Diagnosis by Means of the Cryo Biopsy
Jaroslav Pierog, Pomeranian Medical University, Poland

P3.13 RADIOLOGY/STAGING/SCREENING

P3.13-001: Clinical Significance of Chest Tomography Characteristics in Non Small Cell Lung Cancer Patients Who Received Anatomic Resection
Ching-Yang Wu, Chang Gung Memorial Hospital, Linkou, Taiwan

P3.13-002: Reduced Dose Perfusion CT of Lung Cancer using a 16-cm Coverage Scanner: Effects of Respiratory Motion Correction on Perfusion Assessment
Yoan Joo Jeong, Pusan National University Hospital, Korea

P3.13-003: The Lung Cancer Prognostic Index - a Risk Score to Predict Overall Survival after the Diagnosis of Non-Small Cell Lung Cancer
Marliese Alexander, Monash University, Australia

P3.13-004: Prospective Study of Sequential Ultra-Low then Standard Dose 18F-FDG PET/CT Scans for Lung Lesion Detectability
Ivan WK Tham, National University Cancer Institute, Singapore

P3.13-005: Characteristics of Primary Lung Cancer on PET/CT Imaging in the South African Population
Oxayande Evbuomwan, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand, South Africa

P3.13-006: Correlation between CT Morphology at the Diagnosis and EGFR Status in Patients with Adenocarcinoma of the Lung
Manlio Mencoboni, Villa Scassi Hospital, ASL 3 Genovese, Italy

P3.13-007: A Feasible Follow-Up Program Using FDG-PET/CT for Asymptomatic Postoperative Non-Small-Cell Lung Cancer Patients
Hiroaki Toba, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan

P3.13-008: Lung Cancer Associated with Cystic Airspaces: Clinical, Imaging, Histopathological and Molecular Correlation
Anneeme Sneecx, Antwerp University Hospital and University of Antwerp, Belgium

P3.13-009: Rapid Detection of Lung Cancer by Fluorescent Imaging using a γ-Glutamyltranspeptidase-activatable Fluorescent Probe
Mingyon Mun, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan

P3.13-010: Correlation between HRCT Features of Pulmonary Pure Ground-Glass Nodules and the New Pathologic Classification of Lung Adenocarcinoma
Jindong Guo, Shanghai Chest Hospital, China

Zagham Saghir, Copenhagen University Hospital Gentofte, Denmark

P3.13-012: Fast Fourier Transform Analysis for the Outline of Pulmonary Nodules on Computed Tomography Images
Tatsuya Yoshimatsu, Wakayama Medical University, Japan

P3.13-013: Association of Pleural Tags with Visceral Pleural Invasion of Peripheral Lung Cancer
Mayumi Higashi, Yamaguchi University, Japan

P3.13-014: Prediction of Survival with 18F-FDG-PET/CT Early during Erlotinib Treatment in NSCLC Patients - a Comparison of Four Evaluation Methods
Joan Fledelius, Herning Hospital, Denmark

P3.13-015: 18F-FDG-PET/CT after Induction Chemotherapy for Prediction of Survival after Radical Chemo-Radiotherapy in Locally Advanced NSCLC Patients
Joan Fledelius, Herning Hospital, Denmark

P3.13-016: 18F-FDG-PET/CT for Prediction of Survival after Induction Chemotherapy in Locally Advanced NSCLC - a Comparison of Methods
Joan Fledelius, Herning Hospital, Denmark

P3.13-017: Review of Lung Cancers on the Stage and Growth Rate, Matched with Lung RADs Category, in Previously Treated with Breast Cancer Patients
Soo-Youn Ham, Korea University Anam Hospital, Korea
P3.13-018: CT-Guided Percutaneous Barium Marking Prior to Video-Assisted Thoracoscopic Surgery (VATS) for the Localization of Small Pulmonary Nodules
Ana Caroline Zimmer Gelatti, Hospital do Câncer Mâe de Deus, Brazil

P3.13-019: Preoperative Needle Biopsy Does Not Increase the Risk of Pleural Recurrence in s3cm Lung Adenocarcinoma
Koji Kameda, Memorial Sloan Kettering Cancer Center, USA

P3.13-020: A Pilot Study of the Autoantibodies to Tumor Antigens in Lung Cancer Using the EarlyCDT-Lung Test in Hong Kong
Chu Leuk Lau, Quality HealthCare Medical Service, Hong Kong

P3.13-021: Can Lymph Nodes Visualised on PET/CT Predict the Outcome of Patients with Lung Cancer?
Mbolio Di Tamba Vangu, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand, South Africa

P3.13-022: 3D CNNs for Recognition of Epidermal Growth Factor Receptor Mutation Status in Patients with Lung Adenocarcinoma
Junleng Xiong, Shanghai Jiao Tong University, China

P3.13-023: Clinicopathological Impacts of the Small Ground-Glass Opacity Surrounding the Solid Type Lung Adenocarcinoma
Kazutoshi Hamanaka, Shinshu University, Japan

P3.13-024: Is Alveolar Spread May Be Predictive with PET CT Scanning?
Nil Molinas Mandel, Koc University Medicine and Allergy of Vilnius University Hospital Santaros Klinikos, Lithuania

P3.13-025: Spinal Cord and Cauda Equina Imaging of Recurrences After Surgery
Henda Neji, Abderrahmen Mami Hospital, Tunisia

P3.13-026: Non-Small Cell Lung Cancer: Imaging of Recurrences After Surgery
Henda Neji, Abderrahmen Mami Hospital, Tunisia

P3.13-027: Utilization of PET Scan in Advanced Stage Non-Small Cell Lung Cancer in the United States
Madhusmita Behera, Winship Cancer Institute of Emory University, USA

P3.13-028: Controversies on Lung Cancers Manifesting as Part-Solid Nodules
Rowena Yip, Icahn School of Medicine at Mount Sinai, USA

Joshua Robert Rayburn, Swedish Cancer Institute, USA

P3.13-030: Metabolic Parameters of FDG PET at Early Evaluation of NSCLC Differ with Histological Subtypes
Yosef Landman, Thoracic Cancer Service, Davidoff Cancer Center, Rabin Medical Center, Israel

P3.13-031: Predicting Factor for the Dissociation of the Diameter Between Radiographical Solid Part and Pathological Invasive Part in Lung Adenocarcinoma
Yota Suzuki, Keio University School of Medicine, Japan

P3.13-032: The Impact of Tobacco Exposure on Lung Nodules and Emphysema in a Pilot Silesian Study of Early Lung Cancer with LDCT
Mariusz Adamek, Department of Thoracic Surgery, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Poland

P3.13-033: DNA Methylation of PTGER4 and SHOX2 in Liquid Biopsies Facilitates the Diagnosis of Lung Malignancy After Chest CT-Scan
Lea Maria Schotten, University Medicine Essen - Ruhrlandklinik, Essen, Germany, Germany

P3.13-034: Comparison of Cytological Smears and Cell Blocks of Pleural Fluid Diagnosing Malignant Pleural Effusion in Lung Cancer
Giedre Cincileviciute, Center of Pulmonology and Allergology of Vilnius University Hospital Santaros Klinikos, Lithuania

P3.13-035: Automatic Estimation of Measurement Error on CT Imaging
Ricardo S. Avila, Accumetra, LLC, USA

P3.13-036: Immunohistochemical and Genetic Characteristics of Lung Cancer Mimicking Organizing Pneumonia
Tomohiro Ichikawa, National Cancer Center Hospital East, Japan

P3.13-037: A Functional Equivalent Uniform Dose Correlates with Radiation Pneumonitis in Limited-Stage SCLC for CT-Simulation Based Thoracic Radiotherapy Planning
Masaki Nakamura, National Cancer Center Hospital East, Japan

P3.13-038: Metabolic Parameters of FDG PET at Early Evaluation of NSCLC Differ with Histological Subtypes
Yosef Landman, Thoracic Cancer Service, Davidoff Cancer Center, Rabin Medical Center, Israel

P3.13-039: Predicting Factor for the Dissociation of the Diameter Between Radiographical Solid Part and Pathological Invasive Part in Lung Adenocarcinoma
Yota Suzuki, Keio University School of Medicine, Japan

P3.13-040: The Impact of Tobacco Exposure on Lung Nodules and Emphysema in a Pilot Silesian Study of Early Lung Cancer with LDCT
Mariusz Adamek, Department of Thoracic Surgery, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Poland

P3.14-001: Impact of PCI on Prognosis of LD-SCLC Through Pattern of Brain Metastases as a First Recurrence Site
Mojgan Taremi, Princess Margaret Hospital, Canada

P3.14-002: Multimodality Management of Pancoast Tumors: Does Surgical Resection Need to Be Included?
Margriet Kwint, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Netherlands

P3.14-003: Patterns of Follow-Up Care After Curative Radiotherapy for Stage I–III Non-Small Cell Lung Cancer
Sharanya Mohan, University of NSW, Australia

P3.14-004: Pathological Study on the Clinical Target Volume (CTV) in Limited-Stage SCLC for CT-Simulation Based Thoracic Radiotherapy Planning
Xiao Hu, Zhejiang Cancer Hospital, Zhejiang Key Laboratory of Radiation Oncology, China

P3.14-005: Treatment Response Measured on Conebeam–CT During Concurrent Chemoradiation for NSCLC Patients
Margriet Kwint, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Netherlands

P3.14-006: Slow CT Simulation for GTV Delineation and Planning of Radiotherapy to Lung Cancer Patients; A Sunshine to Developing Countries
Shariff Ahmed, United Hospital Limited, Bangladesh

P3.14-007: A Functional Equivalent Uniform Dose Correlates with Radiation Pneumonitis in Radiation Therapy
Li Yan Dai, Renji Hospital, Shanghai Jiaotong University School of Medicine, China

P3.14-008: Clinical Characteristics Matrix of Lung Tumor Under Stereotactic Ablative Body Radiotherapy (SABR)
Kaile Li, John R Marsh Cancer Center, USA

P3.14-009: Thoracic Re-Irradiation of Lung Cancer Using Highly Conformal Radiotherapy Is Effective as Salvage Treatment Option
Yeon Sil Kim, Seoul St.Mary’s Hospital, Korea

P3.14-010: Magnetic Resonance Imaging (MRI) for Lung Cancer Radiotherapy Planning and Treatment
Michael Dubec, The Christie NHS Foundation Trust, UK

P3.14-011: Mean Heart Dose Is an Independent Risk Factor for Early Mortality After Chemoradiotherapy Treatment for Lung Cancer
Dirk K. De Ruysscher, Maastricht University Medical Centre, Netherlands
P3.15 - SCLC/NEUROENDOCRINE TUMORS

P3.15-001: The Impact ofMET Inhibition on Small-Cell Lung Cancer Cells Exhibiting Ablerrant Activation of the HGF/MET Pathway
Hirokazu Taniguchi, Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan

P3.15-002: Molecular Profiling and Networks Relevant to Disease Mechanisms in Small Cell Lung Cancer and Lung Carcinoid Tumor
Kiyokazu Fujii, St. Marianna University School of Medicine, Japan

P3.15-003: Second Line Chemotherapy in SCLC: The West of Scotland Experience
Sarah Jane Slater, Beatson West of Scotland Cancer Centre, UK

P3.15-004: Distinct Role of FAK Kinase and C-Terminal Domains on Small-Cell Lung Cancer Proliferation
Sebahat Ocak, Cliniques Universitaires UCL Mont-Godinne, Belgium

P3.15-005: Third Line Chemotherapy in SCLC: The West of Scotland Experience
Sarah Jane Slater, Beatson West of Scotland Cancer Centre, UK

P3.15-006: Comprehensive Analysis of EMT Gene Signature in Primary and Metastatic Small Cell and Non-Small Cell Carcinomas of the Lung
Tabatha Gutierrez Prieto, Faculdade de Medicina da USP, Brazil

P3.15-007: A Retrospective Review of Small Cell Lung Cancer (SCLC) Patients Treated at Marmara University Hospital
Faysal Dane, Marmara University Medical School, Marmara University Pendik Training & Research Hospital, Turkey

P3.15-008: [F18]PARPi PET as an In Vivo Pharmacodynamic Biomarker of PARP Inhibitor Therapy in Patient-Derived Xenografts of Small Cell Lung Cancer
Benjamin Lok, Princess Margaret Cancer Centre, Canada

P3.15-009: Impact of Interstitial Lung Disease on Clinical Outcomes in Small Cell Lung Cancer Patients
Kimitaka Akaike, Kumamoto University Hospital, Japan

P3.15-010: Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH): Natural History of the Disease Progression and Management
Zin Myint, University of Kentucky, USA

P3.15-011: Contemporary Treatment and Prognosis of Non-Metastatic Atypical Bronchopulmonary Carcinoid Tumors
Abraham J. Wu, Memorial Sloan Kettering Cancer Center, USA

P3.15-012: Surgical Outcome in Early Stage Small Cell Lung Cancer
Kenji Inafuku, Kanagawa Cancer Center, Japan

P3.15-013: The Addition of Antiangiogenic Agents to Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Meta-Analysis
Min Peng, Renmin Hospital of Wuhan University, China

P3.15-014: Case Series of Small Cell Lung Cancer Transformation as Resistance Mechanism to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Chong-Kin Lam, University of Melaka, Malaysia

P3.15-015: LCNEC Tumor Location, Divided into Central and Peripheral Type, Has Distinct Clinicopathologic Feature, Genomic Characteristics and Survival
Fei Zhou, Tongji University School of Medicine, China

P3.15-016: The Role of Surgery in Combination Treatment of Patients with Small Cell Lung Cancer
Aleksei Aleksandrovich Aksarin, Surgut District Clinical Hospital, Russia

P3.15-016a: Prediction of Potential Biomarkers for Personalized Treatment in Pulmonary Large-Cell Neuroendocrine Carcinoma
Takashi Makino, Toho University School of Medicine, Japan

P3.16 - SURGERY

P3.16-001 – P3.16-036 RISK ASSESSMENT AND PROGNOSTIC FACTORS

P3.16-001: Feasibility of 20 mL of Saline for Pleural Lavage Cytology in Non-Small Cell Lung Cancer
Toru Nakamura, Seirei Hamamatsu General Hospital, Japan

P3.16-002: Postoperative Prognostic Factors in Non-Small Cell Lung Cancer Patients with Lymph Node Metastasis
Tatsuya Goto, Niigata University, Japan

P3.16-003: The Clinical Significance of Immunometabolic Parameters in Surgically Resected Elderly Patients with Non-Small Cell Lung Cancer
Fumihiro Shojo, Kyushu University, Graduate School of Medical Sciences, Japan

P3.16-004: Surgery for Patients with Lung Cancer Associated with Intestinal Pneumonia
Yoko Azuma, Toho University School of Medicine, Japan

P3.16-005: Outcome, Mortality and Morbidity after Lung Cancer Thoracic Surgery
Fadil Gradica, University Hospital Shefqet Ndroqi, Albania

P3.16-006: Impact of Limited Resection or Omitted Adjuvant Therapy in Patients with Pathologic Stage II and III Non-Small-Cell Lung Cancer
Jeong Su Cho, Pusan National University Hospital, Korea

P3.16-007: Incidence and Outcomes of Positive Parenchymal Margins after Lung Resection - an Analysis of 1428 Cases
Patrick James Villeneuve, The Ottawa Hospital, Canada

P3.16-008: Thymidine Phosphorylase Influences Clinical Outcome Following Surgery in Patients with Stage I and II Non-Small Cell Lung Cancer
Naoya Himuro, Showa University School of Medicine, Japan

P3.16-009: Reoperation for Hemostasis within 24 Hours Can Get a Better Short-Term Outcome When Indicated after Lung Cancer Surgery
Qiang Li, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, China
POSTER SESSIONS | WEDNESDAY, OCTOBER 18

P3.16-010: Preoperative Six-Minute Walk Distance Is Associated with Complications of Pneumonia after Lung Resection
Keiko Hattori, Nagoya University Hospital, Japan

P3.16-011: Correlation Between Pulmonary Vein Stump Thrombus and Cerebral Infarction After Left Upper Lobectomy of the Lung
Yoshiyuki Yasuura, Shizuoka Cancer Center, Japan

P3.16-012: Lung Cancer: System Approach
Oleg Kshivets, Roshal Hospital, Russia

P3.16-013: Prognostic Effect of EGFR Gene Mutation for Recurrence in Completely Resected Lung Adenocarcinoma
In Kyu Park, Seoul National University Hospital, Korea

P3.16-014: Post-Recurrence Survival Analysis of Stage I Non-Small Cell Lung Cancer: Prognostic Significance of Local Treatment
Hyeong Ryul Kim, Asan Medical Center, University of Ulsan College of Medicine, Korea

P3.16-015: Rapid Identification of Micropapillary or Solid Component for Early-Stage Lung Adenocarcinoma
Ze-Rui Zhao, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong

P3.16-016: Prognosis of Patients with Remnant Tumor at Bronchial Stump After Pulmonary Resection for NSCLC: Based on Case Series Study
Hye-Seon Kim, Hanyang University Seoul Hospital, Korea

P3.16-017: The Role of Skip Metastases and the Number of Metastatic Lymph Nodes in the Survival of Operated Patients
Mark Krasnik, Copenhagen University Hospital, Denmark

P3.16-018: Null 30-Days Mortality After 72 Consecutive Left Open Pneumonectomies for Lung Cancer
Veronica Manolache, Oncology Institute Bucharest, Romania

P3.16-019: Prognostic Factors for Resected Non-Small Cell Lung Cancer in Patients with Type 2 Diabetes Mellitus
Woo Sik Yu, The Graduate School of Yonsei University, Korea

P3.16-020: Long Term Changes of Pulmonary Function After Lobectomy
Kook Nam Han, Korea University Guro Hospital, Korea

P3.16-021: Thoracic Morbidity and Mortality System in Analysis of Postoperative Complications after Pneumonectomy in NSCLC Patients
Oleg Pikin, P. Hertzen Research Institute of Oncology, Russia

P3.16-022: Segmentectomy for Lung Adenocarcinoma: The Impact of EGFR Mutation Status on Recurrence
Kwangyong Hyun, Seoul National University Hospital, Korea

P3.16-023: Intrapulmonary Lymph Node Metastasis of Non-Small Cell Lung Cancer: Distribution Pattern and Therapeutic Relevance
Nan Wu, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), China

P3.16-024: Feasibility of the Fit4Surgery App - Can It Replace Conventional Pulmonary Rehabilitation in the Surgical Population?
Nicola Oswald, University of Birmingham, UK

P3.16-025: Development and Validation of a Survival Nomogram in Elderly Patients with Resected Non-Small-Cell Lung Cancer
Xizhao Sun, Peking University People’s Hospital, China

P3.16-026: Clinical Implication of Occult Lymph Node Metastasis in the Remaining Lobes After Lobectomy in Non-Small Cell Lung Cancer
Young Tae Kim, Seoul National University Hospital, Korea

P3.16-027: Effects of Surgical Waiting Time on Prognosis in Patients with Lung Cancer
Yuriko Terada, Japanese Red Cross Medical Center, Japan

P3.16-028: Necrosis Is a Predictor of Recurrence in Patients with Small Lung Adenocarcinoma ≤2cm
Yuriko Terada, The University of Tokyo Hospital, Japan

P3.16-029: Recurrence within a Year after Complete Resection of Primary Lung Cancer
Takashi Ibe, Maebashi Red Cross hospital, Japan

P3.16-030: Venous Thromboembolism After Lung Cancer Surgery and Its Risk Factors: A Single Center, Retrospective, Cohort Study from China
Bo Tian, Beijing Chao-Yang Hospital, Capital Medical University, China

P3.16-031: Survival and Prognostic Factors of Synchronous Multiple Primary NSCLC and Further Differentiation from Intrapulmonary Metastasis
Fei Xiao, National Clinical Research Center for Respiratory Diseases, Center for Respiratory Diseases, China-Japan Friendship Hospital, China

P3.16-032: Prediction of Postoperative Lung Function in Patients with Lung Cancer by Lung Lobe
Kantarao Haru, Osaka City University Hospital, Japan

P3.16-033: Significance of Spread through Air Spaces in Resected Pathological Stage I Lung Adenocarcinoma
Gouji Toyokawa, Graduate School of Medical Sciences, Kyushu University, Japan

P3.16-034: Impact of Travel Distance to Treatment Institution on Survival from Stage I to III Lung Cancer
Ana Caroline Zimmer Gelatti, Hospital do Cancer Mde de Deus, Brazil

P3.16-035: The Unknown: Does Body Mass Index (BMI) Influence Outcomes Post Lung Cancer Resection Surgery?
Prakash Balakrishnan, Wellington Regional Hospital, New Zealand

P3.16-036: Feasibility of Lung Cancer Surgery in Septuagenarians
Prakash Balakrishnan, Wellington Regional Hospital, New Zealand

P3.16-037 – P3.16-049
SURGERY FOR LOCALLY ADVANCED AND ADVANCED NSCLC

P3.16-038: Superior Vena Cava Replacement Combined with Veno-Venous Shunt for Lung Cancer and Thymoma: Case Series
Giang Li, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, China

P3.16-039: Right Upper Lobectomy with SVC Reconstruction after Induction Chemoradiotherapy for a Patient with Bulky N2 NSCLC
Hideo Ichimura, University of Tsukuba, Hitachi Medical Education and Research Center, Japan

P3.16-040: Intrapleural Perfusion Thermo-Chemotherapy for Pleural Effusion Caused by Lung Carcinoma under VATS
Runlei Hu, Hangzhou First People’s Hospital, China

P3.16-041: Pleural Photodynamic Therapy and Surgery for Pleural Metastasis by Non-Small Cell Lung Cancer
Ke-Cheng Chen, National Taiwan University Hospital, Taiwan

P3.16-042: Intraoperative Hyper-Thermotherapy with Distilled Water for StageIV Lung Cancer
Ayumi Suzuki, Kariya Toyota General Hospital, Japan

P3.16-043: Resection and Reconstruction of Tracheal Carina in Lung Cancer Surgery
Evgeny Levchenko, N. N. Petrov Research Institute of Oncology, Russia

P3.16-044: Feasible Outcome of Radical Extended Surgery in T4 Locally Advanced NSCLC; 23-Year Japanese Single Center Experience
Ryuchi Waseda, Fukuoka University, Japan

P3.16-045: Evaluation of the Safety and Efficacy of VATS Pneumonectomy in the Treatment of Locally Advanced Lung Cancer
Joshua Goldblatt, St Vincent’s Hospital, Australia

P3.16-046: Pneumonectomy After Induction/Neoadjuvant Treatment for NSCLC: Morbidity, Mortality and Long-Term Survival
Cengiz Gebitekin, Uludag University, Turkey
P3.16-047: Salvage Surgery for Locoregional Recurrence or Persistent Residual Tumor After Definitive Chemoradiation Therapy
Junichiro Osawa, Kanagawa Cancer Center, Japan

P3.16-048: The Role of Pulmonary Resection in Stage IVa Non-Small Cell Carcinoma Patients
Tomoyuki Igarashi, Shiga University of Medical Science, Japan

P3.16-049: Surgery with Continued TKI Therapy After Acquiring Resistance to EGFR or ALK TKI
Shuta Ohara, Kindai University, Japan

P3.16-050 – P3.16-053a
TRANSLATIONAL STUDIES

P3.16-050: Stromal PDGFR-β Expression Influences Postoperative Survival of NSCLC Patients Receiving Preoperative Chemo- or Chemo-Radiotherapy
Ryu Kanzaki, Osaka University Graduate School of Medicine, Japan

P3.16-051: Implications of Preoperative Serum Tumor Levels on Pathological Characteristics in Patients with Lung Adenocarcinoma
Terumoto Koike, Niigata University, Japan

P3.16-052: Use of Decellularised Porcine Intestinal Submucosa Extracellular Matrix in Airway Reconstruction to Enable Lung-Sparing Oncological Surgery
Michelle Lynne Kim, Barwon Health, Australia

P3.16-053: Genomic Challenges for Lung Cancers with Multiple Pulmonary Sites of Involvement
Xiaozheng Kang, Peking University Cancer Hospital, China

P3.16-053a: Surgical Outcome of Bronchoplasty in Non-small Cell Lung Cancer Patients
Katsuyuki Suzuki, Yamagata Prefectural Central Hospital, Japan

P3.17 THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES

P3.17-001: The Prognostic Analysis of Postoperative Radiotherapy for Esophageal Squamous Cell Carcinoma with Different Status of Lymph Node Metastasis
Xin Xu, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, China

Mong-Wei Lin, National Taiwan University Hospital, Taiwan
AUTHOR INDEX
AUTHORS IN BOLD = PRESENTING AUTHORS
AUTHORS IN BOLD = PRESENTING AUTHORS
JOIN TODAY!

As an IASLC member, you will receive:

- Collaboration with a multidisciplinary global team of thoracic oncology experts and leaders
- Member access to the Journal of Thoracic Oncology, the premier journal in lung cancer, as well as the latest classification and staging publications
- Multidisciplinary education including the latest in groundbreaking research and treatment of thoracic malignancies

SPECIAL OFFER
FOR NEW MEMBERS:
REGULAR,
DEVELOPING COUNTRY
AND ALLIED HEALTH
Fellow, Survivor and Caregiver Memberships Complimentary

Don't forget to pick up your Member Appreciation Gift!

See us in the Exhibit Hall at Booth 2404 or at the IASLC Membership Booth at Registration
Apply at iaslc.org
MAPS AND FLOOR PLANS
Visit the IASLC Membership Booth to learn more about this new IASLC clinical resource, developed by the IASLC Nurse & Allied Health Professionals Committee. Or visit IASLC.org for more information.
LUNG CANCER
TRANSLATIONAL SCIENCE
FROM THE BENCH TO THE CLINIC

January 8-11, 2018 | Hard Rock Hotel | San Diego, CA

Submit an Abstract/Apply for an Award By: Tuesday, October 31, 2017
Register and Save By: Monday, November 27, 2017

ABOUT THIS CONFERENCE

Under the leadership of Margaret Foti, PhD, MD (h.c.), CEO of the American Association for Cancer Research (AACR), and Fred R. Hirsch, MD, PhD, CEO of the International Association for the Study of Lung Cancer (IASLC), we are thrilled to join in our fifth biennial conference on lung cancer research and treatment. The translational science featured at this conference will include basic research foundation at the bench to patient care in the clinic. This conference has historically attracted a diverse group of attendees (physicians, patient advocates, and scientists in basic, translational, and clinical lung cancer research) and provided a venue to discuss recent advances and establish new collaborations. As in our past successful conferences, sessions will range in topics spanning immunotherapy, molecular targets, genetics, drug resistance, clinical trials, patient advocacy, and more. This conference is not only a dynamic collaboration of the AACR and the IASLC, two organizations committed to the study of cancer, but also a dynamic collaboration of the many individuals charged with the study and treatment of this disease.

Continuing Medical Education (CME) Activity—AMA PRA Category 1 Credits™ available

Learn more and register atAACR.org/Lung18
#LUNG18
Neo-Adjuvant Workshop
For Lung Cancer
March 2, 2018 | Washington, D.C.

For more information please visit www.iaslc.org
Immunotherapy
2018 March 22–25
Madrid, Spain
IASLC 1st North Africa Meeting On Lung Cancer

2018 April 29-May 1
Tangier, Morocco

For more information please visit www.iaslc.org
JOIN TODAY!

As an IASLC member, you will receive:

- Collaboration with a multidisciplinary global team of thoracic oncology experts and leaders
- Member access to the Journal of Thoracic Oncology, the premier journal in lung cancer, as well as the latest classification and staging publications
- Multidisciplinary education including the latest in ground-breaking research and treatment of thoracic malignancies

See us in the Exhibit Hall at Booth 2404 or at the IASLC Membership Booth at Registration | Apply at iaslc.org
The Evolving I-O Treatment Landscape in Thoracic Cancers: Clinical Updates and Future Directions

Monday, October 16, 2017 | 17:45–19:15
PACIFICO Yokohama Conference Center
Room 1F, Main Hall
Yokohama, Japan

Program:

Current and Evolving Research Landscape in NSCLC
Daniel SW Tan, BSc, MBBS, MRCP, PhD
National Cancer Centre Singapore
Genome Institute of Singapore
Singapore

Meeting Chair

Emerging Data in SCLC and Mesothelioma
Anne-Marie Dingemans, MD, PhD
Maastricht University Medical Center
Maastricht, The Netherlands

The Role of Emerging Biomarkers in Lung Cancer
David P. Carbone, MD, PhD
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States

Panel discussion and audience Q&A to follow presentations

This program was approved by the IASLC 18th World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 18th World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC.
GIOTRIF®: Irreversible ErbB family blocker. **Active substance:** Afatinib. **Indications:** GIOTRIF is indicated as monotherapy for (1) patients with locally advanced or metastatic NSCLC with activating EGFR mutations not previously treated with EGFR TKIs, (2) patients with NSCLC of squamous histology progressing on or after platinum-based chemotherapy. **Posology:** The recommended dose is 40 mg once daily, orally. Not recommended in patients with an eGFR <15ml/min and severe hepatic impairment. **Contraindications:** Hypersensitivity to afatinib or any of the excipients. **Interactions:** Potent P-gp inhibitors may lead to increased afatinib exposure, concomitant treatment with potent P-gp inducers may lead to a reduction in afatinib exposure. Afatinib is not an inhibitor or inducer of CYP enzymes. **Undesirable effects:** Paronychia, cystitis, decreased appetite, dehydration, hypokalaemia, dysgeusia, conjunctivitis, dry eye, epistaxis, rhinorrhea, diarrhoea, stomatitis, nausea, vomiting, cheilitis, dyspepsia, alanine aminotransferase increased, aspartate aminotransferase increased, rash, acneiform dermatitis, pruritus, dry skin, palmar-plantar erythrodysaesthesia syndrome, nail disorders, Stevens-Johnson syndrome, toxic epidermal necrolysis, muscle spasms, renal impairment/renal failure, pyrexia, weight decreased, interstitial lung disease, keratitis, pancreatitis. **Presentations:** 20 mg, 30 mg, 40 mg, and 50 mg film-coated tablets. For detailed information, please refer to the published Prescribing Information.

Supply classification: POM. This medicine is subject to additional monitoring.

EGFR M+=epidermal growth factor receptor mutation positive; NSCLC=non-small cell lung cancer; TKI=tyrosine kinase inhibitor.

Boehringer Ingelheim International GmbH, Binger Strasse 173, 55216 Ingelheim am Rhein, Germany

Copyright © 2017 Boehringer Ingelheim International GmbH. All rights are reserved. Procedure ID: 5991 – August 2017.